


**CUMULATIVE
SUPPLEMENT 8
AUGUST 2014**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

34th EDITION

Department of Health and Human Services

**Food and Drug Administration
Center for Drug Evaluation and Research
Office of Medical Products and Tobacco
Office of Generic Drugs**

2014

Prepared By
Office of Generic Drugs
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Food and Drug Administration

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

34th EDITION

Cumulative Supplement 8

August 2014

CONTENTS

	<i>PAGE</i>
1.0 INTRODUCTION.....	iii
1.1 How to use the Cumulative Supplement	iii
1.2 Cumulative Supplement Content	iv
1.3 Applicant Name Changes	v
1.4 Levothyroxine Sodium.....	v
1.5 Availability of the Edition.....	vi
1.6 Report of Counts for the Prescription Drug Product List.....	vii
1.7 Cumulative Supplement Legend	viii
 DRUG PRODUCT LISTS	
Prescription Drug Product List	1-1
OTC Drug Product List	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List.....	3-1
Orphan Product Designations and Approvals List	4-1
Drug Products Which Must Demonstrate in vivo Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution	5-1
 PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms	B-1

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

34th EDITION

**CUMULATIVE SUPPLEMENT 8
August 2014**

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 34th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; over-the-counter (OTC) drug products that require approved applications as a condition of marketing; drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research; and products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, or have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the next Edition. The current Annual Edition Section 2.1, How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
 - Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).
- New Drug Application (NDA) approvals appear in the CS month they were approved.

- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at drugproducts@fda.hhs.gov.

mail to: FDA/CDER Orange Book Staff
Office of Generic Drugs
7620 Standish Place
Rockville, MD 20855-2773

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

<u>FORMER APPLICANT NAME</u> <u>(FORMER ABBREVIATED NAME)</u>	<u>NEW APPLICANT NAME</u> <u>(NEW ABBREVIATED NAME)</u>
WEST WARD INC (WEST WARD)	HIKMA PHARMACEUTICALS (HIKMA PHARMS)
WEST WARD PHARMACEUTICAL CORP (WEST WARD PHARMS CORP)	HIKMA PHARMACEUTICALS (HIKMA PHARMS)
WEST WARD PHARMACEUTICAL CORP (WEST WARD PHARMS)	HIKMA PHARMACEUTICALS (HIKMA PHARMS)
MARSAM PHARMACEUTICALS LLC (MARSAM PHARMS LLC)	WATSON LABORATORIES INC (WATSON LABS INC)
WATSON LABORATORIES INC (WATSON LABS)	ACTAVIS LABORATORIES INC (ACTAVIS LABS FL INC)

1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following

explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 76187) and Levo-T (Alara NDA 21342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets. Levo-T (Alara NDA 021342), Levothyroxine Sodium (Mylan ANDA 76187), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbott NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210), Levothyroxine Sodium (Mylan ANDA 076187), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 76187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levotheroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Potency	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	76187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	21301	001
SYNTHROID	ABBOTT	0.025MG	AB1	21402	001
LEVO-T	ALARA PHARM	0.025MG	AB1	21342	001
SYNTHROID	ABBOTT	0.025MG	AB2	21402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	76187	001
LEVO-T	ALARA PHARM	0.025MG	AB2	21342	001
UNITHROID	STEVENS J	0.025MG	AB2	21210	001
LEVOXYL	KUNG PHARMS	0.025MG	AB3	21301	001
LEVO-T	ALARA PHARM	0.025MG	AB3	21342	001
UNITHROID	STEVENS J	0.025MG	AB3	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	76187	001
LEVOTHROID	LLOYD	0.025MG	AB4	21116	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	76187	001

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <http://www.fda.gov/opacom/morechoices/fdaforms/default.html>.

The current listing of the Orphan Product Designations and Approvals is available at <http://www.fda.gov/orphan/designat/list.htm>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 2012) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST
COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2013</u>	<u>MAR 2014</u>	<u>JUN 2014</u>	<u>SEPT 2014</u>	<u>DEC 2014</u>
DRUG PRODUCTS LISTED	15711	15885	15823		
SINGLE SOURCE	2517 (16.0%)	2540 (16.0%)	2516 (15.9%)		
MULTISOURCE	13194 (84.0%)	13345 (84.0%)	13307 (84.1%)		
THERAPEUTICALLY EQUIVALENT	13055 (83.1%)	13208 (83.1%)	13169 (83.2%)		
NOT THERAPEUTICALLY EQUIVALENT	139 (0.9%)	137 (0.9%)	138 (0.9%)		
EXCEPTIONS ¹	78 (0.5%)	78 (0.5%)	78 (0.5%)		
NEW MOLECULAR ENTITIES APPROVED	20	12	6		
NUMBER OF APPLICANTS	866	873	889		

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.

CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

>A> ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE

>A> TABLET; ORAL

>A> TRIUMEQ

>A> + VIIV HLTHCARE EQ 600MG BASE; EQ 50MG BASE; 300MG N205551 001 Aug 22, 2014 Aug NEWA

ACAMPROSATE CALCIUM

TABLET, DELAYED RELEASE; ORAL

ACAMPROSATE CALCIUM

AB MYLAN PHARMS INC 333MG A200142 001 Mar 11, 2014 Feb NEWA

ACARBOSE

TABLET; ORAL

ACARBOSE

>D> AB STRIDES ARCOLAB LTD 25MG A090912 001 Jul 27, 2011 Aug CAHN

>D> AB 50MG A090912 002 Jul 27, 2011 Aug CAHN

>D> AB 100MG A090912 003 Jul 27, 2011 Aug CAHN

>A> AB STRIDES PHARMA 25MG A090912 001 Jul 27, 2011 Aug CAHN

>A> AB 50MG A090912 002 Jul 27, 2011 Aug CAHN

>A> AB 100MG A090912 003 Jul 27, 2011 Aug CAHN

ACEBUTOLOL HYDROCHLORIDE

CAPSULE; ORAL

ACEBUTOLOL HYDROCHLORIDE

@ WATSON LABS EQ 200MG BASE A074007 001 Oct 18, 1995 May DISC

@ EQ 400MG BASE A074007 002 Oct 18, 1995 May DISC

ACETAMINOPHEN; BUTALBITAL

CAPSULE; ORAL

PHRENILIN FORTE

@ VALEANT 650MG; 50MG A088831 001 Jun 19, 1985 Apr DISC

TABLET; ORAL

BUTAPAP

@ MIKART 650MG; 50MG A089988 001 Oct 26, 1992 Apr DISC

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL

ESGIC-PLUS

@ MIKART 500MG; 50MG; 40MG A040085 001 Mar 28, 1996 Apr DISC

TABLET; ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

@ MIKART 750MG; 50MG; 40MG A040496 001 Dec 23, 2003 Apr DISC

@ MIRROR PHARMS 325MG; 50MG; 40MG A040864 001 Dec 01, 2008 Mar DISC

AA + VINTAGE PHARMS 325MG; 50MG; 40MG A040511 001 Aug 27, 2003 Mar CRLD

@ 500MG; 50MG; 40MG A040513 001 Aug 25, 2003 Apr DISC

@ WATSON LABS 500MG; 50MG; 40MG A040267 001 Jul 30, 1998 Jan DISC

ESGIC-PLUS

@ MIKART 500MG; 50MG; 40MG A089451 001 May 23, 1988 Apr DISC

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

PHRENILIN WITH CAFFEINE AND CODEINE

@ VALEANT 325MG; 50MG; 40MG; 30MG A074911 001 Aug 22, 2001 Mar DISC

ACETAMINOPHEN; HYDROCODONE BITARTRATE

SOLUTION; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

@ MALLINCKRODT 500MG/15ML; 7.5MG/15ML A040418 001 Jun 27, 2001 Jan DISC

@ MIKART 500MG/15ML; 7.5MG/15ML A081051 001 Aug 28, 1992 Apr DISC

@ PHARM ASSOC 500MG/15ML; 7.5MG/15ML A040182 001 Mar 13, 1998 Apr DISC

AA VINTAGE PHARMS 325MG/15ML; 7.5MG/15ML A040894 001 Jul 19, 2011 Feb CAHN

@ 500MG/15ML; 7.5MG/15ML A040520 001 Oct 30, 2003 Apr DISC

TABLET; ORAL

ANEXSIA

@ MALLINCKRODT 500MG; 5MG A089160 001 Apr 23, 1987 Jan DISC

@ 750MG; 10MG A040468 001 Oct 31, 2002 Jan DISC

ANEXSIA 7.5/650

@ MALLINCKRODT 650MG; 7.5MG A089725 001 Sep 30, 1987 Jan DISC

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

@ AMNEAL PHARMS NY 500MG; 5MG A040729 001 Aug 25, 2006 Apr DISC

TABLET; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

	@		500MG; 7.5MG	A040748	001	Aug 25, 2006	Apr	DISC
	@		500MG; 10MG	A040813	001	Feb 23, 2007	Apr	DISC
	@		650MG; 7.5MG	A040754	001	Aug 25, 2006	Apr	DISC
	@		650MG; 10MG	A040757	001	Aug 25, 2006	Apr	DISC
	@		750MG; 7.5MG	A040769	001	Aug 28, 2006	Apr	DISC
	@	CARACO	500MG; 5MG	A090265	001	Dec 23, 2008	Apr	DISC
	@		500MG; 7.5MG	A090265	002	Dec 23, 2008	Apr	DISC
	@		500MG; 10MG	A090265	003	Dec 23, 2008	Apr	DISC
	@		650MG; 7.5MG	A090380	001	Dec 23, 2008	Apr	DISC
	@		650MG; 10MG	A090380	002	Dec 23, 2008	Apr	DISC
	@		660MG; 10MG	A090380	003	Dec 23, 2008	Apr	DISC
	@		750MG; 7.5MG	A090380	004	Dec 23, 2008	Apr	DISC
	@	MALLINCKRODT	500MG; 5MG	A040084	002	Jun 01, 1995	Jan	DISC
	@		500MG; 7.5MG	A040201	001	Feb 27, 1998	Jan	DISC
	@		500MG; 10MG	A040201	002	Feb 27, 1998	Jan	DISC
	@		650MG; 10MG	A040084	004	Oct 16, 1996	Jan	DISC
	@		660MG; 10MG	A040084	003	Jul 29, 1996	Jan	DISC
	@		750MG; 7.5MG	A040084	001	Jun 01, 1995	Jan	DISC
	@	MIKART	500MG; 7.5MG	A089699	001	Aug 25, 1989	Apr	DISC
	@		650MG; 7.5MG	A089689	001	Jun 29, 1988	Apr	DISC
	@		650MG; 10MG	A081223	001	May 29, 1992	Apr	DISC
AA		SUN PHARM INDS INC	325MG; 5MG	A090118	001	Dec 23, 2008	Jun	CAHN
AA			325MG; 7.5MG	A090118	002	Dec 23, 2008	Jun	CAHN
AA			325MG; 10MG	A090118	003	Dec 23, 2008	Jun	CAHN
AA		VINTAGE PHARMS	300MG; 5MG	A090415	001	Jan 24, 2011	Feb	CAHN
AA			300MG; 7.5MG	A090415	002	Jan 24, 2011	Feb	CAHN
AA			300MG; 10MG	A090415	003	Jan 24, 2011	Feb	CAHN
	@		500MG; 2.5MG	A040144	002	Apr 25, 1997	Apr	DISC
	@		500MG; 5MG	A089971	001	Dec 02, 1988	Apr	DISC
	@		500MG; 7.5MG	A040144	001	Feb 22, 1996	Apr	DISC
	@		500MG; 10MG	A040356	001	May 31, 2000	Apr	DISC
	@		650MG; 7.5MG	A040155	001	Apr 14, 1997	Jan	DISC
	@		650MG; 10MG	A040143	001	Feb 22, 1996	Apr	DISC
	@		660MG; 10MG	A040358	001	May 31, 2000	Apr	DISC
	@		750MG; 7.5MG	A040157	001	Apr 12, 1996	Jan	DISC
	@	WATSON LABS	500MG; 2.5MG	A081079	001	Aug 30, 1991	Apr	DISC
	@		500MG; 5MG	A089883	001	Dec 01, 1988	Apr	DISC
	@		500MG; 7.5MG	A081080	001	Aug 30, 1991	Jan	DISC
	@		650MG; 7.5MG	A040094	001	Sep 29, 1995	Apr	DISC
	@		650MG; 10MG	A040094	002	Sep 29, 1995	Apr	DISC
	@		660MG; 10MG	A040094	003	Aug 08, 2000	Apr	DISC
	@		750MG; 7.5MG	A081083	001	Aug 30, 1991	Jan	DISC
	@		750MG; 10MG	A040094	004	Mar 22, 1999	Apr	DISC
	@	WATSON LABS FLORIDA	660MG; 10MG	A040495	001	May 28, 2003	Apr	DISC
		LORTAB						
	@	UCB INC	500MG; 5MG	A087722	001	Jul 09, 1982	Apr	DISC
	@		500MG; 10MG	A040100	001	Jan 26, 1996	Apr	DISC
		ZYDONE						
	@	VINTAGE PHARMS LLC	400MG; 5MG	A040288	001	Nov 27, 1998	Apr	DISC
	@		400MG; 7.5MG	A040288	002	Nov 27, 1998	Apr	DISC
	@		400MG; 10MG	A040288	003	Nov 27, 1998	Apr	DISC

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

CAPSULE; ORAL

OXYCODONE AND ACETAMINOPHEN

>A>	@	ACTAVIS ELIZABETH	500MG; 5MG	A040199	001	Dec 30, 1998	Aug	CAHN
>D>	@	ACTAVIS TOTOWA	500MG; 5MG	A040199	001	Dec 30, 1998	Aug	CAHN
	@	DURAMED PHARMS BARR	500MG; 5MG	A040289	001	Mar 16, 1999	Apr	DISC
	@	MALLINCKRODT	500MG; 5MG	A040257	001	Aug 04, 1998	Jan	DISC
	@	VINTAGE PHARMS	500MG; 5MG	A040106	001	Jul 30, 1996	Apr	DISC
	@	WATSON LABS	500MG; 5MG	A040234	001	Oct 30, 1997	Jan	DISC
		ROXILOX						
	@	ROXANE	500MG; 5MG	A040061	001	Jul 03, 1995	Apr	DISC
		TYLOX						
	@	JANSSEN PHARMS	500MG; 5MG	A088790	001	Dec 12, 1984	Apr	DISC

TABLET; ORAL

OXYCODONE AND ACETAMINOPHEN

>D>	AA	ACTAVIS TOTOWA	325MG; 7.5MG	A040800	001	Apr 03, 2012	Aug	DISC
>A>	@		325MG; 7.5MG	A040800	001	Apr 03, 2012	Aug	DISC
>D>	AA		325MG; 10MG	A040800	002	Apr 03, 2012	Aug	DISC
>A>	@		325MG; 10MG	A040800	002	Apr 03, 2012	Aug	DISC

TABLET; ORAL

OXYCODONE AND ACETAMINOPHEN

	@ AMNEAL PHARMS NY	500MG; 7.5MG	A040789	001	Nov 27, 2007	Apr	DISC
	@	650MG; 10MG	A040789	002	Nov 27, 2007	Apr	DISC
	@ COASTAL PHARMS	500MG; 7.5MG	A090177	005	Oct 20, 2008	Apr	DISC
	@	650MG; 10MG	A090177	006	Oct 20, 2008	Apr	DISC
	@ MALLINCKRODT	500MG; 7.5MG	A040550	001	Jun 30, 2004	Apr	DISC
	@	650MG; 10MG	A040550	002	Jun 30, 2004	Apr	DISC
	@ MIKART	400MG; 5MG	A040687	001	Apr 27, 2006	Apr	DISC
	@	400MG; 7.5MG	A040698	001	Apr 27, 2006	Apr	DISC
	@	400MG; 10MG	A040692	001	Apr 27, 2006	Apr	DISC
	@	500MG; 10MG	A040676	001	Apr 19, 2006	Apr	DISC
>A> AA	RHODES PHARMS	325MG; 5MG	A201278	001	Aug 28, 2014	Aug	NEWA
>A> AA		325MG; 7.5MG	A201278	002	Aug 28, 2014	Aug	NEWA
>A> AA		325MG; 10MG	A201278	003	Aug 28, 2014	Aug	NEWA
AA	SUN PHARM INDS INC	325MG; 2.5MG	A090535	001	Dec 26, 2013	Jul	CAHN
AA		325MG; 5MG	A090535	002	Dec 26, 2013	Jul	CAHN
AA		325MG; 7.5MG	A090535	003	Dec 26, 2013	Jul	CAHN
AA		325MG; 10MG	A090535	004	Dec 26, 2013	Jul	CAHN
	@ WATSON LABS	500MG; 7.5MG	A040371	001	Dec 29, 2000	Jan	DISC
	@	650MG; 10MG	A040371	002	Dec 29, 2000	Jan	DISC
	PERCOCET						
	@ VINTAGE PHARMS LLC	500MG; 7.5MG	A040341	001	Jul 26, 1999	Jan	DISC
	@	650MG; 10MG	A040341	002	Jul 26, 1999	Jan	DISC

TABLET, EXTENDED RELEASE; ORAL

XARTEMIS XR

+	MALLINCKRODT INC	325MG; 7.5MG	N204031	001	Mar 11, 2014	Mar	NEWA
---	------------------	--------------	---------	-----	--------------	-----	------

ACETAMINOPHEN; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL

ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE

@	GAVIS PHARMS	650MG; EQ 25MG BASE	A076202	001	Aug 02, 2002	Apr	DISC
@	WATSON LABS	650MG; EQ 25MG BASE	A074699	001	Mar 24, 2000	Apr	DISC

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

TABLET; ORAL

TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN

AB	ALLIED PHARMA INC	325MG; 37.5MG	A202076	001	Mar 30, 2012	Apr	CAHN
AB	APOTEX INC	325MG; 37.5MG	A078778	001	Apr 07, 2014	Mar	NEWA
AB	SUN PHARM INDS INC	325MG; 37.5MG	A077184	001	Dec 16, 2005	Jul	CAHN
	@ WATSON LABS	325MG; 37.5MG	A076914	001	Jul 26, 2006	May	DISC

ACETAZOLAMIDE

TABLET; ORAL

DIAMOX

@	TEVA BRANDED PHARM	125MG	N008943	001		Jul	CAHN
@		250MG	N008943	002		Jul	CAHN

ACETAZOLAMIDE SODIUM

INJECTABLE; INJECTION

ACETAZOLAMIDE SODIUM

>D> AP	BEDFORD	EQ 500MG BASE/VIAL	A040089	001	Feb 28, 1995	Aug	CAHN
>A> AP	EUROHLTH INTL	EQ 500MG BASE/VIAL	A040089	001	Feb 28, 1995	Aug	CAHN

ACETOHEXAMIDE

TABLET; ORAL

ACETOHEXAMIDE

@	WATSON LABS	250MG	A071893	001	Nov 25, 1987	May	DISC
@		500MG	A071894	001	Nov 25, 1987	May	DISC

ACETYLCYSTEINE

SOLUTION; INHALATION, ORAL

ACETYLCYSTEINE

AN	INNOPHARMA LICENSING	10%	A204674	001	Feb 11, 2014	Jan	NEWA
>D> AN	ROXANE	10%	A072323	001	Apr 30, 1992	Aug	DISC
>A>	@	10%	A072323	001	Apr 30, 1992	Aug	DISC
AN		10%	A072323	001	Apr 30, 1992	Jun	CAHN
>D> AN		20%	A072324	001	Apr 30, 1992	Aug	DISC
>A>	@	20%	A072324	001	Apr 30, 1992	Aug	DISC
AN		20%	A072324	001	Apr 30, 1992	Jun	CAHN

ACRIVASTINE; PSEUDOEPHEDRINE HYDROCHLORIDECAPSULE;ORAL
SEMPREX-D

+ AUXILIUM PHARMS LLC 8MG;60MG N019806 001 Mar 25, 1994 Apr CAHN

ACYCLOVIRCAPSULE;ORAL
ACYCLOVIRAB CADILA PHARMS LTD 200MG A201445 001 Mar 06, 2014 Feb NEWA
ZOVIRAX

AB + DELCOR ASSET 200MG N018828 001 Jan 25, 1985 Jun CAHN

OINTMENT;TOPICAL
ACYCLOVIR

AB AMNEAL PHARMS 5% A204605 001 Jun 18, 2014 Jun NEWA

TABLET;BUCCAL
SITAVIG

+ INNOCUTIS HOLDINGS 50MG N203791 001 Apr 12, 2013 Apr CMFD

+ 50MG N203791 001 Apr 12, 2013 Apr CAHN

TABLET;ORAL
ACYCLOVIR

>A> AB ZYDUS PHARMS USA INC 400MG A204314 001 Aug 19, 2014 Aug NEWA

>A> AB 800MG A204314 002 Aug 19, 2014 Aug NEWA

ZOVIRAX

AB DELCOR ASSET 400MG N020089 001 Apr 30, 1991 Jun CAHN

AB + 800MG N020089 002 Apr 30, 1991 Jun CAHN

ACYCLOVIR SODIUMINJECTABLE;INJECTION
ACYCLOVIR SODIUM

+ BEDFORD EQ 1GM BASE/VIAL A074596 001 Apr 22, 1997 Feb CRLD

@ HIKMA MAPLE EQ 1GM BASE/VIAL A074913 002 Oct 15, 1997 Feb DISC

@ EQ 500MG BASE/VIAL A074913 001 Oct 15, 1997 Feb DISC

ADENOSINEINJECTABLE;INJECTION
ADENOSINE

AP AGILA SPECLTS 3MG/ML A078640 001 Mar 21, 2014 Mar NEWA

AP 3MG/ML A078686 001 May 13, 2009 Feb CAHN

AP HOSPIRA INC 3MG/ML A203883 001 Mar 24, 2014 Mar NEWA

AP SAGENT STRIDES 3MG/ML A090212 001 Mar 28, 2014 Mar NEWA

ALBUTEROL SULFATESOLUTION;INHALATION
ACCUNEB

AN + MYLAN SPECLT EQ 0.021% BASE N020949 002 Apr 30, 2001 May CAHN

AN + EQ 0.042% BASE N020949 001 Apr 30, 2001 May CAHN

TABLET;ORAL

ALBUTEROL SULFATE

@ WATSON LABS EQ 2MG BASE A072764 001 Aug 28, 1991 May DISC

ALBUTEROL SULFATE; IPRATROPIUM BROMIDESOLUTION;INHALATION
DUONEB

AN + MYLAN SPECLT EQ 0.083% BASE;0.017% N020950 001 Mar 21, 2001 May CAHN

ALISKIREN HEMIFUMARATE; VALSARTANTABLET;ORAL
VALTURNA

@ NOVARTIS EQ 150MG BASE;160MG N022217 001 Sep 16, 2009 May DISC

@ EQ 300MG BASE;320MG N022217 002 Sep 16, 2009 May DISC

ALLOPURINOLTABLET;ORAL
ALLOPURINOL

AB SUN PHARM INDS INC 100MG A078390 001 Aug 30, 2007 Jul CAHN

AB 300MG A078390 002 Aug 30, 2007 Jul CAHN

ALLOPURINOL SODIUMINJECTABLE;INJECTION
ALLOPURINOL SODIUM

>D>	AP	BEDFORD LABS	EQ 500MG BASE/VIAL	A076870	001	Aug 26, 2004	Aug CAHN
>A>	AP	EUROHLTH INTL	EQ 500MG BASE/VIAL	A076870	001	Aug 26, 2004	Aug CAHN

ALPRAZOLAMTABLET;ORAL
ALPRAZOLAM

AB	VINTAGE PHARMS	0.25MG	A090248	001	Sep 17, 2010	Feb CAHN
AB		0.5MG	A090248	002	Sep 17, 2010	Feb CAHN
AB		1MG	A090248	003	Sep 17, 2010	Feb CAHN
AB		2MG	A090248	004	Sep 17, 2010	Feb CAHN

TABLET, EXTENDED RELEASE;ORAL
ALPRAZOLAM

AB	ANI PHARMS INC	0.5MG	A077725	001	Jul 31, 2006	Jan CAHN
	@	0.5MG	A077979	001	Feb 28, 2007	Jan CAHN
AB		1MG	A077725	002	Jul 31, 2006	Jan CAHN
	@	1MG	A077979	002	Feb 28, 2007	Jan CAHN
AB		2MG	A077725	004	Jul 31, 2006	Jan CAHN
	@	2MG	A077979	003	Feb 28, 2007	Jan CAHN
AB		3MG	A077725	003	Jul 31, 2006	Jan CAHN
	@	3MG	A077979	004	Feb 28, 2007	Jan CAHN

ALPROSTADILINJECTABLE;INJECTION
ALPROSTADIL

>D>	AP	BEDFORD	0.5MG/ML	A074815	001	Jan 20, 1998	Aug CAHN
>A>	AP	EUROHLTH INTL	0.5MG/ML	A074815	001	Jan 20, 1998	Aug CAHN
		EDEX					
		@ AUXILIUM PHARMS LLC	0.005MG/VIAL	N020649	001	Jun 12, 1997	Apr CAHN
AP			0.01MG/VIAL	N020649	002	Jun 12, 1997	Apr CAHN
	+		0.01MG/VIAL	N020649	005	Jul 30, 1998	Apr CAHN
AP			0.02MG/VIAL	N020649	003	Jun 12, 1997	Apr CAHN
	+		0.02MG/VIAL	N020649	006	Jul 30, 1998	Apr CAHN
AP			0.04MG/VIAL	N020649	004	Jun 12, 1997	Apr CAHN
	+		0.04MG/VIAL	N020649	007	Jul 30, 1998	Apr CAHN

AMANTADINE HYDROCHLORIDECAPSULE;ORAL
AMANTADINE HYDROCHLORIDE

>A>		@ ACTAVIS ELIZABETH	100MG	A077659	001	Feb 23, 2006	Aug CAHN
>D>		@ ACTAVIS TOTOWA	100MG	A077659	001	Feb 23, 2006	Aug CAHN
AB	+	SANDOZ	100MG	A071293	001	Feb 18, 1987	Feb CRLD
AB		USL PHARMA	100MG	A070589	001	Aug 05, 1986	Feb CRLD

AMBENONIUM CHLORIDETABLET;ORAL
MYTELASE

@	SANOFI AVENTIS US	10MG	N010155	002		Jun DISC
---	-------------------	------	---------	-----	--	----------

AMIKACIN SULFATEINJECTABLE;INJECTION
AMIKACIN SULFATE

>D>	AP	+	BEDFORD	EQ 50MG BASE/ML	A063313	001	Apr 11, 1994	Aug CAHN
>D>	AP	+		EQ 250MG BASE/ML	A063315	001	Apr 11, 1994	Aug CAHN
>A>	AP	+	EUROHLTH INTL	EQ 50MG BASE/ML	A063313	001	Apr 11, 1994	Aug CAHN
>A>	AP	+		EQ 250MG BASE/ML	A063315	001	Apr 11, 1994	Aug CAHN

AMINO ACIDSINJECTABLE;INJECTION
HEPATASOL 8%

@	BAXTER HLTHCARE	8% (8GM/100ML)	A020360	001	Apr 04, 1996	Jul DISC
	RENAMIN W/O ELECTROLYTES					
@	BAXTER HLTHCARE	6.5% (6.5GM/100ML)	N017493	007	Oct 15, 1982	Jul DISC
	TRAVASOL 10% W/O ELECTROLYTES					
@	BAXTER HLTHCARE	10% (10GM/100ML)	N017493	006		Jul DISC
	TRAVASOL 5.5% W/O ELECTROLYTES					
@	BAXTER HLTHCARE	5.5% (5.5GM/100ML)	N017493	004		Jul DISC
	TRAVASOL 8.5% W/O ELECTROLYTES					
@	BAXTER HLTHCARE	8.5% (8.5GM/100ML)	N017493	005		Jul DISC

>A>	<u>AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM GLYCEROPHOSPHATE; SOYBEAN OIL</u>									
>A>	EMULSION; IV (INFUSION)									
>A>	KABIVEN IN PLASTIC CONTAINER									
>A>	FRESENIUS KABI USA	3.3%;29MG/100ML;9.8GM/100ML;96MG/100ML;174MG/100ML;239MG/100ML;147MG/100ML;3.9GM/100ML (1026ML)	N200656	004	Aug 25, 2014	Aug	NEWA			
>A>		3.3%;29MG/100ML;9.8GM/100ML;96MG/100ML;174MG/100ML;239MG/100ML;147MG/100ML;3.9GM/100ML (1540ML)	N200656	005	Aug 25, 2014	Aug	NEWA			
>A>		3.3%;29MG/100ML;9.8GM/100ML;96MG/100ML;174MG/100ML;239MG/100ML;147MG/100ML;3.9GM/100ML (2053ML)	N200656	006	Aug 25, 2014	Aug	NEWA			
>A>	+	3.3%;29MG/100ML;9.8GM/100ML;96MG/100ML;174MG/100ML;239MG/100ML;147MG/100ML;3.9GM/100ML (2566ML)	N200656	007	Aug 25, 2014	Aug	NEWA			
>A>	PERIKABIVEN IN PLASTIC CONTAINER									
>A>	FRESENIUS KABI USA	2.4%;20MG/100ML;6.8GM/100ML;68MG/100ML;124MG/100ML;170MG/100ML;105MG/100ML;3.5GM/100ML (1440ML)	N200656	001	Aug 25, 2014	Aug	NEWA			
>A>		2.4%;20MG/100ML;6.8GM/100ML;68MG/100ML;124MG/100ML;170MG/100ML;105MG/100ML;3.5GM/100ML (1920ML)	N200656	002	Aug 25, 2014	Aug	NEWA			
>A>		2.4%;20MG/100ML;6.8GM/100ML;68MG/100ML;124MG/100ML;170MG/100ML;105MG/100ML;3.5GM/100ML (2400ML)	N200656	003	Aug 25, 2014	Aug	NEWA			
<u>AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE</u>										
INJECTABLE; INJECTION										
	TRAVASOL 3.5% W/ ELECTROLYTES									
	@ BAXTER HLTHCARE	3.5%;51MG/100ML;131MG/100ML;218MG/100ML;35MG/100ML	N017493	003				Jul	DISC	
	TRAVASOL 5.5% W/ ELECTROLYTES									
	@ BAXTER HLTHCARE	5.5%;102MG/100ML;522MG/100ML;431MG/100ML;224MG/100ML	N017493	001				Jul	DISC	
	TRAVASOL 8.5% W/ ELECTROLYTES									
	@ BAXTER HLTHCARE	8.5%;102MG/100ML;522MG/100ML;594MG/100ML;154MG/100ML	N017493	002				Jul	DISC	
<u>AMINOHIPPURATE SODIUM</u>										
INJECTABLE; INJECTION										
	AMINOHIPPURATE SODIUM									
	@ MERCK	20%	N005619	001				Jun	DISC	
<u>AMIODARONE HYDROCHLORIDE</u>										
INJECTABLE; INJECTION										
	AMIODARONE HYDROCHLORIDE									
	@ PAR STERILE PRODUCTS	50MG/ML	A076394	001	Apr 25, 2003	May	CAHN			
<u>AMITRIPTYLINE HYDROCHLORIDE</u>										
TABLET; ORAL										
	AMITRIPTYLINE HYDROCHLORIDE									
AB	MUTUAL PHARM	10MG	A089399	002	Jul 14, 1987	Jun	CMS1			
AB		50MG	A089399	003	Jul 14, 1987	Jun	CMS1			
AB		75MG	A089399	004	Jul 14, 1987	Jun	CMS1			
AB		100MG	A089399	005	Jul 14, 1987	Jun	CMS1			
AB		100MG	A089399	006	Jul 14, 1987	Jun	CMS1			
AB		150MG	A089399	006	Jul 14, 1987	Jul	CPOT			
AB	SUN PHARM INDS INC	10MG	A040816	002	Jun 27, 2008	Jul	CAHN			
AB		25MG	A040816	001	Jun 27, 2008	Jul	CAHN			
AB		50MG	A040816	003	Jun 27, 2008	Jul	CAHN			
AB		75MG	A040816	004	Jun 27, 2008	Jul	CAHN			
AB		100MG	A040816	005	Jun 27, 2008	Jul	CAHN			
AB		150MG	A040816	006	Jun 27, 2008	Jul	CAHN			
	AMITRIPTYLINE HYDROCHORIDE									
AB	ACCORD HLTHCARE	10MG	A202446	001	Jun 04, 2014	May	NEWA			
AB		25MG	A202446	002	Jun 04, 2014	May	NEWA			
AB		50MG	A202446	003	Jun 04, 2014	May	NEWA			
AB		75MG	A202446	004	Jun 04, 2014	May	NEWA			
AB		100MG	A202446	005	Jun 04, 2014	May	NEWA			

TABLET;ORAL

AMITRIPTYLINE HYDROCHORIDE

AB		150MG		A202446	006	Jun 04, 2014	May NEWA
----	--	-------	--	---------	-----	--------------	----------

AMLODIPINE BESYLATE

TABLET;ORAL

AMLODIPINE BESYLATE

	@ PURACAP PHARM	EQ 2.5MG BASE		A078131	001	Sep 04, 2007	Feb DISC
	@	EQ 5MG BASE		A078131	002	Sep 04, 2007	Feb DISC
	@	EQ 10MG BASE		A078131	003	Sep 04, 2007	Feb DISC
AB	SUN PHARM INDS INC	EQ 2.5MG BASE		A078231	001	Nov 30, 2007	Jul CAHN
AB		EQ 5MG BASE		A078231	002	Nov 30, 2007	Jul CAHN
AB		EQ 10MG BASE		A078231	003	Nov 30, 2007	Jul CAHN
AB	VIVIMED LABS	EQ 2.5MG BASE		A077516	001	Jul 11, 2007	Apr CAHN
AB		EQ 5MG BASE		A077516	002	Jul 11, 2007	Apr CAHN
AB		EQ 10MG BASE		A077516	003	Jul 11, 2007	Apr CAHN

AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM

TABLET;ORAL

AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM

AB	DR REDDYS LABS LTD	EQ 2.5MG BASE;EQ 10MG BASE		A203874	001	Mar 07, 2014	Feb NEWA
AB		EQ 2.5MG BASE;EQ 20MG BASE		A203874	002	Mar 07, 2014	Feb NEWA
AB		EQ 2.5MG BASE;EQ 40MG BASE		A203874	003	Mar 07, 2014	Feb NEWA
AB		EQ 5MG BASE;EQ 10MG BASE		A203874	004	Mar 07, 2014	Feb NEWA
AB		EQ 5MG BASE;EQ 20MG BASE		A203874	005	Mar 07, 2014	Feb NEWA
AB		EQ 5MG BASE;EQ 40MG BASE		A203874	006	Mar 07, 2014	Feb NEWA
AB		EQ 5MG BASE;EQ 80MG BASE		A203874	007	Mar 07, 2014	Feb NEWA
AB		EQ 10MG BASE;EQ 10MG BASE		A203874	008	Mar 07, 2014	Feb NEWA
AB		EQ 10MG BASE;EQ 20MG BASE		A203874	009	Mar 07, 2014	Feb NEWA
AB		EQ 10MG BASE;EQ 40MG BASE		A203874	010	Mar 07, 2014	Feb NEWA
AB		EQ 10MG BASE;EQ 80MG BASE		A203874	011	Mar 07, 2014	Feb NEWA

AMLODIPINE BESYLATE; TELMISARTAN

TABLET;ORAL

TELMISARTAN AND AMLODIPINE

>A>	AB	MYLAN PHARMS INC	EQ 5MG BASE;40MG		A202516	001	Aug 26, 2014	Aug NEWA
>A>	AB		EQ 5MG BASE;80MG		A202516	003	Aug 26, 2014	Aug NEWA
>A>	AB		EQ 10MG BASE;40MG		A202516	002	Aug 26, 2014	Aug NEWA
>A>	AB		EQ 10MG BASE;80MG		A202516	004	Aug 26, 2014	Aug NEWA

AMMONIA N-13

INJECTABLE;INTRAVENOUS

AMMONIA N 13

>A>	AP	JOHNS HOPKINS UNIV	30mCi-300mCi/8ML (3.75-37.5mCi/ML)		A204514	001	Aug 19, 2014	Aug NEWA
	AP	UCSF RODIOPHARM	30mCi-300mCi/8ML (3.75-37.5mCi/ML)		A204496	001	Mar 28, 2014	Mar NEWA
	AP	UNIV TX MD ANDERSON	30mCi-300mCi/8ML (3.75-37.5mCi/ML)		A203933	001	Jun 27, 2014	Jun NEWA
	AP	WA UNIV SCH MED	30mCi-300mCi/8ML (3.75-37.5mCi/ML)		A204506	001	Feb 07, 2014	Jan NEWA

AMOXICILLIN

TABLET, EXTENDED RELEASE;ORAL

MOXATAG

+	PRAGMA PHARMS LLC	775MG		N050813	001	Jan 23, 2008	Apr CAHN
---	-------------------	-------	--	---------	-----	--------------	----------

AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE

CAPSULE, CAPSULE, DELAYED REL PELLETS, TABLET;ORAL

LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN

AB	SANDOZ	500MG,N/A,N/A,N/A,500MG,N/A,N/A,N/A,30MG		A202588	001	Mar 04, 2014	Feb NEWA
----	--------	--	--	---------	-----	--------------	----------

AMOXICILLIN; CLARITHROMYCIN; OMEPRAZOLE

CAPSULE, TABLET, CAPSULE, DELAYED RELEASE;ORAL

OMEPRAZOLE AND CLARITHROMYCIN AND AMOXICILLIN

+	GASTROENTERO	500MG,N/A,N/A,N/A,500MG,N/A,N/A,N/A,20MG		N050824	001	Feb 08, 2011	Mar CDFR
---	--------------	--	--	---------	-----	--------------	----------

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

TABLET;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB	WATSON LABS	1.25MG;1.25MG;1.25MG;1.25MG		A040456	001	May 06, 2003	Apr CMFD
AB		2.5MG;2.5MG;2.5MG;2.5MG		A040456	002	May 06, 2003	Apr CMFD
AB		5MG;5MG;5MG;5MG		A040456	003	May 06, 2003	Apr CMFD
AB		7.5MG;7.5MG;7.5MG;7.5MG		A040456	004	May 06, 2003	Apr CMFD

AMPICILLIN SODIUMINJECTABLE; INJECTION
AMPICILLIN SODIUM

AP	AGILA SPECLTS	EQ 10GM BASE/VIAL	A202198	001	Apr 07, 2014	Mar NEWA
AP	ANTIBIOTICE	EQ 1GM BASE/VIAL	A090354	003	Dec 28, 2009	Jun CMFD
AP		EQ 2GM BASE/VIAL	A090354	004	Dec 28, 2009	Jun CMFD
AP		EQ 250MG BASE/VIAL	A090354	001	Dec 28, 2009	Jun CMFD
AP		EQ 500MG BASE/VIAL	A090354	002	Dec 28, 2009	Jun CMFD
AP	ISTITUTO BIO ITA SPA	EQ 1GM BASE/VIAL	A062719	002	May 12, 1987	Feb CAHN
AP		EQ 2GM BASE/VIAL	A062797	002	Jul 12, 1993	Feb CAHN
AP		EQ 10GM BASE/VIAL	A201404	001	Dec 20, 2013	Jan CPOT
AP		EQ 125MG BASE/VIAL	A062797	001	Jul 12, 1993	Feb CAHN
AP		EQ 250MG BASE/VIAL	A062719	001	May 12, 1987	Feb CAHN
AP		EQ 500MG BASE/VIAL	A062719	003	May 12, 1987	Feb CAHN
AP	STRIDES ARCOLAB LTD	EQ 1GM BASE/VIAL	A201025	003	Apr 09, 2014	Mar NEWA
AP		EQ 2GM BASE/VIAL	A201025	004	Apr 09, 2014	Mar NEWA
AP		EQ 250MG BASE/VIAL	A201025	001	Apr 09, 2014	Mar NEWA
AP		EQ 500MG BASE/VIAL	A201025	002	Apr 09, 2014	Mar NEWA

AMPICILLIN SODIUM; SULBACTAM SODIUMINJECTABLE; INJECTION
AMPICILLIN AND SULBACTAM

AP	AGILA SPECLTS	EQ 1GM BASE/VIAL; EQ 500MG BASE/VIAL	A201024	001	Apr 07, 2014	Mar NEWA
AP		EQ 2GM BASE/VIAL; EQ 1GM BASE/VIAL	A201024	002	Apr 07, 2014	Mar NEWA
AP		EQ 10GM BASE/VIAL; EQ 5GM BASE/VIAL	A202197	001	Apr 07, 2014	Mar NEWA
AP	ISTITUTO BIO ITA SPA	EQ 1GM BASE/VIAL; EQ 500MG BASE/VIAL	A065222	001	Nov 29, 2005	Feb CAHN
AP		EQ 2GM BASE/VIAL; EQ 1GM BASE/VIAL	A065222	002	Nov 29, 2005	Feb CAHN
AP		EQ 10GM BASE/VIAL; EQ 5GM BASE/VIAL	A065314	001	Nov 27, 2006	Feb CAHN
AP	MUSTAFA NEVZAT ILAC	EQ 1GM BASE/VIAL; EQ 500MG BASE/VIAL	A065316	001	Jun 29, 2007	May CAHN
AP		EQ 2GM BASE/VIAL; EQ 1GM BASE/VIAL	A065316	002	Jun 29, 2007	May CAHN

ANASTROZOLETABLET; ORAL
ANASTROZOLE

@	WATSON LABS	1MG	A078984	001	Jun 28, 2010	May DISC
---	-------------	-----	---------	-----	--------------	----------

APREMILASTTABLET; ORAL
OTEZLA

	CELGENE CORP	10MG	N205437	001	Mar 21, 2014	Mar NEWA
		20MG	N205437	002	Mar 21, 2014	Mar NEWA
+		30MG	N205437	003	Mar 21, 2014	Mar NEWA

ARGATROBANINJECTABLE; INJECTION
ARGATROBAN

AP	MYLAN INSTITUTIONAL	250MG/2.5ML (100MG/ML)	A202626	001	Jun 30, 2014	Jun NEWA
AP	PAR STERILE PRODUCTS	250MG/2.5ML (100MG/ML)	A091665	001	Jun 30, 2014	Jun NEWA

ARMODAFINILTABLET; ORAL
ARMODAFINIL

AB	WATSON LABS INC	200MG	A200156	004	Aug 29, 2012	May CTEC
	NUVIGIL					
AB	CEPHALON	200MG	N021875	005	Mar 26, 2009	May CMFD

ASENAPINE MALEATETABLET; SUBLINGUAL
SAPHRIS

	FOREST LABS INC	EQ 5MG BASE	N022117	001	Aug 13, 2009	Feb CAHN
+		EQ 10MG BASE	N022117	002	Aug 13, 2009	Feb CAHN

ASPIRIN; BUTALBITAL; CAFFEINETABLET; ORAL
BUTALBITAL, ASPIRIN AND CAFFEINE

>A>	AA	+	HIKMA INTL PHARMS	325MG; 50MG; 40MG	A086162	002	Feb 16, 1984	Aug CAHN
>D>	AA	+	HIKMA PHARMS LLC	325MG; 50MG; 40MG	A086162	002	Feb 16, 1984	Aug CAHN

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE;ORAL

BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE

@ WATSON LABS	325MG;50MG;40MG;30MG	A074359	001	Aug 31, 1995	Mar DISC
---------------	----------------------	---------	-----	--------------	----------

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET;ORAL

ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE

@ STEVENS J	385MG;30MG;25MG	A074988	001	Apr 30, 1999	Mar DISC
-------------	-----------------	---------	-----	--------------	----------

@	770MG;60MG;50MG	A074988	002	Apr 30, 1999	Mar DISC
---	-----------------	---------	-----	--------------	----------

ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE

TABLET;ORAL

CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE

@ MIRROR PHARMS	325MG;200MG;16MG	A040860	001	Jan 07, 2010	Mar DISC
-----------------	------------------	---------	-----	--------------	----------

@ PROSAM LABS	325MG;200MG;16MG	A040283	001	Dec 29, 1998	Mar DISC
---------------	------------------	---------	-----	--------------	----------

ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

TABLET;ORAL

OXYCODONE AND ASPIRIN

@ WATSON LABS	325MG;4.5MG;0.38MG	A040255	001	Feb 27, 1998	May DISC
---------------	--------------------	---------	-----	--------------	----------

ATAZANAVIR SULFATE

CAPSULE;ORAL

ATAZANAVIR SULFATE

>D> AB	TEVA PHARMS USA	EQ 100MG BASE	A091673	001	Apr 22, 2014	Aug CTEC
--------	-----------------	---------------	---------	-----	--------------	----------

>A>		EQ 100MG BASE	A091673	001	Apr 22, 2014	Aug CTEC
-----	--	---------------	---------	-----	--------------	----------

AB		EQ 100MG BASE	A091673	001	Apr 22, 2014	Apr NEWA
----	--	---------------	---------	-----	--------------	----------

AB		EQ 150MG BASE	A091673	002	Apr 22, 2014	Apr NEWA
----	--	---------------	---------	-----	--------------	----------

AB		EQ 200MG BASE	A091673	003	Apr 22, 2014	Apr NEWA
----	--	---------------	---------	-----	--------------	----------

AB		EQ 300MG BASE	A091673	004	Apr 22, 2014	Apr NEWA
----	--	---------------	---------	-----	--------------	----------

REYATAZ

>D> AB	BRISTOL MYERS SQUIBB	EQ 100MG BASE	N021567	001	Jun 20, 2003	Aug DISC
--------	----------------------	---------------	---------	-----	--------------	----------

>A>	@	EQ 100MG BASE	N021567	001	Jun 20, 2003	Aug DISC
-----	---	---------------	---------	-----	--------------	----------

AB		EQ 100MG BASE	N021567	001	Jun 20, 2003	Apr CFTG
----	--	---------------	---------	-----	--------------	----------

AB		EQ 150MG BASE	N021567	002	Jun 20, 2003	Apr CFTG
----	--	---------------	---------	-----	--------------	----------

AB		EQ 200MG BASE	N021567	003	Jun 20, 2003	Apr CFTG
----	--	---------------	---------	-----	--------------	----------

AB	+	EQ 300MG BASE	N021567	004	Oct 16, 2006	Apr CFTG
----	---	---------------	---------	-----	--------------	----------

POWDER;ORAL

REYATAZ

+	BRISTOL MYERS SQUIBB	EQ 50MG BASE/PACKET	N206352	001	Jun 02, 2014	Jun NEWA
---	----------------------	---------------------	---------	-----	--------------	----------

ATENOLOL

TABLET;ORAL

ATENOLOL

AB	MYLAN	50MG	A073457	003	Jan 24, 1992	Apr CMS1
----	-------	------	---------	-----	--------------	----------

AB	SUN PHARM INDS INC	25MG	A078210	001	Jul 10, 2007	Jul CAHN
----	--------------------	------	---------	-----	--------------	----------

AB		50MG	A078210	002	Jul 10, 2007	Jul CAHN
----	--	------	---------	-----	--------------	----------

AB		100MG	A078210	003	Jul 10, 2007	Jul CAHN
----	--	-------	---------	-----	--------------	----------

ATOVAQUONE

SUSPENSION;ORAL

ATOVAQUONE

AB	AMNEAL PHARMS	750MG/5ML	A202960	001	Mar 18, 2014	Mar NEWA
----	---------------	-----------	---------	-----	--------------	----------

MEPRON

AB	+	GLAXOSMITHKLINE LLC	750MG/5ML	N020500	001	Feb 08, 1995	Mar CFTG
----	---	---------------------	-----------	---------	-----	--------------	----------

ATOVAQUONE; PROGUANIL HYDROCHLORIDE

TABLET;ORAL

ATOVAQUONE AND PROGUANIL HYDROCHLORIDE

AB	MYLAN PHARMS INC	62.5MG;25MG	A202362	001	May 27, 2014	May NEWA
----	------------------	-------------	---------	-----	--------------	----------

AB		250MG;100MG	A202362	002	May 27, 2014	May NEWA
----	--	-------------	---------	-----	--------------	----------

MALARONE PEDIATRIC

AB	GLAXOSMITHKLINE	62.5MG;25MG	N021078	002	Jul 14, 2000	May CTEC
----	-----------------	-------------	---------	-----	--------------	----------

ATRACURIUM BESYLATE

INJECTABLE;INJECTION
ATRACURIUM BESYLATE

>D>	AP	+	BEDFORD	10MG/ML	A074901	001	Jul 18, 1997	Aug CAHN
>A>	AP	+	EUROHLTH INTL	10MG/ML	A074901	001	Jul 18, 1997	Aug CAHN
ATRACURIUM BESYLATE PRESERVATIVE FREE								
>D>	AP	+	BEDFORD	10MG/ML	A074900	001	Jul 18, 1997	Aug CAHN
>A>	AP	+	EUROHLTH INTL	10MG/ML	A074900	001	Jul 18, 1997	Aug CAHN

ATROPINE SULFATE

INJECTABLE;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS
ATROPINE SULFATE ANSYR PLASTIC SYRINGE

+ HOSPIRA 0.05MG/ML

N021146 002 Jul 09, 2001 May CRLD

SOLUTION/DROPS;OPHTHALMIC

ATROPINE SULFATE

AKORN 1%

N206289 001 Jul 18, 2014 Jul NEWA

AZATHIOPRINE SODIUM

INJECTABLE;INJECTION
AZATHIOPRINE SODIUM

>D>		+	BEDFORD	EQ 100MG BASE/VIAL	A074419	001	Mar 31, 1995	Aug CAHN
>A>		+	EUROHLTH INTL	EQ 100MG BASE/VIAL	A074419	001	Mar 31, 1995	Aug CAHN

AZELASTINE HYDROCHLORIDE

SPRAY;NASAL

AZELASTINE HYDROCHLORIDE

AB PERRIGO ISRAEL EQ 0.1876MG BASE/SPRAY

A202743 001 May 08, 2014 Apr NEWA

SPRAY, METERED;NASAL

AZELASTINE HYDROCHLORIDE

AB PERRIGO ISRAEL EQ 0.1876MG BASE/SPRAY

A202743 001 May 08, 2014 Jun CDFR

AZILSARTAN KAMEDOXOMIL

TABLET;ORAL

EDARBI

ARBOR PHARMS IRELAND EQ 40MG MEDOXOMIL

N200796 001 Feb 25, 2011 Feb CAHN

+ EQ 80MG MEDOXOMIL

N200796 002 Feb 25, 2011 Feb CAHN

AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE

TABLET;ORAL

EDARBYCLOR

ARBOR PHARMS IRELAND EQ 40MG MEDOXOMIL;12.5MG

N202331 001 Dec 20, 2011 Feb CAHN

+ EQ 40MG MEDOXOMIL;25MG

N202331 002 Dec 20, 2011 Feb CAHN

AZTREONAM

INJECTABLE;INJECTION
AZTREONAM

>D>	AP		BEDFORD	1GM/VIAL	A065286	001	Mar 23, 2011	Aug CAHN
>D>	AP			2GM/VIAL	A065286	002	Mar 23, 2011	Aug CAHN
>A>	AP		EUROHLTH INTL	1GM/VIAL	A065286	001	Mar 23, 2011	Aug CAHN
>A>	AP			2GM/VIAL	A065286	002	Mar 23, 2011	Aug CAHN

BACITRACIN

INJECTABLE;INJECTION
BACITRACIN

>A>	AP		XELLIA PHARMS APS	50,000 UNITS/VIAL	A203177	001	Aug 25, 2014	Aug NEWA
-----	----	--	-------------------	-------------------	---------	-----	--------------	----------

OINTMENT;OPHTHALMIC

BACITRACIN

+ PERRIGO CO TENNESSEE 500 UNITS/GM

A061212 001 Feb CTEC

BACLOFEN

TABLET;ORAL

BACLOFEN

AB SUN PHARM INDS INC 20MG

A077862 002 Aug 14, 2006 Jul CAHN

BELINOSTAT

POWDER;IV (INFUSION)
BELEODAQ

+ SPECTRUM PHARMS 500MG/VIAL

N206256 001 Jul 03, 2014 Jul NEWA

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

>A>	AB	APOTEX INC	5MG; 6.25MG	A078794	001	Aug 21, 2014	Aug NEWA
>A>	AB		10MG; 12.5MG	A078794	002	Aug 21, 2014	Aug NEWA
>A>	AB		20MG; 12.5MG	A078794	003	Aug 21, 2014	Aug NEWA
>A>	AB		20MG; 25MG	A078794	004	Aug 21, 2014	Aug NEWA

BENDROFLUMETHIAZIDE; NADOLOL

TABLET; ORAL

NADOLOL AND BENDROFLUMETHIAZIDE

AB	MYLAN	5MG; 40MG	A078688	001	Feb 15, 2008	Jan CTNA
AB		5MG; 80MG	A078688	002	Feb 15, 2008	Jan CTNA

BENZONATATE

CAPSULE; ORAL

BENZONATATE

AA	SUN PHARM INDS INC	100MG	A040587	001	Mar 19, 2008	Jun CAHN
AA		200MG	A040587	002	Mar 19, 2008	Jun CAHN

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL; TOPICAL

BENZACLIN

AB	+	VALEANT BERMUDA	5%; EQ 1% BASE	N050756	001	Dec 21, 2000	Mar CRLD
	@		5%; EQ 1% BASE	N050756	002	Apr 20, 2007	Jul DISC
	+		5%; EQ 1% BASE	N050756	002	Apr 20, 2007	Mar CTEC

BEPOTASTINE BESILATE

SOLUTION/DROPS; OPHTHALMIC

BEPREVE

+	BAUSCH AND LOMB INC	1.5%	N022288	001	Sep 08, 2009	Apr CAHN
---	---------------------	------	---------	-----	--------------	----------

BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

LOTION; TOPICAL

LOTRISONE

AB	+	MERCK SHARP DOHME	EQ 0.05% BASE; 1%	N020010	001	Dec 08, 2000	Jan CAHN
----	---	-------------------	-------------------	---------	-----	--------------	----------

BETHANECHOL CHLORIDE

TABLET; ORAL

BETHANECHOL CHLORIDE

	@	ACTAVIS ELIZABETH	5MG	A040552	001	Oct 28, 2004	Jul CAHN
	@		10MG	A040553	001	Oct 28, 2004	Jul CAHN
	@		25MG	A040554	001	Oct 28, 2004	Jul CAHN
	@		50MG	A040551	001	Oct 28, 2004	Jul CAHN
AA		SUN PHARM INDS INC	5MG	A040897	001	Apr 22, 2009	Jun CAHN
AA			10MG	A040897	002	Apr 22, 2009	Jun CAHN
AA			25MG	A040897	003	Apr 22, 2009	Jun CAHN
AA			50MG	A040897	004	Apr 22, 2009	Jun CAHN
		DUVOID					
	@	WELLSPRING PHARM	10MG	A086262	001		Mar DISC
	@		25MG	A086263	001		Mar DISC
	@		50MG	A085882	003		Mar DISC

BEXAROTENE

CAPSULE; ORAL

BEXAROTENE

>D>	AB	BANNER PHARMACAPS	75MG	A203174	001	Aug 12, 2014	Aug DISC
>A>	@		75MG	A203174	001	Aug 12, 2014	Aug DISC
	AB		75MG	A203174	001	Aug 12, 2014	Jul NEWA
		TARGRETIN					
>D>	AB	+	VALEANT LUXEMBOURG	75MG	N021055	001	Dec 29, 1999
>A>		+		75MG	N021055	001	Dec 29, 1999
	AB	+		75MG	N021055	001	Dec 29, 1999

BICALUTAMIDE

TABLET; ORAL

BICALUTAMIDE

>A>	AB	ACTAVIS ELIZABETH	50MG	A078634	001	Aug 28, 2009	Aug CAHN
>D>	AB	ACTAVIS TOTOWA	50MG	A078634	001	Aug 28, 2009	Aug CAHN
	@	ROXANE	50MG	A078285	001	Mar 24, 2011	Jun DISC

BIMATOPROSTSOLUTION/DROPS;OPHTHALMIC
LUMIGAN

@ ALLERGAN 0.03% N021275 001 Mar 16, 2001 May DISC

BISACODYL; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDEFOR SOLUTION, TABLET, DELAYED RELEASE;ORAL
HALFLYTELY

>D> + BRAINTREE 5MG,N/A;N/A,210GM;N/A,0.74GM;N/A,2 .86GM;N/A,5.6GM N021551 003 Jul 16, 2010 Aug CFTG

>A> AA + 5MG,N/A;N/A,210GM;N/A,0.74GM;N/A,2 .86GM;N/A,5.6GM N021551 003 Jul 16, 2010 Aug CFTG

>A> PEG-3350, SODIUM CHLORIDE, SODIUM BICARBONATE, POTASSIUM CHLORIDE, AND BISACODYL

>A> AA NOVEL LABS INC 5MG,N/A;N/A,210GM;N/A,0.74GM;N/A,2 A202217 001 Aug 20, 2014 Aug NEWA

BISMUTH SUBCITRATE POTASSIUM; METRONIDAZOLE; TETRACYCLINE

CAPSULE;ORAL

PYLERA

+ FOREST LABS INC 140MG;125MG;125MG N050786 001 Sep 28, 2006 Apr CAHN

+ FOREST RES INST INC 140MG;125MG;125MG N050786 001 Sep 28, 2006 Mar CAHN

BISMUTH SUBSALICYLATE; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDE

>D> TABLET, CHEWABLE, TABLET, CAPSULE;ORAL

>D> HELIDAC

>D> + PROMETHEUS LABS 262.4MG,N/A,N/A;N/A,250MG,N/A;N/A, N/A,500MG N050719 001 Aug 15, 1996 Aug DISC

>A> @ 262.4MG,N/A,N/A;N/A,250MG,N/A;N/A, N/A,500MG N050719 001 Aug 15, 1996 Aug DISC

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE

@ WATSON LABS 2.5MG;6.25MG A075469 001 Sep 25, 2000 May DISC

@ 5MG;6.25MG A075469 002 Sep 25, 2000 May DISC

@ 10MG;6.25MG A075469 003 Sep 25, 2000 May DISC

BLEOMYCIN SULFATE

INJECTABLE;INJECTION

BLEOMYCIN SULFATE

>D> AP BEDFORD EQ 15 UNITS BASE/VIAL A065042 002 Oct 17, 2001 Aug CAHN

>D> AP EQ 30 UNITS BASE/VIAL A065042 001 Oct 17, 2001 Aug CAHN

>A> AP EUROHLTH INTL EQ 15 UNITS BASE/VIAL A065042 002 Oct 17, 2001 Aug CAHN

>A> AP EQ 30 UNITS BASE/VIAL A065042 001 Oct 17, 2001 Aug CAHN

BROMFENAC SODIUM

SOLUTION/DROPS;OPHTHALMIC

BROMDAY

AT + BAUSCH AND LOMB INC EQ 0.09% ACID N021664 002 Oct 16, 2010 Apr CAHN

AT + ISTA PHARMS INC EQ 0.09% ACID N021664 002 Oct 16, 2010 Jan CFTG

BROMFENAC SODIUM

AT1 APOTEX INC EQ 0.09% ACID A202435 001 Jun 19, 2014 Jun NEWA

AT EQ 0.09% ACID A202620 001 Jun 23, 2014 Jun NEWA

AT1 COASTAL PHARMS EQ 0.09% ACID A201211 001 May 11, 2011 Jan CTEC

AT HI-TECH PHARMACAL EQ 0.09% ACID A203395 001 Jan 22, 2014 Jan NEWA

AT1 LUITPOLD EQ 0.09% ACID A202030 001 Jan 09, 2013 Jan CTEC

XIBROM

@ BAUSCH AND LOMB INC EQ 0.09% ACID N021664 001 Mar 24, 2005 Apr CAHN

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SYRUP;ORAL

BROMFED-DM

AA + WOCKHARDT 2MG/5ML;10MG/5ML;30MG/5ML A088811 001 Jun 07, 1985 Jun CTEC

BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE

AA PADDOCK LLC 2MG/5ML;10MG/5ML;30MG/5ML A205292 001 Jul 15, 2014 Jun NEWA

AA VINTAGE PHARMS 2MG/5ML;10MG/5ML;30MG/5ML A202940 001 Jul 21, 2014 Jul NEWA

BUDESONIDE

	CAPSULE;ORAL					
	BUDESONIDE					
AB	BARR LABS DIV TEVA	3MG	A090379	001	Apr 02, 2014	Mar NEWA
	SPRAY, METERED;NASAL					
	BUDESONIDE					
AB	APOTEX INC	0.032MG/INH	A078949	001	May 12, 2014	Apr NEWA
	RHINOCORT					
AB	+ ASTRAZENECA	0.032MG/INH	N020746	001	Oct 01, 1999	Apr CFTG
	TABLET, EXTENDED RELEASE;ORAL					
	UCERIS					
	+ SALIX PHARMS INC	9MG	N203634	001	Jan 14, 2013	Feb CAHN
	+ SANTARUS INC	9MG	N203634	001	Jan 14, 2013	Mar CAHN

BUPIVACAINE HYDROCHLORIDE

INJECTABLE;INJECTION						
BUPIVACAINE HYDROCHLORIDE						
@ HOSPIRA	0.75%	A070587	001	Mar 03, 1987	Jul	DISC

BUPRENORPHINE

FILM, EXTENDED RELEASE;TRANSDERMAL						
BUTRANS						
PURDUE PHARMA LP	7.5MCG/HR	N021306	005	Jun 30, 2014	Jun NEWA	

BUPRENORPHINE HYDROCHLORIDE

INJECTABLE;INJECTION									
BUPRENORPHINE HYDROCHLORIDE									
>D>	AP	BEDFORD	EQ 0.3MG BASE/ML	A076931	001	Mar 02, 2005	Aug	CAHN	
>A>	AP	EUROHLTH INTL	EQ 0.3MG BASE/ML	A076931	001	Mar 02, 2005	Aug	CAHN	

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

FILM;BUCCAL							
BUNAVAIL							
	BIODELIVERY SCI INTL	EQ 2.1MG BASE;EQ 0.3MG BASE	N205637	001	Jun 06, 2014	Jun NEWA	
		EQ 4.2MG BASE;EQ 0.7MG BASE	N205637	002	Jun 06, 2014	Jun NEWA	
	+	EQ 6.3MG BASE;EQ 1MG BASE	N205637	003	Jun 06, 2014	Jun NEWA	
TABLET;SUBLINGUAL							
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE							
AB	ROXANE	EQ 2MG BASE;EQ 0.5MG BASE	A203326	001	Jun 27, 2014	Jun NEWA	
>A>	AB	TEVA PHARMS USA	EQ 2MG BASE;EQ 0.5MG BASE	A091149	001	Sep 08, 2014	Aug NEWA
>A>	AB		EQ 8MG BASE;EQ 2MG BASE	A091149	002	Sep 08, 2014	Aug NEWA
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDRODHCLORIDE							
AB	ROXANE	EQ 8MG BASE;EQ 2MG BASE	A203326	002	Jun 27, 2014	Jun NEWA	

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL									
BUPROPION HYDROCHLORIDE									
	AB1	JUBILANT GENERICS	100MG	A202774	001	Oct 11, 2013	Jul	CAHN	
	AB1		150MG	A202774	002	Oct 11, 2013	Jul	CAHN	
>A>	AB2		150MG	A202775	001	Oct 11, 2013	Aug	CAHN	
	AB1		200MG	A202774	003	Oct 11, 2013	Jul	CAHN	
>D>	AB2	JUBILANT LIFE	150MG	A202775	001	Oct 11, 2013	Aug	CAHN	
	AB3	ZYDUS PHARMS USA INC	300MG	A201567	001	Jan 17, 2014	Jan	NEWA	

BUSPIRONE HYDROCHLORIDE

TABLET;ORAL									
BUSPIRONE HYDROCHLORIDE									
>A>	AB	STRIDES ARCOLAB LTD	5MG	A202330	001	Aug 25, 2014	Aug	NEWA	
>A>	AB		10MG	A202330	002	Aug 25, 2014	Aug	NEWA	
>A>	AB		15MG	A202330	003	Aug 25, 2014	Aug	NEWA	
>A>	AB		30MG	A202330	004	Aug 25, 2014	Aug	NEWA	
	AB	ZYDUS PHARMS USA INC	5MG	A078888	001	Feb 07, 2014	Jan	NEWA	
	AB		10MG	A078888	002	Feb 07, 2014	Jan	NEWA	
	AB		15MG	A078888	003	Feb 07, 2014	Jan	NEWA	
	AB		30MG	A078888	004	Feb 07, 2014	Jan	NEWA	

BUTENAFINE HYDROCHLORIDE

CREAM; TOPICAL
MENTAX-TC
@ MYLAN

1%

N021408 001 Oct 17, 2002 Jun DISC

BUTOCONAZOLE NITRATE

CREAM; VAGINAL
GYNAZOLE-1
@ LUMARA HEALTH INC

2%

N019881 001 Feb 07, 1997 May CAHN

BUTORPHANOL TARTRATE

INJECTABLE; INJECTION
BUTORPHANOL TARTRATE
@ HIKMA FARMACEUTICA

2MG/ML

A078247 001 Apr 29, 2009 May DISC

CAFFEINE CITRATE

SOLUTION; INTRAVENOUS
CAFCIT

>D> AP + BEDFORD LABS EQ 30MG BASE/3ML (EQ 10MG BASE/ML) N020793 001 Sep 21, 1999 Aug CAHN
>A> AP + EUROHLTH INTL EQ 30MG BASE/3ML (EQ 10MG BASE/ML) N020793 001 Sep 21, 1999 Aug CAHN

CAFFEINE CITRATE

AP EXELA PHARMA SCIENCE EQ 30MG BASE/3ML (EQ 10MG BASE/ML) A077233 001 Sep 21, 2006 Feb CAHN

SOLUTION; ORAL
CAFCIT

>D> AA + BEDFORD LABS EQ 30MG BASE/3ML (EQ 10MG BASE/ML) N020793 002 Apr 12, 2000 Aug CAHN
>A> AA + EUROHLTH INTL EQ 30MG BASE/3ML (EQ 10MG BASE/ML) N020793 002 Apr 12, 2000 Aug CAHN

CAFFEINE CITRATE

AA EXELA PHARMA SCS LLC EQ 30MG BASE/3ML (EQ 10MG BASE/ML) A077304 001 Sep 21, 2006 Feb CAHN

CALCIPOTRIENE

SOLUTION; TOPICAL
CALCIPOTRIENE

AT + @ HI TECH PHARMA 0.005% A077579 001 Nov 19, 2009 May DISC
+ TOLMAR 0.005% A077029 001 Nov 20, 2009 Apr CRLD
DOVONEX
@ LEO PHARM 0.005% N020611 001 Mar 03, 1997 Apr DISC

CALCITRIOL

INJECTABLE; INJECTION
CALCITRIOL

@ TEVA PARENTERAL 0.002MG/ML

A075823 002 Mar 31, 2003 Feb DISC

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION
DEXTROSE 5% IN RINGER'S IN PLASTIC CONTAINER

@ BAXTER HLTHCARE 33MG/100ML; 5GM/100ML; 30MG/100ML; 86 0MG/100ML N016695 001 Jul DISC

>A> CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE

>A> TABLET; ORAL
>A> INVOKAMET

>A> JANSSEN PHARMS 50MG; 500MG N204353 001 Aug 08, 2014 Aug NEWA
>A> 50MG; 1GM N204353 002 Aug 08, 2014 Aug NEWA
>A> 150MG; 500MG N204353 003 Aug 08, 2014 Aug NEWA
>A> + 150MG; 1GM N204353 004 Aug 08, 2014 Aug NEWA

CAPECITABINE

TABLET; ORAL
CAPECITABINE

AB MYLAN PHARMS INC 150MG A090943 001 Aug 08, 2014 Jul NEWA
AB 500MG A090943 002 Aug 08, 2014 Jul NEWA

CAPTOPRIL

TABLET; ORAL
CAPTOPRIL

@ DAVA PHARMS INC 12.5MG A074423 001 Feb 13, 1996 May CAHN
@ 25MG A074423 002 Feb 13, 1996 May CAHN
@ 50MG A074423 003 Feb 13, 1996 May CAHN
@ 100MG A074423 004 Feb 13, 1996 May CAHN
@ WATSON LABS 12.5MG A074451 001 Feb 13, 1996 Mar DISC
@ 25MG A074451 002 Feb 13, 1996 Mar DISC

TABLET; ORAL
CAPTOPRIL

@	50MG	A074451	003	Feb 13, 1996	Mar	DISC
@	100MG	A074451	004	Feb 13, 1996	Mar	DISC

CAPTROPIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

CAPOZIDE 25/15						
@	APOTHECON	25MG;15MG	N018709	001	Oct 12, 1984	Mar DISC
CAPOZIDE 25/25						
@	APOTHECON	25MG;25MG	N018709	002	Oct 12, 1984	Mar DISC
CAPOZIDE 50/15						
@	APOTHECON	50MG;15MG	N018709	004	Oct 12, 1984	Mar DISC
CAPOZIDE 50/25						
@	APOTHECON	50MG;25MG	N018709	003	Oct 12, 1984	Mar DISC
CAPTOPRIL AND HYDROCHLOROTHIAZIDE						
AB	+	MYLAN				
		25MG;25MG	A074896	002	Dec 29, 1997	Mar CRLD
AB	+					
		50MG;15MG	A074896	004	Dec 29, 1997	Mar CRLD

CARBIDOPA

TABLET; ORAL

CARBIDOPA						
AB		AMERIGEN PHARMS LTD	25MG	A203261	001	Mar 10, 2014 Feb NEWA
LODOSYN						
AB	+	ATON	25MG	N017830	001	Feb CFTG

CARBIDOPA; LEVODOPA

TABLET, ORALLY DISINTEGRATING; ORAL

CARBIDOPA AND LEVODOPA

>D>	AB	IMPAX LABS	10MG;100MG	A090631	001	Jun 08, 2010	Aug DISC
>A>		@	10MG;100MG	A090631	001	Jun 08, 2010	Aug DISC
>D>	AB		25MG;100MG	A090631	002	Jun 08, 2010	Aug DISC
>A>		@	25MG;100MG	A090631	002	Jun 08, 2010	Aug DISC
>D>	AB		25MG;250MG	A090631	003	Jun 08, 2010	Aug DISC
>A>		@	25MG;250MG	A090631	003	Jun 08, 2010	Aug DISC
>D>	AB	MYLAN	25MG;250MG	A078893	003	Sep 18, 2008	Aug CRLD
>A>	AB	+	25MG;250MG	A078893	003	Sep 18, 2008	Aug CRLD
>D>		PARCOPA					
>D>	AB	UCB INC	10MG;100MG	A076699	001	Aug 27, 2004	Aug DISC
>A>		@	10MG;100MG	A076699	001	Aug 27, 2004	Aug DISC
>D>	AB		25MG;100MG	A076699	002	Aug 27, 2004	Aug DISC
>A>		@	25MG;100MG	A076699	002	Aug 27, 2004	Aug DISC
>D>	AB	+	25MG;250MG	A076699	003	Aug 27, 2004	Aug DISC
>A>		@	25MG;250MG	A076699	003	Aug 27, 2004	Aug DISC

CARBINOXAMINE MALEATE

SOLUTION; ORAL

CARBINOXAMINE MALEATE

AA		VINTAGE PHARMS	4MG/5ML	A040814	001	Feb 26, 2008	Feb CAHN
----	--	----------------	---------	---------	-----	--------------	----------

TABLET; ORAL

CARBINOXAMINE MALEATE

AA		VINTAGE PHARMS	4MG	A040639	002	May 30, 2008	Feb CAHN
----	--	----------------	-----	---------	-----	--------------	----------

CARBOPLATIN

INJECTABLE; INJECTION

CARBOPLATIN

>D>		@	BEDFORD	50MG/VIAL	A076099	001	Oct 14, 2004	Aug CAHN
		@		50MG/VIAL	A076099	001	Oct 14, 2004	May DISC
>D>		@		150MG/VIAL	A076099	002	Oct 14, 2004	Aug CAHN
		@		150MG/VIAL	A076099	002	Oct 14, 2004	May DISC
>D>		@		450MG/VIAL	A076099	003	Oct 14, 2004	Aug CAHN
		@		450MG/VIAL	A076099	003	Oct 14, 2004	May DISC
		@	CIPLA LTD	50MG/VIAL	A077383	001	Jan 27, 2006	May DISC
		@		150MG/VIAL	A077383	002	Jan 27, 2006	May DISC
		@		450MG/VIAL	A077383	003	Jan 27, 2006	May DISC
>A>		@	EUROHLTH INTL	50MG/VIAL	A076099	001	Oct 14, 2004	Aug CAHN
>A>		@		150MG/VIAL	A076099	002	Oct 14, 2004	Aug CAHN
>A>		@		450MG/VIAL	A076099	003	Oct 14, 2004	Aug CAHN
		@	FRESENIUS KABI USA	50MG/VIAL	A076235	001	Oct 14, 2004	May DISC
		@		150MG/VIAL	A076235	002	Oct 14, 2004	May DISC
		@		450MG/VIAL	A076235	003	Oct 14, 2004	May DISC
		@	ONCO THERAPIES LTD	50MG/VIAL	A091510	001	May 29, 2012	May DISC

INJECTABLE; INJECTION
CARBOPLATIN

@	150MG/VIAL	A091510	002	May 29, 2012	May DISC
@	450MG/VIAL	A091510	003	May 29, 2012	May DISC
@ SANDOZ	50MG/VIAL	A076959	001	Mar 18, 2005	May DISC
@	150MG/VIAL	A076959	002	Mar 18, 2005	May DISC
@	450MG/VIAL	A076959	003	Mar 18, 2005	May DISC
@ WATSON LABS	50MG/VIAL	A076162	001	Oct 14, 2004	May DISC
@	150MG/VIAL	A076162	002	Oct 14, 2004	May DISC
@	450MG/VIAL	A076162	003	Oct 14, 2004	May DISC

INJECTABLE; IV (INFUSION)
CARBOPLATIN

>A> AP	ACTAVIS ELIZABETH	50MG/5ML (10MG/ML)	A078732	001	Feb 06, 2012	Aug CAHN
>A> AP		150MG/15ML (10MG/ML)	A078732	002	Feb 06, 2012	Aug CAHN
>A> AP		450MG/45ML (10MG/ML)	A078732	003	Feb 06, 2012	Aug CAHN
>A> AP		600MG/60ML (10MG/ML)	A078732	004	Feb 06, 2012	Aug CAHN
>D> AP	ACTAVIS TOTOWA	50MG/5ML (10MG/ML)	A078732	001	Feb 06, 2012	Aug CAHN
>D> AP		150MG/15ML (10MG/ML)	A078732	002	Feb 06, 2012	Aug CAHN
>D> AP		450MG/45ML (10MG/ML)	A078732	003	Feb 06, 2012	Aug CAHN
>D> AP		600MG/60ML (10MG/ML)	A078732	004	Feb 06, 2012	Aug CAHN
>D> AP	BEDFORD LABS	50MG/5ML (10MG/ML)	A077244	001	Oct 15, 2004	Aug CAHN
>D> AP		150MG/15ML (10MG/ML)	A077244	002	Oct 15, 2004	Aug CAHN
>D> AP		450MG/45ML (10MG/ML)	A077244	003	Oct 15, 2004	Aug CAHN
>D> AP		600MG/60ML (10MG/ML)	A077244	004	Jan 20, 2006	Aug CAHN
>A> AP	EUROHLTH INTL	50MG/5ML (10MG/ML)	A077244	001	Oct 15, 2004	Aug CAHN
>A> AP		150MG/15ML (10MG/ML)	A077244	002	Oct 15, 2004	Aug CAHN
>A> AP		450MG/45ML (10MG/ML)	A077244	003	Oct 15, 2004	Aug CAHN
>A> AP		600MG/60ML (10MG/ML)	A077244	004	Jan 20, 2006	Aug CAHN
AP +	PHARMACHEMIE BV	50MG/5ML (10MG/ML)	A077269	001	Oct 14, 2004	Feb CAHN
AP +		150MG/15ML (10MG/ML)	A077269	002	Oct 14, 2004	Feb CAHN
AP +		450MG/45ML (10MG/ML)	A077269	003	Oct 14, 2004	Feb CAHN
AP +		600MG/60ML (10MG/ML)	A077269	004	Dec 28, 2007	Feb CAHN

CARISOPRODOLTABLET; ORAL
CARISOPRODOL

AA	SCIEGEN PHARMS INC	350MG	A203374	001	Jan 27, 2014	Jan NEWA
----	--------------------	-------	---------	-----	--------------	----------

CARVEDILOLTABLET; ORAL
CARVEDILOL

AB	SUN PHARM INDS INC	3.125MG	A077346	004	Sep 05, 2007	Jul CAHN
AB		6.25MG	A077346	001	Sep 05, 2007	Jul CAHN
AB		12.5MG	A077346	002	Sep 05, 2007	Jul CAHN
AB		25MG	A077346	003	Sep 05, 2007	Jul CAHN

CEFACLOLFOR SUSPENSION; ORAL
CEFACLOL

AB	+ YUNG SHIN PHARM	EQ 375MG BASE/5ML	A065412	004	Feb 17, 2012	Jan CRLD
----	-------------------	-------------------	---------	-----	--------------	----------

CEFADROXIL/CEFADROXIL HEMIHYDRATEFOR SUSPENSION; ORAL
CEFADROXIL

@ ANI PHARMS INC	EQ 125MG BASE/5ML	A062698	001	Mar 01, 1989	Jan CAHN
@	EQ 250MG BASE/5ML	A062698	002	Mar 01, 1989	Jan CAHN
@	EQ 250MG BASE/5ML	A065278	001	Jan 20, 2006	Jan CAHN
@	EQ 500MG BASE/5ML	A062698	003	Mar 01, 1989	Jan CAHN
@	EQ 500MG BASE/5ML	A065278	002	Jan 20, 2006	Jan CAHN

CEFAZOLIN SODIUMINJECTABLE; INJECTION
CEFAZOLIN SODIUM

>A> AP	ACS DOBFAR	EQ 20GM BASE/VIAL	A065306	002	Aug 18, 2014	Aug NEWA
	@ STERI PHARMA	EQ 1GM BASE/VIAL	A063208	001	Dec 27, 1991	Mar DISC

CEFTAZIDIMEINJECTABLE; INJECTION
FORTAZ

AP +	COVIS INJECTABLES	1GM/VIAL	N050578	002	Jul 19, 1985	May CAHN
AP +		2GM/VIAL	N050578	003	Jul 19, 1985	May CAHN
AP +		6GM/VIAL	N050578	004	Jul 19, 1985	May CAHN

		INJECTABLE; INJECTION					
		FORTAZ					
AP	+	500MG/VIAL		N050578	001	Jul 19, 1985	May CAHN
<u>CEFTAZIDIME SODIUM</u>							
		INJECTABLE; INJECTION					
		FORTAZ IN PLASTIC CONTAINER					
	@	COVIS INJECTABLES	EQ 10MG BASE/ML	N050634	001	Apr 28, 1989	Apr CAHN
	+		EQ 20MG BASE/ML	N050634	002	Apr 28, 1989	Apr CAHN
	+		EQ 40MG BASE/ML	N050634	003	Apr 28, 1989	Apr CAHN
<u>CEFTRIAXONE SODIUM</u>							
		INJECTABLE; INJECTION					
		CEFTRIAXONE					
>D>	AP	AGILA SPECLTS	EQ 10GM BASE/VIAL	A091068	001	Jan 07, 2013	Aug DISC
>A>		@	EQ 10GM BASE/VIAL	A091068	001	Jan 07, 2013	Aug DISC
	AP		EQ 10GM BASE/VIAL	A091068	001	Jan 07, 2013	Feb CAHN
		SAMSON MEDCL	EQ 100GM BASE/VIAL	A090057	001	Apr 25, 2014	Apr NEWA
<u>CEFUROXIME SODIUM</u>							
		INJECTABLE; INJECTION					
		ZINACEF					
AP	+	COVIS INJECTABLES	EQ 1.5GM BASE/VIAL	N050558	003	Oct 19, 1983	Apr CAHN
AP	+		EQ 7.5GM BASE/VIAL	N050558	004	Oct 23, 1986	Apr CAHN
		ZINACEF IN PLASTIC CONTAINER					
	@	COVIS INJECTABLES	EQ 15MG BASE/ML	N050643	001	Apr 28, 1989	May CAHN
	+		EQ 30MG BASE/ML	N050643	002	Apr 28, 1989	May CAHN
<u>CELECOXIB</u>							
		CAPSULE; ORAL					
		CELEBREX					
AB		GD SEARLE	50MG	N020998	004	Dec 15, 2006	May CFTG
AB			100MG	N020998	001	Dec 31, 1998	May CFTG
AB			200MG	N020998	002	Dec 31, 1998	May CFTG
AB	+		400MG	N020998	003	Aug 29, 2002	May CFTG
		CELECOXIB					
AB		MYLAN PHARMS INC	50MG	A078857	001	May 30, 2014	May NEWA
AB		TEVA	50MG	A076898	001	May 30, 2014	May NEWA
AB			100MG	A076898	002	May 30, 2014	May NEWA
AB			200MG	A076898	003	May 30, 2014	May NEWA
AB			400MG	A076898	004	May 30, 2014	May NEWA
<u>CEPHALEXIN</u>							
		CAPSULE; ORAL					
		CEPHALEXIN					
	@	FACTA FARMA	EQ 250MG BASE	A062118	001		Jun DISC
	@		EQ 500MG BASE	A062118	002		Jun DISC
	@	STEVENS J	EQ 250MG BASE	A062870	001	Mar 17, 1988	Mar DISC
		FOR SUSPENSION; ORAL					
		CEPHALEXIN					
	@	FACTA FARMA	EQ 125MG BASE/5ML	A062117	002		Jun DISC
	@		EQ 250MG BASE/5ML	A062117	003		Jun DISC
<u>CERITINIB</u>							
		CAPSULE; ORAL					
		ZYKADIA					
	+	NOVARTIS PHARMS CORP	150MG	N205755	001	Apr 29, 2014	Apr NEWA
<u>CEVIMELINE HYDROCHLORIDE</u>							
		CAPSULE; ORAL					
		CEVIMELINE HYDROCHLORIDE					
AB		PACK PHARMS LLC	30MG	A203775	001	Jun 04, 2014	May NEWA
<u>CHLORDIAZEPOXIDE HYDROCHLORIDE</u>							
		CAPSULE; ORAL					
		CHLORDIAZEPOXIDE HYDROCHLORIDE					
	@	WATSON LABS	5MG	A086383	001		May DISC
	@		10MG	A086294	001		May DISC
	@		25MG	A086382	001		May DISC

CHLOROPROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

CHLOROPROCAINE HYDROCHLORIDE

>D>	AP	BEDFORD	2%	A040273	001	Sep 09, 1998	Aug CAHN
>D>	AP		3%	A040273	002	Sep 09, 1998	Aug CAHN
>A>	AP	EUROHLTH INTL	2%	A040273	001	Sep 09, 1998	Aug CAHN
>A>	AP		3%	A040273	002	Sep 09, 1998	Aug CAHN

CHLOROTHIAZIDE SODIUM

INJECTABLE; INJECTION

CHLOROTHIAZIDE SODIUM

AP	MYLAN INSTITUTIONAL	EQ 500MG BASE/VIAL	A202493	001	Jun 18, 2014	Jun NEWA
----	---------------------	--------------------	---------	-----	--------------	----------

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION; ORAL

HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE

AA	PADDOCK LLC	4MG/5ML; 5MG/5ML; 60MG/5ML	A204627	001	Apr 29, 2014	Apr NEWA
	ZUTRIPRO					
AA	+ CYPRESS PHARM	4MG/5ML; 5MG/5ML; 60MG/5ML	N022439	001	Jun 08, 2011	Apr CFTG

CHLORPHENIRAMINE POLISTIREX; HYDROCODONE POLISTIREX

CAPSULE, EXTENDED RELEASE; ORAL

TUSSICAPS

	ECR PHARMA	EQ 4MG MALEATE; EQ 5MG BITARTRATE	A077273	002	Sep 24, 2007	Jul CAHN
+		EQ 8MG MALEATE; EQ 10MG BITARTRATE	A077273	001	Sep 24, 2007	Jul CAHN

CHLORPROPAMIDE

TABLET; ORAL

CHLORPROPAMIDE

	@ ANI PHARMS INC	100MG	A088768	001	Oct 11, 1984	Jan CAHN
	@	100MG	A088812	001	Oct 19, 1984	Jan CAHN
	@	100MG	A088840	001	Oct 25, 1984	Feb CAHN
	@	100MG	A088918	001	Oct 16, 1984	Jan CAHN
AB		100MG	A088921	001	Apr 12, 1985	Jan CAHN
	@	100MG	A089446	001	Nov 17, 1986	Jan CAHN
	@	250MG	A088813	001	Oct 19, 1984	Jan CAHN
	@	250MG	A088919	001	Oct 16, 1984	Jan CAHN
AB		250MG	A088922	001	Apr 12, 1985	Jan CAHN
	@	250MG	A089447	001	Nov 17, 1986	Jan CAHN
	@ TEVA PHARMS USA	250MG	A087353	001		Apr CAHN
	GLUCAMIDE					
	@ ANI PHARMS INC	250MG	A088641	001	Oct 11, 1984	Jan CAHN
	@ TEVA PHARMS USA	250MG	A088641	001	Oct 11, 1984	Apr CAHN

CHLORZOXAZONE

TABLET; ORAL

CHLORZOXAZONE

>A>	@ ACTAVIS ELIZABETH	250MG	A088928	001	May 08, 1987	Jun CAHN
	@	500MG	A040113	001	Sep 29, 1995	Aug CAHN
>D>	@ ACTAVIS TOTOWA	500MG	A040113	001	Sep 29, 1995	Aug CAHN
	@ WATSON LABS	500MG	A040137	001	Aug 09, 1996	May DISC
	@	500MG	A081040	001	Aug 22, 1989	May DISC

CICLOPIROX

CREAM; TOPICAL

CICLOPIROX

AB	TARO	0.77%	A076790	001	Apr 12, 2005	Mar CMFD
	@	0.77%	A076790	001	Apr 12, 2005	Feb DISC

GEL; TOPICAL

LOPROX

AB	+ CNTY LINE PHARMS	0.77%	N020519	001	Jul 21, 1997	Jul CAHN
----	--------------------	-------	---------	-----	--------------	----------

SHAMPOO; TOPICAL

CICLOPIROX

>A>	AT	ACTAVIS MID ATLANTIC	1%	A090490	001	Nov 24, 2009	Aug CAHN
>D>	AT	WATSON LABS INC	1%	A090490	001	Nov 24, 2009	Aug CAHN

CILOSTAZOLTABLET; ORAL
CILOSTAZOL

>A>	@ ACTAVIS ELIZABETH	100MG	A 077028	002	Nov 26, 2004	Aug CAHN
>D>	@ ACTAVIS TOTOWA	100MG	A 077028	002	Nov 26, 2004	Aug CAHN

CIMETIDINETABLET; ORAL
CIMETIDINE

	@ DAVA PHARMS INC	300MG	A 074340	001	Jun 23, 1995	Jul DISC
	@	400MG	A 074340	002	Jun 23, 1995	Jul DISC
	@ IVAX SUB TEVA PHARMS	200MG	A 074424	001	Jul 28, 1995	Jul DISC
	@	300MG	A 074424	002	Jul 28, 1995	Jul DISC
	@	400MG	A 074424	003	Jul 28, 1995	Jul DISC
	@	800MG	A 074424	004	Jul 28, 1995	Jul DISC
AB	+ MYLAN	800MG	A 074246	004	May 17, 1994	Jul CRLD
	@ PLIVA	200MG	A 074568	001	Feb 27, 1997	Jul DISC
	@	300MG	A 074568	002	Feb 27, 1997	Jul DISC
	@	400MG	A 074568	003	Feb 27, 1997	Jul DISC
	TAGAMET					
	@ GLAXOSMITHKLINE	200MG	N 017920	002		Jul DISC
	@	300MG	N 017920	003		Jul DISC
	@	400MG	N 017920	004	Dec 14, 1983	Jul DISC
	@	800MG	N 017920	005	Apr 30, 1986	Jul DISC

CIMETIDINE HYDROCHLORIDESOLUTION; ORAL
CIMETIDINE HYDROCHLORIDE

AA	ANI PHARMS INC	EQ 300MG BASE/5ML	A 074610	001	Sep 26, 1996	Jan CAHN
	@	EQ 300MG BASE/5ML	A 074859	001	Jul 09, 1998	Feb CAHN
	@	EQ 300MG BASE/5ML	A 075110	001	Jun 18, 1998	Jan CAHN

CIPROFLOXACINFOR SUSPENSION; ORAL
CIPRO

AB	BAYER HLTHCARE	250MG/5ML	N 020780	001	Sep 26, 1997	Feb CFTG
AB	+ CIPROFLOXACIN	500MG/5ML	N 020780	002	Sep 26, 1997	Feb CFTG
AB	LUPIN LTD	250MG/5ML	A 200563	001	Mar 05, 2014	Feb NEWA
AB		500MG/5ML	A 200563	002	Mar 05, 2014	Feb NEWA

CIPROFLOXACIN HYDROCHLORIDESOLUTION/DROPS; OPHTHALMIC
CIPROFLOXACIN HYDROCHLORIDE

AT	WATSON LABS INC	EQ 0.3% BASE	A 076673	001	Jan 21, 2005	Apr CAHN
----	-----------------	--------------	----------	-----	--------------	----------

CISPLATININJECTABLE; INJECTION
CISPLATIN

>D>	AP	BEDFORD	1MG/ML	A 075036	001	Nov 07, 2000	Aug CAHN
>A>	AP	EUROHLTH INTL	1MG/ML	A 075036	001	Nov 07, 2000	Aug CAHN
	AP	PHARMACHEMIE BV	1MG/ML	A 074656	001	May 16, 2000	Feb CAHN

CITALOPRAM HYDROBROMIDETABLET; ORAL
CITALOPRAM HYDROBROMIDE

AB	SUN PHARM INDS INC	EQ 10MG BASE	A 077032	001	Nov 12, 2004	Jul CAHN
AB		EQ 20MG BASE	A 077032	002	Nov 12, 2004	Jul CAHN
AB		EQ 40MG BASE	A 077032	003	Nov 12, 2004	Jul CAHN
	@ WATSON LABS	EQ 10MG BASE	A 077034	001	Jun 30, 2005	May DISC
	@	EQ 20MG BASE	A 077034	002	Jun 30, 2005	May DISC
	@	EQ 40MG BASE	A 077034	003	Jun 30, 2005	May DISC

CLADRIBINEINJECTABLE; INJECTION
CLADRIBINE

>D>	AP	BEDFORD	1MG/ML	A 075405	001	Feb 28, 2000	Aug CAHN
>A>	AP	EUROHLTH INTL	1MG/ML	A 075405	001	Feb 28, 2000	Aug CAHN

CLINDAMYCIN PALMITATE HYDROCHLORIDE

FOR SOLUTION;ORAL

CLINDAMYCIN PALMITATE HYDROCHLORIDE

AA	AMNEAL PHARMS	EQ 75MG BASE/5ML	A203513	001	Mar 13, 2014	Feb NEWA
----	---------------	------------------	---------	-----	--------------	----------

CLINDAMYCIN PHOSPHATE

CREAM;VAGINAL

CLINDESSE

+ LUMARA HEALTH INC EQ 2% BASE

N050793	001	Nov 30, 2004	May CAHN
---------	-----	--------------	----------

SOLUTION;TOPICAL

CLINDAMYCIN PHOSPHATE

AB	ACTAVIS MID ATLANTIC	EQ 1% BASE	A062811	001	Sep 01, 1988	Apr CMFD
AT	G AND W LABS INC	EQ 1% BASE	A062811	001	Sep 01, 1988	Jun CTEC
AB		EQ 1% BASE	A062811	001	Sep 01, 1988	May CAHN
	@ VINTAGE PHARMS	EQ 1% BASE	A062930	001	Jun 28, 1989	Feb CAHN

CLOBETASOL PROPIONATE

AEROSOL, FOAM;TOPICAL

OLUX

AB1	+ DELCOR ASSET	0.05%	N021142	001	May 26, 2000	Jun CAHN
-----	----------------	-------	---------	-----	--------------	----------

CLONAZEPAM

TABLET;ORAL

CLONAZEPAM

AB	SUN PHARM INDS INC	0.5MG	A075423	001	Apr 27, 2001	Jul CAHN
AB		1MG	A075423	002	Apr 27, 2001	Jul CAHN
AB		2MG	A075423	003	Apr 27, 2001	Jul CAHN

TABLET, ORALLY DISINTEGRATING;ORAL

CLONAZEPAM

>A>	AB	SUN PHARM INDS INC	0.125MG	A078654	001	Aug 27, 2014	Aug NEWA
>A>	AB		0.25MG	A078654	002	Aug 27, 2014	Aug NEWA
>A>	AB		0.5MG	A078654	003	Aug 27, 2014	Aug NEWA
>A>	AB		1MG	A078654	004	Aug 27, 2014	Aug NEWA
>A>	AB		2MG	A078654	005	Aug 27, 2014	Aug NEWA

CLONIDINE

FILM, EXTENDED RELEASE;TRANSDERMAL

CLONIDINE

AB	WATSON LABS INC	0.1MG/24HR	A090873	001	May 06, 2014	Apr NEWA
AB		0.2MG/24HR	A090873	002	May 06, 2014	Apr NEWA
AB		0.3MG/24HR	A090873	003	May 06, 2014	Apr NEWA

CLONIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

CLONIDINE HYDROCHLORIDE

AP	ZYDUS PHARMS USA INC	1MG/10ML (0.1MG/ML)	A202601	001	Feb 20, 2014	Feb NEWA
AP		5MG/10ML (0.5MG/ML)	A202601	002	Feb 20, 2014	Feb NEWA

TABLET;ORAL

CLONIDINE HYDROCHLORIDE

AB	CARACO	0.1MG	A090329	001	Jul 03, 2014	Jun NEWA
AB		0.2MG	A090329	002	Jul 03, 2014	Jun NEWA
AB		0.3MG	A090329	003	Jul 03, 2014	Jun NEWA
AB	SUN PHARM INDS INC	0.1MG	A090329	001	Jul 03, 2014	Jul CAHN
AB		0.2MG	A090329	002	Jul 03, 2014	Jul CAHN
AB		0.3MG	A090329	003	Jul 03, 2014	Jul CAHN
	@ WATSON LABS	0.3MG	A070963	001	Jul 08, 1986	May DISC

TABLET, EXTENDED RELEASE;ORAL

CLONIDINE HYDROCHLORIDE

AB	ANCHEN PHARMS	0.1MG	A202983	001	Apr 02, 2014	Mar NEWA
AB		0.2MG	A202983	002	Apr 02, 2014	Mar NEWA

CLOPIDOGREL

TABLET;ORAL

CLOPIDOGREL

AB	AMNEAL PHARMS	75MG	A203751	001	Apr 11, 2014	Mar NEWA
----	---------------	------	---------	-----	--------------	----------

CLOPIDOGREL BISULFATE

TABLET; ORAL

CLOPIDOGREL BISULFATE

>A>	AB	ACTAVIS ELIZABETH	EQ 75MG BASE	A090307	001	May 28, 2013	Aug CAHN
>D>	AB	ACTAVIS TOTOWA	EQ 75MG BASE	A090307	001	May 28, 2013	Aug CAHN
	AB	APOTEX INC	EQ 300MG BASE	A076274	002	Mar 04, 2014	Feb NEWA
	AB	MACLEODS PHARMS LTD	EQ 75MG BASE	A202928	001	Feb 10, 2014	Jan NEWA

CLORAZEPATE DIPOTASSIUM

TABLET; ORAL

CLORAZEPATE DIPOTASSIUM

@	WATSON LABS	3.75MG	A071852	001	Feb 09, 1988	May DISC
@		7.5MG	A071853	001	Feb 09, 1988	May DISC
@		15MG	A071854	001	Feb 09, 1988	May DISC

CLOZAPINE

TABLET; ORAL

CLOZAPINE

AB	IVAX SUB TEVA PHARMS	12.5MG	A074949	003	Jul 31, 2003	Mar CTEC
AB		200MG	A076809	001	Dec 16, 2005	Mar CTEC
AB	MYLAN	12.5MG	A075417	003	Apr 15, 2010	Mar NEWA
AB		50MG	A075417	004	Apr 15, 2010	Mar NEWA
AB		200MG	A075417	005	Apr 15, 2010	Mar NEWA
AB	SUN PHARM INDS INC	25MG	A075713	001	Nov 15, 2002	Jul CAHN
AB		50MG	A075713	003	Aug 19, 2005	Jul CAHN
AB		100MG	A075713	002	Nov 15, 2002	Jul CAHN

CODEINE SULFATE

TABLET; ORAL

CODEINE SULFATE

AB	LANNETT HOLDINGS INC	15MG	A203046	001	Jun 13, 2014	Jun NEWA
AB		30MG	A203046	002	Jun 13, 2014	Jun NEWA
AB		60MG	A203046	003	Jun 13, 2014	Jun NEWA
AB	ROXANE	15MG	N022402	001	Jul 16, 2009	Jun CFTG
AB		30MG	N022402	002	Jul 16, 2009	Jun CFTG
AB	+	60MG	N022402	003	Jul 16, 2009	Jun CFTG

COLISTIMETHATE SODIUM

INJECTABLE; INJECTION

COLISTIMETHATE SODIUM

AP	SAGENT PHARMS	EQ 150MG BASE/VIAL	A201365	001	Feb 19, 2014	Feb NEWA
AP	+	COLY-MYCIN M				
AP	+	PAR STERILE PRODUCTS	EQ 150MG BASE/VIAL	N050108	002	Apr CAHN

COLISTIN SULFATE; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; THONZONIUM BROMIDE

SUSPENSION/DROPS; OTIC

COLY-MYCIN S

+	PAR STERILE PRODUCTS	EQ 3MG BASE/ML; 10MG/ML; EQ 3.3MG BASE/ML; 0.5MG/ML	N050356	001		Apr CAHN
---	----------------------	---	---------	-----	--	----------

CONIVAPTAN HYDROCHLORIDE

INJECTABLE; IV (INFUSION)

VAPRISOL

@	CUMBERLAND PHARMS	20MG/4ML (5MG/ML)	N021697	001	Dec 29, 2005	Feb CAHN
	VAPRISOL IN 5% DEXTROSE	IN PLASTIC CONTAINER				
+	CUMBERLAND PHARMS	20MG/100ML (0.2MG/ML)	N021697	002	Oct 08, 2008	Feb CAHN

CROMOLYN SODIUM

SOLUTION; INHALATION

CROMOLYN SODIUM

AN	MYLAN SPECLT	10MG/ML	A074209	001	Apr 26, 1994	May CAHN	
	@ WATSON LABS	10MG/ML	A076469	001	Jun 17, 2005	May DISC	
	SOLUTION/DROPS; OPHTHALMIC						
	CROMOLYN SODIUM						
AT	+	AKORN	4%	A074706	001	Apr 29, 1998	Jun CRLD
		OPTICROM					
	@ ALLERGAN	4%	N018155	001	Oct 03, 1984	Jun DISC	

CYCLOSPORINEINJECTABLE; INJECTION
CYCLOSPORINE

>D>	AP	BEDFORD	50MG/ML	A065004	001	Oct 29, 1999	Aug CAHN
>A>	AP	EUROHLTH INTL	50MG/ML	A065004	001	Oct 29, 1999	Aug CAHN

CYSTEAMINE BITARTRATECAPSULE, DELAYED RELEASE; ORAL
PROCYSBI

>A>		RAPTOR INC	EQ 25MG BASE	N203389	001	Apr 30, 2013	Aug CAHN
>A>	+		EQ 75MG BASE	N203389	002	Apr 30, 2013	Aug CAHN
>D>		RAPTOR PHARMS	EQ 25MG BASE	N203389	001	Apr 30, 2013	Aug CAHN
>D>	+		EQ 75MG BASE	N203389	002	Apr 30, 2013	Aug CAHN

CYTARABINEINJECTABLE; INJECTION
CYTARABINE

>D>	AP	BEDFORD	1GM/VIAL	A074245	001	Aug 31, 1994	Aug CAHN
>D>	AP		2GM/VIAL	A074245	002	Aug 31, 1994	Aug CAHN
>D>	AP		100MG/VIAL	A071471	001	Aug 02, 1989	Aug CAHN
>D>	AP		500MG/VIAL	A071472	001	Aug 02, 1989	Aug CAHN
>A>	AP	EUROHLTH INTL	1GM/VIAL	A074245	001	Aug 31, 1994	Aug CAHN
>A>	AP		2GM/VIAL	A074245	002	Aug 31, 1994	Aug CAHN
>A>	AP		100MG/VIAL	A071471	001	Aug 02, 1989	Aug CAHN
>A>	AP		500MG/VIAL	A071472	001	Aug 02, 1989	Aug CAHN

DACARBAZINEINJECTABLE; INJECTION
DACARBAZINE

>D>	AP	BEDFORD	200MG/VIAL	A075812	001	Jun 15, 2001	Aug CAHN
>D>	AP		500MG/VIAL	A075812	002	Oct 31, 2002	Aug CAHN
>A>	AP	EUROHLTH INTL	200MG/VIAL	A075812	001	Jun 15, 2001	Aug CAHN
>A>	AP		500MG/VIAL	A075812	002	Oct 31, 2002	Aug CAHN

DACTINOMYCININJECTABLE; INJECTION
DACTINOMYCIN

>D>	AP	BEDFORD	0.5MG/VIAL	A090304	001	Mar 16, 2010	Aug CAHN
>A>	AP	EUROHLTH INTL	0.5MG/VIAL	A090304	001	Mar 16, 2010	Aug CAHN

DALBAVANCIN HYDROCHLORIDEINJECTABLE; IV (INFUSION)
DALVANCE

+		DURATA THERAPS INTL	EQ 500MG BASE/VIAL	N021883	001	May 23, 2014	May NEWA
---	--	---------------------	--------------------	---------	-----	--------------	----------

DANTROLENE SODIUMCAPSULE; ORAL
DANTRIUM

AB		PAR STERILE PRODUCTS	25MG	N017443	001		Mar CAHN
AB			50MG	N017443	003		Mar CAHN
AB	+		100MG	N017443	002		Mar CAHN

FOR SUSPENSION; INTRAVENOUS
RYANODEX

		EAGLE PHARMS	250MG/VIAL	N205579	001	Jul 22, 2014	Jul NEWA
--	--	--------------	------------	---------	-----	--------------	----------

INJECTABLE; INJECTION
DANTRIUM

AP	+	PAR STERILE PRODUCTS	20MG/VIAL	N018264	001		Apr CAHN
		REVONTO					

AP		US WORLDMEDS	20MG/VIAL	A078378	001	Jul 24, 2007	Mar CTNA
----	--	--------------	-----------	---------	-----	--------------	----------

DAPAGLIFLOZINTABLET; ORAL
FARXIGA

		ASTRAZENECA AB	5MG	N202293	001	Jan 08, 2014	Feb CAHN
	+		10MG	N202293	002	Jan 08, 2014	Feb CAHN
		BRISTOL MYERS SQUIBB	5MG	N202293	001	Jan 08, 2014	Jan NEWA
	+		10MG	N202293	002	Jan 08, 2014	Jan NEWA

DAUNORUBICIN HYDROCHLORIDEINJECTABLE; INJECTION
CERUBIDINE

>D>	AP	+	BEDFORD	EQ 20MG BASE/VIAL	A064103	001	Feb 03, 1995	Aug CAHN
>A>	AP	+	EUROHLTH INTL	EQ 20MG BASE/VIAL	A064103	001	Feb 03, 1995	Aug CAHN
DAUNORUBICIN HYDROCHLORIDE								
>D>	AP	+	BEDFORD	EQ 5MG BASE/ML	N050731	001	Jan 30, 1998	Aug CAHN
>A>	AP	+	EUROHLTH INTL	EQ 5MG BASE/ML	N050731	001	Jan 30, 1998	Aug CAHN

DECITABINEINJECTABLE; INTRAVENOUS
DECITABINE

>A>	AP		SANDOZ	50MG/VIAL	A202969	001	Aug 28, 2014	Aug NEWA
POWDER; INTRAVENOUS								
DECITABINE								
		+	SUN PHARMA GLOBAL	50MG/VIAL	N205582	001	Jan 28, 2014	Jan NEWA

DEFEROXAMINE MESYLATEINJECTABLE; INJECTION
DEFEROXAMINE MESYLATE

>D>	AP		BEDFORD	2GM/VIAL	A078086	002	May 30, 2007	Aug CAHN
>D>	AP			500MG/VIAL	A078086	001	May 30, 2007	Aug CAHN
>A>	AP		EUROHLTH INTL	2GM/VIAL	A078086	002	May 30, 2007	Aug CAHN
>A>	AP			500MG/VIAL	A078086	001	May 30, 2007	Aug CAHN
		@	WATSON LABS	2GM/VIAL	A076806	002	Mar 31, 2006	May DISC
		@		500MG/VIAL	A076806	001	Mar 31, 2006	May DISC

DESIPRAMINE HYDROCHLORIDETABLET; ORAL
DESIPRAMINE HYDROCHLORIDE

>A>	AB		ACTAVIS ELIZABETH	10MG	A074430	001	Feb 09, 1996	Aug CAHN
>A>	AB			25MG	A071601	001	Jun 05, 1987	Aug CAHN
>A>	AB			50MG	A071588	001	Jun 05, 1987	Aug CAHN
>A>	AB			75MG	A071602	001	Oct 05, 1987	Aug CAHN
>A>	AB			100MG	A071766	001	Oct 05, 1987	Aug CAHN
>A>	AB			150MG	A074430	002	Feb 09, 1996	Aug CAHN
>D>	AB		ACTAVIS TOTOWA	10MG	A074430	001	Feb 09, 1996	Aug CAHN
>D>	AB			25MG	A071601	001	Jun 05, 1987	Aug CAHN
>D>	AB			50MG	A071588	001	Jun 05, 1987	Aug CAHN
>D>	AB			75MG	A071602	001	Oct 05, 1987	Aug CAHN
>D>	AB			100MG	A071766	001	Oct 05, 1987	Aug CAHN
>D>	AB			150MG	A074430	002	Feb 09, 1996	Aug CAHN
		@	ANI PHARMS INC	25MG	A071800	001	Dec 08, 1987	Jan CAHN
		@		50MG	A071801	001	Dec 08, 1987	Jan CAHN
		@		75MG	A071802	001	Dec 08, 1987	Jan CAHN
		@		100MG	A071803	001	May 29, 1997	Feb CAHN
		@		150MG	A071804	001	May 29, 1997	Feb CAHN

DESLORATADINESOLUTION; ORAL
CLARINEX

		+	MERCK SHARP DOHME	0.5MG/ML	N021300	001	Sep 01, 2004	May CDFR
--	--	---	-------------------	----------	---------	-----	--------------	----------

DESMOPRESSIN ACETATESPRAY, METERED; NASAL
DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION)

AB			SUN PHARMA GLOBAL	0.01MG/SPRAY	A078271	001	Dec 23, 2013	Jan CMS2
----	--	--	-------------------	--------------	---------	-----	--------------	----------

TABLET; ORAL

DESMOPRESSIN ACETATE

AB			MYLAN PHARMS INC	0.1MG	A200653	001	Jun 27, 2014	Jun NEWA
AB				0.2MG	A200653	002	Jun 27, 2014	Jun NEWA

DESONIDEAEROSOL, FOAM; TOPICAL
VERDESO

		+	AQUA PHARMS	0.05%	N021978	001	Sep 19, 2006	May CAHN
--	--	---	-------------	-------	---------	-----	--------------	----------

DESOXIMETASONEOINTMENT;TOPICAL
DESOXIMETASONE

AB	VERSAPHARM INC	0.25%	A201005	001	Apr 24, 2014	Apr NEWA
----	----------------	-------	---------	-----	--------------	----------

DESVENLAFAXINETABLET, EXTENDED RELEASE;ORAL
DESVENLAFAXINE

BC	SUN PHARMA GLOBAL	50MG	N205583	001	Jan 28, 2014	Jan NEWA
BC	+	100MG	N205583	002	Jan 28, 2014	Jan NEWA

DESVENLAFAXINE FUMARATETABLET, EXTENDED RELEASE;ORAL
DESVENLAFAXINE

+	SUN PHARMA GLOBAL	EQ 50MG BASE	N205583	001	Jan 28, 2014	Jun CTNA
+		EQ 100MG BASE	N205583	002	Jan 28, 2014	Jun CTNA
@	TEVA PHARMS USA	EQ 50MG BASE	N205208	001	Oct 11, 2013	Jun DISC
+		EQ 50MG BASE	N205208	001	Oct 11, 2013	Jun CTNA
@		EQ 100MG BASE	N205208	002	Oct 11, 2013	Jun DISC
+		EQ 100MG BASE	N205208	002	Oct 11, 2013	Jun CTNA
	DESVENLAFAXINE FUMARATE					
+	SUN PHARMA GLOBAL	EQ 50MG BASE	N205583	001	Jan 28, 2014	Feb CTEC
+		EQ 100MG BASE	N205583	002	Jan 28, 2014	Feb CTEC

DEXCHLORPHENIRAMINE MALEATETABLET;ORAL
DEXCHLORPHENIRAMINE MALEATE
@ ANI PHARMS INC

2MG

A088682	001	Jan 17, 1986	Jan CAHN
---------	-----	--------------	----------

DEXLANSOPRAZOLECAPSULE, DELAYED RELEASE;ORAL
DEXILANT

	TAKEDA PHARMS USA	30MG	N022287	001	Jan 30, 2009	Jun CAHN
+		60MG	N022287	002	Jan 30, 2009	Jun CAHN

DEXMEDETOMIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

>A>	DEXMEDETOMIDINE HYDROCHLORIDE						
>A> AP	MYLAN INSTITUTIONAL	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A202881	001	Aug 18, 2014	Aug NEWA	
>A> AP	PAR STERILE PRODUCTS	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A203972	001	Aug 18, 2014	Aug NEWA	
	PRECEDEX						
>D>	+	HOSPIRA	EQ 100MCG BASE/ML (EQ100MCG BASE/ML)	N021038	001	Dec 17, 1999	Aug CFTG
>A> AP	+		EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	N021038	001	Dec 17, 1999	Aug CFTG

DEXMETHYLPHENIDATE HYDROCHLORIDECAPSULE, EXTENDED RELEASE;ORAL
DEXMETHYLPHENIDATE HYDROCHLORIDE

AB	TEVA PHARMS USA	15MG	A078908	004	May 19, 2014	May NEWA
AB		30MG	A202731	003	May 19, 2014	May NEWA
AB	WATSON LABS INC	15MG	A079108	003	May 19, 2014	May NEWA

DEXRAZOXANE HYDROCHLORIDE

INJECTABLE;INJECTION

DEXRAZOXANE HYDROCHLORIDE

>D> AP	BEDFORD	EQ 250MG BASE/VIAL	A076068	001	Sep 28, 2004	Aug CAHN
>D> AP		EQ 500MG BASE/VIAL	A076068	002	Sep 28, 2004	Aug CAHN
>A> AP	EUROHLTH INTL	EQ 250MG BASE/VIAL	A076068	001	Sep 28, 2004	Aug CAHN
>A> AP		EQ 500MG BASE/VIAL	A076068	002	Sep 28, 2004	Aug CAHN

DEXTROAMPHETAMINE SULFATE

TABLET;ORAL

DEXTROAMPHETAMINE SULFATE

AA	COREPHARMA	5MG	A090652	001	Mar 07, 2014	Feb NEWA
AA		10MG	A090652	002	Mar 07, 2014	Feb NEWA

DIAZEPAMCONCENTRATE;ORAL
DIAZEPAM

AA	LANNETT HOLDINGS INC	5MG/ML	A204433	001	Apr 14, 2014	Mar NEWA
	DIAZEPAM INTENSOL					
AA	+ ROXANE	5MG/ML	A071415	001	Apr 03, 1987	Mar CFTG
	TABLET;ORAL					
	DIAZEPAM					
	@ DAVA PHARMS INC	2MG	A070226	001	Sep 26, 1985	Mar DISC

DICLOFENAC POTASSIUMFOR SOLUTION;ORAL
CAMBIA

	+ DEPOMED INC	50MG	N022165	001	Jun 17, 2009	Jan CAHN
--	---------------	------	---------	-----	--------------	----------

DICLOFENAC SODIUMSOLUTION;TOPICAL
DICLOFENAC SODIUM

AT	APOTEX INC	1.5%	A202027	001	May 27, 2014	May NEWA
	PENNSAID					
AT	+ MALLINCKRODT	1.5%	N020947	001	Nov 04, 2009	May CFTG
	+ MALLINCKRODT INC	2%	N204623	001	Jan 16, 2014	Jan NEWA

DICLOFENAC SODIUM; MISOPROSTOLTABLET, DELAYED RELEASE;ORAL
DICLOFENAC SODIUM AND MISOPROSTOL

AB	EAGLE PHARMS	50MG;0.2MG	A200540	001	Mar 14, 2014	Mar NEWA
AB		75MG;0.2MG	A200540	002	Mar 14, 2014	Mar NEWA

DICYCLOMINE HYDROCHLORIDECAPSULE;ORAL
BENTYL

AB	+ FOREST LABS INC	10MG	N007409	003	Oct 15, 1984	Apr CAHN
	INJECTABLE;INJECTION					
	BENTYL					
AP	+ FOREST LABS INC	10MG/ML	N008370	001	Oct 15, 1984	Apr CAHN
	BENTYL PRESERVATIVE FREE					
AP	+ FOREST LABS INC	10MG/ML	N008370	002	Oct 15, 1984	Apr CAHN
	DICYCLOMINE HYDROCHLORIDE (PRESERVATIVE-FREE)					
>D> AP	BEDFORD	10MG/ML	A040465	001	Jun 30, 2003	Aug CAHN
>A> AP	EUROHLTH INTL	10MG/ML	A040465	001	Jun 30, 2003	Aug CAHN
	TABLET;ORAL					
	BENTYL					
AB	+ FOREST LABS INC	20MG	N007409	001	Oct 15, 1984	Apr CAHN

DIGOXININJECTABLE;INJECTION
LANOXIN

AP	+ COVIS INJECTABLES	0.25MG/ML	N009330	002		Apr CAHN
	LANOXIN PEDIATRIC					
	+ COVIS INJECTABLES	0.1MG/ML	N009330	004		Apr CAHN
	TABLET;ORAL					
	DIGOXIN					
	@ SUN PHARM INDS INC	0.125MG	A076363	001	Jan 31, 2003	Jul CAHN
	@	0.25MG	A076363	002	Jan 31, 2003	Jul CAHN
	LANOXIN					
	COVIS PHARMA	0.0625MG	N020405	001	Sep 30, 1997	Jan CMFD
		0.1875MG	N020405	003	Sep 30, 1997	Jan CMFD

DILTIAZEM HYDROCHLORIDECAPSULE, EXTENDED RELEASE;ORAL
DILTIAZEM HYDROCHLORIDE

	@ NESHER PHARMS	120MG	A076563	002	Sep 12, 2006	Mar DISC
	@	180MG	A076563	003	Sep 12, 2006	Mar DISC
	@	240MG	A076563	004	Sep 12, 2006	Mar DISC
	@	300MG	A076563	005	Sep 12, 2006	Mar DISC
	@	360MG	A076563	006	Sep 12, 2006	Mar DISC
	@	420MG	A076563	001	Sep 12, 2006	Mar DISC

INJECTABLE; INJECTION

DILTIAZEM HYDROCHLORIDE

@ AGILA SPECLTS 5MG/ML

A075375 001 Sep 30, 1999 Feb CAHN

DIPHENHYDRAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE

@ INTL MEDICATION 50MG/ML

A084094 001 Jun DISC

DIPIVEFRIN HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

AKPRO

@ AKORN 0.1%

A074382 001 Sep 29, 1995 Jun DISC

DIPIVEFRIN HYDROCHLORIDE

@ FALCON PHARMS 0.1%

A073636 001 Jun 30, 1994 Jun DISC

PROPINE

@ ALLERGAN 0.1%

N018239 001 Jun DISC

DIPYRIDAMOLE

TABLET; ORAL

DIPYRIDAMOLE

@ GLENMARK GENERICS 25MG

A088999 001 Feb 05, 1991 Mar DISC

@ 50MG

A089000 001 Feb 05, 1991 Mar DISC

@ 75MG

A089001 001 Feb 05, 1991 Mar DISC

@ WATSON LABS 50MG

A087160 001 Jun 07, 1996 May DISC

DISULFIRAM

TABLET; ORAL

DISULFIRAM

AB ROXANE 250MG

A202652 001 Feb 05, 2014 Jan NEWA

AB 500MG

A202652 002 Feb 05, 2014 Jan NEWA

DIVALPROEX SODIUM

TABLET, EXTENDED RELEASE; ORAL

DIVALPROEX SODIUM

AB AUROBINDO PHARMA LTD EQ 250MG VALPROIC ACID

A202419 001 Jun 02, 2014 May NEWA

AB EQ 500MG VALPROIC ACID

A202419 002 Jun 02, 2014 May NEWA

DOBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DOBUTAMINE HYDROCHLORIDE

>D> AP BEDFORD EQ 12.5MG BASE/ML

A074277 001 Oct 31, 1994 Aug CAHN

>A> AP EUROHLTH INTL EQ 12.5MG BASE/ML

A074277 001 Oct 31, 1994 Aug CAHN

@ WATSON LABS EQ 12.5MG BASE/ML

A074114 001 Nov 30, 1993 May DISC

>D> DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5%

>D> AP + HOSPIRA EQ 50MG BASE/100ML

N020269 001 Oct 19, 1993 Aug DISC

>A> @ EQ 50MG BASE/100ML

N020269 001 Oct 19, 1993 Aug DISC

>D> AP + EQ 100MG BASE/100ML

N020269 002 Oct 19, 1993 Aug DISC

>A> @ EQ 100MG BASE/100ML

N020269 002 Oct 19, 1993 Aug DISC

>D> AP + EQ 200MG BASE/100ML

N020269 003 Oct 19, 1993 Aug DISC

>A> @ EQ 200MG BASE/100ML

N020269 003 Oct 19, 1993 Aug DISC

DOCETAXEL

INJECTABLE; INJECTION

DOCETAXEL

ACCORD HLTHCARE 20MG/0.5ML (40MG/ML)

N201195 001 Jun 08, 2011 Jul CTEC

80MG/2ML (40MG/ML)

N201195 002 Jun 08, 2011 Jul CTEC

>D> AP 160MG/8ML (20MG/ML)

N201195 005 Apr 20, 2012 Aug CRLD

>A> AP + 160MG/8ML (20MG/ML)

N201195 005 Apr 20, 2012 Aug CRLD

PFIZER LABS 20MG/2ML (10MG/ML)

N202356 001 Mar 13, 2014 Mar NEWA

80MG/8ML (10MG/ML)

N202356 002 Mar 13, 2014 Mar NEWA

130MG/13ML (10MG/ML)

N202356 003 Mar 13, 2014 Mar NEWA

200MG/20ML (10MG/ML)

N202356 004 Mar 13, 2014 Mar NEWA

DONEPEZIL HYDROCHLORIDE

TABLET; ORAL

DONEPEZIL HYDROCHLORIDE

AB JUBILANT GENERICS 5MG

A090768 001 May 31, 2011 Jul CAHN

AB 10MG

A090768 002 May 31, 2011 Jul CAHN

AB MACLEODS PHARMS LTD 23MG

A202631 001 Jan 22, 2014 Jan NEWA

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS;OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

>A>	AT	WATSON LABS INC	EQ 2% BASE;EQ 0.5% BASE	A202054	001	Sep 03, 2014	Aug NEWA
-----	----	-----------------	-------------------------	---------	-----	--------------	----------

DOXAPRAM HYDROCHLORIDE

INJECTABLE;INJECTION

DOXAPRAM HYDROCHLORIDE

	@	WATSON LABS	20MG/ML	A073529	001	Jan 30, 1992	May DISC
--	---	-------------	---------	---------	-----	--------------	----------

DOXAZOSIN MESYLATE

TABLET;ORAL

DOXAZOSIN MESYLATE

AB		ACCORD HLTHCARE	EQ 1MG BASE	A202824	001	Jun 11, 2014	May NEWA
AB			EQ 2MG BASE	A202824	002	Jun 11, 2014	May NEWA
AB			EQ 4MG BASE	A202824	003	Jun 11, 2014	May NEWA
AB			EQ 8MG BASE	A202824	004	Jun 11, 2014	May NEWA

DOXERCALCIFEROL

INJECTABLE;INJECTION

DOXERCALCIFEROL

AP		SANDOZ	4MCG/2ML (2MCG/ML)	A091333	001	May 05, 2014	Apr NEWA
AP			4MCG/2ML (2MCG/ML)	A200926	001	Feb 04, 2014	Jan NEWA

DOXORUBICIN HYDROCHLORIDE

INJECTABLE;INJECTION

DOXORUBICIN HYDROCHLORIDE

AP		ACTAVIS INC	2MG/ML	A203622	001	Jun 27, 2014	Jun NEWA
>D>	AP	+	BEDFORD	2MG/ML	A062975	001	Mar 17, 1989
>D>	AP	+		10MG/VIAL	A062921	001	Mar 17, 1989
>D>	AP	+		20MG/VIAL	A062921	002	Mar 17, 1989
>D>	AP	+		50MG/VIAL	A062921	003	Mar 17, 1989
>D>	AP	+		200MG/100ML	A064097	001	Sep 13, 1994
>A>	AP	+	EUROHLTH INTL	2MG/ML	A062975	001	Mar 17, 1989
>A>	AP	+		10MG/VIAL	A062921	001	Mar 17, 1989
>A>	AP	+		20MG/VIAL	A062921	002	Mar 17, 1989
>A>	AP	+		50MG/VIAL	A062921	003	Mar 17, 1989
>A>	AP	+		200MG/100ML	A064097	001	Sep 13, 1994
AP		PHARMACHEMIE BV	2MG/ML	A063336	001	Feb 28, 1995	Feb CAHN
AP			10MG/VIAL	A063097	001	May 21, 1990	Feb CAHN
AP			20MG/VIAL	A063097	002	May 21, 1990	Feb CAHN
AP			50MG/VIAL	A063097	003	May 21, 1990	Feb CAHN
AP			200MG/100ML	A063336	004	Feb 28, 1995	Feb CAHN

DOXYCYCLINE

CAPSULE;ORAL

DOXYCYCLINE

AB		LUPIN LTD	EQ 50MG BASE	A204234	001	Mar 05, 2014	Feb NEWA
AB			EQ 75MG BASE	A204234	002	Mar 05, 2014	Feb NEWA
AB			EQ 100MG BASE	A204234	003	Mar 05, 2014	Feb NEWA
		@ WATSON LABS	EQ 50MG BASE	A065041	001	Apr 28, 2000	May DISC
		@	EQ 100MG BASE	A065041	002	Apr 28, 2000	May DISC
		ORACEA					
	+	GALDERMA LABS LP	40MG	N050805	001	May 26, 2006	Jul CTEC

DOXYCYCLINE HYCLATE

CAPSULE;ORAL

DOXYCYCLINE HYCLATE

AB		MYLAN	EQ 50MG BASE	A062337	001	Mar 29, 1982	Jul CMFD
AB			EQ 100MG BASE	A062337	002	Mar 29, 1982	Jul CMFD

INJECTABLE;INJECTION

DOXYCYCLINE

>D>	AP	+	BEDFORD	EQ 100MG BASE/VIAL	A062569	001	Mar 09, 1988
>D>		@		EQ 200MG BASE/VIAL	A062569	002	Mar 09, 1988
>A>	AP	+	EUROHLTH INTL	EQ 100MG BASE/VIAL	A062569	001	Mar 09, 1988
>A>		@		EQ 200MG BASE/VIAL	A062569	002	Mar 09, 1988

TABLET;ORAL

ACTICLATE

AQUA PHARMS LLC

		EQ 75MG BASE	N205931	001	Jul 25, 2014	Jul NEWA
		EQ 150MG BASE	N205931	002	Jul 25, 2014	Jul NEWA

TABLET;ORAL							
DOXYCYCLINE HYCLATE							
AB	MYLAN	EQ 100MG BASE	A062432	001	Feb 15, 1983	Jul	CMFD
TABLET, DELAYED RELEASE;ORAL							
DORYX							
AB	MAYNE PHARMA	EQ 150MG BASE	N050795	003	Jun 20, 2008	Feb	CRLD
+		EQ 200MG BASE	N050795	005	Apr 11, 2013	Feb	CRLD
<u>DRONABINOL</u>							
CAPSULE;ORAL							
DRONABINOL							
AB	AKORN INC	2.5MG	A079217	001	Jun 20, 2014	Jun	NEWA
AB		5MG	A079217	002	Jun 20, 2014	Jun	NEWA
AB		10MG	A079217	003	Jun 20, 2014	Jun	NEWA
<u>DROSPIRENONE; ETHINYL ESTRADIOL</u>							
TABLET;ORAL							
NIKKI							
AB	LUPIN LTD	3MG;0.02MG	A201661	001	May 27, 2014	May	NEWA
<u>DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM</u>							
TABLET;ORAL							
BEYAZ							
	BAYER HLTHCARE	3MG,N/A;0.02MG,N/A;0.451MG,0.451MG	N022532	001	Sep 24, 2010	Jul	CRLD
	SAFYRAL						
+	BAYER HLTHCARE	3MG,N/A;0.03MG,N/A;0.451MG,0.451MG	N022574	001	Dec 16, 2010	Jul	CRLD
<u>DROXIDOPA</u>							
CAPSULE;ORAL							
NORTHERA							
	CHELSEA THERAPS INC	100MG	N203202	001	Feb 18, 2014	Feb	NEWA
		200MG	N203202	002	Feb 18, 2014	Feb	NEWA
+		300MG	N203202	003	Feb 18, 2014	Feb	NEWA
	LUNDBECK NA LTD	100MG	N203202	001	Feb 18, 2014	Jun	CAHN
		200MG	N203202	002	Feb 18, 2014	Jun	CAHN
+		300MG	N203202	003	Feb 18, 2014	Jun	CAHN
<u>DULOXETINE HYDROCHLORIDE</u>							
CAPSULE, DELAYED REL PELLETS;ORAL							
DULOXETINE HYDROCHLORIDE							
AB	ALEMBIC PHARMS LTD	EQ 20MG BASE	A202949	001	Jun 09, 2014	May	NEWA
AB		EQ 30MG BASE	A202949	002	Jun 09, 2014	May	NEWA
AB		EQ 60MG BASE	A202949	003	Jun 09, 2014	May	NEWA
AB	APOTEX INC	EQ 20MG BASE	A202045	001	Jun 11, 2014	May	NEWA
AB		EQ 30MG BASE	A202045	002	Jun 11, 2014	May	NEWA
AB		EQ 60MG BASE	A202045	003	Jun 11, 2014	May	NEWA
AB	BRECKENRIDGE PHARM	EQ 20MG BASE	A203088	001	Jun 11, 2014	May	NEWA
AB		EQ 30MG BASE	A203088	002	Jun 11, 2014	May	NEWA
AB		EQ 60MG BASE	A203088	003	Jun 11, 2014	May	NEWA
<u>DUTASTERIDE; TAMSULOSIN HYDROCHLORIDE</u>							
CAPSULE;ORAL							
DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE							
AB	ANCHEN PHARMS	0.5MG;0.4MG	A202509	001	Feb 26, 2014	Feb	NEWA
JALYN							
AB	GLAXOSMITHKLINE	0.5MG;0.4MG	N022460	001	Jun 14, 2010	Feb	CFTG
<u>ECONAZOLE NITRATE</u>							
AEROSOL, FOAM;TOPICAL							
ECOZA							
+	VELDANA MEDICAL SA	1%	N205175	001	Oct 24, 2013	Feb	CAHN
CREAM;TOPICAL							
SPECTAZOLE							
	@ MERZ PHARMS LLC	1%	N018751	001	Dec 23, 1982	Jan	CAHN
<u>EFINACONAZOLE</u>							
SOLUTION;TOPICAL							
JUBLIA							
+	DOW PHARM	10%	N203567	001	Jun 06, 2014	Jun	NEWA

>A>	<u>ELIGLUSTAT TARTRATE</u>				
>A>	CAPSULE;ORAL				
>A>	CERDELGA				
>A>	+	GENZYME CORP	EQ 84MG BASE	N205494 001	Aug 19, 2014 Aug NEWA
>A>	<u>EMPAGLIFLOZIN</u>				
>A>	TABLET;ORAL				
>A>	JARDIANCE				
>A>		BOEHRINGER INGELHEIM	10MG	N204629 001	Aug 01, 2014 Aug NEWA
>A>	+		25MG	N204629 002	Aug 01, 2014 Aug NEWA
	<u>ENALAPRIL MALEATE</u>				
	TABLET;ORAL				
	ENALAPRIL MALEATE				
	@	WATSON LABS	2.5MG	A075501 001	Aug 22, 2000 May DISC
	@		5MG	A075501 002	Aug 22, 2000 May DISC
	@		10MG	A075501 003	Aug 22, 2000 May DISC
	@		20MG	A075501 004	Aug 22, 2000 May DISC
	<u>ENOXAPARIN SODIUM</u>				
	INJECTABLE;SUBCUTANEOUS				
	ENOXAPARIN SODIUM (PRESERVATIVE FREE)				
AP		TEVA	30MG/0.3ML (100MG/ML)	A076726 001	Jun 23, 2014 Jun NEWA
AP			40MG/0.4ML (100MG/ML)	A076726 002	Jun 23, 2014 Jun NEWA
AP			60MG/0.6ML (100MG/ML)	A076726 003	Jun 23, 2014 Jun NEWA
AP			80MG/0.8ML (100MG/ML)	A076726 004	Jun 23, 2014 Jun NEWA
AP			100MG/ML (100MG/ML)	A076726 005	Jun 23, 2014 Jun NEWA
AP			120MG/0.8ML (150MG/ML)	A076726 006	Jun 23, 2014 Jun NEWA
AP			150MG/ML (150MG/ML)	A076726 007	Jun 23, 2014 Jun NEWA
	<u>ENTECAVIR</u>				
	TABLET;ORAL				
	BARACLUDE				
>D>		BRISTOL MYERS SQUIBB	0.5MG	N021797 001	Mar 29, 2005 Aug CFTG
>A> AB			0.5MG	N021797 001	Mar 29, 2005 Aug CFTG
>D>	+		1MG	N021797 002	Mar 29, 2005 Aug CFTG
>A> AB	+		1MG	N021797 002	Mar 29, 2005 Aug CFTG
>A>	ENTECAVIR				
>A> AB		TEVA PHARMS USA	0.5MG	A202122 001	Aug 26, 2014 Aug NEWA
>A> AB			1MG	A202122 002	Aug 26, 2014 Aug NEWA
	<u>EPINASTINE HYDROCHLORIDE</u>				
	SOLUTION/DROPS;OPHTHALMIC				
	EPINASTINE HYDROCHLORIDE				
AT		TESA PHARMS LLC	0.05%	A090951 001	Oct 31, 2011 Jul CAHN
	<u>EPINEPHRINE</u>				
	INJECTABLE;INTRAMUSCULAR, INTRAOCULAR, SUBCUTANEOUS				
	ADRENALIN				
	+	PAR STERILE PRODUCTS	1MG/ML	N204200 001	Dec 07, 2012 Apr CAHN
	INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS				
	ADRENALIN				
	+	PAR STERILE PRODUCTS	30MG/30ML (1MG/ML)	N204640 001	Dec 18, 2013 Apr CAHN
	<u>EPINEPHRINE HYDROCHLORIDE</u>				
	INJECTABLE;INTRAMUSCULAR, INTRAOCULAR, SUBCUTANEOUS				
	ADRENALIN				
	+	PAR STERILE PRODUCTS	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N204200 001	Dec 07, 2012 Jul CAIN
	INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS				
	ADRENALIN				
	+	PAR STERILE PRODUCTS	EQ 30MG BASE/30ML (EQ 1MG BASE/ML)	N204640 001	Dec 18, 2013 Jul CAIN
	SOLUTION;IV (INFUSION)				
	EPINEPHRINE				
		BELCHER PHARMS LLC	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N205029 001	Jul 29, 2014 Jul NEWA

EPIRUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

EPIRUBICIN HYDROCHLORIDE

>A>	AP	ACTAVIS ELIZABETH	10MG/5ML (2MG/ML)	A 065445	001	Sep 18, 2008	Aug CAHN
>A>	AP		50MG/25ML (2MG/ML)	A 065445	002	Sep 18, 2008	Aug CAHN
>A>	AP		200MG/100ML (2MG/ML)	A 065445	003	Sep 18, 2008	Aug CAHN
>D>	AP	ACTAVIS TOTOWA	10MG/5ML (2MG/ML)	A 065445	001	Sep 18, 2008	Aug CAHN
>D>	AP		50MG/25ML (2MG/ML)	A 065445	002	Sep 18, 2008	Aug CAHN
>D>	AP		200MG/100ML (2MG/ML)	A 065445	003	Sep 18, 2008	Aug CAHN
>D>	AP	BEDFORD	50MG/25ML (2MG/ML)	A 065289	001	Jun 27, 2007	Aug CAHN
>D>	AP		200MG/100ML (2MG/ML)	A 065289	002	Jun 27, 2007	Aug CAHN
>A>	AP	EUROHLTH INTL	50MG/25ML (2MG/ML)	A 065289	001	Jun 27, 2007	Aug CAHN
>A>	AP		200MG/100ML (2MG/ML)	A 065289	002	Jun 27, 2007	Aug CAHN
		@ HOSPIRA	50MG/25ML (2MG/ML)	A 065343	002	Apr 19, 2007	May DISC
		@ MUSTAFA NEVSAT	50MG/25ML (2MG/ML)	A 090266	001	Apr 15, 2011	Mar DISC
		@	200MG/100ML (2MG/ML)	A 090266	002	Apr 15, 2011	Mar DISC

INJECTABLE; IV (INFUSION)

EPIRUBICIN HYDROCHLORIDE

@ HOSPIRA

50MG/VIAL

N 050807 001 Sep 15, 2006 Jun DISC

ERGOALCIFEROL

CAPSULE; ORAL

ERGOALCIFEROL

>D>	AA	STRIDES ARCOLAB LTD	50,000 IU	A 090455	001	Aug 03, 2010	Aug CAHN
>A>	AA	STRIDES PHARMA	50,000 IU	A 090455	001	Aug 03, 2010	Aug CAHN

ERGOLOID MESYLATES

TABLET; SUBLINGUAL

ERGOLOID MESYLATES

@ WATSON LABS

0.5MG

A 087233 001 May DISC

ERLOTINIB HYDROCHLORIDE

TABLET; ORAL

ERLOTINIB HYDROCHLORIDE

AB		MYLAN PHARMS INC	EQ 25MG BASE	A 091002	001	Jun 11, 2014	May NEWA
AB			EQ 100MG BASE	A 091002	002	Jun 11, 2014	May NEWA
AB			EQ 150MG BASE	A 091002	003	Jun 11, 2014	May NEWA
		TARCEVA					
AB		OSI PHARMS	EQ 25MG BASE	N 021743	001	Nov 18, 2004	May CFTG
AB			EQ 100MG BASE	N 021743	002	Nov 18, 2004	May CFTG
AB	+		EQ 150MG BASE	N 021743	003	Nov 18, 2004	May CFTG

ERYTHROMYCIN

SWAB; TOPICAL

ERYTHROMYCIN

@ FOUGERA PHARMS

2%

A 065320 001 Jul 25, 2006 May DISC

ERYTHROMYCIN LACTOBIONATE

INJECTABLE; INJECTION

ERYTHROCIN

+ HOSPIRA

EQ 1GM BASE/VIAL

A 062638 002 Oct 31, 1986 May CTEC

ERYTHROMYCIN STEARATE

TABLET; ORAL

ERYTHROMYCIN STEARATE

@ ANI PHARMS INC

EQ 250MG BASE

A 061461 001

Feb CAHN

@

EQ 250MG BASE

A 061591 001

Jan CAHN

@

EQ 500MG BASE

A 061461 002

Feb CAHN

@

EQ 500MG BASE

A 063179 001 May 15, 1990

Feb CAHN

ESCITALOPRAM OXALATE

TABLET; ORAL

ESCITALOPRAM OXALATE

>A>	AB	JUBILANT GENERICS	EQ 5MG BASE	A 202280	001	Sep 12, 2012	Aug CAHN
>A>	AB		EQ 10MG BASE	A 202280	002	Sep 12, 2012	Aug CAHN
>A>	AB		EQ 20MG BASE	A 202280	003	Sep 12, 2012	Aug CAHN
>D>	AB	JUBILANT ORGANOSYS	EQ 5MG BASE	A 202280	001	Sep 12, 2012	Aug CAHN
>D>	AB		EQ 10MG BASE	A 202280	002	Sep 12, 2012	Aug CAHN
>D>	AB		EQ 20MG BASE	A 202280	003	Sep 12, 2012	Aug CAHN
AB		TEVA PHARMS USA	EQ 5MG BASE	A 076765	001	Mar 14, 2012	Feb CAHN
AB			EQ 10MG BASE	A 076765	002	Mar 14, 2012	Feb CAHN

TABLET;ORAL		ESCITALOPRAM OXALATE					
AB		EQ 20MG BASE	A076765	003	Mar 14, 2012	Feb	CAHN
<u>ESMOLOL HYDROCHLORIDE</u>							
INJECTABLE;INJECTION		ESMOLOL HYDROCHLORIDE					
>D>	AP	BEDFORD LABS	10MG/ML	A076323	001	Aug 10, 2004	Aug CAHN
>A>	AP	EUROHLTH INTL	10MG/ML	A076323	001	Aug 10, 2004	Aug CAHN
<u>ESOMEPRAZOLE MAGNESIUM</u>							
CAPSULE, DELAYED RELEASE;ORAL		NEXIUM					
		ASTRAZENECA LP	EQ 20MG BASE	N204655	001	Mar 28, 2014	Mar NEWA
<u>ESTRADIOL</u>							
GEL;TOPICAL		ESTROGEL					
		@ ASCEND THERAPS US	0.06%	N021166	001	Feb 09, 2004	May CAHN
GEL;TRANSDERMAL		DIVIGEL					
		VERTICAL PHARMS LLC	0.1% (0.25GM/PACKET)	N022038	001	Jun 04, 2007	Apr CAHN
			0.1% (0.5GM/PACKET)	N022038	002	Jun 04, 2007	Apr CAHN
	+		0.1% (1GM/PACKET)	N022038	003	Jun 04, 2007	Apr CAHN
GEL, METERED;TRANSDERMAL		ESTROGEL					
	+	ASCEND THERAPS US	0.06% (1.25GM/ACTIVATION)	N021166	002	Feb 09, 2004	May CAHN
SPRAY;TRANSDERMAL		EVAMIST					
	+	LUMARA HEALTH INC	1.53MG/SPRAY	N022014	001	Jul 27, 2007	May CAHN
<u>ESTRADIOL CYPIONATE</u>							
INJECTABLE;INJECTION		DEPO-ESTRADIOL					
	+	PHARMACIA AND UPJOHN	5MG/ML	A085470	003		May CTEC
		ESTRADIOL CYPIONATE					
		@ WATSON LABS	5MG/ML	A085620	001		May DISC
<u>ESTRADIOL VALERATE</u>							
INJECTABLE;INJECTION		DELESTROGEN					
AO	+	PAR STERILE PRODUCTS	10MG/ML	N009402	002		Apr CAHN
AO	+		20MG/ML	N009402	004		Apr CAHN
AO	+		40MG/ML	N009402	003		Apr CAHN
<u>ESTRADIOL; NORETHINDRONE ACETATE</u>							
TABLET;ORAL		ACTIVELLA					
AB		AMNEAL PHARMS LLC	0.5MG;0.1MG	N020907	002	Dec 28, 2006	Jun CAHN
AB	+		1MG;0.5MG	N020907	001	Nov 18, 1998	Jun CAHN
<u>ESTROPIPATE</u>							
TABLET;ORAL		ESTROPIPATE					
		@ WATSON LABS	6MG	A081216	001	Sep 23, 1993	May DISC
		OGEN 5					
		PHARMACIA AND UPJOHN	6MG	A083220	004		May CTEC
		ORTHO-EST					
		@ SUN PHARM INDS INC	0.75MG	A089567	001	Feb 27, 1991	Jun CAHN
		@	1.5MG	A089582	001	Jul 17, 1991	Jun CAHN
<u>ESZOPICLONE</u>							
TABLET;ORAL		ESZOPICLONE					
AB		DR REDDYS LABS LTD	1MG	A091024	001	Apr 15, 2014	Mar NEWA
AB			2MG	A091024	002	Apr 15, 2014	Mar NEWA
AB			3MG	A091024	003	Apr 15, 2014	Mar NEWA
AB		GLENMARK GENERICS	1MG	A091166	001	Apr 15, 2014	Mar NEWA
AB			2MG	A091166	002	Apr 15, 2014	Mar NEWA
AB			3MG	A091166	003	Apr 15, 2014	Mar NEWA
AB		LUPIN LTD	1MG	A091124	001	Sep 13, 2011	Mar CMFD

TABLET;ORAL									
ESZOPICLONE									
AB		2MG	A091124	002	Sep 13, 2011	Mar	CMFD		
AB		3MG	A091124	003	Sep 13, 2011	Mar	CMFD		
AB	ORCHID HLTHCARE	1MG	A091113	001	Jun 10, 2014	May	NEWA		
AB		2MG	A091113	002	Jun 10, 2014	May	NEWA		
AB		3MG	A091113	003	Jun 10, 2014	May	NEWA		
AB	ROXANE	1MG	A091153	001	Apr 15, 2014	Mar	NEWA		
AB		2MG	A091153	002	Apr 15, 2014	Mar	NEWA		
AB		3MG	A091153	003	Apr 15, 2014	Mar	NEWA		
AB	TEVA	1MG	A091169	001	May 23, 2011	Jan	CMFD		
AB		2MG	A091169	002	May 23, 2011	Jan	CMFD		
AB		3MG	A091169	003	May 23, 2011	Jan	CMFD		
<u>ETHINYL ESTRADIOL; ETONOGESTREL</u>									
RING;VAGINAL									
NUVARING									
+	ORGANON USA INC	0.015MG/24HR;0.12MG/24HR	N021187	001	Oct 03, 2001	Apr	CPOT		
<u>ETHINYL ESTRADIOL; LEVONORGESTREL</u>									
TABLET;ORAL-28									
LEVONORGESTREL AND ETHINYL ESTRADIOL									
AB1	HAUPT PHARMA	0.02MG;0.1MG	A201108	001	Feb 05, 2014	Jan	NEWA		
<u>ETHINYL ESTRADIOL; NORELGESTROMIN</u>									
FILM, EXTENDED RELEASE;TRANSDERMAL									
ORTHO EVRA									
AB	+	JANSSEN PHARMS	0.035MG/24HR;0.15MG/24HR	N021180	001	Nov 20, 2001	Mar	CFTG	
	+		0.035MG/24HR;0.15MG/24HR	N021180	001	Nov 20, 2001	Mar	CPOT	
XULANE									
AB	MYLAN TECHNOLOGIES	0.035MG/24HR;0.15MG/24HR	A200910	001	Apr 16, 2014	Mar	NEWA		
<u>ETHINYL ESTRADIOL; NORETHINDRONE</u>									
TABLET;ORAL-21									
NORETHIN 1/35E-21									
	@	WATSON LABS	0.035MG;1MG	A071480	001	Apr 12, 1988	May	DISC	
NORETHINDRONE AND ETHINYL ESTRADIOL									
	@	WATSON LABS	0.035MG;0.4MG	A078379	001	Feb 23, 2010	May	DISC	
	@		0.035MG;1MG	A070685	001	Jan 29, 1987	May	DISC	
NORETHINDRONE AND ETHINYL ESTRADIOL (10/11)									
	@	WATSON LABS	0.035MG,0.035MG;0.5MG,1MG	A071043	001	Apr 01, 1988	May	DISC	
NORETHINDRONE AND ETHINYL ESTRADIOL (7/14)									
	@	WATSON LABS	0.035MG,0.035MG;0.5MG,1MG	A071041	001	Sep 24, 1991	May	DISC	
TABLET;ORAL-28									
NORETHIN 1/35E-28									
	@	WATSON LABS	0.035MG;1MG	A071481	001	Apr 12, 1988	May	DISC	
NORETHINDRONE AND ETHINYL ESTRADIOL									
	@	WATSON LABS	0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG	A076393	001	Feb 04, 2010	May	DISC	
NORETHINDRONE AND ETHINYL ESTRADIOL (7/14)									
	@	WATSON LABS	0.035MG,0.035MG;0.5MG,1MG	A071042	001	Sep 24, 1991	May	DISC	
TABLET, CHEWABLE;ORAL									
NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE									
AB	FAMY CARE LTD	0.025MG;0.8MG	A203371	001	Apr 23, 2014	Apr	NEWA		
AB	+	WARNER CHILCOTT	0.025MG;0.8MG	N022573	001	Dec 22, 2010	Apr	CFTG	
<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE</u>									
TABLET;ORAL-21									
GILDESS 1.5/30									
AB	VINTAGE PHARMS LLC	0.03MG;1.5MG	A077075	002	Jul 24, 2012	Mar	NEWA		
GILDESS 1/20									
AB	VINTAGE PHARMS LLC	0.02MG;1MG	A077077	002	Jul 24, 2012	Mar	NEWA		
LARIN 1.5/30									
AB	NOVAST LABS LTD	0.03MG;1.5MG	A202996	001	Mar 20, 2014	Mar	NEWA		
LOESTRIN 21 1.5/30									
	@	WARNER CHILCOTT LLC	0.03MG;1.5MG	N017875	001		May	DISC	
LOESTRIN 21 1/20									
	@	WARNER CHILCOTT LLC	0.02MG;1MG	N017876	001		May	DISC	
TABLET;ORAL-28									
LOESTRIN FE 1.5/30									
	@	WARNER CHILCOTT LLC	0.03MG;1.5MG	N017355	001		May	DISC	

TABLET;ORAL-28						
LOESTRIN FE 1/20						
	@ WARNER CHILCOTT	0.02MG;1MG	N017354	001		May DISC
MICROGESTIN FE 1.5/30						
AB	+ WATSON LABS	0.03MG;1.5MG	A075548	001	Feb 05, 2001	May CRLD

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET;ORAL-28						
NORGESTIMATE AND ETHINYL ESTRADIOL						
	@ WATSON LABS	0.025MG,0.025MG;0.025MG;0.18MG,0.2	A090479	001	Mar 09, 2011	May DISC
		15MG,0.25MG				
	@	0.035MG,0.035MG;0.035MG;0.18MG,0.2	A076626	001	Aug 17, 2006	May DISC
		15MG,0.25MG				
	@	0.035MG;0.25MG	A076627	001	Aug 17, 2006	May DISC

ETHINYL ESTRADIOL; NORGESTREL

TABLET;ORAL-21						
LOW-OGESTREL-21						
	@ WATSON LABS	0.03MG;0.3MG	A075288	001	Jul 28, 1999	May DISC
TABLET;ORAL-28						
LOW-OGESTREL-28						
	@ WATSON LABS	0.03MG;0.3MG	A075288	002	Jul 28, 1999	May DISC

ETHIODIZED OIL

OIL;INTRALYMPHATIC, INTRAUTERINE						
ETHIODOL						
	+ GUERBET	99%	N009190	001		Apr CMFD
LIPIODOL						
	+ GUERBET	99%	N009190	001		Apr CTNA

ETODOLAC

CAPSULE;ORAL						
ETODOLAC						
	@ ANI PHARMS INC	200MG	A074899	001	Jul 08, 1997	Feb CAHN
	@	200MG	A075126	001	Sep 16, 1999	Jan CAHN
	@	300MG	A074899	002	Jul 08, 1997	Feb CAHN
AB		300MG	A075126	002	Sep 16, 1999	Jan CAHN
TABLET, EXTENDED RELEASE;ORAL						
ETODOLAC						
AB	ZYDUS PHARMS USA INC	400MG	A091134	001	Jan 23, 2014	May NEWA
AB		500MG	A091134	002	Jan 23, 2014	May NEWA
AB		600MG	A091134	003	Jan 23, 2014	May NEWA

ETOMIDATE

INJECTABLE;INJECTION						
ETOMIDATE						
AP	AGILA SPECLTS	2MG/ML	A078289	001	Jan 02, 2009	Feb CAHN
>A>	AP EMCURE PHARMS LTD	2MG/ML	A204618	001	Aug 13, 2014	Aug NEWA
AP	PAR STERILE PRODUCTS	2MG/ML	A091297	001	Jun 20, 2012	Jul CAHN
AP	ZYDUS PHARMS USA INC	2MG/ML	A202360	001	Jul 18, 2014	Jul NEWA

ETOPOSIDE

INJECTABLE;INJECTION						
ETOPOSIDE						
>D>	AP BEDFORD	20MG/ML	A074290	001	Jul 17, 1995	Aug CAHN
>A>	AP EUROHLTH INTL	20MG/ML	A074290	001	Jul 17, 1995	Aug CAHN
	@ PHARMACHEMIE BV	20MG/ML	A074227	001	Feb 22, 1996	Feb CAHN
	@ TEVA PHARMS USA	20MG/ML	A074284	001	Feb 10, 1994	May DISC

EXEMESTANE

TABLET;ORAL						
EXEMESTANE						
>A>	AB ALVOGEN INC	25MG	A200898	001	Jul 28, 2014	Aug CAHN
>D>	AB EIRGEN PHARMA LTD	25MG	A200898	001	Jul 28, 2014	Aug CAHN
AB		25MG	A200898	001	Jul 28, 2014	Jul NEWA

EXENATIDE SYNTHETIC

FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS						
BYDUREON						
	+ ASTRAZENECA AB	2MG/VIAL	N022200	001	Jan 27, 2012	Jun CAHN

INJECTABLE;SUBCUTANEOUS

BYETTA

+	ASTRAZENECA AB	300MCG/1.2ML (250MCG/ML)	N021773	001	Apr 28, 2005	Mar CAHN
+		600MCG/2.4ML (250MCG/ML)	N021773	002	Apr 28, 2005	Mar CAHN

FAMOTIDINE

FOR SUSPENSION;ORAL

FAMOTIDINE

AB	HI-TECH PHARMA CO	40MG/5ML	A201995	001	May 30, 2014	May NEWA
----	-------------------	----------	---------	-----	--------------	----------

INJECTABLE;INJECTION

FAMOTIDINE PRESERVATIVE FREE

AP	BEDFORD LABS	10MG/ML	A075825	001	Apr 17, 2001	Feb CAHN
----	--------------	---------	---------	-----	--------------	----------

FENOFIBRATE

TABLET;ORAL

FENOGLIDE

	SANTARUS INC	40MG	N022118	001	Aug 10, 2007	Feb CAHN
+		120MG	N022118	002	Aug 10, 2007	Feb CAHN

TRIGLIDE

@	SKYEPHARMA AG	50MG	N021350	001	May 07, 2005	May DISC
---	---------------	------	---------	-----	--------------	----------

FENOLDOPAM MESYLATE

INJECTABLE;INJECTION

FENOLDOPAM MESYLATE

>D> AP	BEDFORD LABS	EQ 10MG BASE/ML	A076582	001	Oct 12, 2004	Aug CAHN
>A> AP	EUROHLTH INTL	EQ 10MG BASE/ML	A076582	001	Oct 12, 2004	Aug CAHN

FENTANYL

FILM, EXTENDED RELEASE;TRANSDERMAL

FENTANYL-100

@	NOVEN	100MCG/HR	A077775	004	Oct 16, 2009	Apr DISC
---	-------	-----------	---------	-----	--------------	----------

FENTANYL-25

@	NOVEN	25MCG/HR	A077775	001	Oct 16, 2009	Apr DISC
---	-------	----------	---------	-----	--------------	----------

FENTANYL-50

@	NOVEN	50MCG/HR	A077775	002	Oct 16, 2009	Apr DISC
---	-------	----------	---------	-----	--------------	----------

FENTANYL-75

@	NOVEN	75MCG/HR	A077775	003	Oct 16, 2009	Apr DISC
---	-------	----------	---------	-----	--------------	----------

FENTANYL CITRATE

TABLET;BUCCAL

FENTANYL CITRATE

@	WATSON LABS	EQ 0.1MG BASE	A079075	001	Jan 07, 2011	May DISC
@		EQ 0.2MG BASE	A079075	002	Jan 07, 2011	May DISC
@		EQ 0.4MG BASE	A079075	003	Jan 07, 2011	May DISC
@		EQ 0.6MG BASE	A079075	004	Jan 07, 2011	May DISC
@		EQ 0.8MG BASE	A079075	005	Jan 07, 2011	May DISC

TABLET;BUCCAL, SUBLINGUAL

FENTANYL CITRATE

@	WATSON LABS	EQ 0.1MG BASE	A079075	001	Jan 07, 2011	Jun CDFR
@		EQ 0.2MG BASE	A079075	002	Jan 07, 2011	Jun CDFR
@		EQ 0.4MG BASE	A079075	003	Jan 07, 2011	Jun CDFR
@		EQ 0.6MG BASE	A079075	004	Jan 07, 2011	Jun CDFR
@		EQ 0.8MG BASE	A079075	005	Jan 07, 2011	Jun CDFR

FENTORA

	CEPHALON	EQ 0.1MG BASE	N021947	001	Sep 25, 2006	Jun CTEC
		EQ 0.2MG BASE	N021947	002	Sep 25, 2006	Jun CTEC
+		EQ 0.4MG BASE	N021947	003	Sep 25, 2006	Jun CTEC
		EQ 0.6MG BASE	N021947	004	Sep 25, 2006	Jun CTEC
		EQ 0.8MG BASE	N021947	005	Sep 25, 2006	Jun CTEC

TABLET;SUBLINGUAL

FENTANYL CITRATE

@	WATSON LABS	EQ 0.1MG BASE	A079075	001	Jan 07, 2011	May CDFR
@		EQ 0.2MG BASE	A079075	002	Jan 07, 2011	May CDFR
@		EQ 0.4MG BASE	A079075	003	Jan 07, 2011	May CDFR
@		EQ 0.6MG BASE	A079075	004	Jan 07, 2011	May CDFR
@		EQ 0.8MG BASE	A079075	005	Jan 07, 2011	May CDFR

FIDAXOMICINTABLET; ORAL
DIFICID

+ CUBIST PHARMS 200MG N201699 001 May 27, 2011 Jul CAHN

FINASTERIDETABLET; ORAL
FINASTERIDE

>A>	AB	ACTAVIS ELIZABETH	1MG	A078371	001	Nov 05, 2013	Aug CAHN
>A>	AB		5MG	A077914	001	Mar 28, 2007	Aug CAHN
>D>	AB	ACTAVIS TOTOWA	1MG	A078371	001	Nov 05, 2013	Aug CAHN
>D>	AB		5MG	A077914	001	Mar 28, 2007	Aug CAHN

FLECAINIDE ACETATETABLET; ORAL
TAMBOCOR

@	CNTY LINE PHARMS	50MG	N018830	004	Aug 23, 1988	Jul CAHN
@		100MG	N018830	001	Oct 31, 1985	Jul CAHN
@		150MG	N018830	003	Jun 03, 1988	Jul CAHN
@		200MG	N018830	002	Oct 31, 1985	Jul CAHN

FLORBETABEN F-18SOLUTION; INTRAVENOUS
NEURACEQ

+ PIRAMAL IMAGING 30ML (1.4-135mCi/ML) N204677 001 Mar 19, 2014 Mar NEWA

FLOXURIDINEINJECTABLE; INJECTION
FLOXURIDINE

>D>	AP	+ BEDFORD	500MG/VIAL	A075387	001	Apr 16, 2000	Aug CAHN
>A>	AP	+ EUROHLTH INTL	500MG/VIAL	A075387	001	Apr 16, 2000	Aug CAHN

FLUCONAZOLE

INJECTABLE; INJECTION

FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

@	TEVA PHARMS	200MG/100ML (2MG/ML)	A076837	001	Jan 13, 2005	Apr DISC
@		400MG/200ML (2MG/ML)	A076837	002	Jan 13, 2005	Apr DISC

FLUDARABINE PHOSPHATE

INJECTABLE; INJECTION

FLUDARABINE PHOSPHATE

>A>	AP	ACTAVIS ELIZABETH	50MG/VIAL	A078610	001	Feb 11, 2009	Aug CAHN
>D>	AP	ACTAVIS TOTOWA	50MG/VIAL	A078610	001	Feb 11, 2009	Aug CAHN
	AP	MUSTAFA NEVZAT ILAC	50MG/2ML (25MG/ML)	A090724	001	Sep 27, 2010	May CAHN

FLUDEOXYGLUCOSE F-18

INJECTABLE; INTRAVENOUS

FLUDEOXYGLUCOSE F18

AP	ESSENTIAL ISOTOPES	20-300mCi/ML	A203946	001	Feb 05, 2014	Jan NEWA
AP	LANTHEUS MEDICAL	20-200mCi/ML	A203664	001	Feb 04, 2014	Jan NEWA
AP	UCSF RODIOPHARM	20-300mCi/ML	A203902	001	May 09, 2014	Apr NEWA
AP	UIHC PET IMAGING	20-300mCi/ML	A203990	001	Aug 06, 2014	Jul NEWA
	@ WEILL MEDCL COLL	10-100mCi/ML	N021768	001	Aug 05, 2004	Feb DISC
AP	WUSM CYCLOTRON	20-300mCi/ML	A203935	001	Feb 05, 2014	Jan NEWA

FLUDROCORTISONE ACETATE

TABLET; ORAL

FLUDROCORTISONE ACETATE

AB	HIKMA PHARMS	0.1MG	A091302	001	Jul 22, 2011	Jan CAHN
----	--------------	-------	---------	-----	--------------	----------

FLUNISOLIDE

AEROSOL, METERED; INHALATION

AEROSPAN HFA

>D>	+	MEDA PHARMS INC	EQ 78MG BASE/INH	N021247	001	Jan 27, 2006	Aug CPOT
>A>	+		0.078MG/INH	N021247	001	Jan 27, 2006	Aug CPOT
	+		EQ 78MG BASE/INH	N021247	001	Jan 27, 2006	Mar CAHN

FLUOCINOLONE ACETONIDE; NEOMYCIN SULFATECREAM; TOPICAL
NEO-SYNALAR

+ MEDIMETRIKS PHARMS 0.025%;EQ 3.5MG BASE/GM

A060700 001

Apr CMFD

FLUOCINONIDE

CREAM; TOPICAL

FLUOCINONIDE

AB FOUGERA PHARMS INC

0.1%

A200735 001

Jul 14, 2014

Jun NEWA

AB GLENMARK GENERICS

0.1%

A091282 001

Jul 14, 2014

Jun NEWA

AB TARO

0.1%

A200734 001

Jul 14, 2014

Jun NEWA

SOLUTION; TOPICAL

FLUOCINONIDE

AT G AND W LABS INC

0.05%

A071535 001

Dec 02, 1988

May CAHN

LIDEX

AT CNTY LINE PHARMS

0.05%

N018849 001

Apr 06, 1984

Apr CMFD

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL

FLUOXETINE HYDROCHLORIDE

AB2 ANI PHARMS INC

EQ 10MG BASE

A076287 001

May 20, 2008

Jan CAHN

AB2

EQ 20MG BASE

A076287 002

May 20, 2008

Jan CAHN

TABLET; ORAL

SARAFEM

AB1 WARNER CHILCOTT LLC

EQ 10MG BASE

N021860 001

May 19, 2006

Jan CFTG

AB1

EQ 15MG BASE

N021860 002

May 19, 2006

Jan CFTG

AB1 +

EQ 20MG BASE

N021860 003

May 19, 2006

Jan CFTG

SELFEMRA

AB1 TEVA PHARMS USA

EQ 10MG BASE

A200151 001

Feb 03, 2014

Jan NEWA

AB1

EQ 15MG BASE

A200151 002

Feb 03, 2014

Jan NEWA

AB1

EQ 20MG BASE

A200151 003

Feb 03, 2014

Jan NEWA

FLUPHENAZINE DECANOATE

INJECTABLE; INJECTION

FLUPHENAZINE DECANOATE

>D> AO BEDFORD

25MG/ML

A074531 001

Aug 30, 1996

Aug CAHN

>A> AO EUROHLTH INTL

25MG/ML

A074531 001

Aug 30, 1996

Aug CAHN

AO PAR STERILE PRODUCTS

25MG/ML

A203732 001

Jul 03, 2014

Jun NEWA

FLUPHENAZINE HYDROCHLORIDE

ELIXIR; ORAL

FLUPHENAZINE HYDROCHLORIDE

@ ANI PHARMS INC

2.5MG/5ML

A081310 001

Apr 29, 1993

Feb CAHN

FLURAZEPAM HYDROCHLORIDE

CAPSULE; ORAL

FLURAZEPAM HYDROCHLORIDE

MYLAN PHARMS INC

15MG

A070345 002

Nov 27, 1985

May CTEC

+

30MG

A070345 001

Nov 27, 1985

May CTEC

@ WATSON LABS

15MG

A071205 001

Nov 25, 1986

May DISC

@

30MG

A071068 001

Nov 25, 1986

May DISC

@

30MG

A072369 001

Mar 30, 1989

May DISC

FLURBIPROFEN

TABLET; ORAL

FLURBIPROFEN

AB SUN PHARM INDS INC

50MG

A075058 001

Apr 27, 2001

Jul CAHN

AB

100MG

A075058 002

Apr 27, 2001

Jul CAHN

FLUTICASONE FUROATE

>A> POWDER; INHALATION

>A> ARNUITY ELLIPTA

>A> GLAXOSMITHKLINE

0.1MG/INH

N205625 001

Aug 20, 2014

Aug NEWA

>A> +

0.2MG/INH

N205625 002

Aug 20, 2014

Aug NEWA

FLUVOXAMINE MALEATE

TABLET; ORAL

FLUVOXAMINE MALEATE

@ SUN PHARM INDS INC	25MG	A075900	001	Feb 23, 2006	Jul CAHN
@	50MG	A075900	002	Feb 23, 2006	Jul CAHN
@	100MG	A075900	003	Feb 23, 2006	Jul CAHN

FOLIC ACID

TABLET; ORAL

FOLIC ACID

AA	CADILA PHARMS LTD	1 MG	A202437	001	Jan 27, 2014	Jan NEWA
----	-------------------	------	---------	-----	--------------	----------

FOLLITROPIN ALFA/BETA

INJECTABLE; SUBCUTANEOUS

GONAL-F RFF REDI-JECT

+	EMD SERONO	300 IU/0.5ML	N021684	001	May 25, 2004	May CTNA
+		450 IU/0.75ML	N021684	002	May 25, 2004	May CTNA
+		900 IU/1.5ML	N021684	003	May 25, 2004	May CTNA

FOMEPIZOLE

INJECTABLE; INJECTION

FOMEPIZOLE

@ MYLAN INSTITUTIONAL	1.5GM/1.5ML (1GM/ML)	A079033	001	Apr 07, 2009	Jun DISC
-----------------------	----------------------	---------	-----	--------------	----------

FONDAPARINUX SODIUM

INJECTABLE; SUBCUTANEOUS

ARIXTRA

AP	+	AGI	2.5MG/0.5ML	N021345	001	Dec 07, 2001	May CAHN
AP	+		5MG/0.4ML	N021345	002	May 28, 2004	May CAHN
AP	+		7.5MG/0.6ML	N021345	003	May 28, 2004	May CAHN
AP	+		10MG/0.8ML	N021345	004	May 28, 2004	May CAHN

FOSINOPRIL SODIUM

TABLET; ORAL

FOSINOPRIL SODIUM

@ WATSON LABS	10MG	A077531	001	Aug 31, 2006	May DISC
@	20MG	A077531	002	Aug 31, 2006	May DISC
@	40MG	A077531	003	Aug 31, 2006	May DISC

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE

TABLET; ORAL

FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

AB	EMCURE PHARMS INDIA	10MG;12.5MG	A079025	001	Sep 17, 2010	Feb CAIN
AB	+	20MG;12.5MG	A079025	002	Sep 17, 2010	Feb CAIN

FOSINOPRIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

AB	+	EMCURE PHARMS INDIA	20MG;12.5MG	A079025	002	Sep 17, 2010	Jan CRLD
----	---	---------------------	-------------	---------	-----	--------------	----------

FOSPHENYTOIN SODIUM

INJECTABLE; INJECTION

CEREBYX

AP	PARKE DAVIS	EQ 50MG PHENYTOIN NA/ML	N020450	001	Aug 05, 1996	Feb CMFD
	FOSPHENYTOIN SODIUM					
AP	AGILA SPECLTS	EQ 50MG PHENYTOIN NA/ML	A078736	001	Jun 08, 2010	Feb CAHN
AP	AMNEAL PHARMS CO	EQ 50MG PHENYTOIN NA/ML	A078476	001	Mar 18, 2008	Jun CAHN

FROVATRIPTAN SUCCINATE

TABLET; ORAL

FROVA

>D>	+	ENDO PHARMS	EQ 2.5MG BASE	N021006	001	Nov 08, 2001	Aug CFTG
>A>	AB	+	EQ 2.5MG BASE	N021006	001	Nov 08, 2001	Aug CFTG
>A>		FROVATRIPTAN SUCCINATE					
>A>	AB	MYLAN PHARMS INC	EQ 2.5MG BASE	A202931	001	Aug 28, 2014	Aug NEWA

FUROSEMIDEINJECTABLE;INJECTION
FUROSEMIDE

AP	CLARIS LIFESCIENCES	10MG/ML	A202747	001	Jan 27, 2014	Jan NEWA
>A> AP	EMCURE PHARMS LTD	10MG/ML	A203428	001	Aug 26, 2014	Aug NEWA

TABLET;ORAL
FUROSEMIDE

AB	CARACO	20MG	A091258	001	Apr 01, 2014	Mar NEWA
AB		40MG	A091258	002	Apr 01, 2014	Mar NEWA
AB		80MG	A091258	003	Apr 01, 2014	Mar NEWA
AB	SUN PHARM INDS INC	20MG	A091258	001	Apr 01, 2014	Jul CAHN
AB		40MG	A091258	002	Apr 01, 2014	Jul CAHN
AB		80MG	A091258	003	Apr 01, 2014	Jul CAHN
	@ WATSON LABS	20MG	A070412	001	Feb 26, 1986	May DISC
	@	20MG	A070449	001	Nov 22, 1985	May DISC
	@	20MG	A071379	001	Jan 02, 1987	May DISC
	@	40MG	A070450	001	Nov 22, 1985	May DISC
	@	80MG	A070528	001	Jan 07, 1986	May DISC
	@	80MG	A071594	001	Feb 09, 1988	May DISC

GABAPENTINCAPSULE;ORAL
GABAPENTIN

	@ WATSON LABS	100MG	A075485	003	May 11, 2007	May DISC
	@	300MG	A075485	002	May 11, 2007	May DISC
	@	400MG	A075485	001	May 11, 2007	May DISC

TABLET;ORAL
GABAPENTIN

AB	ACI HEALTHCARE LTD	600MG	A203244	002	Jul 12, 2013	Feb CAHN
AB		800MG	A203244	001	Jul 12, 2013	Feb CAHN

GALANTAMINE HYDROBROMIDE

TABLET;ORAL

GALANTAMINE HYDROBROMIDE

	@ YABAO PHARM	EQ 4MG BASE	A077604	001	Feb 06, 2009	May CAHN
	@	EQ 8MG BASE	A077604	002	Feb 06, 2009	May CAHN
	@	EQ 12MG BASE	A077604	003	Feb 06, 2009	May CAHN

GANCICLOVIR SODIUMINJECTABLE;INJECTION
GANCICLOVIR SODIUM

>D>	@ BEDFORD	EQ 500MG BASE/VIAL	A076222	001	Jul 16, 2003	Aug CAHN
>A>	@ EUROHLTH INTL	EQ 500MG BASE/VIAL	A076222	001	Jul 16, 2003	Aug CAHN

GATIFLOXACINSOLUTION/DROPS;OPHTHALMIC
GATIFLOXACIN

>A> AT	HI-TECH PHARMA CO	0.5%	A203189	001	Sep 03, 2014	Aug NEWA
--------	-------------------	------	---------	-----	--------------	----------

GEMCITABINE HYDROCHLORIDEINJECTABLE;INJECTION
GEMCITABINE HYDROCHLORIDE

>A> AP	ACTAVIS ELIZABETH	EQ 1GM BASE/VIAL	A079160	002	Jul 25, 2011	Aug CAHN
>A> AP		EQ 200MG BASE/VIAL	A079160	001	Jul 25, 2011	Aug CAHN
>D> AP	ACTAVIS TOTOWA	EQ 1GM BASE/VIAL	A079160	002	Jul 25, 2011	Aug CAHN
>D> AP		EQ 200MG BASE/VIAL	A079160	001	Jul 25, 2011	Aug CAHN

GEMFIBROZILTABLET;ORAL
GEMFIBROZIL

AB	SUN PHARM INDS INC	600MG	A079239	001	Dec 29, 2008	Jun CAHN
	@ WATSON LABS	600MG	A074442	001	Apr 28, 1995	May DISC

GLATIRAMER ACETATEINJECTABLE;SUBCUTANEOUS
COPAXONE

+	TEVA PHARMS USA	40MG/ML	N020622	003	Jan 28, 2014	Jan NEWA
---	-----------------	---------	---------	-----	--------------	----------

GLIMEPIRIDE

TABLET; ORAL

GLIMEPIRIDE

@ WATSON LABS	1MG	A077280	001	Feb 03, 2006	May DISC
@	2MG	A077280	002	Feb 03, 2006	May DISC
@	4MG	A077280	003	Feb 03, 2006	May DISC

GLIPIZIDE

TABLET; ORAL

GLIPIZIDE

AB	SUN PHARM INDS INC	5MG	A077820	001	Jul 11, 2006	Jul CAHN
AB		10MG	A077820	002	Jul 11, 2006	Jul CAHN
	@ WATSON LABS	5MG	A074370	001	Nov 22, 1994	May DISC
	@	10MG	A074370	002	Nov 22, 1994	May DISC

GLIPIZIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

GLIPIZIDE AND METFORMIN HYDROCHLORIDE

AB	SUN PHARM INDS INC	2.5MG; 250MG	A077620	001	Jan 11, 2008	Jul CAHN
AB		2.5MG; 500MG	A077620	002	Jan 11, 2008	Jul CAHN
AB		5MG; 500MG	A077620	003	Jan 11, 2008	Jul CAHN

GLYBURIDE

TABLET; ORAL

GLYBURIDE

>A>	@ ACTAVIS ELIZABETH	1.5MG	A075947	001	Nov 14, 2002	Aug CAHN
>A>	@	3MG	A075947	002	Nov 14, 2002	Aug CAHN
>A>	@	6MG	A075947	003	Nov 14, 2002	Aug CAHN
>D>	@ ACTAVIS TOTOWA	1.5MG	A075947	001	Nov 14, 2002	Aug CAHN
>D>	@	3MG	A075947	002	Nov 14, 2002	Aug CAHN
>D>	@	6MG	A075947	003	Nov 14, 2002	Aug CAHN

GLYCOPYRROLATE

TABLET; ORAL

GLYCOPYRROLATE

AA	STASON PHARMS	1MG	A091182	001	Feb 03, 2014	Jan NEWA
AA		2MG	A091182	002	Feb 03, 2014	Jan NEWA
AA	VINTAGE PHARMS	1MG	A090020	001	Oct 19, 2011	Feb CAHN
AA		2MG	A090020	002	Oct 19, 2011	Feb CAHN

GRANISETRON HYDROCHLORIDE

INJECTABLE; INJECTION

GRANISETRON HYDROCHLORIDE

>A> AP	BANNER PHARMACAPS	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078863	001	Jun 30, 2008	Aug CAHN
>D> AP	DSM PHARMS INC	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078863	001	Jun 30, 2008	Aug CAHN
	@ SANDOZ	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078808	001	Apr 29, 2008	Jun CAHN
AP	SANDOZ INC	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078835	001	Jun 30, 2008	Jun CAHN
AP		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078835	002	Jun 30, 2008	Jun CAHN
	GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE					
>A> AP	BANNER PHARMACAPS	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078863	002	Jun 30, 2008	Aug CAHN
>D> AP	DSM PHARMS INC	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078863	002	Jun 30, 2008	Aug CAHN

SOLUTION; ORAL

GRANISOL

@ PEDIATR	EQ 2MG BASE/10ML	A078334	001	Feb 28, 2008	Jul DISC
+	EQ 2MG BASE/10ML	A078334	001	Feb 28, 2008	Jul CTNA

GUANABENZ ACETATE

TABLET; ORAL

GUANABENZ ACETATE

	ANI PHARMS INC	EQ 4MG BASE	A074149	001	Apr 07, 1995	Jan CAHN
	@	EQ 4MG BASE	A074267	001	Jun 01, 1994	Mar CAHN
+		EQ 8MG BASE	A074149	002	Apr 07, 1995	Jan CAHN
	@	EQ 8MG BASE	A074267	002	Jun 01, 1994	Mar CAHN

HALOBETASOL PROPIONATE

OINTMENT; TOPICAL

HALOBETASOL PROPIONATE

AB	TARO	0.05%	A076994	001	Dec 16, 2004	Apr	CMFD
----	------	-------	---------	-----	--------------	-----	------

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION

HALOPERIDOL DECANOATE

AO	AGILA SPECLTS	EQ 50MG BASE/ML	A075440	001	Feb 28, 2000	Feb	CMFD
AO		EQ 100MG BASE/ML	A075440	002	Feb 28, 2000	Feb	CMFD
>D> AO	BEDFORD	EQ 50MG BASE/ML	A074811	001	Jan 30, 1998	Aug	CAHN
>D> AO		EQ 100MG BASE/ML	A075305	001	Sep 28, 1998	Aug	CAHN
>A> AO	EUROHLTH INTL	EQ 50MG BASE/ML	A074811	001	Jan 30, 1998	Aug	CAHN
>A> AO		EQ 100MG BASE/ML	A075305	001	Sep 28, 1998	Aug	CAHN

HALOPERIDOL LACTATE

INJECTABLE; INJECTION

HALOPERIDOL

>D> AP	BEDFORD	EQ 5MG BASE/ML	A075858	001	Jun 18, 2001	Aug	CAHN
>A> AP	EUROHLTH INTL	EQ 5MG BASE/ML	A075858	001	Jun 18, 2001	Aug	CAHN

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM

+	FRESENIUS KABI USA	10,000 UNITS/ML	N017029	020	Mar 31, 2011	Mar	NEWA
+	HOSPIRA	5,000 UNITS/ML	A088100	001	Apr 28, 1983	Mar	CRLD
+	PFIZER	1,000 UNITS/ML	N201370	001	Jul 21, 2011	Mar	CRLD
+		5,000 UNITS/ML	N201370	002	Jul 21, 2011	Mar	CRLD
+		10,000 UNITS/ML	N201370	003	Jul 21, 2011	Mar	CRLD
AP	SHENZHEN TECHDOW	1,000 UNITS/ML	A202957	001	Jun 12, 2014	Jun	NEWA
AP		5,000 UNITS/ML	A202733	001	Jun 12, 2014	Jun	NEWA
AP		5,000 UNITS/ML	A202957	002	Jun 12, 2014	Jun	NEWA
AP		10,000 UNITS/ML	A203198	001	Jun 12, 2014	Jun	NEWA
AP		20,000 UNITS/ML	A203198	002	Jun 12, 2014	Jun	NEWA

HEPARIN SODIUM IN PLASTIC CONTAINER

AP	+	FRESENIUS KABI USA	1,000 UNITS/ML	N017029	013	Dec 05, 1985	Jun	CTEC
	+		1,000 UNITS/ML	N017029	013	Dec 05, 1985	Mar	CTEC
AP	+		10,000 UNITS/ML	N017029	015	Dec 05, 1985	Jun	CTEC
	+		10,000 UNITS/ML	N017029	015	Dec 05, 1985	Mar	CTEC
AP	+		20,000 UNITS/ML	N017029	016	Dec 05, 1985	Jun	CTEC
	+		20,000 UNITS/ML	N017029	016	Dec 05, 1985	Mar	CTEC

HEPARIN SODIUM PRESERVATIVE FREE

+	FRESENIUS KABI USA	10,000 UNITS/ML	N017029	019	Nov 22, 2010	Mar	NEWA
+	HOSPIRA	10,000 UNITS/ML	A089522	001	May 04, 1987	Mar	CTEC
+	PFIZER	1,000 UNITS/ML	N201370	004	Jul 21, 2011	Mar	CRLD
AP	SHENZHEN TECHDOW	1,000 UNITS/ML	A202732	001	Jun 12, 2014	Jun	NEWA

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

TABLET; ORAL

HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE

>A>	@ ACTAVIS ELIZABETH	1.5MG; 5MG	A040295	001	Dec 01, 2000	Aug	CAHN
>D>	@ ACTAVIS TOTOWA	1.5MG; 5MG	A040295	001	Dec 01, 2000	Aug	CAHN

HYDRALAZINE HYDROCHLORIDE

TABLET; ORAL

HYDRALAZINE HYDROCHLORIDE

>A>	@ ACTAVIS ELIZABETH	25MG	A088560	001	Oct 04, 1984	Aug	CAHN
>A>	@	50MG	A088649	001	Oct 18, 1984	Aug	CAHN
>D>	@ ACTAVIS TOTOWA	25MG	A088560	001	Oct 04, 1984	Aug	CAHN
>D>	@	50MG	A088649	001	Oct 18, 1984	Aug	CAHN
>D> AA	STRIDES ARCOLAB LTD	25MG	A200770	001	May 03, 2013	Aug	CAHN
>D> AA		50MG	A200770	002	May 03, 2013	Aug	CAHN
>D> AA		100MG	A200770	003	May 03, 2013	Aug	CAHN
>A> AA	STRIDES PHARMA	25MG	A200770	001	May 03, 2013	Aug	CAHN
>A> AA		50MG	A200770	002	May 03, 2013	Aug	CAHN
>A> AA		100MG	A200770	003	May 03, 2013	Aug	CAHN
	@ WATSON LABS	25MG	A084504	001		May	DISC
	@	50MG	A084503	001		May	DISC

HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

HYDROCHLOROTHIAZIDE

AB	CARACO	12.5MG	A090651	001	Apr 07, 2014	Mar	NEWA
AB	SUN PHARM INDS INC	12.5MG	A090651	001	Apr 07, 2014	Jul	CAHN

TABLET; ORAL

HYDROCHLOROTHIAZIDE

AB	SCIEGEN PHARMS INC	25MG	A203018	001	Jul 23, 2014	Jul	NEWA
AB		50MG	A203018	002	Jul 23, 2014	Jul	NEWA
AB	SUN PHARM INDS INC	12.5MG	A040857	001	May 30, 2008	Jul	CAHN
AB		25MG	A040810	001	Mar 27, 2007	Jul	CAHN
AB		50MG	A040810	002	Mar 27, 2007	Jul	CAHN

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL

IRBESARTAN AND HYDROCHLOROTHIAZIDE

AB	PRINSTON INC	12.5MG; 150MG	A203072	001	May 09, 2014	Apr	NEWA
AB		12.5MG; 300MG	A203072	002	May 09, 2014	Apr	NEWA

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET; ORAL

LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

@	WATSON LABS	12.5MG; 50MG
@		12.5MG; 100MG
@		25MG; 100MG

A200180	001	Jan 12, 2011	May	DISC
A200180	002	Jan 12, 2011	May	DISC
A200180	003	Jan 12, 2011	May	DISC

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL

METHYLDOPA AND HYDROCHLOROTHIAZIDE

MYLAN	15MG; 250MG
-------	-------------

A070265	002	Jan 23, 1986	Mar	CMS1
---------	-----	--------------	-----	------

HYDROCHLOROTHIAZIDE; METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

DUTOPIROL

COVIS PHARMA SARL	12.5MG; EQ 25MG TARTRATE
	12.5MG; EQ 50MG TARTRATE
+	12.5MG; EQ 100MG TARTRATE

N021956	001	Aug 28, 2006	Jun	CAHN
N021956	002	Aug 28, 2006	Jun	CAHN
N021956	003	Aug 28, 2006	Jun	CAHN

HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL

MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB	HERITAGE PHARMS INC	12.5MG; 7.5MG	A202150	001	Mar 07, 2014	Apr	CAHN
AB		12.5MG; 15MG	A202150	002	Mar 07, 2014	Apr	CAHN
AB		25MG; 15MG	A202150	003	Mar 07, 2014	Apr	CAHN
AB	INDICUS PHARMA	12.5MG; 7.5MG	A202150	001	Mar 07, 2014	Feb	NEWA
AB		12.5MG; 15MG	A202150	002	Mar 07, 2014	Feb	NEWA
AB		25MG; 15MG	A202150	003	Mar 07, 2014	Feb	NEWA

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL

PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB	MYLAN	25MG; 40MG	A070947	002	Mar 04, 1987	Mar	CMS1
----	-------	------------	---------	-----	--------------	-----	------

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET; ORAL

SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE

@	WATSON LABS	25MG; 25MG
---	-------------	------------

A087398	001		May	DISC
---------	-----	--	-----	------

HYDROCHLOROTHIAZIDE; TELMISARTAN

TABLET; ORAL

MICARDIS HCT

AB	BOEHRINGER INGELHEIM	12.5MG; 40MG	N021162	001	Nov 17, 2000	Feb	CFTG
AB		12.5MG; 80MG	N021162	002	Nov 17, 2000	Feb	CFTG
AB	+	25MG; 80MG	N021162	003	Apr 19, 2004	Feb	CFTG

TELMISARTAN AND HYDROCHLOROTHIAZIDE

AB	ALEMBIC PHARMS LTD	12.5MG; 40MG	A203010	001	Feb 25, 2014	Feb	NEWA
AB		12.5MG; 80MG	A203010	002	Feb 25, 2014	Feb	NEWA
AB		25MG; 80MG	A203010	003	Feb 25, 2014	Feb	NEWA
AB	LUPIN LTD	12.5MG; 40MG	A091351	001	Aug 07, 2014	Jul	NEWA
AB		12.5MG; 80MG	A091351	002	Aug 07, 2014	Jul	NEWA
AB		25MG; 80MG	A091351	003	Aug 07, 2014	Jul	NEWA

TABLET;ORAL

TELMISARTAN AND HYDROCHLOROTHIAZIDE									
AB	MYLAN PHARMS INC	12.5MG;40MG	A091648	001	Feb 25, 2014	Feb	NEWA		
AB		12.5MG;80MG	A091648	002	Feb 25, 2014	Feb	NEWA		
AB		25MG;80MG	A091648	003	Feb 25, 2014	Feb	NEWA		
AB	TORRENT PHARMS LTD	12.5MG;40MG	A201192	001	Feb 25, 2014	Feb	NEWA		
AB		12.5MG;80MG	A201192	002	Feb 25, 2014	Feb	NEWA		
AB		25MG;80MG	A201192	003	Feb 25, 2014	Feb	NEWA		

HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION;ORAL									
HYDROCODONE BITARTRATE AND PSEUDOEPHEDRINE HYDROCHLORIDE									
AA	PADDOCK LLC		5MG/5ML;60MG/5ML		A204658	001	Apr 29, 2014	Apr	NEWA
REZIRA									
AA	+	CYPRESS PHARM	5MG/5ML;60MG/5ML		N022442	001	Jun 08, 2011	Apr	CFTG

HYDROCORTISONE

CREAM;TOPICAL									
HYDROCORTISONE									
	@ TARO	1%	A086155	001		Mar	DISC		
LOTION;TOPICAL									
ALA-CORT									
	@ CROWN LABS	1%	A083201	001		Mar	DISC		
NUTRACORT									
	@ DOW PHARM	1%	A080443	003		Mar	DISC		

HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE

AEROSOL, METERED;TOPICAL									
HYDROCORTISONE ACETATE 1% AND PRAMOXINE HYDROCHLORIDE 1%									
	@ VINTAGE PHARMS	1%;1%	A089440	001	May 17, 1988	Feb	CAHN		

HYDROCORTISONE BUTYRATE

CREAM;TOPICAL									
HYDROCORTISONE BUTYRATE									
>D>	AB	GLENMARK GENERICS	0.1%	A202145	001	Sep 27, 2013	Aug	CTEC	
>A>	AB2		0.1%	A202145	001	Sep 27, 2013	Aug	CTEC	
>D>	AB	TARO PHARM INDS	0.1%	A076654	001	Aug 03, 2005	Aug	CTEC	
>A>	AB1		0.1%	A076654	001	Aug 03, 2005	Aug	CTEC	
LOCOID									
>D>	AB	+ PRECISION DERMAT	0.1%	N018514	001	Mar 31, 1982	Aug	CTEC	
>A>	AB1	+	0.1%	N018514	001	Mar 31, 1982	Aug	CTEC	
LOCOID LIPOCREAM									
>D>	AB	+ PRECISION DERMAT	0.1%	N020769	001	Sep 08, 1997	Aug	CTEC	
>A>	AB2	+	0.1%	N020769	001	Sep 08, 1997	Aug	CTEC	

HYDROMORPHONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL									
EXALGO									
AB	MALLINCKRODT INC	8MG	N021217	001	Mar 01, 2010	Apr	CFTG		
AB		12MG	N021217	002	Mar 01, 2010	Apr	CFTG		
AB		16MG	N021217	003	Mar 01, 2010	Apr	CFTG		
HYDROMORPHONE HYDROCHLORIDE									
AB	ACTAVIS LABS FL INC	8MG	A202144	001	May 12, 2014	Apr	NEWA		
AB		12MG	A202144	002	May 12, 2014	Apr	NEWA		
AB		16MG	A202144	003	May 12, 2014	Apr	NEWA		

HYDROXYCHLOROQUINE SULFATE

TABLET;ORAL									
HYDROXYCHLOROQUINE SULFATE									
	@ WATSON LABS	200MG	A040133	001	Nov 30, 1995	May	DISC		

HYDROXYPROGESTERONE CAPROATE

SOLUTION;INTRAMUSCULAR									
MAKENA									
+	LUMARA HEALTH INC	1250MG/5ML (250MG/ML)	N021945	001	Feb 03, 2011	May	CAHN		

HYDROXYZINE HYDROCHLORIDE

TABLET; ORAL

HYDROXYZINE HYDROCHLORIDE

>A>	@	ACTAVIS ELIZABETH	10MG	A089071	001	Jul 22, 1986	Aug CAHN
>A>	@		25MG	A089072	001	Jul 22, 1986	Aug CAHN
>A>	@		50MG	A089073	001	Jul 22, 1986	Aug CAHN
>D>	@	ACTAVIS TOTOWA	10MG	A089071	001	Jul 22, 1986	Aug CAHN
>D>	@		25MG	A089072	001	Jul 22, 1986	Aug CAHN
>D>	@		50MG	A089073	001	Jul 22, 1986	Aug CAHN
>A>	AB	EMCURE PHARMS USA	10MG	A204279	001	Aug 20, 2014	Aug NEWA
>A>	AB		25MG	A204279	002	Aug 20, 2014	Aug NEWA
>A>	AB		50MG	A204279	003	Aug 20, 2014	Aug NEWA
	AB	SUN PHARM INDS INC	10MG	A040899	001	Jun 10, 2008	Jun CAHN
	AB		25MG	A040899	002	Jun 10, 2008	Jun CAHN
	AB		50MG	A040899	003	Jun 10, 2008	Jun CAHN
	@	WATSON LABS	10MG	A081149	001	Mar 18, 1994	May DISC
	@		25MG	A081150	001	Mar 18, 1994	May DISC
	@		50MG	A081151	001	Mar 18, 1994	May DISC

HYDROXYZINE PAMOATE

CAPSULE; ORAL

HYDROXYZINE PAMOATE

AB		EMCURE PHARMS USA	EQ 25MG HYDROCHLORIDE	A201507	001	Jun 03, 2013	Jun CPOT
AB			EQ 50MG HYDROCHLORIDE	A201507	002	Jun 03, 2013	Jun CPOT
	@	WATSON LABS	EQ 25MG HYDROCHLORIDE	A081165	001	Jul 31, 1991	May DISC

IBANDRONATE SODIUM

INJECTABLE; INTRAVENOUS

BONIVA

AP	+	ROCHE	EQ 3MG BASE/3ML	N021858	001	Jan 06, 2006	Feb CFTG
		IBANDRONATE SODIUM					
>A>	AP	AGILA SPECLTS	EQ 3MG BASE/3ML	A202671	001	Sep 02, 2014	Aug NEWA
>A>	AP	EMCURE PHARMS LTD	EQ 3MG BASE/3ML	A203987	001	Sep 02, 2014	Aug NEWA
>A>	AP	SAGENT PHARMS	EQ 3MG BASE/3ML	A202235	001	Sep 02, 2014	Aug NEWA
AP		SUN PHARM INDS LTD	EQ 3MG BASE/3ML	A090853	001	Feb 14, 2014	Feb NEWA

IBUPROFEN

TABLET; ORAL

IBUPROFEN

	@	WATSON LABS	400MG	A070436	001	Aug 21, 1985	May DISC
	@		600MG	A070437	001	Aug 21, 1985	May DISC

IDARUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

IDARUBICIN HYDROCHLORIDE

>D>	AP	BEDFORD LABS	1MG/ML	A065275	001	Dec 14, 2006	Aug CAHN
>D>	AP		1MG/ML	A065288	001	May 15, 2007	Aug CAHN
>A>	AP	EUROHLTH INTL	1MG/ML	A065275	001	Dec 14, 2006	Aug CAHN
>A>	AP		1MG/ML	A065288	001	May 15, 2007	Aug CAHN

IDELALISIB

TABLET; ORAL

ZYDELIG

		GILEAD SCIENCES INC	100MG	N205858	001	Jul 23, 2014	Jul NEWA
	+		150MG	N205858	002	Jul 23, 2014	Jul NEWA

IFOSFAMIDE

INJECTABLE; INJECTION

IFOSFAMIDE

>D>	AP	BEDFORD LABS	1GM/20ML (50MG/ML)	A076619	001	Jun 29, 2011	Aug CAHN
>D>	AP		3GM/60ML (50MG/ML)	A076619	002	Jun 29, 2011	Aug CAHN
>A>	AP	EUROHLTH INTL	1GM/20ML (50MG/ML)	A076619	001	Jun 29, 2011	Aug CAHN
>A>	AP		3GM/60ML (50MG/ML)	A076619	002	Jun 29, 2011	Aug CAHN

IMIQUIMOD

CREAM; TOPICAL

IMIQUIMOD

>D>	AB	STRIDES ARCOLAB LTD	5%	A202002	001	Jun 24, 2014	Aug CAHN
	AB		5%	A202002	001	Jun 24, 2014	Jun NEWA
>A>	AB	STRIDES PHARMA	5%	A202002	001	Jun 24, 2014	Aug CAHN

INAMRINONE LACTATE

INJECTABLE; INJECTION
AMRINONE LACTATE

>D>	+	BEDFORD	EQ 5MG BASE/ML	A075513	001	May 09, 2000	Aug CAHN
>A>	+	EUROHLTH INTL	EQ 5MG BASE/ML	A075513	001	May 09, 2000	Aug CAHN

INDAPAMIDE

TABLET; ORAL
INDAPAMIDE

	@	AMERIGEN PHARMS LTD	1.25MG	A075201	001	Dec 04, 1998	Jul CAHN
	@		2.5MG	A075201	002	Dec 04, 1998	Jul CAHN
	@	WATSON LABS	1.25MG	A074585	001	Sep 26, 1996	May DISC
	@		2.5MG	A074585	002	Sep 26, 1996	May DISC

INDOMETHACIN

CAPSULE; ORAL
INDOCIN

	@	IROKO PHARMS LLC	25MG	N016059	001		May CAHN
	@		50MG	N016059	002		May CAHN

INDOMETHACIN

AB		SUN PHARM INDS INC	25MG	A091401	001	Mar 28, 2013	Jun CAHN
AB			50MG	A091401	002	Mar 28, 2013	Jun CAHN

TIVORBEX

		IROKO PHARMS LLC	20MG	N204768	001	Feb 24, 2014	Feb NEWA
+			40MG	N204768	002	Feb 24, 2014	Feb NEWA

CAPSULE, EXTENDED RELEASE; ORAL
INDOMETHACIN

AB		MYLAN PHARMS INC	75MG	A202139	001	Mar 20, 2014	Mar NEWA
----	--	------------------	------	---------	-----	--------------	----------

INDOMETHACIN SODIUM

INJECTABLE; INJECTION
INDOMETHACIN SODIUM

>D>	AP	BEDFORD	EQ 1MG BASE/VIAL	A078713	001	Jul 16, 2008	Aug CAHN
>A>	AP	EUROHLTH INTL	EQ 1MG BASE/VIAL	A078713	001	Jul 16, 2008	Aug CAHN

INSULIN ASPART RECOMBINANT

INJECTABLE; SUBCUTANEOUS
NOVOLOG FLEXTOUCH

+		NOVO NORDISK INC	300 UNITS/3ML (100 UNITS/ML)	N020986	005	Oct 31, 2013	Feb NEWA
---	--	------------------	------------------------------	---------	-----	--------------	----------

INSULIN DETEMIR RECOMBINANT

INJECTABLE; SUBCUTANEOUS
LEVEMIR FLEXTOUCH

+		NOVO NORDISK INC	300 UNITS/3ML (100 UNITS/ML)	N021536	005	Oct 31, 2013	Feb NEWA
---	--	------------------	------------------------------	---------	-----	--------------	----------

INSULIN RECOMBINANT HUMAN

POWDER; INHALATION
AFREZZA

		MANNKIND	4 UNITS/INH	N022472	001	Jun 27, 2014	Jun NEWA
+			8 UNITS/INH	N022472	002	Jun 27, 2014	Jun NEWA

IPRATROPIUM BROMIDE

SOLUTION; INHALATION
IPRATROPIUM BROMIDE

AN	+	MYLAN SPECLT	0.02%	A074755	001	Jan 10, 1997	Mar CAHN
----	---	--------------	-------	---------	-----	--------------	----------

SPRAY, METERED; NASAL
IPRATROPIUM BROMIDE

AB		MYLAN SPECLT	0.021MG/SPRAY	A075552	001	Mar 31, 2003	May CAHN
AB			0.042MG/SPRAY	A075553	001	Mar 31, 2003	May CAHN

IRINOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION
IRINOTECAN HYDROCHLORIDE

>A>	AP	ACTAVIS ELIZABETH	40MG/2ML (20MG/ML)	A078589	001	Feb 27, 2008	Aug CAHN
>A>	AP		100MG/5ML (20MG/ML)	A078589	002	Feb 27, 2008	Aug CAHN
>D>	AP	ACTAVIS TOTOWA	40MG/2ML (20MG/ML)	A078589	001	Feb 27, 2008	Aug CAHN
>D>	AP		100MG/5ML (20MG/ML)	A078589	002	Feb 27, 2008	Aug CAHN
	AP	MUSTAFA NEVZAT ILAC	40MG/2ML (20MG/ML)	A090393	002	May 13, 2011	May CAHN
	AP		100MG/5ML (20MG/ML)	A090393	003	May 13, 2011	May CAHN

ISOFLURANELIQUID; INHALATION
ISOFLURANE

AN	PIRAMAL ENT	99.9%	A074502	001	Jun 27, 1995	Feb CAHN
----	-------------	-------	---------	-----	--------------	----------

ISOSORBIDE DINITRATECAPSULE, EXTENDED RELEASE; ORAL
DILATRATE-SR

	+ AUXILIUM PHARMS LLC	40MG	N019790	001	Sep 02, 1988	Apr CAHN
--	-----------------------	------	---------	-----	--------------	----------

TABLET; ORAL

ISOSORBIDE DINITRATE

AB	HIKMA INTL PHARMS	5MG	A086067	001	Oct 29, 1987	Jul CAHN
----	-------------------	-----	---------	-----	--------------	----------

AB		10MG	A086066	001	Oct 29, 1987	Jul CAHN
----	--	------	---------	-----	--------------	----------

AB		20MG	A088088	001	Nov 02, 1987	Jul CAHN
----	--	------	---------	-----	--------------	----------

AB		30MG	A040591	001	Jan 10, 2007	Jul CAHN
----	--	------	---------	-----	--------------	----------

TABLET; SUBLINGUAL

ISOSORBIDE DINITRATE

@ HIKMA INTL PHARMS 2.5MG

A086054	001	Oct 29, 1987	Jul CAHN
---------	-----	--------------	----------

@ 5MG

A086055	001	Nov 02, 1987	Jul CAHN
---------	-----	--------------	----------

TABLET, EXTENDED RELEASE; ORAL

ISOSORBIDE DINITRATE

AB	+ SUN PHARM INDS INC	40MG	A040009	001	Dec 30, 1998	Jul CAHN
----	----------------------	------	---------	-----	--------------	----------

ISOSORBIDE MONONITRATE

TABLET; ORAL

ISOSORBIDE MONONITRATE

AB	ANI PHARMS INC	20MG	A075147	001	Nov 27, 1998	Jan CAHN
----	----------------	------	---------	-----	--------------	----------

TABLET, EXTENDED RELEASE; ORAL

ISOSORBIDE MONONITRATE

@ ACTAVIS ELIZABETH 30MG

A075306	001	Dec 31, 1998	May DISC
---------	-----	--------------	----------

@ 60MG

A075306	002	Dec 31, 1998	May DISC
---------	-----	--------------	----------

ISRADIPINE

CAPSULE; ORAL

ISRADIPINE

AB	MIKAH PHARMA	2.5MG	A077169	001	Apr 24, 2006	May CMFD
----	--------------	-------	---------	-----	--------------	----------

@ 2.5MG

A077169	001	Apr 24, 2006	Feb DISC
---------	-----	--------------	----------

AB		5MG	A077169	002	Apr 24, 2006	May CMFD
----	--	-----	---------	-----	--------------	----------

@ 5MG

A077169	002	Apr 24, 2006	Feb DISC
---------	-----	--------------	----------

AB	WATSON LABS	2.5MG	A077317	001	Jan 05, 2006	May CTEC
----	-------------	-------	---------	-----	--------------	----------

		2.5MG	A077317	001	Jan 05, 2006	Feb CTEC
--	--	-------	---------	-----	--------------	----------

AB	+	5MG	A077317	002	Jan 05, 2006	May CTEC
----	---	-----	---------	-----	--------------	----------

	+	5MG	A077317	002	Jan 05, 2006	Feb CTEC
--	---	-----	---------	-----	--------------	----------

KETAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

KETALAR

AP	+ PAR STERILE PRODUCTS	EQ 10MG BASE/ML	N016812	001		Apr CAHN
----	------------------------	-----------------	---------	-----	--	----------

AP	+	EQ 50MG BASE/ML	N016812	002		Apr CAHN
----	---	-----------------	---------	-----	--	----------

AP	+	EQ 100MG BASE/ML	N016812	003		Apr CAHN
----	---	------------------	---------	-----	--	----------

KETAMINE HYDROCHLORIDE

>D>	AP	BEDFORD	EQ 50MG BASE/ML	A074524	001	Mar 22, 1996	Aug CAHN
-----	----	---------	-----------------	---------	-----	--------------	----------

>D>	AP		EQ 100MG BASE/ML	A074524	002	Mar 22, 1996	Aug CAHN
-----	----	--	------------------	---------	-----	--------------	----------

>A>	AP	EUROHLTH INTL	EQ 50MG BASE/ML	A074524	001	Mar 22, 1996	Aug CAHN
-----	----	---------------	-----------------	---------	-----	--------------	----------

>A>	AP		EQ 100MG BASE/ML	A074524	002	Mar 22, 1996	Aug CAHN
-----	----	--	------------------	---------	-----	--------------	----------

KETOCONAZOLEAEROSOL, FOAM; TOPICAL
EXTINA

AT	+ DELCOR ASSET CORP	2%	N021738	001	Jun 12, 2007	Jun CAHN
----	---------------------	----	---------	-----	--------------	----------

TABLET; ORAL

NIZORAL

AB	+ JANSSEN PHARMS	200MG	N018533	001		Mar CAHN
----	------------------	-------	---------	-----	--	----------

KETOROLAC TROMETHAMINE

INJECTABLE; INJECTION

KETOROLAC TROMETHAMINE

AP	AGILA SPECLTS	15MG/ML	A201155	001	Aug 04, 2014	Jul NEWA
----	---------------	---------	---------	-----	--------------	----------

AP		30MG/ML	A201155	002	Aug 04, 2014	Jul NEWA
----	--	---------	---------	-----	--------------	----------

@ BEDFORD 15MG/ML

A075222	001	Apr 26, 1999	Jul DISC
---------	-----	--------------	----------

@ 30MG/ML

A075222	002	Apr 26, 1999	Jul DISC
---------	-----	--------------	----------

INJECTABLE; INJECTION

KETOROLAC TROMETHAMINE

	@		30MG/ML	A075228	001	Apr 26, 1999	Jul DISC
	@	HIKMA MAPLE	15MG/ML	A075299	001	Nov 03, 1999	Jun DISC
	@		15MG/ML	A075772	001	Jul 21, 2004	Jun DISC
	@		30MG/ML	A075299	002	Nov 03, 1999	Jun DISC
	@		30MG/ML	A075772	002	Jul 21, 2004	Jun DISC
AP	+	HOSPIRA	15MG/ML	A074802	001	Jun 05, 1997	Jul CRLD
AP	+		30MG/ML	A074802	002	Jun 05, 1997	Jul CRLD
	@	SANDOZ	15MG/ML	A076271	001	Oct 06, 2004	Jul DISC
	@	SUN PHARMA GLOBAL	15MG/ML	A078737	001	Oct 06, 2008	Jul DISC
	@		30MG/ML	A078737	002	Oct 06, 2008	Jul DISC
	@	WOCKHARDT	30MG/ML	A077943	001	Mar 27, 2007	Jun DISC

SOLUTION/DROPS; OPHTHALMIC

ACUVAIL

AT	+	ALLERGAN	0.45%	N022427	001	Jul 22, 2009	Jan CFTG
		KETOROLAC TROMETHAMINE					
	@	AKORN	0.45%	A203376	001	Feb 10, 2014	Feb DISC
AT			0.45%	A203376	001	Feb 10, 2014	Jan NEWA

KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE

SOLUTION; IRRIGATION

OMIDRIA

	+	OMEROS	EQ 2.88MG BASE/ML; EQ 10.16MG BASE/ML	N205388	001	May 30, 2014	Jun CPOT
	+		EQ 4.24MG BASE/ML; EQ 12.4MG BASE/ML	N205388	001	May 30, 2014	May NEWA

LABETALOL HYDROCHLORIDE

INJECTABLE; INJECTION

LABETALOL HYDROCHLORIDE

>D>	AP	BEDFORD	5MG/ML	A075303	001	May 28, 1999	Aug CAHN
>A>	AP	EUROHLTH INTL	5MG/ML	A075303	001	May 28, 1999	Aug CAHN

LAMIVUDINE; ZIDOVUDINE

TABLET; ORAL

LAMIVUDINE AND ZIDOVUDINE

AB		HETERO LABS LTD V	150MG; 300MG	A203259	001	Feb 03, 2014	Jan NEWA
>A>	AB	MYLAN PHARMS INC	150MG; 300MG	A204005	001	Aug 28, 2014	Aug NEWA

LAMOTRIGINE

TABLET; ORAL

LAMOTRIGINE

>A>	@	ACTAVIS ELIZABETH	25MG	A078669	001	Apr 08, 2011	Aug CAHN
>A>	@		100MG	A078669	002	Apr 08, 2011	Aug CAHN
>A>	@		150MG	A078669	003	Apr 08, 2011	Aug CAHN
>A>	@		200MG	A078669	004	Apr 08, 2011	Aug CAHN
>D>	@	ACTAVIS TOTOWA	25MG	A078669	001	Apr 08, 2011	Aug CAHN
	@		25MG	A078669	001	Apr 08, 2011	May DISC
>D>	@		100MG	A078669	002	Apr 08, 2011	Aug CAHN
	@		100MG	A078669	002	Apr 08, 2011	May DISC
>D>	@		150MG	A078669	003	Apr 08, 2011	Aug CAHN
	@		150MG	A078669	003	Apr 08, 2011	May DISC
>D>	@		200MG	A078669	004	Apr 08, 2011	Aug CAHN
	@		200MG	A078669	004	Apr 08, 2011	May DISC
	@	PHARMASCIENCE INC	25MG	A078310	001	Feb 04, 2009	Jul DISC
BX			25MG	A078310	001	Feb 04, 2009	Jul CAHN
	@		100MG	A078310	002	Feb 04, 2009	Jul DISC
BX			100MG	A078310	002	Feb 04, 2009	Jul CAHN
	@		150MG	A078310	003	Feb 04, 2009	Jul DISC
BX			150MG	A078310	003	Feb 04, 2009	Jul CAHN
	@		200MG	A078310	004	Feb 04, 2009	Jul DISC
BX			200MG	A078310	004	Feb 04, 2009	Jul CAHN

TABLET, CHEWABLE; ORAL

LAMOTRIGINE

AB		ALEMBIC PHARMS LTD	5MG	A201168	001	Jun 12, 2014	May NEWA
AB			25MG	A201168	002	Jun 12, 2014	May NEWA
AB		JUBILANT GENERICS	5MG	A200220	001	Feb 28, 2011	Jul CAHN
AB			25MG	A200220	002	Feb 28, 2011	Jul CAHN

TABLET, ORALLY DISINTEGRATING; ORAL

LAMOTRIGINE

AB		IMPAX LABS INC	25MG	A200828	001	Jul 15, 2013	Jul CAHN
AB			50MG	A200828	002	Jul 15, 2013	Jul CAHN

TABLET, ORALLY DISINTEGRATING;ORAL
LAMOTRIGINE

AB		100MG	A200828	003	Jul 15, 2013	Jul CAHN
AB		200MG	A200828	004	Jul 15, 2013	Jul CAHN

LANSOPRAZOLE

TABLET, DELAYED RELEASE, ORALLY DISINTEGRATING;ORAL
LANSOPRAZOLE

@ ANI PHARMS INC	15MG	A078730	001	Oct 15, 2010	Jan CAHN
@	30MG	A078730	002	Oct 15, 2010	Jan CAHN

LETROZOLE

TABLET;ORAL
LETROZOLE

>A>	@ ACTAVIS ELIZABETH	2.5MG	A090292	001	Jul 13, 2011	Aug CAHN
>D>	@ ACTAVIS TOTOWA	2.5MG	A090292	001	Jul 13, 2011	Aug CAHN
	@	2.5MG	A090292	001	Jul 13, 2011	May DISC

LEUCOVORIN CALCIUM

INJECTABLE;INJECTION
LEUCOVORIN CALCIUM

>D>	AP	+	BEDFORD	EQ 50MG BASE/VIAL	A089384	001	Sep 14, 1987	Aug CAHN
>D>	AP	+		EQ 100MG BASE/VIAL	A089717	001	Mar 28, 1988	Aug CAHN
>A>	AP	+	EUROHLTH INTL	EQ 50MG BASE/VIAL	A089384	001	Sep 14, 1987	Aug CAHN
>A>	AP	+		EQ 100MG BASE/VIAL	A089717	001	Mar 28, 1988	Aug CAHN
			LEUCOVORIN CALCIUM PRESERVATIVE FREE					
>D>		+	BEDFORD	EQ 10MG BASE/ML	A040347	001	Apr 25, 2000	Aug CAHN
>D>	AP	+		EQ 200MG BASE/VIAL	A040056	001	May 23, 1995	Aug CAHN
>D>	AP	+		EQ 350MG BASE/VIAL	A040335	001	Apr 20, 2000	Aug CAHN
>A>		+	EUROHLTH INTL	EQ 10MG BASE/ML	A040347	001	Apr 25, 2000	Aug CAHN
>A>	AP	+		EQ 200MG BASE/VIAL	A040056	001	May 23, 1995	Aug CAHN
>A>	AP	+		EQ 350MG BASE/VIAL	A040335	001	Apr 20, 2000	Aug CAHN

LEUPROLIDE ACETATE

INJECTABLE;INJECTION
LUPRON DEPOT

@ ABBVIE ENDOCRINE INC	3.75MG/VIAL	N020011	001	Oct 22, 1990	May DISC
+	3.75MG	N020011	002	Oct 26, 1995	May NEWA

LEVALBUTEROL HYDROCHLORIDE

SOLUTION;INHALATION
LEVALBUTEROL HYDROCHLORIDE

AN	MYLAN SPECLT	EQ 0.0103% BASE	A077800	001	Mar 15, 2013	May CAHN
AN		EQ 0.021% BASE	A077800	002	Mar 15, 2013	May CAHN
AN		EQ 0.042% BASE	A077800	003	Mar 15, 2013	May CAHN
AN	WATSON LABS INC	EQ 0.0103% BASE	A077756	003	Apr 09, 2008	Jun CMFD
	@	EQ 0.0103% BASE	A077756	003	Apr 09, 2008	May DISC
AN		EQ 0.021% BASE	A077756	001	Apr 09, 2008	Jun CMFD
	@	EQ 0.021% BASE	A077756	001	Apr 09, 2008	May DISC
AN		EQ 0.042% BASE	A077756	002	Apr 09, 2008	Jun CMFD
	@	EQ 0.042% BASE	A077756	002	Apr 09, 2008	May DISC

LEVETIRACETAM

TABLET;ORAL
LEVETIRACETAM

@ SANDOZ	1GM	A077324	004	Jan 15, 2009	Jun DISC	
@	250MG	A077324	001	Jan 15, 2009	Jun DISC	
@	500MG	A077324	002	Jan 15, 2009	Jun DISC	
@	750MG	A077324	003	Jan 15, 2009	Jun DISC	
AB	VINTAGE PHARMS	250MG	A077319	001	Mar 20, 2009	Feb CAHN
AB		500MG	A077319	002	Mar 20, 2009	Feb CAHN
AB		750MG	A077319	003	Mar 20, 2009	Feb CAHN
@ WATSON LABS INC	1GM	A078797	001	Jan 15, 2009	May DISC	
	TABLET, EXTENDED RELEASE;ORAL					
	LEVETIRACETAM					
AB	VINTAGE PHARMS	500MG	A201464	001	May 25, 2012	Feb CAHN
AB		750MG	A201464	002	May 25, 2012	Feb CAHN

LEVOCARNITINE

INJECTABLE; INJECTION
LEVOCARNITINE

>D>	AP	BEDFORD	200MG/ML	A075567	001	Mar 29, 2001	Aug CAHN
>A>	AP	EUROHLTH INTL	200MG/ML	A075567	001	Mar 29, 2001	Aug CAHN

LEVOCETIRIZINE DIHYDROCHLORIDE

SOLUTION; ORAL
LEVOCETIRIZINE DIHYDROCHLORIDE

>A>	AA	APOTEX INC	2.5MG/5ML	A202915	001	Aug 21, 2014	Aug NEWA
	AA	L PERRIGO CO	2.5MG/5ML	A091263	001	Nov 07, 2011	Jan CAHN

TABLET; ORAL
LEVOCETIRIZINE DIHYDROCHLORIDE

		@ SANDOZ	5MG	A090486	001	Mar 26, 2013	May DISC
>A>	AB	SCIEGEN PHARMS INC	5MG	A203646	001	Sep 09, 2014	Aug NEWA

LEVOFLOXACIN

SOLUTION/DROPS; OPHTHALMIC
IQUIX

		@ SANTEN	1.5%	N021571	001	Mar 01, 2004	Jun DISC
AT		WATSON LABS INC	0.5%	A076826	001	Feb 10, 2011	May CAHN

LEVONORGESTREL

TABLET; ORAL
LEVONORGESTREL

>D>	AB	WATSON LABS	0.75MG	A078666	001	Jun 24, 2009	Aug DISC
>A>		@	0.75MG	A078666	001	Jun 24, 2009	Aug DISC

LEVORPHANOL TARTRATE

TABLET; ORAL
LEVORPHANOL TARTRATE

		+ ROXANE	2MG	A074278	001	Mar 31, 2000	Feb CRLD
--	--	----------	-----	---------	-----	--------------	----------

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION
LIDOCAINE HYDROCHLORIDE

AP		AGILA SPECLTS	2%	A202242	001	Apr 11, 2014	Mar NEWA
		LIDOPEN					
		@ MERIDIAN MEDCL TECHN	10%	N017549	001		Mar DISC
		XYLOCAINE PRESERVATIVE FREE					
		@ FRESENIUS KABI USA	10%	N016801	003		Jun DISC
		+	10%	N016801	003		Mar CTEC

JELLY; TOPICAL
ANESTACON

		@ BANNER PHARMACAPS	2%	A080429	001		Jun CAHN
		@ DSM PHARMS INC	2%	A080429	001		Jan CAHN

AT		GLYDO					
		SAGENT PHARMS	2%	A201094	001	Apr 28, 2014	Apr NEWA

AT		LIDOCAINE HYDROCHLORIDE					
		WATSON LABS INC	2%	A040837	001	Mar 23, 2011	May CAHN

SOLUTION; TOPICAL
LIDOCAINE HYDROCHLORIDE

AT		IGI LABS INC	4%	A204494	001	Mar 12, 2014	Feb NEWA
----	--	--------------	----	---------	-----	--------------	----------

SYSTEM; INTRADERMAL
ZINGO

		POWDER PHARMS	0.5MG	N022114	001	Aug 16, 2007	Mar CMFD
--	--	---------------	-------	---------	-----	--------------	----------

LIDOCAINE; PRILCAINE

CREAM; TOPICAL
EMLA

AB		+ WATSON LABS INC	2.5%; 2.5%	N019941	001	Dec 30, 1992	May CAHN
----	--	-------------------	------------	---------	-----	--------------	----------

LIOTHYRONINE SODIUM

INJECTABLE; INJECTION
TRIOSTAT

AP		+ PAR STERILE PRODUCTS	EQ 0.01MG BASE/ML	N020105	001	Dec 31, 1991	Apr CAHN
----	--	------------------------	-------------------	---------	-----	--------------	----------

LISINOPRILTABLET; ORAL
LISINOPRIL

AB	HIKMA INTL PHARMS	2.5MG	A076063	001	Jul 01, 2002	Jul CAHN
AB		5MG	A076063	002	Jul 01, 2002	Jul CAHN
AB		10MG	A076063	003	Jul 01, 2002	Jul CAHN
AB		20MG	A076063	004	Jul 01, 2002	Jul CAHN
AB		30MG	A076063	006	Jun 27, 2003	Jul CAHN
AB		40MG	A076063	005	Jul 01, 2002	Jul CAHN

LITHIUM CARBONATETABLET, EXTENDED RELEASE; ORAL
LITHOBID

AB	+ ANI PHARMS INC	300MG	N018027	001		Jun CAHN
----	------------------	-------	---------	-----	--	----------

LOMUSTINE

CAPSULE; ORAL

>D>	CEENU					
>D>	CORDEN PHARMA	10MG	N017588	001		Aug CTNA
>D>		40MG	N017588	002		Aug CTNA
>D>	+	100MG	N017588	003		Aug CTNA
>A>	GLEOSTINE					
>A>	CORDEN PHARMA	10MG	N017588	001		Aug CTNA
>A>		40MG	N017588	002		Aug CTNA
>A>	+	100MG	N017588	003		Aug CTNA

LORAZEPAMINJECTABLE; INJECTION
ATIVAN

AP	+ HIKMA MAPLE	2MG/ML	N018140	001		Jun CAHN
AP	+	4MG/ML	N018140	002		Jun CAHN

TABLET; ORAL
LORAZEPAM

@ WATSON LABS	1MG	A071118	001	Jul 24, 1986	May DISC
---------------	-----	---------	-----	--------------	----------

LOTEPREDNOL ETABONATEGEL; OPHTHALMIC
LOTEMAX

+ BAUSCH AND LOMB INC	0.5%	N202872	001	Sep 28, 2012	Feb CAHN
-----------------------	------	---------	-----	--------------	----------

LUBIPROSTONECAPSULE; ORAL
AMITIZA

>A>	SUCAMPO PHARMA LLC	8MCG	N021908	002	Apr 29, 2008	Aug CAHN
>A>	+	24MCG	N021908	001	Jan 31, 2006	Aug CAHN
>D>	SUCAMPO PHARMS	8MCG	N021908	002	Apr 29, 2008	Aug CAHN
>D>	+	24MCG	N021908	001	Jan 31, 2006	Aug CAHN

LULICONAZOLECREAM; TOPICAL
LUZU

+ MEDICIS	1%	N204153	001	Nov 14, 2013	Jan CRLD
-----------	----	---------	-----	--------------	----------

MAFENIDE ACETATEFOR SOLUTION; TOPICAL
MAFENIDE ACETATE

>D> AB	PAR FORM	5%	A201511	001	Feb 12, 2013	Aug CTEC
>A> AT		5%	A201511	001	Feb 12, 2013	Aug CTEC
	SULFAMYLON					
>D> AB	+ MYLAN INSTITUTIONAL	5%	N019832	003	Jun 05, 1998	Aug CTEC
>A> AT	+	5%	N019832	003	Jun 05, 1998	Aug CTEC

MAGNESIUM SULFATEINJECTABLE; INJECTION
MAGNESIUM SULFATE

AP	+ HOSPIRA	500MG/ML	A075151	001	Apr 25, 2000	Jun CRLD
----	-----------	----------	---------	-----	--------------	----------

MALATHION

LOTION; TOPICAL
MALATHION

@ MYLAN PHARMS INC 0.5% A078743 001 Mar 06, 2009 Mar DISC

MEBENDAZOLE

TABLET, CHEWABLE; ORAL
MEBENDAZOLE

+ AMEDRA PHARMS LLC 100MG A073580 001 Jan 04, 1995 Jun CAHN

MECHLORETHAMINE HYDROCHLORIDE

GEL; TOPICAL
VALCHLOR

+ ACTELION PHARMS LTD EQ 0.016% BASE N202317 001 Aug 23, 2013 Jun CPOT

MECLIZINE HYDROCHLORIDE

TABLET; ORAL
MECLIZINE HYDROCHLORIDE
@ WATSON LABS

25MG A085740 001 May DISC

MEDROXYPROGESTERONE ACETATE

TABLET; ORAL
MEDROXYPROGESTERONE ACETATE
@ USL PHARMA

10MG A088484 001 Jul 26, 1984 Mar DISC

MEFENAMIC ACID

CAPSULE; ORAL
MEFENAMIC ACID

AB VINTAGE PHARMS LLC 250MG A091608 001 Jun 02, 2014 May NEWA

MEGESTROL ACETATE

SUSPENSION; ORAL
MEGACE ES

>D> + PAR PHARM 125MG/ML N021778 001 Jul 05, 2005 Aug CFTG

>A> AB + 125MG/ML N021778 001 Jul 05, 2005 Aug CFTG

>A> MEGESTROL ACETATE

>A> AB TWI PHARMS INC 125MG/ML A203139 001 Aug 27, 2014 Aug NEWA

MELOXICAM

TABLET; ORAL
MELOXICAM

>D> AB STRIDES ARCOLAB LTD 7.5MG A077928 001 May 13, 2009 Aug CAHN

>D> AB 15MG A077928 002 May 13, 2009 Aug CAHN

>A> AB STRIDES PHARMA 7.5MG A077928 001 May 13, 2009 Aug CAHN

>A> AB 15MG A077928 002 May 13, 2009 Aug CAHN

AB SUN PHARM INDS INC 7.5MG A077937 001 Jul 19, 2006 Jul CAHN

AB 15MG A077937 002 Jul 19, 2006 Jul CAHN

@ YABAO PHARM 7.5MG A077933 001 Jul 19, 2006 May CAHN

@ 15MG A077933 002 Jul 19, 2006 May CAHN

MELPHALAN HYDROCHLORIDE

INJECTABLE; INJECTION
MELPHALAN HYDROCHLORIDE

>D> AP BEDFORD LABS EQ 50MG BASE/VIAL A090303 001 Oct 28, 2010 Aug CAHN

>A> AP EUROHLTH INTL EQ 50MG BASE/VIAL A090303 001 Oct 28, 2010 Aug CAHN

MEMANTINE HYDROCHLORIDE

TABLET; ORAL
MEMANTINE HYDROCHLORIDE
@ DR REDDYS LABS LTD

5MG A090048 001 Apr 14, 2010 Jul DISC

AB 5MG A090048 001 Apr 14, 2010 Jun CMFD

@ 10MG A090048 002 Apr 14, 2010 Jul DISC

AB 10MG A090048 002 Apr 14, 2010 Jun CMFD

>D> NAMENDA

>D> FOREST LABS 5MG N021487 001 Oct 16, 2003 Aug DISC

>A> @ 5MG N021487 001 Oct 16, 2003 Aug DISC

5MG N021487 001 Oct 16, 2003 Jul CTEC

AB 5MG N021487 001 Oct 16, 2003 Jun CTEC

>D> + 10MG N021487 002 Oct 16, 2003 Aug DISC

>A> @ 10MG N021487 002 Oct 16, 2003 Aug DISC

+ 10MG N021487 002 Oct 16, 2003 Jul CTEC

TABLET; ORAL								
NAMENDA								
AB	+	10MG	N021487	002	Oct 16, 2003	Jun	CTEC	
<u>MEPERIDINE HYDROCHLORIDE</u>								
INJECTABLE; INJECTION								
MEPERIDINE HYDROCHLORIDE								
	@ WATSON LABS	50MG/ML	A073444	001	Mar 17, 1992	May	DISC	
	@	100MG/ML	A073445	001	Mar 17, 1992	May	DISC	
MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE								
	@ INTL MEDICATION	10MG/ML	A081309	001	Aug 30, 1993	Mar	DISC	
	@ WATSON LABS	10MG/ML	A073443	001	Mar 17, 1992	May	DISC	
TABLET; ORAL								
MEPERIDINE HYDROCHLORIDE								
AA	SUN PHARM INDS INC	50MG	A040446	001	Aug 08, 2002	Jul	CAHN	
AA		100MG	A040446	002	Aug 08, 2002	Jul	CAHN	
	@ WATSON LABS	50MG	A040186	001	Jun 30, 1997	May	DISC	
	@	100MG	A040186	002	Jun 30, 1997	May	DISC	
<u>MEPIVACAINE HYDROCHLORIDE</u>								
INJECTABLE; INJECTION								
MEPIVACAINE HYDROCHLORIDE								
	@ WATSON LABS	1%	A088769	001	Nov 20, 1984	May	DISC	
	@	2%	A088770	001	Nov 20, 1984	May	DISC	
<u>MERCAPTOPURINE</u>								
SUSPENSION; ORAL								
PURIXAN								
+	NOVA LABS LTD	20MG/ML	N205919	001	Apr 28, 2014	Apr	NEWA	
<u>MESALAMINE</u>								
SUPPOSITORY; RECTAL								
CANASA								
+	FOREST LABS INC	1GM	N021252	002	Nov 05, 2004	Apr	CAHN	
@		500MG	N021252	001	Jan 05, 2001	Apr	CAHN	
<u>MESNA</u>								
INJECTABLE; INTRAVENOUS								
MESNA								
AP	AGILA SPECLTS	100MG/ML	A203364	001	Jul 18, 2014	Jul	NEWA	
>D> AP	BEDFORD	100MG/ML	A075739	001	Jan 09, 2004	Aug	CAHN	
>A> AP	EUROHLTH INTL	100MG/ML	A075739	001	Jan 09, 2004	Aug	CAHN	
<u>METAPROTERENOL SULFATE</u>								
SOLUTION; INHALATION								
METAPROTERENOL SULFATE								
AN	+	MYLAN SPECLT	0.4%	A071786	001	Aug 05, 1988	May	CAHN
AN	+		0.6%	A070804	001	Aug 17, 1987	May	CAHN
<u>METFORMIN HYDROCHLORIDE</u>								
TABLET; ORAL								
METFORMIN HYDROCHLORIDE								
AB	ATLAS PHARMS LLC	1GM	A076033	003	Jan 24, 2002	May	CAHN	
AB		500MG	A076033	001	Jan 24, 2002	May	CAHN	
AB		850MG	A076033	002	Jan 24, 2002	May	CAHN	
AB	SUN PHARM INDS INC	1GM	A075967	003	Jan 29, 2002	Jul	CAHN	
AB		500MG	A075967	001	Jan 29, 2002	Jul	CAHN	
AB		850MG	A075967	002	Jan 29, 2002	Jul	CAHN	
	@ WATSON LABS	1GM	A075979	003	Jan 24, 2002	May	DISC	
	@	500MG	A075979	001	Jan 24, 2002	May	DISC	
	@	850MG	A075979	002	Jan 24, 2002	May	DISC	
>A> AB	ZYDUS HLTHCARE	1GM	A203686	003	Aug 28, 2014	Aug	NEWA	
>A> AB		500MG	A203686	001	Aug 28, 2014	Aug	NEWA	
>A> AB		850MG	A203686	002	Aug 28, 2014	Aug	NEWA	
TABLET, EXTENDED RELEASE; ORAL								
GLUMETZA								
+	SALIX PHARMS INC	1GM	N021748	002	Jun 03, 2005	Feb	CTEC	
		500MG	N021748	001	Jun 03, 2005	Feb	CTEC	
+	SANTARUS INC	1GM	N021748	002	Jun 03, 2005	Mar	CAHN	
		500MG	N021748	001	Jun 03, 2005	Mar	CAHN	

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE

AB	TEVA PHARMS USA	500MG;EQ 15MG BASE	A091155	001	Mar 10, 2014	Feb NEWA
AB		850MG;EQ 15MG BASE	A091155	002	Mar 10, 2014	Feb NEWA

METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE

TABLET; ORAL

AVANDAMET

AB	SB PHARMCO	1GM;EQ 2MG BASE	N021410	004	Aug 25, 2003	Apr CFTG
AB	+	1GM;EQ 4MG BASE	N021410	005	Aug 25, 2003	Apr CFTG
AB		500MG;EQ 2MG BASE	N021410	002	Oct 10, 2002	Apr CFTG
AB		500MG;EQ 4MG BASE	N021410	003	Oct 10, 2002	Apr CFTG

ROSIGLITAZONE MALEATE AND METFORMIN HYDROCHLORIDE

AB	TEVA	1GM;EQ 4MG BASE	A077337	004	May 07, 2014	Apr NEWA
AB		1GM;EQ 2MG BASE	A077337	003	May 07, 2014	Apr NEWA
AB		500MG;EQ 2MG BASE	A077337	001	May 07, 2014	Apr NEWA
AB		500MG;EQ 4MG BASE	A077337	002	May 07, 2014	Apr NEWA

METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

KOMBIGLYZE XR

	ASTRAZENECA AB	1GM;EQ 2.5MG BASE	N200678	003	Nov 05, 2010	Apr CAHN
+		1GM;EQ 5MG BASE	N200678	002	Nov 05, 2010	Apr CAHN
		500MG;EQ 5MG BASE	N200678	001	Nov 05, 2010	Apr CAHN

METHAZOLAMIDE

TABLET; ORAL

METHAZOLAMIDE

AB	ANI PHARMS INC	25MG	A040001	001	Jun 30, 1993	Jan CAHN
AB		50MG	A040001	002	Jun 30, 1993	Jan CAHN

METHIMAZOLE

TABLET; ORAL

METHIMAZOLE

AB	SUN PHARM INDS INC	5MG	A040870	001	Sep 25, 2007	Jul CAHN
AB		10MG	A040870	002	Sep 25, 2007	Jul CAHN
AB	VINTAGE PHARMS	5MG	A202068	001	Mar 07, 2012	Feb CAHN
AB		10MG	A202068	002	Mar 07, 2012	Feb CAHN

METHOCARBAMOL

TABLET; ORAL

METHOCARBAMOL

AA	HIKMA INTL PHARMS	500MG	A085159	001		Jul CAHN
AA		750MG	A085123	001		Jul CAHN
	@ WATSON LABS	500MG	A085180	001		May DISC
	@	750MG	A085192	001		May DISC
	ROBAXIN					
AA	+ AUXILIUM PHARMS LLC	500MG	N011011	004		Apr CAHN
	ROBAXIN-750					
AA	+ AUXILIUM PHARMS LLC	750MG	N011011	006		Apr CAHN

METHOHEXITAL SODIUM

INJECTABLE; INJECTION

BREVITAL SODIUM

+	PAR STERILE PRODUCTS	2.5GM/VIAL	N011559	002		Apr CAHN
@		5GM/VIAL	N011559	003		Apr CAHN
+		200MG/VIAL	N011559	004	Dec 21, 2012	Apr CAHN
+		500MG/VIAL	N011559	001		Apr CAHN

METHOTREXATE

SOLUTION; SUBCUTANEOUS

RASUVO

MEDAC PHARMA INC

7.5MG/0.15ML	N205776	001	Jul 10, 2014	Jul NEWA
10MG/0.20ML	N205776	002	Jul 10, 2014	Jul NEWA
12.5MG/0.25ML	N205776	003	Jul 10, 2014	Jul NEWA
15MG/0.30ML	N205776	004	Jul 10, 2014	Jul NEWA
17.5MG/0.35ML	N205776	005	Jul 10, 2014	Jul NEWA
20MG/0.4ML	N205776	006	Jul 10, 2014	Jul NEWA
22.5MG/0.45ML	N205776	007	Jul 10, 2014	Jul NEWA
25MG/0.5ML	N205776	008	Jul 10, 2014	Jul NEWA

SOLUTION;SUBCUTANEOUS
RASUVO27.5MG/0.55ML
30MG/0.6MLN205776 009 Jul 10, 2014 Jul NEWA
N205776 010 Jul 10, 2014 Jul NEWAMETHOTREXATE SODIUMINJECTABLE;INJECTION
METHOTREXATE SODIUM

>D>	AP	+	BEDFORD	EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	A089341	001	Sep 16, 1986	Aug CAHN
>D>		+		EQ 200MG BASE/8ML (EQ 25MG BASE/ML)	A089342	001	Sep 16, 1986	Aug CAHN
>A>	AP	+	EUROHLTH INTL	EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	A089341	001	Sep 16, 1986	Aug CAHN
>A>		+		EQ 200MG BASE/8ML (EQ 25MG BASE/ML)	A089342	001	Sep 16, 1986	Aug CAHN
METHOTREXATE SODIUM PRESERVATIVE FREE								
>D>		+	BEDFORD	EQ 1GM BASE/VIAL	A040632	001	Aug 12, 2005	Aug CAHN
>D>	AP	+		EQ 50MG BASE/2ML (EQ 25MG BASE/ML)	A089340	001	Sep 16, 1986	Aug CAHN
>D>	AP	+		EQ 250MG BASE/10ML (EQ 25MG BASE/ML)	A089343	001	Sep 16, 1986	Aug CAHN
>A>		+	EUROHLTH INTL	EQ 1GM BASE/VIAL	A040632	001	Aug 12, 2005	Aug CAHN
>A>	AP	+		EQ 50MG BASE/2ML (EQ 25MG BASE/ML)	A089340	001	Sep 16, 1986	Aug CAHN
>A>	AP	+		EQ 250MG BASE/10ML (EQ 25MG BASE/ML)	A089343	001	Sep 16, 1986	Aug CAHN

METHOXSALLENCAPSULE;ORAL
METHOXSALLEN

>D>	AB		STRIDES ARCOLAB LTD	10MG	A202687	001	Jun 05, 2014	Aug CAHN
	AB			10MG	A202687	001	Jun 05, 2014	May NEWA
>A>	AB		STRIDES PHARMA	10MG	A202687	001	Jun 05, 2014	Aug CAHN
OXSORALEN-ULTRA								
	AB	+	DOW PHARM	10MG	N019600	001	Oct 30, 1986	May CTEC

METHSCOPOLAMINE BROMIDETABLET;ORAL
METHSCOPOLAMINE BROMIDE

AA			VINTAGE PHARMS	2.5MG	A040624	001	Dec 28, 2006	Feb CAHN
AA				5MG	A040624	002	Dec 28, 2006	Feb CAHN

METHYLDOPATABLET;ORAL
METHYLDOPA

AB			MYLAN	250MG	A070076	002	Apr 18, 1985	Apr CMS1
----	--	--	-------	-------	---------	-----	--------------	----------

METHYLERGONOVINE MALEATEINJECTABLE;INJECTION
METHERGINE

AP	+	EDISON THERAPS LLC	0.2MG/ML	N006035	004			Feb CAHN
----	---	--------------------	----------	---------	-----	--	--	----------

TABLET;ORAL
METHERGINE

AB	+	EDISON THERAPS LLC	0.2MG	N006035	003			Feb CAHN
----	---	--------------------	-------	---------	-----	--	--	----------

METHYLPHENIDATE HYDROCHLORIDETABLET;ORAL
METHYLPHENIDATE HYDROCHLORIDE

AB			COREPHARMA	5MG	A091159	001	Mar 12, 2014	Feb NEWA
AB				10MG	A091159	002	Mar 12, 2014	Feb NEWA
AB				20MG	A091159	003	Mar 12, 2014	Feb NEWA
AB			SUN PHARM INDS INC	5MG	A090710	001	Mar 15, 2012	Jun CAHN
AB				10MG	A090710	002	Mar 15, 2012	Jun CAHN
AB				20MG	A090710	003	Mar 15, 2012	Jun CAHN

TABLET, EXTENDED RELEASE;ORAL
METHYLPHENIDATE HYDROCHLORIDE
@ WATSON LABS 20MG

A040410	001	Feb 09, 2001	May DISC
---------	-----	--------------	----------

METOCLOPRAMIDE HYDROCHLORIDETABLET, ORALLY DISINTEGRATING;ORAL
METOCLOPRAMIDE HYDROCHLORIDE

>A>	AB		NOVEL LABS INC	EQ 5MG BASE	A202191	001	Aug 15, 2014	Aug NEWA
>A>				EQ 10MG BASE	A202191	002	Aug 15, 2014	Aug NEWA

TABLET, ORALLY DISINTEGRATING;ORAL
METOZOLV ODT

>D>	+	SALIX PHARMS	EQ 5MG BASE	N022246	001	Sep 04, 2009	Aug CFTG
>A>	AB	+	EQ 5MG BASE	N022246	001	Sep 04, 2009	Aug CFTG

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE;ORAL
METOPROLOL SUCCINATE

>D>	AB	REDDYS	EQ 100MG BASE	A078889	001	Aug 15, 2012	Aug CPOT
>A>	AB		EQ 100MG TARTRATE	A078889	001	Aug 15, 2012	Aug CPOT
>D>	AB		EQ 200MG BASE	A078889	002	Aug 15, 2012	Aug CPOT
>A>	AB		EQ 200MG TARTRATE	A078889	002	Aug 15, 2012	Aug CPOT

METOPROLOL TARTRATE

INJECTABLE;INJECTION
METOPROLOL TARTRATE

>A>	AP	GLAND PHARMA LTD	1MG/ML	A204205	001	Aug 27, 2014	Aug NEWA
		TABLET;ORAL					
		METOPROLOL TARTRATE					
	AB	SUN PHARM INDS INC	25MG	A076670	001	Jan 15, 2004	Jul CAHN
	AB		50MG	A074644	001	Dec 10, 1996	Jul CAHN
	AB		100MG	A074644	002	Dec 10, 1996	Jul CAHN

METRONIDAZOLE

GEL;VAGINAL
METRONIDAZOLE

		VALEANT PHARM NORTH	1.3%	N205223	001	Mar 24, 2014	Mar NEWA
		WATSON LABS INC	1.3%	N205223	001	Mar 24, 2014	Jun CAHN

TABLET;ORAL

METRONIDAZOLE

AB		UNICHEM LABS LTD	250MG	A203458	001	Jan 22, 2014	Jan NEWA
AB			500MG	A203458	002	Jan 22, 2014	Jan NEWA
	@	VIVIMED LABS	250MG	A070040	001	Jan 29, 1985	Apr CAHN
	@		500MG	A070039	001	Jan 29, 1985	Apr CAHN
	@	WATSON LABS	250MG	N018764	001	Sep 17, 1982	May DISC
	@		500MG	N018764	002	Dec 20, 1982	May DISC
AB		WATSON LABS INC	500MG	A070044	001	Feb 08, 1985	Mar CAHN

MICONAZOLE

TABLET;BUCCAL
ORAVIG

+	BIOALLIANCE PHARMA	50MG	N022404	001	Apr 16, 2010	Apr CAHN
---	--------------------	------	---------	-----	--------------	----------

MICONAZOLE NITRATE; PETROLATUM, WHITE; ZINC OXIDE

OINTMENT;TOPICAL
VUSION

+	DELCOR ASSET	0.25%;81.35%;15%	N021026	001	Feb 16, 2006	Jun CAHN
---	--------------	------------------	---------	-----	--------------	----------

MIDAZOLAM HYDROCHLORIDE

INJECTABLE;INJECTION
MIDAZOLAM HYDROCHLORIDE

AP		BEDFORD LABS	EQ 1MG BASE/ML	A075421	002	Jun 20, 2000	Apr CAHN
AP			EQ 5MG BASE/ML	A075421	001	Jun 20, 2000	Apr CAHN
		MIDAZOLAM HYDROCHLORIDE	PRESERVATIVE FREE				
>A>	AP	BD RX	EQ 1MG BASE/ML	A203460	001	Aug 22, 2014	Aug NEWA
>A>	AP		EQ 5MG BASE/ML	A203460	002	Aug 22, 2014	Aug NEWA

MILRINONE LACTATE

INJECTABLE;INJECTION
MILRINONE LACTATE

>A>	AP	HOSPIRA INC	EQ 1MG BASE/ML	A203280	001	Sep 03, 2014	Aug NEWA
-----	----	-------------	----------------	---------	-----	--------------	----------

MILTEFOSINE

CAPSULE;ORAL
IMPAVIDO

		PALADIN THERAP	50MG	N204684	001	Mar 19, 2014	Mar NEWA
--	--	----------------	------	---------	-----	--------------	----------

MINOCYCLINE HYDROCHLORIDE

CAPSULE;ORAL

DYNACIN

>A>	@ CNTY LINE PHARMS	EQ 50MG BASE	A063066	001	Aug 14, 1990	Aug CAHN
AB		EQ 75MG BASE	A063067	002	Sep 15, 1999	Jul CAHN
AB		EQ 100MG BASE	A063067	001	Jul 31, 1990	Jul CAHN
>D>	@ MEDICIS	EQ 50MG BASE	A063066	001	Aug 14, 1990	Aug CAHN
AB		EQ 75MG BASE	A063067	002	Sep 15, 1999	May CAHN
AB		EQ 100MG BASE	A063067	001	Jul 31, 1990	May CAHN

MINOCYCLINE HYDROCHLORIDE

AB	SUN PHARM INDS INC	EQ 50MG BASE	A090867	001	May 13, 2013	Jul CAHN
AB		EQ 75MG BASE	A090867	002	May 13, 2013	Jul CAHN
AB		EQ 100MG BASE	A090867	003	May 13, 2013	Jul CAHN

TABLET, EXTENDED RELEASE;ORAL

MINOCYCLINE HYDROCHLORIDE

>A> AB	MYLAN PHARMS INC	EQ 80MG BASE	A203443	002	Aug 22, 2014	Aug NEWA
>A> AB		EQ 105MG BASE	A203443	003	Aug 22, 2014	Aug NEWA

SOLODYN

>D>	+ MEDICIS	EQ 80MG BASE	N050808	007	Aug 27, 2010	Aug CTEC
>A> AB	+	EQ 80MG BASE	N050808	007	Aug 27, 2010	Aug CTEC
>D>		EQ 105MG BASE	N050808	006	Aug 27, 2010	Aug CTEC
>A> AB		EQ 105MG BASE	N050808	006	Aug 27, 2010	Aug CTEC

MIRTAZAPINE

TABLET;ORAL

MIRTAZAPINE

>A>	@ ACTAVIS ELIZABETH	15MG	A076241	001	Jun 25, 2003	Aug CAHN
>A>	@	30MG	A076241	002	Jun 25, 2003	Aug CAHN
>A>	@	45MG	A076241	003	Jun 25, 2003	Aug CAHN
>D>	@ ACTAVIS TOTOWA	15MG	A076241	001	Jun 25, 2003	Aug CAHN
>D>	@	30MG	A076241	002	Jun 25, 2003	Aug CAHN
>D>	@	45MG	A076241	003	Jun 25, 2003	Aug CAHN
AB	SUN PHARM INDS INC	7.5MG	A076541	004	Apr 22, 2004	Jul CAHN
AB		15MG	A076541	001	Apr 22, 2004	Jul CAHN
AB		30MG	A076541	002	Apr 22, 2004	Jul CAHN
AB		45MG	A076541	003	Apr 22, 2004	Jul CAHN

TABLET, ORALLY DISINTEGRATING;ORAL

MIRTAZAPINE

@	ACTAVIS ELIZABETH	15MG	A076689	001	Aug 31, 2005	Jun CAHN
@		30MG	A076689	002	Aug 31, 2005	Jun CAHN
@		45MG	A076689	003	Aug 31, 2005	Jun CAHN

MITOXANTRONE HYDROCHLORIDE

INJECTABLE;INJECTION

MITOXANTRONE HYDROCHLORIDE

>D> AP	BEDFORD	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	A076611	001	Apr 11, 2006	Aug CAHN
>D> AP		EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)	A076611	002	Apr 11, 2006	Aug CAHN
>D> AP		EQ 30MG BASE/15ML (EQ 2MG BASE/ML)	A076611	003	Apr 11, 2006	Aug CAHN
>A> AP	EUROHLTH INTL	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	A076611	001	Apr 11, 2006	Aug CAHN
>A> AP		EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)	A076611	002	Apr 11, 2006	Aug CAHN
>A> AP		EQ 30MG BASE/15ML (EQ 2MG BASE/ML)	A076611	003	Apr 11, 2006	Aug CAHN

MIVACURIUM CHLORIDE

INJECTABLE;INJECTION

MIVACURIUM CHLORIDE

@	AGILA SPECLTS	EQ 2MG BASE/ML	A078562	001	Apr 30, 2009	Feb CAHN
---	---------------	----------------	---------	-----	--------------	----------

MODAFINIL

TABLET;ORAL

MODAFINIL

AB	APOTEX INC	100MG	A077667	001	Feb 03, 2014	Jan NEWA
AB		200MG	A077667	002	Feb 03, 2014	Jan NEWA

MOMETASONE FUROATE

AEROSOL, METERED;INHALATION

ASMANEX HFA

	MERCK SHARP DOHME	0.10MG/INH	N205641	001	Apr 25, 2014	Apr NEWA
+		0.20MG/INH	N205641	002	Apr 25, 2014	Apr NEWA

POWDER; INHALATION

ASMANEX TWISTHALER

MERCK SHARP DOHME	0.11MG/INH	N021067	002	Feb 01, 2008	Mar CAHN
+	0.22MG/INH	N021067	001	Mar 30, 2005	Mar CAHN

MOMETASONE FUROATE MONOHYDRATE

SPRAY, METERED; NASAL

NASONEX

+	MERCK SHARP DOHME	EQ 0.05MG BASE/SPRAY	N020762	001	Oct 01, 1997	May CAHN
---	-------------------	----------------------	---------	-----	--------------	----------

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

AVINZA

AB2	KING PHARMS LLC	30MG	N021260	001	Mar 20, 2002	Mar CAHN
AB2		45MG	N021260	005	Dec 18, 2008	Mar CAHN
AB2		60MG	N021260	002	Mar 20, 2002	Mar CAHN
AB2		75MG	N021260	006	Dec 18, 2008	Mar CAHN
AB2		90MG	N021260	003	Mar 20, 2002	Mar CAHN
AB2	+	120MG	N021260	004	Mar 20, 2002	Mar CAHN

INJECTABLE; INJECTION

MORPHINE SULFATE

@ WATSON LABS

@

@

@

SOLUTION; ORAL

MORPHINE SULFATE

AA	CARACO	10MG/5ML	A201011	001	Feb 05, 2014	Jan NEWA
AA		20MG/5ML	A201011	002	Feb 05, 2014	Jan NEWA

MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

EMBEDA

	ALPHARMA PHARMS	20MG; 0.8MG	N022321	001	Aug 13, 2009	Mar CAHN
		30MG; 1.2MG	N022321	002	Aug 13, 2009	Mar CAHN
		50MG; 2MG	N022321	003	Aug 13, 2009	Mar CAHN
+		60MG; 2.4MG	N022321	004	Aug 13, 2009	Mar CAHN
		80MG; 3.2MG	N022321	005	Aug 13, 2009	Mar CAHN
		100MG; 4MG	N022321	006	Aug 13, 2009	Mar CAHN

MOXIFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

>A> MOXIFLOXACIN HYDROCHLORIDE

>A> AT	LUPIN LTD	EQ 0.5% BASE	A202867	001	Sep 04, 2014	Aug NEWA
	VIGAMOX					

>D>	+	ALCON PHARMS LTD	EQ 0.5% BASE	N021598	001	Apr 15, 2003	Aug CFTG
>A> AT	+		EQ 0.5% BASE	N021598	001	Apr 15, 2003	Aug CFTG

TABLET; ORAL

AVELOX

AB	+	BAYER HLTHCARE	EQ 400MG BASE	N021085	001	Dec 10, 1999	Feb CFTG
		MOXIFLOXACIN HYDROCHLORIDE					
AB		AUROBINDO PHARMA LTD	EQ 400MG BASE	A202632	001	Mar 04, 2014	Feb NEWA
AB		DR REDDYS LABS LTD	EQ 400MG BASE	A076938	001	Mar 04, 2014	Feb NEWA
AB		TEVA PHARMS USA	EQ 400MG BASE	A077437	001	Feb 18, 2014	Feb NEWA
AB		TORRENT PHARMS LTD	EQ 400MG BASE	A200160	001	Apr 03, 2014	Mar NEWA

MYCOPHENOLATE MOFETIL

CAPSULE; ORAL

MYCOPHENOLATE MOFETIL

>D> AB	STRIDES ARCOLAB LTD	250MG	A090055	001	Jun 10, 2010	Aug CAHN
>A> AB	STRIDES PHARMA	250MG	A090055	001	Jun 10, 2010	Aug CAHN

TABLET; ORAL

MYCOPHENOLATE MOFETIL

>D> AB	STRIDES ARCOLAB LTD	500MG	A090456	001	Jun 10, 2010	Aug CAHN
>A> AB	STRIDES PHARMA	500MG	A090456	001	Jun 10, 2010	Aug CAHN

MYCOPHENOLIC ACID

TABLET, DELAYED RELEASE;ORAL
MYCOPHENOLIC ACID

>A> AB APOTEX INC 360MG A091558 002 Aug 19, 2014 Aug NEWA

NAFCILLIN SODIUM

INJECTABLE;INJECTION
NAFCILLIN SODIUM

AP AGILA SPECLTS EQ 1GM BASE/VIAL A200002 001 Apr 07, 2014 Mar NEWA
 AP EQ 2GM BASE/VIAL A200002 002 Apr 07, 2014 Mar NEWA
 AP ANTIBIOTICE EQ 1GM BASE/VIAL A090560 001 Oct 03, 2011 Jan CPOT
 AP EQ 2GM BASE/VIAL A090560 002 Oct 03, 2011 Jan CPOT
 AP ISTITUTO BIO ITA SPA EQ 1GM BASE/VIAL A090002 001 Jun 30, 2011 Feb CAHN
 AP EQ 2GM BASE/VIAL A090002 002 Jun 30, 2011 Feb CAHN
 AP EQ 10GM BASE/VIAL A090005 001 Apr 20, 2011 Feb CAHN

NALOXONE HYDROCHLORIDE

INJECTABLE;INJECTION
NALOXONE HYDROCHLORIDE

AP MYLAN INSTITUTIONAL 0.4MG/ML A204997 001 Mar 06, 2014 Feb NEWA
 SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS
 EVZIO
 + KALEO INC 0.4MG/0.4ML N205787 001 Apr 03, 2014 Apr NEWA

NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL
TARGINIQ

@ PURDUE PHARMA LP 5MG;10MG N205777 001 Jul 23, 2014 Jul DISC
 @ 10MG;20MG N205777 002 Jul 23, 2014 Jul DISC
 @ 20MG;40MG N205777 003 Jul 23, 2014 Jul DISC

NAPHAZOLINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC
ALBALON

@ ALLERGAN 0.1% A080248 001 Jun DISC
 NAPHAZOLINE HYDROCHLORIDE
 + AKORN INC 0.1% A083590 001 Jun CRLD

NAPROXEN

TABLET;ORAL
NAPROXEN

@ DAVA PHARMS INC 250MG A074410 001 Apr 28, 1995 Feb DISC
 @ 375MG A074410 002 Apr 28, 1995 Feb DISC
 @ 500MG A074410 003 Apr 28, 1995 Feb DISC
 @ WATSON LABS 250MG A074457 001 May 31, 1995 May DISC
 @ 375MG A074457 002 May 31, 1995 May DISC
 @ 500MG A074457 003 May 31, 1995 May DISC

NAPROXEN SODIUM

TABLET;ORAL
NAPROXEN SODIUM

@ WATSON LABS EQ 250MG BASE A074455 001 May 31, 1995 May DISC
 @ EQ 500MG BASE A074455 002 May 31, 1995 May DISC

TABLET, EXTENDED RELEASE;ORAL
NAPRELAN

>D> ALMATICA PHARMA INC EQ 375MG BASE N020353 001 Jan 05, 1996 Aug CTEC
 >A> AB EQ 375MG BASE N020353 001 Jan 05, 1996 Aug CTEC
 >D> EQ 500MG BASE N020353 002 Jan 05, 1996 Aug CTEC
 >A> AB EQ 500MG BASE N020353 002 Jan 05, 1996 Aug CTEC
 NAPROXEN SODIUM
 >D> @ ACTAVIS LABS FL INC EQ 375MG BASE A075416 002 Apr 23, 2003 Aug CMFD
 >A> AB EQ 375MG BASE A075416 002 Apr 23, 2003 Aug CMFD
 >D> @ EQ 500MG BASE A075416 001 Aug 27, 2002 Aug CMFD
 >A> AB EQ 500MG BASE A075416 001 Aug 27, 2002 Aug CMFD

NARATRIPTAN HYDROCHLORIDE

TABLET;ORAL
NARATRIPTAN

AB APOTEX CORP EQ 1MG BASE A091373 001 Apr 22, 2011 Jan CAIN
 AB EQ 2.5MG BASE A091373 002 Apr 22, 2011 Jan CAIN
 AB SUN PHARM INDS LTD EQ 2.5MG BASE A091552 001 Feb 14, 2011 Jan CAIN

NEVIRAPINETABLET; ORAL
NEVIRAPINE

>D>	AB	STRIDES ARCOLAB LTD	200MG	A078195	001	May 22, 2012	Aug CAHN
	AB		200MG	A078195	001	May 22, 2012	Jan CAHN
>A>	AB	STRIDES PHARMA	200MG	A078195	001	May 22, 2012	Aug CAHN

TABLET, EXTENDED RELEASE; ORAL
NEVIRAPINE

	AB	APOTEX INC	400MG	A205258	001	Apr 03, 2014	Mar NEWA
	AB	SANDOZ	400MG	A203411	001	Apr 03, 2014	Mar NEWA
	AB	VIRAMUNE XR					
	AB	+ BOEHRINGER INGELHEIM	400MG	N201152	001	Mar 25, 2011	Mar CFTG

NIACINTABLET, EXTENDED RELEASE; ORAL
NIACIN

	AB	LUPIN LTD	1GM	A090446	001	Mar 20, 2014	Mar NEWA
	AB		500MG	A090860	001	Mar 20, 2014	Mar NEWA
	AB		750MG	A090892	001	Mar 20, 2014	Mar NEWA
	AB	SUN PHARMA GLOBAL	1GM	A200484	002	Apr 23, 2014	Apr NEWA
	AB		500MG	A200484	001	Apr 23, 2014	Apr NEWA
	AB		750MG	A201273	001	Apr 23, 2014	Apr NEWA

NICARDIPINE HYDROCHLORIDECAPSULE; ORAL
CARDENE

	AB	CHIESI USA INC	20MG	N019488	001	Dec 21, 1988	Apr CAHN
	AB	+	30MG	N019488	002	Dec 21, 1988	Apr CAHN

NICARDIPINE HYDROCHLORIDE

	AB	ANI PHARMS INC	20MG	A074439	001	Dec 10, 1996	Jan CAHN
	AB		20MG	A074540	001	Oct 28, 1996	Jan CAHN
	AB		30MG	A074439	002	Dec 10, 1996	Jan CAHN
	AB		30MG	A074540	002	Oct 28, 1996	Jan CAHN
		@ WATSON LABS	20MG	A074670	001	Oct 28, 1996	May DISC
		@	30MG	A074670	002	Oct 28, 1996	May DISC

CAPSULE, EXTENDED RELEASE; ORAL
CARDENE SR

	+	CHIESI USA INC	30MG	N020005	001	Feb 21, 1992	Apr CAHN
		@	45MG	N020005	002	Feb 21, 1992	Apr CAHN
	+		60MG	N020005	003	Feb 21, 1992	Apr CAHN

INJECTABLE; INJECTION

CARDENE

AP	+	CHIESI USA INC	25MG/10ML (2.5MG/ML)	N019734	001	Jan 30, 1992	Apr CAHN
----	---	----------------	----------------------	---------	-----	--------------	----------

NICARDIPINE HYDROCHLORIDE

AP		LUITPOLD	25MG/10ML (2.5MG/ML)	A090534	001	Nov 17, 2009	Jan CAHN
----	--	----------	----------------------	---------	-----	--------------	----------

INJECTABLE; INTRAVENOUS

CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER

+	CHIESI USA INC	40MG/200ML (0.2MG/ML)	N019734	004	Nov 07, 2008	Apr CAHN
---	----------------	-----------------------	---------	-----	--------------	----------

CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER

+	CHIESI USA INC	20MG/200ML (0.1MG/ML)	N019734	003	Jul 31, 2008	Apr CAHN
---	----------------	-----------------------	---------	-----	--------------	----------

CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER

+	CHIESI USA INC	20MG/200ML (0.1MG/ML)	N019734	002	Jul 31, 2008	Apr CAHN
---	----------------	-----------------------	---------	-----	--------------	----------

CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER

+	CHIESI USA INC	40MG/200ML (0.2MG/ML)	N019734	005	Nov 07, 2008	Apr CAHN
---	----------------	-----------------------	---------	-----	--------------	----------

NIFEDIPINETABLET, EXTENDED RELEASE; ORAL
NIFEDIPINE

	AB2	TWI PHARMS INC	30MG	A203126	001	Apr 03, 2014	Mar NEWA
	AB2		60MG	A203126	002	Apr 03, 2014	Mar NEWA
	AB2		90MG	A203126	003	Apr 03, 2014	Mar NEWA

NIMODIPINECAPSULE; ORAL
NIMODIPINE

	AB	THEPHARMANETWORK LLC	30MG	A090103	001	Apr 07, 2014	Mar NEWA
--	----	----------------------	------	---------	-----	--------------	----------

NITROFURANTOINSUSPENSION;ORAL
NITROFURANTOIN

>A>	AB	NOVEL LABS INC	25MG/5ML	A201693	001	Sep 08, 2014	Aug NEWA
-----	----	----------------	----------	---------	-----	--------------	----------

NITROGLYCERINFILM, EXTENDED RELEASE;TRANSDERMAL
MINITRAN

>D>	AB1	MEDICIS	0.1MG/HR	A089771	001	Aug 30, 1996	Aug CAHN
>D>	AB1		0.6MG/HR	A089774	001	Aug 30, 1996	Aug CAHN
>A>	AB1	VALEANT PHARM NORTH	0.1MG/HR	A089771	001	Aug 30, 1996	Aug CAHN
>A>	AB1		0.6MG/HR	A089774	001	Aug 30, 1996	Aug CAHN

NITROGLYCERIN

@ KREMERS URBAN PHARMS 0.2MG/HR
@ 0.4MG/HR

A075115	001	Aug 10, 2004	May DISC
A075115	002	Aug 10, 2004	May DISC

OINTMENT;INTRA-ANAL
RECTIV

+	FOREST LABS INC	0.4%	N021359	001	Jun 21, 2011	Apr CAHN
---	-----------------	------	---------	-----	--------------	----------

NIZATIDINECAPSULE;ORAL
NIZATIDINE

		@ ANI PHARMS INC	150MG	A075461	001	Jul 08, 2002	Jan CAHN
AB			150MG	A075668	001	Sep 12, 2002	Jan CAHN
		@	300MG	A075461	002	Jul 08, 2002	Jan CAHN
AB			300MG	A075668	002	Sep 12, 2002	Jan CAHN

NORFLOXACINTABLET;ORAL
NOROXIN

@	MERCK	400MG	N019384	002	Oct 31, 1986	Jul DISC
---	-------	-------	---------	-----	--------------	----------

NORTRIPTYLINE HYDROCHLORIDESOLUTION;ORAL
NORTRIPTYLINE HYDROCHLORIDE

AA	+	PHARM ASSOC	EQ 10MG BASE/5ML	A075606	001	Aug 28, 2000	Apr CRLD
----	---	-------------	------------------	---------	-----	--------------	----------

NYSTATINCREAM;TOPICAL
MYCOSTATIN

@	DELCOR ASSET CORP	100,000 UNITS/GM	A060575	001		Jul CAHN
---	-------------------	------------------	---------	-----	--	----------

OINTMENT;TOPICAL
MYCOSTATIN

@	DELCOR ASSET CORP	100,000 UNITS/GM	A060571	001		Jul CAHN
---	-------------------	------------------	---------	-----	--	----------

POWDER;TOPICAL
MYCOSTATIN

@	DELCOR ASSET CORP	100,000 UNITS/GM	A060578	001		Jul CAHN
---	-------------------	------------------	---------	-----	--	----------

SUSPENSION;ORAL
MYCOSTATIN

@	DELCOR ASSET CORP	100,000 UNITS/ML	A061533	001		Jul CAHN
---	-------------------	------------------	---------	-----	--	----------

TABLET;ORAL
MYCOSTATIN

@	DELCOR ASSET CORP	500,000 UNITS	A060574	001		Jul CAHN
---	-------------------	---------------	---------	-----	--	----------

TABLET;VAGINAL
MYCOSTATIN

@	DELCOR ASSET CORP	100,000 UNITS	A060577	001		Jul CAHN
---	-------------------	---------------	---------	-----	--	----------

OCTREOTIDE ACETATEINJECTABLE;INJECTION
OCTREOTIDE ACETATE

>D>	AP	+	BEDFORD	EQ 0.2MG BASE/ML	A076330	001	Apr 08, 2005	Aug CAHN
>D>	AP	+		EQ 1MG BASE/ML	A076330	002	Apr 08, 2005	Aug CAHN
>A>	AP	+	EUROHLTH INTL	EQ 0.2MG BASE/ML	A076330	001	Apr 08, 2005	Aug CAHN
>A>	AP	+		EQ 1MG BASE/ML	A076330	002	Apr 08, 2005	Aug CAHN

OCTREOTIDE ACETATE (PRESERVATIVE FREE)

>D>	AP	+	BEDFORD	EQ 0.05MG BASE/ML	A076313	001	Mar 28, 2005	Aug CAHN
>D>	AP	+		EQ 0.1MG BASE/ML	A076313	003	Mar 28, 2005	Aug CAHN
>D>	AP	+		EQ 0.5MG BASE/ML	A076313	002	Mar 28, 2005	Aug CAHN
>A>	AP	+	EUROHLTH INTL	EQ 0.05MG BASE/ML	A076313	001	Mar 28, 2005	Aug CAHN
>A>	AP	+		EQ 0.1MG BASE/ML	A076313	003	Mar 28, 2005	Aug CAHN

INJECTABLE;INJECTION

OCTREOTIDE ACETATE (PRESERVATIVE FREE)

>A>	AP	+	EQ 0.5MG BASE/ML	A076313	002	Mar 28, 2005	Aug CAHN
-----	----	---	------------------	---------	-----	--------------	----------

OLANZAPINE

TABLET;ORAL

OLANZAPINE

>A>	AB		MACLEODS PHARMS LTD	2.5MG	A202862	001	Aug 15, 2014	Aug NEWA
>A>	AB			5MG	A202862	002	Aug 15, 2014	Aug NEWA
>A>	AB			7.5MG	A202862	003	Aug 15, 2014	Aug NEWA
>A>	AB			10MG	A202862	004	Aug 15, 2014	Aug NEWA
>A>	AB			15MG	A202862	005	Aug 15, 2014	Aug NEWA
>A>	AB			20MG	A202862	006	Aug 15, 2014	Aug NEWA

TABLET, ORALLY DISINTEGRATING;ORAL

OLANZAPINE

AB			AUROBINDO PHARMA LTD	5MG	A203708	001	May 15, 2014	Apr NEWA
AB				10MG	A203708	002	May 15, 2014	Apr NEWA
AB				15MG	A203708	003	May 15, 2014	Apr NEWA
AB				20MG	A203708	004	May 15, 2014	Apr NEWA
AB			JUBILANT GENERICS	5MG	A200221	001	Sep 12, 2012	Jul CAHN
AB				10MG	A200221	002	Sep 12, 2012	Jul CAHN
AB				15MG	A200221	003	Sep 12, 2012	Jul CAHN
AB				20MG	A200221	004	Sep 12, 2012	Jul CAHN
AB			MYLAN PHARMS INC	5MG	A202285	001	May 12, 2014	Apr NEWA
AB				10MG	A202285	002	May 12, 2014	Apr NEWA
AB				15MG	A202285	003	May 12, 2014	Apr NEWA
AB				20MG	A202285	004	May 12, 2014	Apr NEWA

OLODATEROL HYDROCHLORIDE

SPRAY, METERED;INHALATION

STRIVERDI RESPIMAT

+	BOEHRINGER INGELHEIM	EQ 2.5MG BASE/INH	N203108	001	Jul 31, 2014	Jul NEWA
---	----------------------	-------------------	---------	-----	--------------	----------

OMEGA-3-ACID ETHYL ESTERS

CAPSULE;ORAL

LOVAZA

AB	+	SMITHKLINE BEECHAM	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	N021654	001	Nov 10, 2004	Mar CFTG
AB		OMEGA-3-ACID ETHYL ESTERS					
AB		TEVA PHARMS USA	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A091028	001	Apr 07, 2014	Mar NEWA
		OMTRYG					
+		TRYGG	1.2GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	N204977	001	Apr 23, 2014	Apr NEWA

OMEGA-3-CARBOXYLIC ACIDS

CAPSULE;ORAL

EPANOVA

+	ASTRAZENECA PHARMS	1GM CONTAINS AT LEAST 850MG OF POLYUNSATURATED FATTY ACIDS	N205060	001	May 05, 2014	May NEWA
---	--------------------	--	---------	-----	--------------	----------

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE;ORAL

ZEGERID

AB		SANTARUS INC	20MG;1.1GM	N021849	001	Feb 27, 2006	Feb CAHN
AB	+		40MG;1.1GM	N021849	002	Feb 27, 2006	Feb CAHN

FOR SUSPENSION;ORAL

OMEPRAZOLE AND SODIUM BICARBONATE

		@ PAR PHARM	20MG/PACKET;1.68GM/PACKET	A079182	001	Apr 19, 2013	Jun DISC
		@	40MG/PACKET;1.68GM/PACKET	A079182	002	Apr 19, 2013	Jun DISC
		ZEGERID					
AB		SANTARUS INC	20MG/PACKET;1.68GM/PACKET	N021636	001	Jun 15, 2004	Jun CTEC
			20MG/PACKET;1.68GM/PACKET	N021636	001	Jun 15, 2004	Feb CAHN
	+		40MG/PACKET;1.68GM/PACKET	N021636	002	Dec 21, 2004	Jun CTEC
	+		40MG/PACKET;1.68GM/PACKET	N021636	002	Dec 21, 2004	Feb CAHN

ONDANSETRONFILM; ORAL
ZUPLENZ

>A>		GALENA BIOPHARMA INC	4MG	N022524	001	Jul 02, 2010	Aug CAHN
>A>	+		8MG	N022524	002	Jul 02, 2010	Aug CAHN
>D>		VESTIQ PHARMS	4MG	N022524	001	Jul 02, 2010	Aug CAHN
>D>	+		8MG	N022524	002	Jul 02, 2010	Aug CAHN

ONDANSETRON HYDROCHLORIDEINJECTABLE; INJECTION
ONDANSETRON HYDROCHLORIDE

>A>	AP	@ LANNETT	EQ 2MG BASE/ML	A090116	001	Apr 14, 2010	Jan DISC
		QILU PHARM CO LTD	EQ 2MG BASE/ML	A203711	001	Sep 08, 2014	Aug NEWA

TABLET; ORAL

ONDANSETRON HYDROCHLORIDE

AB		IPCA LABS LTD	EQ 4MG BASE	A203761	001	Jan 23, 2014	Jan NEWA
AB			EQ 8MG BASE	A203761	002	Jan 23, 2014	Jan NEWA

>A> ORITAVANCIN DIPHOSPHATE

>A> POWDER; IV (INFUSION)

>A> ORBACTIV

>A>	+	MEDICINES CO	EQ 400MG BASE/VIAL	N206334	001	Aug 06, 2014	Aug NEWA
-----	---	--------------	--------------------	---------	-----	--------------	----------

ORPHENADRINE CITRATEINJECTABLE; INJECTION
ORPHENADRINE CITRATE

>D>	AP	BEDFORD LABS	30MG/ML	A040463	001	Mar 04, 2003	Aug CAHN
>A>	AP	EUROHLTH INTL	30MG/ML	A040463	001	Mar 04, 2003	Aug CAHN
		@ WATSON LABS	30MG/ML	A087062	001		May DISC

OXACILLIN SODIUMINJECTABLE; INJECTION
OXACILLIN SODIUM

>A>	AP	AGILA SPECLTS	EQ 1GM BASE/VIAL	A091486	001	Aug 25, 2014	Aug NEWA
>A>	AP		EQ 2GM BASE/VIAL	A091486	002	Aug 25, 2014	Aug NEWA
		@ ISTITUTO BIO ITA SPA	EQ 1GM BASE/VIAL	A062798	001	Dec 11, 1995	Feb CAHN
		@	EQ 2GM BASE/VIAL	A062798	002	Dec 11, 1995	Feb CAHN
		@	EQ 125MG BASE/VIAL	A062798	003	Dec 11, 1995	Feb CAHN
		@	EQ 250MG BASE/VIAL	A062798	004	Dec 11, 1995	Feb CAHN
		@	EQ 500MG BASE/VIAL	A062798	005	Dec 11, 1995	Feb CAHN

OXALIPLATININJECTABLE; IV (INFUSION)
OXALIPLATIN

>A>	AP	ACTAVIS ELIZABETH	50MG/VIAL	A078803	001	Aug 08, 2012	Aug CAHN
>A>	AP		100MG/VIAL	A078803	002	Aug 08, 2012	Aug CAHN
>D>	AP	ACTAVIS TOTOWA	50MG/VIAL	A078803	001	Aug 08, 2012	Aug CAHN
>D>	AP		100MG/VIAL	A078803	002	Aug 08, 2012	Aug CAHN
	AP	JIANGSU HENGRUI MED	50MG/10ML (5MG/ML)	A203869	001	Jun 18, 2014	Jun NEWA
	AP		100MG/20ML (5MG/ML)	A203869	002	Jun 18, 2014	Jun NEWA
	AP	SUN PHARMA GLOBAL	50MG/10ML (5MG/ML)	A202922	001	Apr 08, 2014	Mar NEWA
	AP		100MG/20ML (5MG/ML)	A202922	002	Apr 08, 2014	Mar NEWA

OXANDROLONETABLET; ORAL
OXANDRIN

AB		CREALTA PHARMS LLC	2.5MG	N013718	001		Jan CAHN
AB	+		10MG	N013718	002	Nov 05, 2001	Jan CAHN

OXAPROZINTABLET; ORAL
OXAPROZIN

AB		SUN PHARM INDS INC	600MG	A075844	001	Jan 03, 2002	Jul CAHN
		@ WATSON LABS	600MG	A075848	001	Feb 09, 2001	May DISC

OXAZEPAMCAPSULE; ORAL
OXAZEPAM

@	IVAX SUB TEVA PHARMS	10MG
@		15MG
@		30MG

A070943	001	Aug 03, 1987	Apr DISC
A070944	001	Aug 03, 1987	Apr DISC
A070945	001	Aug 03, 1987	Apr DISC

CAPSULE;ORAL

OXAZEPAM

@ WATSON LABS

10MG

A072952 001 Sep 28, 1990 May DISC

@

15MG

A072953 001 Sep 28, 1990 May DISC

@

30MG

A072954 001 Sep 28, 1990 May DISC

OXCARBAZEPINE

TABLET;ORAL

OXCARBAZEPINE

@ ANI PHARMS INC

150MG

A078005 001 Dec 11, 2007 Jan CAHN

@

300MG

A078005 002 Dec 11, 2007 Jan CAHN

@

600MG

A078005 003 Dec 11, 2007 Jan CAHN

OXYBUTYNIN

FILM, EXTENDED RELEASE;TRANSDERMAL

OXYBUTYNIN

AB BARR LABS DIV TEVA 3.9MG/24HR

A090526 001 Mar 04, 2014 Feb NEWA

OXYTROL

AB + WATSON LABS (UTAH) 3.9MG/24HR

N021351 002 Feb 26, 2003 Feb CFTG

OXYCODONE HYDROCHLORIDE

CAPSULE;ORAL

OXYCODONE HYDROCHLORIDE

AB LANNETT HOLDINGS INC 5MG

A203823 001 Aug 01, 2014 Jul NEWA

SOLUTION;ORAL

OXYCODONE HYDROCHLORIDE

AA COASTAL PHARMS 100MG/5ML

A204092 001 Jun 05, 2014 May NEWA

>A> AA LANNETT HOLDINGS INC 100MG/5ML

A204085 001 Sep 09, 2014 Aug NEWA

AA LEHIGH VALLEY 5MG/5ML

N200535 002 Aug 22, 2013 Jun NEWA

TABLET;ORAL

OXYCTA

ACURA PHARMS INC

5MG

N202080 001 Jun 17, 2011 May CAHN

7.5MG

N202080 002 Jun 17, 2011 May CAHN

OXYCODONE HYDROCHLORIDE

AB ACTAVIS ELIZABETH 15MG

A076636 001 Feb 06, 2004 Jul CAHN

AB 30MG

A076636 002 Feb 06, 2004 Jul CAHN

AB AMNEAL PHARMS 5MG

A203638 001 Jun 03, 2014 May NEWA

AB 10MG

A203638 002 Jun 03, 2014 May NEWA

AB 15MG

A203638 003 Jun 03, 2014 May NEWA

AB 20MG

A203638 004 Jun 03, 2014 May NEWA

AB 30MG

A203638 005 Jun 03, 2014 May NEWA

OXYMORPHONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

OXYMORPHONE HYDROCHLORIDE

AB MALLINCKRODT INC 5MG

A202946 001 Jun 27, 2014 Jun NEWA

AB 7.5MG

A202946 002 Jun 27, 2014 Jun NEWA

AB 10MG

A202946 003 Jun 27, 2014 Jun NEWA

AB 15MG

A202946 004 Jun 27, 2014 Jun NEWA

AB 20MG

A202946 005 Jun 27, 2014 Jun NEWA

AB 30MG

A202946 006 Jun 27, 2014 Jun NEWA

AB 40MG

A202946 007 Jun 27, 2014 Jun NEWA

OXYTOCIN

INJECTABLE;INJECTION

OXYTOCIN

AP + HIKMA MAPLE 10USP UNITS/ML (10USP UNITS/ML)

N018243 001

AP + 100USP UNITS/10ML (10USP UNITS/ML)

N018243 002 Jan 10, 2007 May CAHN

PITOCIN

AP + PAR STERILE PRODUCTS 10USP UNITS/ML (10USP UNITS/ML)

N018261 001 Apr CAHN

AP 100USP UNITS/10ML (10USP UNITS/ML)

N018261 002 Jul 27, 2007 Apr CAHN

500USP UNITS/50ML (10USP UNITS/ML)

N018261 003 Sep 05, 2012 Apr CAHN

SOLUTION;NASAL

SYNTOCINON

@ RETROPHIN INC

40USP UNITS/ML

N012285 001 Feb CAHN

PACLITAXELINJECTABLE; INJECTION
PACLITAXEL

>A>	AP	ACTAVIS ELIZABETH	6MG/ML	A090130	001	Dec 09, 2009	Aug CAHN
>D>	AP	ACTAVIS TOTOWA	6MG/ML	A090130	001	Dec 09, 2009	Aug CAHN
>D>	AP	BEDFORD	6MG/ML	A075190	001	Jan 28, 2002	Aug CAHN
>A>	AP	EUROHLTH INTL	6MG/ML	A075190	001	Jan 28, 2002	Aug CAHN
		@ MYLAN	6MG/ML	A075278	001	Jan 25, 2002	Jun DISC

PAMIDRONATE DISODIUMINJECTABLE; INJECTION
PAMIDRONATE DISODIUM

>D>	AP	BEDFORD	30MG/VIAL	A075290	001	Apr 30, 2001	Aug CAHN
>D>	AP	+	30MG/10ML (3MG/ML)	N021113	001	Mar 04, 2002	Aug CAHN
>D>	AP		90MG/VIAL	A075290	003	Apr 30, 2001	Aug CAHN
>D>	AP	+	90MG/10ML (9MG/ML)	N021113	002	Mar 04, 2002	Aug CAHN
>A>	AP	EUROHLTH INTL	30MG/VIAL	A075290	001	Apr 30, 2001	Aug CAHN
>A>	AP	+	30MG/10ML (3MG/ML)	N021113	001	Mar 04, 2002	Aug CAHN
>A>	AP		90MG/VIAL	A075290	003	Apr 30, 2001	Aug CAHN
>A>	AP	+	90MG/10ML (9MG/ML)	N021113	002	Mar 04, 2002	Aug CAHN
		@ MN PHARMS	30MG/VIAL	A078300	001	Mar 10, 2009	Jan DISC
		@	90MG/VIAL	A078300	002	Mar 10, 2009	Jan DISC

PANCRELIPASE (AMYLASE; LIPASE; PROTEASE)CAPSULE, DELAYED RELEASE; ORAL
PANCREAZE

		JANSSEN PHARMS	10,850USP UNITS; 2,600USP UNITS; 6,200USP UNITS	N022523	005	Mar 07, 2014	Jun NEWA
--	--	----------------	---	---------	-----	--------------	----------

ULTRESA

		FOREST LABS INC	27,600USP UNITS; 13,800USP UNITS; 27,600USP UNITS	N022222	001	Mar 01, 2012	May CAHN
			41,400USP UNITS; 20,700USP UNITS; 41,400USP UNITS	N022222	002	Mar 01, 2012	May CAHN
		+	46,000USP UNITS; 23,000USP UNITS; 46,000USP UNITS	N022222	003	Mar 01, 2012	May CAHN

ZENPEP

		APTALIS PHARMA US	218,000USP UNITS; 40,00USP UNITS; 136,000 USP UNITS	N022210	007	Mar 25, 2014	Mar NEWA
		FOREST LABS INC	218,000USP UNITS; 40,00USP UNITS; 136,000 USP UNITS	N022210	007	Mar 25, 2014	Apr CAHN
			16,000USP UNITS; 3,000USP UNITS; 10,000USP UNITS	N022210	005	Jun 15, 2011	Apr CAHN
			55,000USP UNITS; 10,000USP UNITS; 34,000USP UNITS	N022210	002	Aug 27, 2009	Apr CAHN
			82,000USP UNITS; 15,000USP UNITS; 51,000USP UNITS	N022210	003	Aug 27, 2009	Apr CAHN
			27,000USP UNITS; 5,000USP UNITS; 17,000USP UNITS	N022210	001	Aug 27, 2009	Apr CAHN
			109,000USP UNITS; 20,000USP UNITS; 68,000USP UNITS	N022210	004	Aug 27, 2009	Apr CAHN
		+	136,000USP UNITS; 25,000USP UNITS; 85,000USP UNITS	N022210	006	Jul 13, 2011	Apr CAHN

TABLET; ORAL

VIOKACE

		FOREST LABS INC	39,150USP UNITS; 10,440USP UNITS; 39,150USP UNITS	N022542	001	Mar 01, 2012	Apr CAHN
		+	78,300USP UNITS; 20,880USP UNITS; 78,300USP UNITS	N022542	002	Mar 01, 2012	Apr CAHN
		FOREST RES INST INC	39,150USP UNITS; 10,440USP UNITS; 39,150USP UNITS	N022542	001	Mar 01, 2012	Mar CAHN
		+	78,300USP UNITS; 20,880USP UNITS; 78,300USP UNITS	N022542	002	Mar 01, 2012	Mar CAHN

PANTOPRAZOLE SODIUMTABLET, DELAYED RELEASE; ORAL
PANTOPRAZOLE SODIUM

>A>	AB	ACTAVIS ELIZABETH	EQ 20MG BASE	A090797	001	Feb 07, 2011	Aug CAHN
>A>	AB		EQ 40MG BASE	A090797	002	Feb 07, 2011	Aug CAHN
>D>	AB	ACTAVIS TOTOWA	EQ 20MG BASE	A090797	001	Feb 07, 2011	Aug CAHN
>D>	AB		EQ 40MG BASE	A090797	002	Feb 07, 2011	Aug CAHN
>A>	AB	HETERO LABS LTD V	EQ 20MG BASE	A202882	001	Sep 10, 2014	Aug NEWA
>A>	AB		EQ 40MG BASE	A202882	002	Sep 10, 2014	Aug NEWA
	AB	JUBILANT GENERICS	EQ 20MG BASE	A090901	001	Aug 30, 2011	Jul CAHN
	AB		EQ 40MG BASE	A090901	002	Aug 30, 2011	Jul CAHN
	AB	PERRIGO R AND D	EQ 20MG BASE	A203024	001	May 07, 2014	Apr NEWA

PARICALCITOLCAPSULE;ORAL
PARICALCITOL

AB	ANCHEN PHARMS	1MCG	A202124	001	Jun 24, 2014	Jun NEWA
AB		2MCG	A202124	002	Jun 24, 2014	Jun NEWA
AB		4MCG	A202124	003	Jun 24, 2014	Jun NEWA
AB	BANNER PHARMACAPS	1MCG	A202539	001	Mar 27, 2014	Mar NEWA
AB		2MCG	A202539	002	Mar 27, 2014	Mar NEWA
AB		4MCG	A202539	003	Mar 27, 2014	Mar NEWA
AB	DR REDDYS LABS LTD	1MCG	A091412	001	Jun 24, 2014	Jun NEWA
AB		2MCG	A091412	002	Jun 24, 2014	Jun NEWA
AB		4MCG	A091412	003	Jun 24, 2014	Jun NEWA

PAROMOMYCIN SULFATECAPSULE;ORAL
PAROMOMYCIN SULFATE

AA	+ SUN PHARM INDS INC	EQ 250MG BASE	A064171	001	Jun 30, 1997	Jul CAHN
----	----------------------	---------------	---------	-----	--------------	----------

PAROXETINE HYDROCHLORIDECAPSULE;ORAL
PAXIL

@	APOTEX TECHNOLOGIES	EQ 10MG BASE	N020885	001	Oct 09, 1998	Feb CAHN
@		EQ 20MG BASE	N020885	002	Oct 09, 1998	Feb CAHN
@		EQ 30MG BASE	N020885	003	Oct 09, 1998	Feb CAHN
@		EQ 40MG BASE	N020885	004	Oct 09, 1998	Feb CAHN

SUSPENSION;ORAL

PAXIL

AB	+ APOTEX TECHNOLOGIES	EQ 10MG BASE/5ML	N020710	001	Jun 25, 1997	Feb CAHN
----	-----------------------	------------------	---------	-----	--------------	----------

TABLET;ORAL

PAROXETINE HYDROCHLORIDE

AB	SUN PHARM INDS INC	EQ 10MG BASE	A078194	001	Jun 29, 2007	Jul CAHN
AB		EQ 20MG BASE	A078194	002	Jun 29, 2007	Jul CAHN
AB		EQ 30MG BASE	A078194	003	Jun 29, 2007	Jul CAHN
AB		EQ 40MG BASE	A078194	004	Jun 29, 2007	Jul CAHN

PAXIL

AB	APOTEX TECHNOLOGIES	EQ 10MG BASE	N020031	001	Dec 29, 1992	Jan CAHN
AB		EQ 20MG BASE	N020031	002	Dec 29, 1992	Jan CAHN
AB		EQ 30MG BASE	N020031	003	Dec 29, 1992	Jan CAHN
AB	+ @	EQ 40MG BASE	N020031	005	Dec 29, 1992	Jan CAHN
		EQ 50MG BASE	N020031	004	Dec 29, 1992	Jan CAHN

TABLET, EXTENDED RELEASE;ORAL

PAXIL CR

AB	APOTEX TECHNOLOGIES	EQ 12.5MG BASE	N020936	001	Feb 16, 1999	Feb CAHN
AB		EQ 25MG BASE	N020936	002	Feb 16, 1999	Feb CAHN
AB	+ @	EQ 37.5MG BASE	N020936	003	Dec 06, 2000	Feb CAHN

PEGVISOMANTINJECTABLE;SUBCUTANEOUS
SOMAVERT

+	PHARMACIA AND UPJOHN	25MG/VIAL	N021106	004	Jul 31, 2014	Jul NEWA
+		30MG/VIAL	N021106	005	Jul 31, 2014	Jul NEWA

PEMIROLAST POTASSIUMSOLUTION/DROPS;OPHTHALMIC
ALAMAST

@	SANTEN	0.1%	N021079	001	Sep 24, 1999	Jun DISC
---	--------	------	---------	-----	--------------	----------

PEMOLINETABLET;ORAL
PEMOLINE

>A>	@ ACTAVIS ELIZABETH	18.75MG	A075595	001	Feb 28, 2000	Aug CAHN
>A>	@	37.5MG	A075595	002	Feb 28, 2000	Aug CAHN
>A>	@	75MG	A075595	003	Feb 28, 2000	Aug CAHN
>D>	@ ACTAVIS TOTOWA	18.75MG	A075595	001	Feb 28, 2000	Aug CAHN
>D>	@	37.5MG	A075595	002	Feb 28, 2000	Aug CAHN
>D>	@	75MG	A075595	003	Feb 28, 2000	Aug CAHN

TABLET, CHEWABLE;ORAL

PEMOLINE

>A>	@ ACTAVIS ELIZABETH	37.5MG	A075678	001	Jul 26, 2000	Aug CAHN
>D>	@ ACTAVIS TOTOWA	37.5MG	A075678	001	Jul 26, 2000	Aug CAHN

PENBUTOLOL SULFATE

TABLET; ORAL

LEVATOL

@ AUXILIUM PHARMS LLC

10MG

N018976 001 Dec 30, 1987 Apr CAHN

+

20MG

N018976 004 Jan 05, 1989 Apr CAHN

PENICILLIN G POTASSIUM

INJECTABLE; INJECTION

PENICILLIN G POTASSIUM

AP ISTITUTO BIO ITA SPA

5,000,000 UNITS/VIAL

A065448 001 Aug 18, 2009 Feb CAHN

AP

20,000,000 UNITS/VIAL

A065448 002 Aug 18, 2009 Feb CAHN

PENTAMIDINE ISETHIONATE

INJECTABLE; INJECTION

PENTAM

+ FRESENIUS KABI USA

300MG/VIAL

N019264 001 Oct 16, 1984 May CTEC

PENTAMIDINE ISETHIONATE

@ WATSON LABS

300MG/VIAL

A074303 001 Aug 17, 1995 May DISC

PENTOSTATIN

INJECTABLE; INJECTION

PENTOSTATIN

>D> AP

BEDFORD LABS

10MG/VIAL

A077841 001 Aug 07, 2007 Aug CAHN

>A> AP

EUROHLTH INTL

10MG/VIAL

A077841 001 Aug 07, 2007 Aug CAHN

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE; ORAL

PENTOXIFYLLINE

@ WATSON LABS

400MG

A075107 001 Sep 04, 1998 May DISC

TRENTAL

@ SANOFI AVENTIS US

400MG

N018631 001 Aug 30, 1984 Jun DISC

PERINDOPRIL ERBUMINE

TABLET; ORAL

ACEON

AB SYMPLMED PHARMS LLC

2MG

N020184 001 Dec 30, 1993 Jul CAHN

AB

4MG

N020184 002 Dec 30, 1993 Jul CAHN

AB

+

8MG

N020184 003 Dec 30, 1993 Jul CAHN

PERINDOPRIL ERBUMINE

AB ANI PHARMS INC

2MG

A078138 001 Nov 10, 2009 Jan CAHN

AB

4MG

A078138 002 Nov 10, 2009 Jan CAHN

AB

8MG

A078138 003 Nov 10, 2009 Jan CAHN

PERPHENAZINE

TABLET; ORAL

PERPHENAZINE

@ ANI PHARMS INC

8MG

A089456 001 Sep 10, 1987 Apr CAHN

@ TEVA PHARMS USA

2MG

A089707 001 Sep 10, 1987 Apr CAHN

@

4MG

A089708 001 Sep 10, 1987 Apr CAHN

@

16MG

A089457 001 Sep 10, 1987 Apr CAHN

PHENDIMETRAZINE TARTRATE

TABLET; ORAL

PHENDIMETRAZINE TARTRATE

AA ELITE LABS INC

35MG

A040762 001 Jan 28, 2008 Apr CAHN

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL

PHENTERMINE HYDROCHLORIDE

AA INVAGEN PHARMS

15MG

A202858 001 Feb 14, 2014 Feb NEWA

AA

30MG

A202858 002 Feb 14, 2014 Feb NEWA

AA

30MG

A204414 001 May 05, 2014 Apr NEWA

AA

37.5MG

A202846 001 Feb 05, 2014 Jan NEWA

TABLET; ORAL

PHENTERMINE HYDROCHLORIDE

AA AUROLIFE PHARMA LLC

37.5MG

A203068 001 Aug 06, 2014 Jul NEWA

AA

INVAGEN PHARMS

37.5MG

A202942 001 Feb 05, 2014 Jan NEWA

AA

MIKAH PHARMA

37.5MG

A040190 001 May 30, 1997 May CMFD

AA

SUN PHARM INDS INC

37.5MG

A040790 001 Aug 21, 2007 Jul CAHN

PHENTOLAMINE MESYLATE

INJECTABLE; INJECTION
PHENTOLAMINE MESYLATE

>D>	AP	BEDFORD	5MG/VIAL	A040235	001	Mar 11, 1998	Aug CAHN
>A>	AP	EUROHLTH INTL	5MG/VIAL	A040235	001	Mar 11, 1998	Aug CAHN

PHENYLEPHRINE HYDROCHLORIDE

SOLUTION; IV (INFUSION)
VAZCULEP

		ECLAT PHARMS LLC	10MG/ML (10MG/ML)	N204300	001	Jun 27, 2014	Jun NEWA
			50MG/5ML (10MG/ML)	N204300	002	Jun 27, 2014	Jun NEWA
	+		100MG/10ML (10MG/ML)	N204300	003	Jun 27, 2014	Jun NEWA

PHENYTOIN

TABLET, CHEWABLE; ORAL
PHENYTOIN

AB		TARO	50MG	A200565	001	Apr 17, 2014	Apr NEWA
----	--	------	------	---------	-----	--------------	----------

PHENYTOIN SODIUM

CAPSULE; ORAL
EXTENDED PHENYTOIN SODIUM

		@ ANI PHARMS INC	100MG EXTENDED	A040435	001	Jun 20, 2003	Apr CAHN
		@	100MG EXTENDED	A089441	001	Dec 18, 1986	Jan CAHN
		PROMPT PHENYTOIN SODIUM					
		@ ANI PHARMS INC	100MG PROMPT	A080259	001		Jan CAHN

PINDOLOL

TABLET; ORAL
PINDOLOL

AB		MUTUAL PHARM	5MG	A074063	001	Jan 27, 1994	Feb CMFD
AB			10MG	A074063	002	Jan 27, 1994	Feb CMFD
AB		MYLAN PHARMS INC	5MG	A074019	001	Sep 03, 1992	Feb CTEC
AB	+		10MG	A074019	002	Sep 03, 1992	Feb CTEC

PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL
PIOGLITAZONE HYDROCHLORIDE

AB		LUPIN LTD	EQ 15MG BASE	A204133	001	Apr 07, 2014	Mar NEWA
AB			EQ 30MG BASE	A204133	002	Apr 07, 2014	Mar NEWA
AB			EQ 45MG BASE	A204133	003	Apr 07, 2014	Mar NEWA

PIPERACILLIN SODIUM

INJECTABLE; INJECTION
PIPERACILLIN

+		ISTITUTO BIO ITA SPA	EQ 2GM BASE/VIAL	A065114	001	Nov 14, 2003	Feb CAHN
+			EQ 3GM BASE/VIAL	A065114	002	Nov 14, 2003	Feb CAHN
+			EQ 4GM BASE/VIAL	A065114	003	Nov 14, 2003	Feb CAHN
+			EQ 40GM BASE/VIAL	A065157	001	Jul 12, 2004	Feb CAHN

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE; INJECTION
PIPERACILLIN AND TAZOBACTAM

>A>	AP	AGILA SPECLTS	EQ 2GM BASE/VIAL; EQ 250MG BASE/VIAL	A065458	001	Aug 15, 2014	Aug NEWA
>A>	AP		EQ 3MG BASE/VIAL; EQ 375MG BASE/VIAL	A065458	002	Aug 15, 2014	Aug NEWA
>A>	AP		EQ 4GM BASE/VIAL; EQ 500MG BASE/VIAL	A065458	003	Aug 15, 2014	Aug NEWA
	AP	ISTITUTO BIO ITA SPA	EQ 2GM BASE/VIAL; EQ 250MG BASE/VIAL	A065523	001	May 31, 2011	Feb CAHN
	AP		EQ 3GM BASE/VIAL; EQ 375MG BASE/VIAL	A065523	002	May 31, 2011	Feb CAHN
	AP		EQ 4GM BASE/VIAL; EQ 500MG BASE/VIAL	A065523	003	May 31, 2011	Feb CAHN
	AP		EQ 36GM BASE/VIAL; EQ 4.5GM BASE/VIAL	A090498	001	May 31, 2011	Feb CAHN

PIRBUTEROL ACETATEAEROSOL, METERED; INHALATION
MAXAIR

@ VALEANT PHARM NORTH EQ 0.2MG BASE/INH N019009 001 Dec 30, 1986 Jul CAHN

PIROXICAMCAPSULE; ORAL
PIROXICAM

@ WATSON LABS	10MG	A074287	001	May 16, 1996	May DISC
@	10MG	A074460	001	Sep 29, 1995	May DISC
@	20MG	A074287	002	May 16, 1996	May DISC
@	20MG	A074460	002	Sep 29, 1995	May DISC

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUSFOR SUSPENSION; ORAL
CO-LAV

@ VINTAGE PHARMS 240GM/BOT; 2.98GM/BOT; 6.72GM/BOT; 5.84GM/BOT; 22.72GM/BOT A073428 001 Jan 28, 1992 Feb CAHN

GO-EVAC

@ VINTAGE PHARMS 236GM/BOT; 2.97GM/BOT; 6.74GM/BOT; 5.86GM/BOT; 22.74GM/BOT A073433 001 Apr 28, 1992 Feb CAHN

POLYMYXIN B SULFATEINJECTABLE; INJECTION
POLYMYXIN B SULFATE

>D> AP	+	BEDFORD	EQ 500,000 U BASE/VIAL	A060716	001		Aug CAHN
>A> AP	+	EUROHLTH INTL	EQ 500,000 U BASE/VIAL	A060716	001		Aug CAHN

PORACTANT ALFASUSPENSION; INTRATRACHEAL
CUROSURF

+ CHIESI USA INC 80MG/ML N020744 001 Nov 18, 1999 Apr CAHN

POSACONAZOLESOLUTION; IV (INFUSION)
NOXAFIL

+ MERCK SHARP DOHME 300MG/16.7ML (18MG/ML) N205596 001 Mar 13, 2014 Mar NEWA

POTASSIUM CHLORIDEINJECTABLE; INJECTION
POTASSIUM CHLORIDE

@ INTL MEDICATION 2MEQ/ML A083163 001 Mar DISC

TABLET, EXTENDED RELEASE; ORAL
KLOR-CON

>D>		UPSHER-SMITH LABS	8MEQ	N019123	001	Apr 17, 1986	Aug CTEC
>A>	AB2		8MEQ	N019123	001	Apr 17, 1986	Aug CTEC
>D>	BC	+	10MEQ	N019123	002	Apr 17, 1986	Aug CTEC
>A>	AB2	+	10MEQ	N019123	002	Apr 17, 1986	Aug CTEC

KLOR-CON M10

>D>	AB		UPSHER SMITH LABS	10MEQ	A074726	002	Aug 09, 2000	Aug CTEC
>A>	AB1			10MEQ	A074726	002	Aug 09, 2000	Aug CTEC

KLOR-CON M20

>D>	AB	+	UPSHER SMITH LABS	20MEQ	A074726	001	Nov 20, 1998	Aug CTEC
>A>	AB1	+		20MEQ	A074726	001	Nov 20, 1998	Aug CTEC

POTASSIUM CHLORIDE

>D>	AB		ACTAVIS LABS FL INC	10MEQ	A075604	001	Apr 10, 2002	Aug CTEC
>A>	AB1			10MEQ	A075604	001	Apr 10, 2002	Aug CTEC
>D>	AB			20MEQ	A075604	002	Apr 10, 2002	Aug CTEC
>A>	AB1			20MEQ	A075604	002	Apr 10, 2002	Aug CTEC
>D>	AB		EURAND	20MEQ	A076368	001	Aug 18, 2004	Aug CTEC
>A>	AB1			20MEQ	A076368	001	Aug 18, 2004	Aug CTEC
>A>	AB2		MYLAN PHARMS INC	8.0MEQ	A204662	001	Aug 21, 2014	Aug NEWA
>A>	AB2			10.0MEQ	A204662	002	Aug 21, 2014	Aug NEWA

POTASSIUM CITRATEFOR SOLUTION; ORAL
POTASSIUM CITRATE

@ UT SW MEDCTR	10MEQ/PACKET	N019647	002	Oct 13, 1988	Jul CAHN
@	20MEQ/PACKET	N019647	001	Oct 13, 1988	Jul CAHN

TABLET, EXTENDED RELEASE;ORAL
POTASSIUM CITRATE

AB	ZYDUS PHARMS USA INC	5MEQ	A203546	001	Aug 06, 2014	Jul NEWA
AB		10MEQ	A203546	002	Aug 06, 2014	Jul NEWA
AB		15MEQ	A203546	003	Aug 06, 2014	Jul NEWA
UROCIT-K						
AB	+ MISSION PHARMA	15MEQ	N019071	003	Dec 30, 2009	Jul CTEC

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET;ORAL
PRAMIPEXOLE DIHYDROCHLORIDE

>D>	AB	STRIDES ARCOLAB LTD	0.125MG	A202702	001	Jun 03, 2014	Aug CAHN
	AB		0.125MG	A202702	001	Jun 03, 2014	May NEWA
>D>	AB		0.25MG	A202702	002	Jun 03, 2014	Aug CAHN
	AB		0.25MG	A202702	002	Jun 03, 2014	May NEWA
>D>	AB		0.5MG	A202702	003	Jun 03, 2014	Aug CAHN
	AB		0.5MG	A202702	003	Jun 03, 2014	May NEWA
>D>	AB		0.75MG	A202702	004	Jun 03, 2014	Aug CAHN
	AB		0.75MG	A202702	004	Jun 03, 2014	May NEWA
>D>	AB		1MG	A202702	005	Jun 03, 2014	Aug CAHN
	AB		1MG	A202702	005	Jun 03, 2014	May NEWA
>D>	AB		1.5MG	A202702	006	Jun 03, 2014	Aug CAHN
	AB		1.5MG	A202702	006	Jun 03, 2014	May NEWA
>A>	AB	STRIDES PHARMA	0.125MG	A202702	001	Jun 03, 2014	Aug CAHN
>A>	AB		0.25MG	A202702	002	Jun 03, 2014	Aug CAHN
>A>	AB		0.5MG	A202702	003	Jun 03, 2014	Aug CAHN
>A>	AB		0.75MG	A202702	004	Jun 03, 2014	Aug CAHN
>A>	AB		1MG	A202702	005	Jun 03, 2014	Aug CAHN
>A>	AB		1.5MG	A202702	006	Jun 03, 2014	Aug CAHN

TABLET, EXTENDED RELEASE;ORAL
MIRAPEX ER

AB	+ BOEHRINGER INGELHEIM	0.375MG	N022421	001	Feb 19, 2010	Jan CFTG
AB		0.75MG	N022421	002	Feb 19, 2010	Jan CFTG
AB		1.5MG	N022421	003	Feb 19, 2010	Jan CFTG
AB		2.25MG	N022421	006	Jun 17, 2011	Jan CFTG
AB		3MG	N022421	004	Feb 19, 2010	Jan CFTG
AB		3.75MG	N022421	007	Jun 17, 2011	Jan CFTG
AB		4.5MG	N022421	005	Feb 19, 2010	Jan CFTG

PRAMIPEXOLE DIHYDROCHLORIDE

AB	ANCHEN PHARMS	0.375MG	A202206	001	Feb 06, 2014	Jan NEWA
AB		0.75MG	A202206	002	Feb 06, 2014	Jan NEWA
AB		1.5MG	A202206	003	Feb 06, 2014	Jan NEWA
AB		2.25MG	A202206	004	Feb 06, 2014	Jan NEWA
AB		3MG	A202206	005	Feb 06, 2014	Jan NEWA
AB		3.75MG	A202206	006	Feb 06, 2014	Jan NEWA
AB		4.5MG	A202206	007	Feb 06, 2014	Jan NEWA

PRAMLINTIDE ACETATE

INJECTABLE;SUBCUTANEOUS
SYMMLIN

	ASTRAZENECA AB	EQ 1.5MG BASE/1.5ML (EQ 1MG BASE/ML)	N021332	002	Sep 25, 2007	Feb CAHN
+		EQ 2.7MG BASE/2.7ML (EQ 1MG BASE/ML)	N021332	003	Sep 25, 2007	Feb CAHN
@		EQ 3MG BASE/5ML (EQ 600MCG BASE/ML)	N021332	001	Mar 16, 2005	Feb CAHN

PRAVASTATIN SODIUM

TABLET;ORAL
PRAVASTATIN SODIUM

AB	SANDOZ	10MG	A076397	003	Oct 23, 2006	Apr CMFD
AB		20MG	A076397	002	Oct 23, 2006	Apr CMFD
AB		40MG	A076397	001	Oct 23, 2006	Apr CMFD
>D>	@	80MG	A077491	001	Feb 11, 2008	Aug CMFD
>A>	AB	80MG	A077491	001	Feb 11, 2008	Aug CMFD

PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM

SOLUTION/DROPS;OPHTHALMIC
SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE

AT	+ BAUSCH AND LOMB	EQ 0.23% PHOSPHATE;10% VASOCIDIN	A074449	001	Dec 29, 1995	Feb CRLD
	@ NOVARTIS	EQ 0.23% PHOSPHATE;10%	N018988	001	Aug 26, 1988	Feb DISC

PRIMAQUINE PHOSPHATE

TABLET; ORAL

PRIMAQUINE

AB	+	SANOFI AVENTIS US	EQ 15MG BASE	N008316	001		Jan	CFTG
		PRIMAQUINE PHOSPHATE						
AB		ALVOGEN INC	EQ 15MG BASE	A203924	001	Feb 03, 2014	Jan	NEWA
AB		BAYSHORE PHARMS LLC	EQ 15MG BASE	A204476	001	Feb 25, 2014	Feb	NEWA

PROCAINAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

PROCAINAMIDE HYDROCHLORIDE

+	HOSPIRA	100MG/ML	A089069	001	Feb 12, 1986	Jul	CTEC
+		500MG/ML	A089070	001	Feb 12, 1986	Jul	CTEC
@	INTL MEDICATION	100MG/ML	A088636	001	Jul 31, 1984	Jul	DISC
@		500MG/ML	A088637	001	Jul 31, 1984	Jul	DISC

TABLET, EXTENDED RELEASE; ORAL

PROCAINAMIDE HYDROCHLORIDE

@	ANI PHARMS INC	1GM	A040111	001	Dec 13, 1996	Jan	CAHN
@		250MG	A088958	001	Dec 02, 1985	Jan	CAHN
@		500MG	A088959	001	Dec 02, 1985	Jan	CAHN
@		500MG	A088974	001	Jul 22, 1985	Mar	CAHN
@		750MG	A089438	001	Mar 23, 1987	Jan	CAHN

PROMETHAZINE HYDROCHLORIDE

SUPPOSITORY; RECTAL

PHENERGAN

@	DELCOR ASSET CORP	50MG	N011689	001		Apr	CAHN
---	-------------------	------	---------	-----	--	-----	------

TABLET; ORAL

PHENERGAN

@	DELCOR ASSET CORP	12.5MG	N007935	002		Jul	CAHN
@		12.5MG	N007935	002		Apr	CAHN
@		25MG	N007935	003		Jul	CAHN
@		25MG	N007935	003		Apr	CAHN
@		50MG	N007935	004		Jul	CAHN
@		50MG	N007935	004		Apr	CAHN
@	SHIONOGI INC	12.5MG	N007935	002		May	CAHN
@		25MG	N007935	003		May	CAHN
@		50MG	N007935	004		May	CAHN

PROMETHAZINE HYDROCHLORIDE

AB		SANDOZ	25MG	A084176	003		Apr	CMS1
AB		SUN PHARM INDS INC	12.5MG	A040863	001	Dec 30, 2008	Jun	CAHN
AB			25MG	A040863	002	Dec 30, 2008	Jun	CAHN
AB			50MG	A040863	003	Dec 30, 2008	Jun	CAHN

PROPAFENONE HYDROCHLORIDE

TABLET; ORAL

PROPAFENONE HYDROCHLORIDE

AB		ANI PHARMS INC	150MG	A076550	001	Apr 23, 2004	Jan	CAHN
AB			225MG	A076550	002	Apr 23, 2004	Jan	CAHN
AB			300MG	A076550	003	Apr 23, 2004	Jan	CAHN

PROPARACAINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

ALCAINE

AT	+	ALCON	0.5%	A080027	001		Jun	CRLD
		OPHTHAINE						
	@	APOTHECON	0.5%	N008883	001		Jun	DISC
		OPHTHETIC						
	@	ALLERGAN	0.5%	N012583	001		Jun	DISC

PROPOFOL

INJECTABLE; INJECTION

PROPOFOL

>D>	@	BEDFORD	10MG/ML	A074848	001	Apr 19, 2005	Aug	CAHN
>A>	@	EUROHLTH INTL	10MG/ML	A074848	001	Apr 19, 2005	Aug	CAHN

PROPOXYPHENE HYDROCHLORIDE

>D>	CAPSULE;ORAL					
>D>	PROPOXYPHENE HYDROCHLORIDE					
>D>	MUTUAL PHARM	65MG	A083186	001		Aug DISC
>A>	@	65MG	A083186	001		Aug DISC

PROPRANOLOL HYDROCHLORIDE

SOLUTION;ORAL

HEMANGEOL

+	PIERRE FABRE DERMA	4.28MG/ML	N205410	001	Mar 14, 2014	Mar NEWA
---	--------------------	-----------	---------	-----	--------------	----------

TABLET;ORAL

INDERAL

@	WYETH PHARMS INC	40MG	N016418	002		Jan DISC
---	------------------	------	---------	-----	--	----------

@		60MG	N016418	009	Oct 18, 1982	Jan DISC
---	--	------	---------	-----	--------------	----------

PROPRANOLOL HYDROCHLORIDE

@	ANI PHARMS INC	90MG	A071977	001	Apr 06, 1988	Jan CAHN
---	----------------	------	---------	-----	--------------	----------

PROPYLTHIOURACIL

TABLET;ORAL

PROPYLTHIOURACIL

@	ANI PHARMS INC	50MG	A080215	001		Jan CAHN
---	----------------	------	---------	-----	--	----------

PYRIDOSTIGMINE BROMIDE

SYRUP;ORAL

MESTINON

>D>	+	VALEANT PHARM INTL	60MG/5ML	N015193	001	Aug CAHN
-----	---	--------------------	----------	---------	-----	----------

>A>	+	VALEANT PHARM NORTH	60MG/5ML	N015193	001	Aug CAHN
-----	---	---------------------	----------	---------	-----	----------

QUETIAPINE FUMARATE

TABLET;ORAL

QUETIAPINE FUMARATE

AB	JUBILANT GENERICS	EQ 25MG BASE	A203150	001	Nov 26, 2013	Jul CAHN
----	-------------------	--------------	---------	-----	--------------	----------

QUINAPRIL HYDROCHLORIDE

TABLET;ORAL

QUINAPRIL HYDROCHLORIDE

>A>	@	ACTAVIS ELIZABETH	EQ 5MG BASE	A076459	001	Dec 22, 2004	Aug CAHN
-----	---	-------------------	-------------	---------	-----	--------------	----------

>A>	@		EQ 10MG BASE	A076459	002	Dec 22, 2004	Aug CAHN
-----	---	--	--------------	---------	-----	--------------	----------

>A>	@		EQ 20MG BASE	A076459	003	Dec 22, 2004	Aug CAHN
-----	---	--	--------------	---------	-----	--------------	----------

>A>	@		EQ 40MG BASE	A076459	004	Dec 22, 2004	Aug CAHN
-----	---	--	--------------	---------	-----	--------------	----------

>D>	@	ACTAVIS TOTOWA	EQ 5MG BASE	A076459	001	Dec 22, 2004	Aug CAHN
-----	---	----------------	-------------	---------	-----	--------------	----------

>D>	@		EQ 10MG BASE	A076459	002	Dec 22, 2004	Aug CAHN
-----	---	--	--------------	---------	-----	--------------	----------

>D>	@		EQ 20MG BASE	A076459	003	Dec 22, 2004	Aug CAHN
-----	---	--	--------------	---------	-----	--------------	----------

>D>	@		EQ 40MG BASE	A076459	004	Dec 22, 2004	Aug CAHN
-----	---	--	--------------	---------	-----	--------------	----------

QUINIDINE GLUCONATE

TABLET, EXTENDED RELEASE;ORAL

QUINIDINE GLUCONATE

@	WATSON LABS	324MG	A087810	001	Sep 29, 1982	May DISC
---	-------------	-------	---------	-----	--------------	----------

RALOXIFENE HYDROCHLORIDE

TABLET;ORAL

EVISTA

AB	+	LILLY	60MG	N020815	001	Dec 09, 1997	Feb CFTG
----	---	-------	------	---------	-----	--------------	----------

RALOXIFENE HYDROCHLORIDE

AB	TEVA PHARMS USA	60MG	A078193	001	Mar 04, 2014	Feb NEWA
----	-----------------	------	---------	-----	--------------	----------

RAMIPRIL

CAPSULE;ORAL

RAMIPRIL

AB	ACCORD HLTHCARE INC	1.25MG	A202392	001	Apr 15, 2014	Mar NEWA
----	---------------------	--------	---------	-----	--------------	----------

AB		2.5MG	A202392	002	Apr 15, 2014	Mar NEWA
----	--	-------	---------	-----	--------------	----------

AB		5MG	A202392	003	Apr 15, 2014	Mar NEWA
----	--	-----	---------	-----	--------------	----------

AB		10MG	A202392	004	Apr 15, 2014	Mar NEWA
----	--	------	---------	-----	--------------	----------

RANITIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

RANITIDINE HYDROCHLORIDE

>D>	AP	BEDFORD	EQ 25MG BASE/ML	A077458	001	Feb 16, 2006	Aug CAHN
>D>	AP	BEN VENUE	EQ 25MG BASE/ML	A074777	001	Mar 02, 2005	Aug CAHN
>A>	AP	EUROHLTH INTL	EQ 25MG BASE/ML	A074777	001	Mar 02, 2005	Aug CAHN
>A>	AP		EQ 25MG BASE/ML	A077458	001	Feb 16, 2006	Aug CAHN
		ZANTAC					
AP	+	COVIS INJECTABLES	EQ 25MG BASE/ML	N019090	001	Oct 19, 1984	Apr CAHN
		ZANTAC IN PLASTIC CONTAINER					
		@ COVIS INJECTABLES	EQ 1MG BASE/ML	N019593	002	Sep 27, 1991	Apr CAHN
		@	EQ 50MG BASE/100ML	N019593	001	Dec 17, 1986	Apr CAHN
		TABLET, EFFERVESCENT;ORAL					
		ZANTAC 25					
		@ GLAXO GRP LTD	EQ 25MG BASE	N020251	003	Apr 01, 2004	Feb DISC

RASAGILINE MESYLATE

TABLET;ORAL

RASAGILINE MESYLATE

@	WATSON LABS INC	EQ 0.5MG BASE	A201823	001	Jul 01, 2013	May DISC
@		EQ 1MG BASE	A201823	002	Jul 01, 2013	May DISC

REPAGLINIDE

TABLET;ORAL

REPAGLINIDE

>A>	AB	ACTAVIS ELIZABETH	0.5MG	A090008	001	Jan 22, 2014	Aug CAHN
>A>	AB		1MG	A090008	002	Jan 22, 2014	Aug CAHN
>A>	AB		2MG	A090008	003	Jan 22, 2014	Aug CAHN
>D>	AB	ACTAVIS TOTOWA	0.5MG	A090008	001	Jan 22, 2014	Aug CAHN
	AB		0.5MG	A090008	001	Jan 22, 2014	Jan NEWA
>D>	AB		1MG	A090008	002	Jan 22, 2014	Aug CAHN
	AB		1MG	A090008	002	Jan 22, 2014	Jan NEWA
>D>	AB		2MG	A090008	003	Jan 22, 2014	Aug CAHN
	AB		2MG	A090008	003	Jan 22, 2014	Jan NEWA
	AB	AUROBINDO PHARMA LTD	0.5MG	A203820	001	Jan 22, 2014	Jan NEWA
	AB		1MG	A203820	002	Jan 22, 2014	Jan NEWA
	AB		2MG	A203820	003	Jan 22, 2014	Jan NEWA
	AB	MYLAN PHARMS INC	1MG	A090252	002	Jan 22, 2014	Jan NEWA
	AB		2MG	A090252	003	Jan 22, 2014	Jan NEWA
	AB	PADDOCK LLC	1MG	A201189	002	Jan 22, 2014	Jan NEWA
	AB		2MG	A201189	003	Jan 22, 2014	Jan NEWA
	AB	SANDOZ	1MG	A078555	002	Jan 22, 2014	Jan NEWA
	AB		2MG	A078555	003	Jan 22, 2014	Jan NEWA
	AB	SUN PHARM INDS INC	1MG	A077571	002	Jul 11, 2013	Jul CAHN
	AB		2MG	A077571	003	Jul 11, 2013	Jul CAHN

RIBAVIRIN

TABLET;ORAL

RIBAVIRIN

>A>	AB	SANDOZ	200MG	A202546	001	Aug 12, 2014	Aug NEWA
>A>	AB		400MG	A202546	002	Aug 12, 2014	Aug NEWA
>A>	AB		500MG	A202546	003	Aug 12, 2014	Aug NEWA
>A>	AB		600MG	A202546	004	Aug 12, 2014	Aug NEWA
>D>		ZYDUS PHARMS USA	500MG	A077094	004	Apr 18, 2008	Aug CTEC
>A>	AB		500MG	A077094	004	Apr 18, 2008	Aug CTEC

RIFABUTIN

CAPSULE;ORAL

MYCOBUTIN

AB	+	PHARMACIA AND UPJOHN	150MG	N050689	001	Dec 23, 1992	Feb CFTG
		RIFABUTIN					
AB		LUPIN LTD	150MG	A090033	001	Feb 24, 2014	Feb NEWA

RIFAMPIN

INJECTABLE;INJECTION

RIFAMPIN

>A>	AP	EMCURE PHARMS LTD	600MG/VIAL	A204101	001	Aug 18, 2014	Aug NEWA
>A>	AP	FRESENIUS KABI USA	600MG/VIAL	A091181	001	Aug 21, 2014	Aug NEWA

RIMANTADINE HYDROCHLORIDE

TABLET; ORAL

RIMANTADINE HYDROCHLORIDE

>A>	@ ACTAVIS ELIZABETH	100MG	A076375	001	Jan 14, 2003	Aug CAHN
>D>	@ ACTAVIS TOTOWA	100MG	A076375	001	Jan 14, 2003	Aug CAHN

RISEDRONATE SODIUM

TABLET; ORAL

ACTONEL

AB	+ WARNER CHILCOTT LLC	150MG	N020835	005	Apr 22, 2008	May CTEC
	RISEDRONATE SODIUM					
AB	APOTEX INC	75MG	A090877	002	Jun 10, 2014	May NEWA
AB		150MG	A090877	003	Jun 10, 2014	May NEWA
AB	MYLAN PHARMS INC	75MG	A200477	004	Jun 10, 2014	May NEWA
AB		150MG	A200477	005	Jun 10, 2014	May NEWA
AB	SUN PHARMA GLOBAL	75MG	A090886	004	Jun 10, 2014	May NEWA
AB		150MG	A090886	005	Jun 10, 2014	May NEWA
AB	TEVA PHARMS USA	150MG	A079215	001	Jun 13, 2014	Jun NEWA

RISPERIDONE

SOLUTION; ORAL

RISPERIDONE

AA	ANI PHARMS INC	1MG/ML	A076440	001	Jan 30, 2009	Jan CAHN
----	----------------	--------	---------	-----	--------------	----------

TABLET; ORAL

RISPERIDONE

AB	CARACO	0.25MG	A078036	001	Mar 10, 2014	Feb NEWA
AB		0.5MG	A078036	002	Mar 10, 2014	Feb NEWA
AB		1MG	A078036	003	Mar 10, 2014	Feb NEWA
AB		2MG	A078036	004	Mar 10, 2014	Feb NEWA
AB		3MG	A078036	005	Mar 10, 2014	Feb NEWA
AB		4MG	A078036	006	Mar 10, 2014	Feb NEWA
AB	SUN PHARM INDS INC	0.25MG	A078036	001	Mar 10, 2014	Jul CAHN
AB		0.5MG	A078036	002	Mar 10, 2014	Jul CAHN
AB		1MG	A078036	003	Mar 10, 2014	Jul CAHN
AB		2MG	A078036	004	Mar 10, 2014	Jul CAHN
AB		3MG	A078036	005	Mar 10, 2014	Jul CAHN
AB		4MG	A078036	006	Mar 10, 2014	Jul CAHN

TABLET, ORALLY DISINTEGRATING; ORAL

RISPERIDONE

AB	JUBILANT GENERICS	0.5MG	A090839	001	Nov 04, 2011	Jul CAHN
AB		1MG	A090839	002	Nov 04, 2011	Jul CAHN
AB		2MG	A090839	003	Nov 04, 2011	Jul CAHN
AB		3MG	A090839	004	Nov 04, 2011	Jul CAHN
AB		4MG	A090839	005	Nov 04, 2011	Jul CAHN

RIVASTIGMINE TARTRATE

CAPSULE; ORAL

RIVASTIGMINE TARTRATE

>A>	AB	MACLEODS PHARMS LTD	EQ 1.5MG BASE	A203148	001	Aug 22, 2014	Aug NEWA
>A>	AB		EQ 3MG BASE	A203148	002	Aug 22, 2014	Aug NEWA
>A>	AB		EQ 4.5MG BASE	A203148	003	Aug 22, 2014	Aug NEWA
>A>	AB		EQ 6MG BASE	A203148	004	Aug 22, 2014	Aug NEWA

SOLUTION; ORAL

EXELON

@ NOVARTIS	EQ 2MG BASE/ML	N021025	001	Apr 21, 2000	Jun DISC
------------	----------------	---------	-----	--------------	----------

RIZATRIPTAN BENZOATE

TABLET; ORAL

RIZATRIPTAN BENZOATE

AB	MACLEODS PHARMS LTD	EQ 5MG BASE	A203147	001	Feb 11, 2014	Jan NEWA
AB		EQ 10MG BASE	A203147	002	Feb 11, 2014	Jan NEWA

ROPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

NAROPIN

AP	FRESENIUS KABI USA	5MG/ML	N020533	003	Sep 24, 1996	Jul CFTG
AP	+	10MG/ML	N020533	005	Sep 24, 1996	Jul CFTG
	ROPIVACAINE HYDROCHLORIDE					
AP	NAVINTA LLC	5MG/ML	A078601	002	Jul 17, 2014	Jul NEWA
AP		10MG/ML	A078601	003	Jul 17, 2014	Jul NEWA

SAXAGLIPTIN HYDROCHLORIDETABLET; ORAL
ONGLYZA+ ASTRAZENECA AB EQ 2.5MG BASE
+ EQ 5MG BASEN022350 001 Jul 31, 2009 May CAHN
N022350 002 Jul 31, 2009 May CAHNSELENIUM SULFIDELOTION/SHAMPOO; TOPICAL
SELENIUM SULFIDE>A> @ G AND W LABS INC 2.5%
>D> @ TARO 2.5%A086209 001 Aug CAHN
A086209 001 Aug CAHNSIMEPREVIR SODIUMCAPSULE; ORAL
OLYSIO+ JANSSEN PRODS EQ 150MG BASE
+ JANSSEN RES AND DEV EQ 150MG BASEN205123 001 Nov 22, 2013 Jun CAHN
N205123 001 Nov 22, 2013 Feb CAINSODIUM BENZOATE; SODIUM PHENYLACETATESOLUTION; IV (INFUSION)
AMMONUL

+ MEDICIS 10%; 10% (5GM/50ML; 5GM/50ML)

N020645 001 Feb 17, 2005 Jul CAHN

SODIUM CHLORIDEINJECTABLE; INJECTION
SODIUM CHLORIDE 0.9%@ MEDEFIL INC 18MG/2ML (9MG/ML)
@ 22.5MG/2.5ML (9MG/ML)
@ 27MG/3ML (9MG/ML)
@ 45MG/5ML (9MG/ML)
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
@ MEDEFIL INC 9MG/ML (9MG/ML)N202832 002 Jan 06, 2012 Jun DISC
N202832 003 Jan 06, 2012 Jun DISC
N202832 004 Jan 06, 2012 Jun DISC
N202832 005 Jan 06, 2012 Jun DISC
N202832 001 Jan 06, 2012 Jun DISCSODIUM FLUORIDE F-18INJECTABLE; INTRAVENOUS
SODIUM FLUORIDE F-18

AP UCSF RODIOPHARM 10-200mCi/ML

A204437 001 Mar 13, 2014 Mar NEWA

SODIUM POLYSTYRENE SULFONATEPOWDER; ORAL, RECTAL
SODIUM POLYSTYRENE SULFONATE

AA EPIC PHARMA LLC 453.6GM/BOT

A202333 001 Mar 19, 2014 Mar NEWA

SOLIFENACIN SUCCINATETABLET; ORAL
SOLIFENACIN SUCCINATEAB TEVA PHARMS USA 5MG
AB 10MGA091464 001 Apr 02, 2014 Mar NEWA
A091464 002 Apr 02, 2014 Mar NEWA

VESICARE

AB ASTELLAS 5MG
AB + 10MGN021518 001 Nov 19, 2004 Mar CFTG
N021518 002 Nov 19, 2004 Mar CFTGSOMATROPIN RECOMBINANTINJECTABLE; INJECTION
ACCRETROPIN

@ EMERGENT 5MG/ML (5MG/ML)

N021538 001 Jan 23, 2008 Feb CAHN

SPIRONOLACTONETABLET; ORAL
SPIRONOLACTONE>A> AB JUBILANT GENERICS 25MG
>A> AB 50MG
>A> AB 100MG
>D> AB JUBILANT LIFE 25MG
AB 25MG
>D> AB 50MG
AB 50MG
>D> AB 100MG
AB 100MG
AB 100MG
AB ORION CORP ORION 25MG
AB 50MGA203253 001 Apr 23, 2014 Aug CAHN
A203253 002 Apr 23, 2014 Aug CAHN
A203253 003 Apr 23, 2014 Aug CAHN
A203253 001 Apr 23, 2014 Aug CAHN
A203253 001 Apr 23, 2014 Apr NEWA
A203253 002 Apr 23, 2014 Aug CAHN
A203253 002 Apr 23, 2014 Apr NEWA
A203253 003 Apr 23, 2014 Aug CAHN
A203253 003 Apr 23, 2014 Apr NEWA
A202187 001 Mar 06, 2014 Feb NEWA
A202187 002 Mar 06, 2014 Feb NEWA

TABLET;ORAL							
SPIRONOLACTONE							
AB		100MG		A202187	003	Mar 06, 2014	Feb NEWA
<u>SUCRALFATE</u>							
SUSPENSION;ORAL							
CARAFATE							
	+ FOREST LABS INC	1GM/10ML		N019183	001	Dec 16, 1993	Apr CAHN
TABLET;ORAL							
CARAFATE							
AB	+ FOREST LABS INC	1GM		N018333	001		Apr CAHN
<u>SULFASALAZINE</u>							
TABLET;ORAL							
SULFASALAZINE							
	@ WATSON LABS	500MG		A087197	001		May DISC
<u>SUMATRIPTAN SUCCINATE</u>							
INJECTABLE;SUBCUTANEOUS							
IMITREX STATDOSE							
BX	+ GLAXOSMITHKLINE	EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)		N020080	002	Feb 01, 2006	May CTEC
SUMATRIPTAN SUCCINATE							
AP	AGILA SPECLTS	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)		A203322	001	Apr 14, 2014	Mar NEWA
AB	DR REDDYS LABS INC	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)		A090495	001	Jan 29, 2014	Jan NEWA
AP	PAR STERILE PRODUCTS	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)		A077871	001	Jul 09, 2009	Jun CAHN
SUMAVEL DOSEPRO							
>A> BX	+ ENDO VENTURES LTD	EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)		N022239	002	Nov 26, 2013	Aug CAHN
>A> BX	+	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)		N022239	001	Jul 15, 2009	Aug CAHN
>D> BX	+ ZOGENIX INC	EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)		N022239	002	Nov 26, 2013	Aug CAHN
BX	+	EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)		N022239	002	Nov 26, 2013	May NEWA
>D> BX	+	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)		N022239	001	Jul 15, 2009	Aug CAHN
SYSTEM;IONTOPHORESIS							
ZECUITY							
	+ TEVA BRANDED PHARM	EQ 6.5MG BASE/4HR		N202278	001	Jan 17, 2013	May CAHN
<u>SUNITINIB MALATE</u>							
CAPSULE;ORAL							
SUNITINIB MALATE							
AB	MYLAN PHARMS INC	EQ 12.5MG BASE		A201275	001	Jan 30, 2014	Jan NEWA
AB		EQ 25MG BASE		A201275	002	Jan 30, 2014	Jan NEWA
AB		EQ 37.5MG BASE		A201275	003	Jan 30, 2014	Jan NEWA
AB		EQ 50MG BASE		A201275	004	Jan 30, 2014	Jan NEWA
SUTENT							
AB	CPPI CV	EQ 12.5MG BASE		N021938	001	Jan 26, 2006	Jan CFTG
AB		EQ 25MG BASE		N021938	002	Jan 26, 2006	Jan CFTG
AB		EQ 37.5MG BASE		N021938	004	Mar 31, 2009	Jan CFTG
AB	+	EQ 50MG BASE		N021938	003	Jan 26, 2006	Jan CFTG
>A>	<u>SUVOREXANT</u>						
>A>	TABLET;ORAL						
>A>	BELSOMRA						
>A>	MERCK SHARP DOHME	5MG		N204569	001	Aug 13, 2014	Aug NEWA
>A>		10MG		N204569	002	Aug 13, 2014	Aug NEWA
>A>		15MG		N204569	003	Aug 13, 2014	Aug NEWA
>A>	+	20MG		N204569	004	Aug 13, 2014	Aug NEWA
<u>TACROLIMUS</u>							
CAPSULE;ORAL							
TACROLIMUS							
>D> AB	STRIDES ARCOLAB LTD	EQ 0.5MG BASE		A090687	001	Jul 22, 2014	Aug CAHN
AB		EQ 0.5MG BASE		A090687	001	Jul 22, 2014	Jul NEWA
>D> AB		EQ 1MG BASE		A090687	002	Jul 22, 2014	Aug CAHN
AB		EQ 1MG BASE		A090687	002	Jul 22, 2014	Jul NEWA
>D> AB		EQ 5MG BASE		A090687	003	Jul 22, 2014	Aug CAHN
AB		EQ 5MG BASE		A090687	003	Jul 22, 2014	Jul NEWA
>A> AB	STRIDES PHARMA	EQ 0.5MG BASE		A090687	001	Jul 22, 2014	Aug CAHN
>A> AB		EQ 1MG BASE		A090687	002	Jul 22, 2014	Aug CAHN
>A> AB		EQ 5MG BASE		A090687	003	Jul 22, 2014	Aug CAHN

	CAPSULE;ORAL						
	TACROLIMUS						
	@ WATSON LABS	EQ 5MG BASE	A090402	001	Jul 01, 2010	May	DISC
	OINTMENT;TOPICAL						
	PROTOPIC						
>D>	+ ASTELLAS	0.03%	N050777	001	Dec 08, 2000	Aug	CFTG
>A> AB	+	0.03%	N050777	001	Dec 08, 2000	Aug	CFTG
>D>	+	0.1%	N050777	002	Dec 08, 2000	Aug	CFTG
>A> AB	+	0.1%	N050777	002	Dec 08, 2000	Aug	CFTG
>A>	TACROLIMUS						
>A> AB	FOUGERA PHARMS INC	0.03%	A200744	001	Sep 09, 2014	Aug	NEWA
>A> AB		0.1%	A200744	002	Sep 09, 2014	Aug	NEWA

TAFILUPROST

SOLUTION/DROPS;OPHTHALMIC

ZIOPTAN

+ OAK PHARMS INC	0.0015%	N202514	001	Feb 10, 2012	Apr	CAHN
------------------	---------	---------	-----	--------------	-----	------

TASIMELTEON

CAPSULE;ORAL

HETLIOZ

+ VANDA PHARMS INC	20MG	N205677	001	Jan 31, 2014	Jan	NEWA
--------------------	------	---------	-----	--------------	-----	------

TAVABOROLE

SOLUTION;TOPICAL

KERYDIN

+ ANACOR PHARMS INC	5%	N204427	001	Jul 07, 2014	Jul	NEWA
---------------------	----	---------	-----	--------------	-----	------

TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR

SOLUTION;INJECTION, ORAL

TECHNELITE

@ LANTHEUS MEDCL	0.0083-2.7 CI/GENERATOR	N017771	001		May	DISC
------------------	-------------------------	---------	-----	--	-----	------

ULTRA-TECHNEKOW FM

@ MALLINCKRODT	0.25-3 CI/GENERATOR	N017243	002		May	DISC
----------------	---------------------	---------	-----	--	-----	------

SOLUTION;INTRAVENOUS

TECHNELITE

+ LANTHEUS MEDCL	1-20 CI/GENERATOR	N017771	002	Feb 12, 2014	May	NEWA
------------------	-------------------	---------	-----	--------------	-----	------

@	0.0083-2.7 CI/GENERATOR	N017771	001		May	CDFR
---	-------------------------	---------	-----	--	-----	------

ULTRA-TECHNEKOW FM

+ MALLINCKRODT	1-19 CI/GENERATOR	N017243	003	Feb 18, 2014	May	NEWA
----------------	-------------------	---------	-----	--------------	-----	------

@	0.25-3 CI/GENERATOR	N017243	002		May	CDFR
---	---------------------	---------	-----	--	-----	------

SOLUTION;INTRAVENOUS, ORAL

TECHNETIUM TC 99M GENERATOR

+ GE HEALTHCARE	68-2703mCi/GENERATOR	N017693	002	Dec 13, 2013	May	NEWA
-----------------	----------------------	---------	-----	--------------	-----	------

	830-16600mCi/GENERATOR	N017693	001		May	CDFR
--	------------------------	---------	-----	--	-----	------

TEDIZOLID PHOSPHATE

POWDER;IV (INFUSION)

SIVEXTRO

+ CUBIST PHARMS INC	200MG/VIAL	N205436	001	Jun 20, 2014	Jun	NEWA
---------------------	------------	---------	-----	--------------	-----	------

TABLET;ORAL

SIVEXTRO

+ CUBIST PHARMS INC	200MG	N205435	001	Jun 20, 2014	Jun	NEWA
---------------------	-------	---------	-----	--------------	-----	------

TELAVANCIN HYDROCHLORIDE

POWDER;IV (INFUSION)

VIBATIV

THERAVANCE BIOPHARMA	EQ 250MG BASE/VIAL	N022110	001	Sep 11, 2009	Jun	CAHN
----------------------	--------------------	---------	-----	--------------	-----	------

+	EQ 750MG BASE/VIAL	N022110	002	Sep 11, 2009	Jun	CAHN
---	--------------------	---------	-----	--------------	-----	------

TELMISARTAN

TABLET;ORAL

TELMISARTAN

AB	ALEMBIC PHARMS LTD	20MG	A202130	001	Jul 07, 2014	Jun	NEWA
----	--------------------	------	---------	-----	--------------	-----	------

AB		40MG	A202130	002	Jul 07, 2014	Jun	NEWA
----	--	------	---------	-----	--------------	-----	------

AB		80MG	A202130	003	Jul 07, 2014	Jun	NEWA
----	--	------	---------	-----	--------------	-----	------

AB	GLENMARK GENERICS	20MG	A090032	001	Jul 07, 2014	Jun	NEWA
----	-------------------	------	---------	-----	--------------	-----	------

AB		40MG	A090032	002	Jul 07, 2014	Jun	NEWA
----	--	------	---------	-----	--------------	-----	------

AB		80MG	A090032	003	Jul 07, 2014	Jun	NEWA
----	--	------	---------	-----	--------------	-----	------

AB	MYLAN PHARMS INC	20MG	A202397	001	Jul 07, 2014	Jun	NEWA
----	------------------	------	---------	-----	--------------	-----	------

AB		40MG	A202397	002	Jul 07, 2014	Jun	NEWA
----	--	------	---------	-----	--------------	-----	------

TABLET;ORAL
TELMISARTAN

AB		80MG	A202397	003	Jul 07, 2014	Jun NEWA	
AB	TORRENT PHARMS LTD	20MG	A203171	001	Jul 07, 2014	Jun NEWA	
AB		40MG	A203171	002	Jul 07, 2014	Jun NEWA	
AB		80MG	A203171	003	Jul 07, 2014	Jun NEWA	
>A>	AB	ZYDUS PHARMS USA INC	20MG	A203325	001	Aug 26, 2014	Aug NEWA
>A>	AB		40MG	A203325	002	Aug 26, 2014	Aug NEWA
>A>	AB		80MG	A203325	003	Aug 26, 2014	Aug NEWA

TEMAZEPAM

CAPSULE;ORAL
TEMAZEPAM

@	WATSON LABS	15MG	A071446	001	May 21, 1993	May DISC
@		30MG	A071447	001	May 21, 1993	May DISC

TEMOZOLOMIDE

CAPSULE;ORAL
TEMOZOLOMIDE

AB	SUN PHARMA GLOBAL	5MG	A201742	001	Feb 12, 2014	Feb NEWA
AB		20MG	A201742	002	Feb 12, 2014	Feb NEWA
AB		100MG	A201742	003	Feb 12, 2014	Feb NEWA
AB		140MG	A201742	004	Feb 12, 2014	Feb NEWA
AB		180MG	A201742	005	Feb 12, 2014	Feb NEWA
AB		250MG	A201742	006	Feb 12, 2014	Feb NEWA

TERAZOSIN HYDROCHLORIDE

CAPSULE;ORAL
TERAZOSIN HYDROCHLORIDE

AB	+	SANDOZ	EQ 2MG BASE	A074823	002	Mar 30, 1998	Apr CRLD
		TABLET;ORAL					
		HYTRIN					
	@	ABBOTT	EQ 1MG BASE	N019057	001	Aug 07, 1987	Apr DISC
	@		EQ 2MG BASE	N019057	002	Aug 07, 1987	Apr DISC
	@		EQ 5MG BASE	N019057	003	Aug 07, 1987	Apr DISC
	@		EQ 10MG BASE	N019057	004	Aug 07, 1987	Apr DISC

TESAMORELIN ACETATE

POWDER;SUBCUTANEOUS
EGRIFTA

>D>	@	THERATECHNOLOGIES	EQ 1MG BASE/VIAL	N022505	001	Nov 10, 2010	Aug CMFD
>A>	+		EQ 1MG BASE/VIAL	N022505	001	Nov 10, 2010	Aug CMFD
	@		EQ 1MG BASE/VIAL	N022505	001	Nov 10, 2010	May CAHN
>D>	+		EQ 2MG BASE/VIAL	N022505	002	Nov 29, 2011	Aug DISC
>A>	@		EQ 2MG BASE/VIAL	N022505	002	Nov 29, 2011	Aug DISC
	+		EQ 2MG BASE/VIAL	N022505	002	Nov 29, 2011	May CAHN

TESTOSTERONE

GEL;TRANSDERMAL
ANDROGEL

AB		ABBVIE	25MG/2.5GM PACKET	N021015	001	Feb 28, 2000	Jul CTEC
AB	+		50MG/5GM PACKET	N021015	002	Feb 28, 2000	Jul CTEC
		TESTOSTERONE					
AB		PERRIGO ISRAEL	25MG/2.5GM PACKET	N203098	002	Jan 31, 2013	Jul CTEC
AB			50MG/5GM PACKET	N203098	003	Jan 31, 2013	Jul CTEC
BX		TEVA PHARMS	25MG/2.5GM PACKET	N202763	001	Feb 14, 2012	Jul CTEC
BX			50MG/5GM PACKET	N202763	002	Feb 14, 2012	Jul CTEC
		VOGELXO					
		UPSHER SMITH	50MG/5GM PACKET	N204399	002	Jun 04, 2014	Jun NEWA
		GEL, METERED;NASAL					
		NATESTO					
	@	TRIMEL BIOPHARMA SRL	5.5MG/0.122GM ACTUATION	N205488	001	May 28, 2014	Jun DISC
	+		5.5MG/0.122GM ACTUATION	N205488	001	May 28, 2014	May NEWA
		GEL, METERED;TRANSDERMAL					
		ANDROGEL					
AB	+	ABBVIE	12.5MG/1.25GM ACTUATION	N021015	003	Sep 26, 2003	Jul CTEC
		TESTOSTERONE					
AB		PERRIGO ISRAEL	12.5MG/1.25GM ACTUATION	N203098	001	Jan 31, 2013	Jul CTEC
		VOGELXO					
		UPSHER SMITH	12.5MG/1.25GM ACTUATION	N204399	003	Jun 04, 2014	Jun NEWA

TABLET, EXTENDED RELEASE;BUCCAL
STRIANT

+ AUXILIUM PHARMS LLC 30MG N021543 001 Jun 19, 2003 Apr CAHN

TESTOSTERONE UNDECANOATE

INJECTABLE;INTRAMUSCULAR
AVEED

+ ENDO PHARMS INC 750MG/3ML (250MG/ML) N022219 001 Mar 04, 2014 Mar NEWA

THEOPHYLLINE

SOLUTION, ELIXIR;ORAL
ELIXOPHYLLIN

+ CARACO 80MG/15ML A085186 001 Jun CDFR

+ SUN PHARM INDS INC 80MG/15ML A085186 001 Jul CAHN

TABLET, EXTENDED RELEASE;ORAL
THEOCHRON

AB @ CARACO 300MG A087400 002 Jan 11, 1983 Jan DISC

AB @ SUN PHARM INDS INC 100MG A088320 001 Feb 21, 1985 Jul CAHN

@ 200MG A088321 001 Feb 21, 1985 Jul CAHN

@ 300MG A087400 002 Jan 11, 1983 Jul CAHN

THIAMINE HYDROCHLORIDE

INJECTABLE;INJECTION
THIAMINE HYDROCHLORIDE

@ WATSON LABS 100MG/ML A080571 001 May DISC

@ 200MG/ML A080571 002 May DISC

THIORIDAZINE HYDROCHLORIDE

CONCENTRATE;ORAL
THIORIDAZINE HYDROCHLORIDE

@ ANI PHARMS INC 100MG/ML A089603 001 Nov 09, 1987 Feb CAHN

TABLET;ORAL

THIORIDAZINE HYDROCHLORIDE

@ ANI PHARMS INC 10MG A088270 001 Apr 14, 1983 Feb CAHN

@ 10MG A088493 001 May 17, 1985 Feb CAHN

@ 15MG A088271 001 Apr 14, 1983 Feb CAHN

@ 25MG A088272 001 Apr 14, 1983 Feb CAHN

@ 50MG A088194 001 Apr 14, 1983 Feb CAHN

@ 100MG A088273 001 Oct 03, 1983 Feb CAHN

@ 100MG A088456 001 May 17, 1985 Feb CAHN

THIOTEPA

INJECTABLE;INJECTION

THIOTEPA

>D> BEDFORD 15MG/VIAL A075547 001 Apr 02, 2001 Aug CAHN

>A> EUROHLTH INTL 15MG/VIAL A075547 001 Apr 02, 2001 Aug CAHN

THIOTHIXENE

CAPSULE;ORAL
THIOTHIXENE

@ WATSON LABS 2MG A070601 001 Jun 05, 1987 May DISC

@ 5MG A070602 001 Jun 05, 1987 May DISC

TICLOPIDINE HYDROCHLORIDE

TABLET;ORAL
TICLOPIDINE HYDROCHLORIDE

AB SUN PHARM INDS INC 250MG A075526 001 Sep 26, 2002 Jul CAHN

TIMOLOL

SOLUTION/DROPS;OPHTHALMIC
BETIMOL

+ OAK PHARMS AKORN EQ 0.25% BASE N020439 001 Mar 31, 1995 Apr CAHN

+ EQ 0.5% BASE N020439 002 Mar 31, 1995 Apr CAHN

TIZANIDINE HYDROCHLORIDE

TABLET;ORAL
TIZANIDINE HYDROCHLORIDE

AB SUN PHARM INDS INC EQ 2MG BASE A076416 001 Sep 29, 2003 Jul CAHN

AB EQ 4MG BASE A076416 002 Sep 29, 2003 Jul CAHN

TOBRAMYCINSOLUTION; INHALATION
BETHKIS

	CHIESI USA INC	300MG/4ML	N201820	001	Oct 12, 2012	Apr CAHN
AN	AKORN INC	300MG/5ML	A201422	001	May 28, 2014	May NEWA

TOBRAMYCIN SULFATEINJECTABLE; INJECTION
TOBRAMYCIN SULFATE

@	WATSON LABS INC	EQ 10MG BASE/ML	A062945	001	Aug 09, 1989	May DISC
---	-----------------	-----------------	---------	-----	--------------	----------

TOPIRAMATECAPSULE, DELAYED RELEASE; ORAL
QUDEXY XR

	UPSHER SMITH	25MG	N205122	001	Mar 11, 2014	Mar NEWA
		50MG	N205122	002	Mar 11, 2014	Mar NEWA
		100MG	N205122	003	Mar 11, 2014	Mar NEWA
		150MG	N205122	004	Mar 11, 2014	Mar NEWA
+		200MG	N205122	005	Mar 11, 2014	Mar NEWA

CAPSULE, EXTENDED RELEASE; ORAL
QUDEXY XR

	UPSHER SMITH	25MG	N205122	001	Mar 11, 2014	Apr CDFR
		50MG	N205122	002	Mar 11, 2014	Apr CDFR
		100MG	N205122	003	Mar 11, 2014	Apr CDFR
		150MG	N205122	004	Mar 11, 2014	Apr CDFR
+		200MG	N205122	005	Mar 11, 2014	Apr CDFR

TABLET; ORAL

TOPIRAMATE

@	WATSON LABS	25MG	A077643	001	Mar 27, 2009	May DISC
@		50MG	A077643	002	Mar 27, 2009	May DISC
@		100MG	A077643	003	Mar 27, 2009	May DISC
@		200MG	A077643	004	Mar 27, 2009	May DISC

TOPOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION

TOPOTECAN HYDROCHLORIDE

>A>	AP	ACTAVIS ELIZABETH	EQ 4MG BASE/VIAL	A090620	001	Dec 02, 2010	Aug CAHN
>D>	AP	ACTAVIS TOTOWA	EQ 4MG BASE/VIAL	A090620	001	Dec 02, 2010	Aug CAHN
	AP	INNOPHARMA LICENSING	EQ 4MG BASE/VIAL	A201166	001	Aug 08, 2012	Apr CAHN

TORSEMIDE

INJECTABLE; INJECTION

TORSEMIDE

>D>	AP	+	BEDFORD LABS	20MG/2ML (10MG/ML)	A078007	001	Jun 11, 2008	Aug CAHN
>D>	AP	+		50MG/5ML (10MG/ML)	A078007	002	Jun 11, 2008	Aug CAHN
>A>	AP	+	EUROHLTH INTL	20MG/2ML (10MG/ML)	A078007	001	Jun 11, 2008	Aug CAHN
>A>	AP	+		50MG/5ML (10MG/ML)	A078007	002	Jun 11, 2008	Aug CAHN

TRAMADOL HYDROCHLORIDE

TABLET; ORAL

TRAMADOL HYDROCHLORIDE

AB	ALLIED PHARMA INC	50MG	A202075	001	Nov 28, 2011	Apr CAHN
AB	AUROBINDO PHARMA LTD	50MG	A203494	001	Mar 31, 2014	Mar NEWA
AB	SUN PHARM INDS INC	50MG	A075964	001	Jun 19, 2002	Jul CAHN
	@ WATSON LABS	50MG	A075962	001	Jun 24, 2002	May DISC

TRANDOLAPRIL

TABLET; ORAL

TRANDOLAPRIL

@	COREPHARMA	1MG	A077256	001	Jun 12, 2007	Jun DISC
@		2MG	A077256	002	Jun 12, 2007	Jun DISC
@		4MG	A077256	003	Jun 12, 2007	Jun DISC

TRANEXAMIC ACID

INJECTABLE; INJECTION

TRANEXAMIC ACID

AP	ACIC FINE CHEMS	100MG/ML	A202436	001	Feb 11, 2014	Jan NEWA	
>A>	AP	EMCURE PHARMS LTD	100MG/ML	A203521	001	Aug 12, 2014	Aug NEWA

TABLET;ORAL							
TRANEXAMIC ACID							
AB	APOTEX INC	650 MG	A202286	001	Jan 27, 2014	Jan	NEWA
<u>TRAVOPROST</u>							
SOLUTION/DROPS;OPHTHALMIC							
IZBA							
+	ALCON LABS INC	0.003%	N204822	001	May 15, 2014	May	NEWA
TRAVOPROST							
+	PAR PHARM	0.004%	A091340	001	Mar 01, 2013	Feb	CRLD
<u>TRAZODONE HYDROCHLORIDE</u>							
TABLET;ORAL							
TRAZODONE HYDROCHLORIDE							
@	WATSON LABS	50MG	A070857	001	Oct 10, 1986	May	DISC
@		100MG	A070858	001	Oct 10, 1986	May	DISC
<u>TREPROSTINIL DIOLAMINE</u>							
TABLET, EXTENDED RELEASE;ORAL							
ORENITRAM							
	UNITED THERAP	EQ 0.125MG BASE	N203496	001	Dec 20, 2013	Jun	CAIN
		EQ 0.25MG BASE	N203496	002	Dec 20, 2013	Jun	CAIN
		EQ 1MG BASE	N203496	003	Dec 20, 2013	Jun	CAIN
+		EQ 2.5MG BASE	N203496	004	Dec 20, 2013	Jun	CAIN
<u>TRETINOIN</u>							
GEL;TOPICAL							
RETIN-A-MICRO							
+	VALEANT INTL	0.08%	N020475	003	Jan 28, 2014	Jan	NEWA
SOLUTION;TOPICAL							
RETIN-A							
+	VALEANT INTL	0.05%	N016921	001		Feb	CTEC
TRETINOIN							
@	WOCKHARDT	0.05%	A075260	001	Jan 25, 1999	Feb	DISC
<u>TRIAMCINOLONE ACETONIDE</u>							
CREAM;TOPICAL							
KENALOG							
@	DELCOR ASSET CORP	0.025%	N011601	003		Jul	CAHN
@		0.1%	N011601	006		Jul	CAHN
INJECTABLE;INJECTION							
KENALOG-10							
	APOTHECON	10MG/ML	N012041	001		May	CTEC
KENALOG-40							
+	APOTHECON	40MG/ML	N014901	001		May	CTEC
TRIAMCINOLONE ACETONIDE							
@	SANDOZ	10MG/ML	A090166	001	May 27, 2009	May	DISC
@	SANDOZ CANADA INC	40MG/ML	A090164	001	Jun 01, 2009	May	DISC
LOTION;TOPICAL							
TRIAMCINOLONE ACETONIDE							
>A>	@ G AND W LABS INC	0.1%	A089129	001	Aug 14, 1986	Aug	CAHN
>D>	@ TARO	0.1%	A089129	001	Aug 14, 1986	Aug	CAHN
	@	0.1%	A089129	001	Aug 14, 1986	Mar	DISC
OINTMENT;TOPICAL							
KENALOG							
@	DELCOR ASSET CORP	0.025%	N011600	003		Jul	CAHN
@		0.1%	N011600	001		Jul	CAHN
<u>TRIAZOLAM</u>							
TABLET;ORAL							
TRIAZOLAM							
@	WATSON LABS	0.125MG	A074445	001	Oct 20, 1995	May	DISC
@		0.25MG	A074445	002	Oct 20, 1995	May	DISC
<u>TRIHEXYPHENIDYL HYDROCHLORIDE</u>							
TABLET;ORAL							
TRIHEXYPHENIDYL HYDROCHLORIDE							
@	WATSON LABS	2MG	A040184	001	Feb 06, 1998	May	DISC
@		5MG	A040184	002	Feb 06, 1998	May	DISC

TRIMETHOBENZAMIDE HYDROCHLORIDEINJECTABLE; INJECTION
TIGAN

AP	+	PAR STERILE PRODUCTS	100MG/ML	N017530	001		May	CAHN
----	---	----------------------	----------	---------	-----	--	-----	------

UMECLIDINIUM BROMIDEPOWDER; INHALATION
INCRUSE ELLIPTA

	+	GLAXO GRP ENGLAND	EQ 62.5MCG BASE/INH	N205382	001	Apr 30, 2014	Apr	NEWA
--	---	-------------------	---------------------	---------	-----	--------------	-----	------

UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATEPOWDER; INHALATION
ANORO ELLIPTA

	+	GLAXOSMITHKLINE	EQ 0.0625MG BASE/INH; EQ 0.025MG BASE/INH	N203975	001	Dec 18, 2013	Apr	CAHN
--	---	-----------------	---	---------	-----	--------------	-----	------

UNOPROSTONE ISOPROPYLSOLUTION/DROPS; OPHTHALMIC
RESCULA

>D>		SUCAMPO PHARMS	0.15%	N021214	001	Aug 03, 2000	Aug	CRLD
>A>	+		0.15%	N021214	001	Aug 03, 2000	Aug	CRLD

UREA C-13FOR SOLUTION; ORAL
BREATHTEK UBT FOR H-PYLORI

	@	OTSUKA AMERICA	EQ 75MG /POUCH	N020586	002	May 10, 2001	May	DISC
--	---	----------------	----------------	---------	-----	--------------	-----	------

URSODIOLTABLET; ORAL
URSO 250

AB		FOREST LABS INC	250MG	N020675	001	Dec 10, 1997	Apr	CAHN
----	--	-----------------	-------	---------	-----	--------------	-----	------

AB	+	FOREST LABS INC	500MG	N020675	002	Jul 21, 2004	Apr	CAHN
		URSODIOL						

AB		IMPAX LABS INC	250MG	A200826	001	Dec 23, 2011	Jul	CAHN
AB			500MG	A200826	002	Dec 23, 2011	Jul	CAHN

VALACYCLOVIR HYDROCHLORIDETABLET; ORAL
VALACYCLOVIR HYDROCHLORIDE

AB		APOTEX INC	EQ 1GM BASE	A090500	002	Apr 04, 2014	Mar	NEWA
AB			EQ 500MG BASE	A090500	001	Apr 04, 2014	Mar	NEWA
AB		CIPLA LTD	EQ 1GM BASE	A077135	002	May 24, 2010	Jan	CAHN
AB			EQ 500MG BASE	A077135	001	May 24, 2010	Jan	CAHN
>A> AB		JUBILANT GENERICS	EQ 1GM BASE	A201506	002	Apr 03, 2012	Aug	CAHN
>A> AB			EQ 500MG BASE	A201506	001	Apr 03, 2012	Aug	CAHN
>D> AB		JUBILANT ORGANOSYS	EQ 1GM BASE	A201506	002	Apr 03, 2012	Aug	CAHN
>D> AB			EQ 500MG BASE	A201506	001	Apr 03, 2012	Aug	CAHN
AB		WATSON LABS INC	EQ 1GM BASE	A090370	002	Mar 16, 2011	Apr	CAHN
AB			EQ 500MG BASE	A090370	001	Mar 16, 2011	Apr	CAHN

VALPROIC ACIDSYRUP; ORAL
VALPROIC ACID

AA		ANI PHARMS INC	250MG/5ML	A073178	001	Aug 25, 1992	Jan	CAHN
----	--	----------------	-----------	---------	-----	--------------	-----	------

VALSARTANTABLET; ORAL
DIOVAN

AB		NOVARTIS	40MG	N021283	004	Aug 14, 2002	Jun	CFTG
AB			80MG	N021283	001	Jul 18, 2001	Jun	CFTG
AB			160MG	N021283	002	Jul 18, 2001	Jun	CFTG
AB	+		320MG	N021283	003	Jul 18, 2001	Jun	CFTG

VALSARTAN

AB		OHM LABS INC	40MG	A077492	001	Jun 26, 2014	Jun	NEWA
AB			80MG	A077492	002	Jun 26, 2014	Jun	NEWA
AB			160MG	A077492	003	Jun 26, 2014	Jun	NEWA
AB			320MG	A077492	004	Jun 26, 2014	Jun	NEWA

VANCOMYCIN HYDROCHLORIDE

CAPSULE; ORAL

VANCOCIN HYDROCHLORIDE

>A>	AB	ANI PHARMS INC	EQ 125MG BASE	N050606	001	Apr 15, 1986	Aug CAHN
>A>	AB	+	EQ 250MG BASE	N050606	002	Apr 15, 1986	Aug CAHN
>D>	AB	SHIRE VIROPHARM INC	EQ 125MG BASE	N050606	001	Apr 15, 1986	Aug CAHN
	AB		EQ 125MG BASE	N050606	001	Apr 15, 1986	May CAHN
>D>	AB	+	EQ 250MG BASE	N050606	002	Apr 15, 1986	Aug CAHN
	AB	+	EQ 250MG BASE	N050606	002	Apr 15, 1986	May CAHN

VANCOMYCIN HYDROCHLORIDE

>D>	AB	STRIDES ARCOLAB LTD	EQ 125MG BASE	A065490	001	Apr 09, 2012	Aug CAHN
>D>	AB		EQ 250MG BASE	A065490	002	Apr 09, 2012	Aug CAHN
>A>	AB	STRIDES PHARMA	EQ 125MG BASE	A065490	001	Apr 09, 2012	Aug CAHN
>A>	AB		EQ 250MG BASE	A065490	002	Apr 09, 2012	Aug CAHN

FOR SOLUTION; ORAL

VANCOCIN HYDROCHLORIDE

>A>	@	ANI PHARMS INC	EQ 250MG BASE/5ML	A061667	002	Jul 13, 1983	Aug CAHN
>A>	@		EQ 500MG BASE/6ML	A061667	001		Aug CAHN
>D>	@	VIROPHARMA	EQ 250MG BASE/5ML	A061667	002	Jul 13, 1983	Aug CAHN
>D>	@		EQ 500MG BASE/6ML	A061667	001		Aug CAHN

INJECTABLE; INJECTION

VANCOCIN HYDROCHLORIDE

>A>	@	ANI PHARMS INC	EQ 1GM BASE/VIAL	A060180	002	Mar 21, 1986	Aug CAHN
>A>	@		EQ 1GM BASE/VIAL	A062476	002	Mar 21, 1986	Aug CAHN
>A>	@		EQ 1GM BASE/VIAL	A062716	002	Mar 13, 1987	Aug CAHN
>A>	@		EQ 1GM BASE/VIAL	A062812	002	Nov 17, 1987	Aug CAHN
>A>	@		EQ 10GM BASE/VIAL	A062812	003	Nov 17, 1987	Aug CAHN
>A>	@		EQ 500MG BASE/VIAL	A060180	001		Aug CAHN
>A>	@		EQ 500MG BASE/VIAL	A062476	001	Mar 15, 1984	Aug CAHN
>A>	@		EQ 500MG BASE/VIAL	A062716	001	Mar 13, 1987	Aug CAHN
>A>	@		EQ 500MG BASE/VIAL	A062812	001	Nov 17, 1987	Aug CAHN
>D>	@	VIROPHARMA	EQ 1GM BASE/VIAL	A060180	002	Mar 21, 1986	Aug CAHN
>D>	@		EQ 1GM BASE/VIAL	A062476	002	Mar 21, 1986	Aug CAHN
>D>	@		EQ 1GM BASE/VIAL	A062716	002	Mar 13, 1987	Aug CAHN
>D>	@		EQ 1GM BASE/VIAL	A062812	002	Nov 17, 1987	Aug CAHN
>D>	@		EQ 10GM BASE/VIAL	A062812	003	Nov 17, 1987	Aug CAHN
>D>	@		EQ 500MG BASE/VIAL	A060180	001		Aug CAHN
>D>	@		EQ 500MG BASE/VIAL	A062476	001	Mar 15, 1984	Aug CAHN
>D>	@		EQ 500MG BASE/VIAL	A062716	001	Mar 13, 1987	Aug CAHN
>D>	@		EQ 500MG BASE/VIAL	A062812	001	Nov 17, 1987	Aug CAHN

VANCOMYCIN HYDROCHLORIDE

AP		AGILA SPECLTS	EQ 10GM BASE/VIAL	A091554	001	Sep 19, 2011	Feb CAHN
AP		MUSTAFA NEVZAT ILAC	EQ 1GM BASE/VIAL	A065401	002	Jun 30, 2008	May CAHN
AP			EQ 500MG BASE/VIAL	A065401	001	Jun 30, 2008	May CAHN
>A>	AP	SAGENT PHARMS	EQ 10GM BASE/VIAL	A200837	002	Sep 02, 2014	Aug NEWA

VASOPRESSIN

SOLUTION; IV (INFUSION)

VASOSTRICT

+	PAR STERILE PRODUCTS	20UNITS/ML (20UNITS/ML)	N204485	001	Apr 17, 2014	Apr NEWA
---	----------------------	-------------------------	---------	-----	--------------	----------

VECURONIUM BROMIDE

INJECTABLE; INJECTION

VECURONIUM BROMIDE

@	WATSON LABS	10MG/VIAL	A074334	001	Aug 31, 1995	May DISC
@		20MG/VIAL	A074334	002	Aug 31, 1995	May DISC

VENLAFAXINE HYDROCHLORIDE

TABLET; ORAL

VENLAFAXINE HYDROCHLORIDE

AB	SUN PHARM INDS INC	EQ 25MG BASE	A078627	001	Jun 13, 2008	Jul CAHN
AB		EQ 37.5MG BASE	A078627	002	Jun 13, 2008	Jul CAHN
AB		EQ 50MG BASE	A078627	003	Jun 13, 2008	Jul CAHN
AB		EQ 75MG BASE	A078627	004	Jun 13, 2008	Jul CAHN
AB		EQ 100MG BASE	A078627	005	Jun 13, 2008	Jul CAHN

VERAPAMIL HYDROCHLORIDE

TABLET; ORAL

VERAPAMIL HYDROCHLORIDE

AB	MYLAN	80MG	A071483	002	Feb 15, 1989	Apr CMS1
	@ WATSON LABS	40MG	A072923	001	Jun 29, 1993	May DISC
	@	80MG	A070855	001	Sep 24, 1986	May DISC
	@	80MG	A071366	001	Oct 01, 1986	May DISC
	@	120MG	A070856	001	Sep 24, 1986	May DISC
	@	120MG	A071367	001	Oct 01, 1986	May DISC

TABLET, EXTENDED RELEASE; ORAL

VERAPAMIL HYDROCHLORIDE

AB	ANI PHARMS INC	120MG	A090529	001	Dec 30, 2011	Jun CAHN
AB		180MG	A090529	002	Dec 30, 2011	Jun CAHN
AB		240MG	A090529	003	Dec 30, 2011	Jun CAHN
AB	SUN PHARM INDS INC	120MG	A090529	001	Dec 30, 2011	Jul CAHN
AB		180MG	A090529	002	Dec 30, 2011	Jul CAHN
AB		240MG	A090529	003	Dec 30, 2011	Jul CAHN

VINBLASTINE SULFATE

INJECTABLE; INJECTION

VINBLASTINE SULFATE

>D>	+	BEDFORD	10MG/VIAL	A089395	001	Apr 09, 1987	Aug CAHN
>A>	+	EUROHLTH INTL	10MG/VIAL	A089395	001	Apr 09, 1987	Aug CAHN

VINORELBINE TARTRATE

INJECTABLE; INJECTION

VINORELBINE TARTRATE

>A>	AP	ACTAVIS ELIZABETH	EQ 10MG BASE/ML	A078011	001	Jul 22, 2009	Aug CAHN
>D>	AP	ACTAVIS TOTOWA	EQ 10MG BASE/ML	A078011	001	Jul 22, 2009	Aug CAHN

VORAPAXAR SULFATE

TABLET; ORAL

ZONTIVITY

+	MERCK SHARP DOHME	EQ 2.08MG BASE	N204886	001	May 08, 2014	Jun CPOT
+		EQ 2.5MG BASE	N204886	001	May 08, 2014	May NEWA

WARFARIN SODIUM

INJECTABLE; INJECTION

COUMADIN

@	BRISTOL MYERS SQUIBB	5MG/VIAL	N009218	024	Feb 07, 1995	Mar DISC
---	----------------------	----------	---------	-----	--------------	----------

TABLET; ORAL

COUMADIN

AB	BRISTOL MYERS SQUIBB	1MG	N009218	022	Mar 01, 1990	Apr CMFD
	@	1MG	N009218	022	Mar 01, 1990	Mar DISC
AB		2MG	N009218	013		Apr CMFD
	@	2MG	N009218	013		Mar DISC
AB		2.5MG	N009218	018		Apr CMFD
	@	2.5MG	N009218	018		Mar DISC
AB		3MG	N009218	025	Nov 18, 1996	Apr CMFD
	@	3MG	N009218	025	Nov 18, 1996	Mar DISC
AB		4MG	N009218	023	Aug 24, 1993	Apr CMFD
	@	4MG	N009218	023	Aug 24, 1993	Mar DISC
AB		5MG	N009218	007		Apr CMFD
	@	5MG	N009218	007		Mar DISC
AB		6MG	N009218	026	Nov 18, 1996	Apr CMFD
	@	6MG	N009218	026	Nov 18, 1996	Mar DISC
AB		7.5MG	N009218	016		Apr CMFD
	@	7.5MG	N009218	016		Mar DISC
AB	+	10MG	N009218	005		Apr CMFD
	@	10MG	N009218	005		Mar DISC

ZICONOTIDE ACETATE

INJECTABLE; INTRATHECAL

PRIALT

@	JAZZ PHARMS INTL	200MCG/2ML (100MCG/ML)	N021060	003	Dec 28, 2004	Feb CAIN
---	------------------	------------------------	---------	-----	--------------	----------

ZIDOVUDINEINJECTABLE;INJECTION
ZIDOVUDINE

@ LIAONING CHENGDA	10MG/ML	A204538	001	Nov 26, 2013	Mar DISC
--------------------	---------	---------	-----	--------------	----------

ZILEUTONTABLET;ORAL
ZYFLO

@ CHIESI USA INC	300MG	N020471	001	Dec 09, 1996	Apr CAHN
+	600MG	N020471	003	Dec 09, 1996	Apr CAHN

TABLET, EXTENDED RELEASE;ORAL
ZYFLO CR

+ CHIESI USA INC	600MG	N022052	001	May 30, 2007	Apr CAHN
------------------	-------	---------	-----	--------------	----------

ZOLEDRONIC ACIDINJECTABLE;IV (INFUSION)
ZOLEDRONIC ACID

>A> AP	AKORN	EQ 5MG BASE/100ML	A200918	001	Aug 21, 2014	Aug NEWA
AP	AKORN INC	EQ 4MG BASE/5ML	A202548	001	May 22, 2014	May NEWA
>A> AP	USV NORTH AMERICA	EQ 4MG BASE/VIAL	A202923	001	Sep 04, 2014	Aug NEWA

ZOLMITRIPTANTABLET;ORAL
ZOLMITRIPTAN

AB	INVAGEN PHARMS	2.5MG	A204284	001	Apr 09, 2014	Mar NEWA
AB		5MG	A204284	002	Apr 09, 2014	Mar NEWA
AB	TEVA PHARMS USA	2.5MG	A090861	001	Mar 04, 2014	Feb NEWA
AB		5MG	A090861	002	Mar 04, 2014	Feb NEWA

ZOLPIDEM TARTRATETABLET;ORAL
ZOLPIDEM TARTRATE

AB	SUN PHARM INDS INC	5MG	A077359	001	Apr 23, 2007	Jul CAHN
AB		10MG	A077359	002	Apr 23, 2007	Jul CAHN
	@ VIVIMED LABS	5MG	A076062	001	Apr 23, 2007	Apr CAHN
	@	10MG	A076062	002	Apr 23, 2007	Apr CAHN
	@ WATSON LABS	5MG	A077773	001	Apr 23, 2007	May DISC
	@	10MG	A077773	002	Apr 23, 2007	May DISC

ZONISAMIDECAPSULE;ORAL
ZONISAMIDE

AB	ANI PHARMS INC	25MG	A077639	001	Dec 22, 2005	Jan CAHN
	@	25MG	A077641	003	Dec 22, 2005	Jan CAHN
AB		50MG	A077639	002	Dec 22, 2005	Jan CAHN
	@	50MG	A077641	002	Dec 22, 2005	Jan CAHN
AB		100MG	A077639	003	Dec 22, 2005	Jan CAHN
	@	100MG	A077641	001	Dec 22, 2005	Jan CAHN
	@ SANDOZ	25MG	A077644	001	Dec 22, 2005	Feb DISC
	@	50MG	A077644	002	Dec 22, 2005	Feb DISC
	@	100MG	A077644	003	Dec 22, 2005	Feb DISC

ACETAMINOPHEN; DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL

DRIXORAL PLUS

@ SCHERING PLOUGH	500MG;3MG;60MG	N019453	001	May 22, 1987	Feb DISC
-------------------	----------------	---------	-----	--------------	----------

CETIRIZINE HYDROCHLORIDE

TABLET;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

IPCA LABS LTD	5MG	A202277	002	Mar 11, 2014	Feb NEWA
---------------	-----	---------	-----	--------------	----------

	10MG	A202277	004	Mar 11, 2014	Feb NEWA
--	------	---------	-----	--------------	----------

SUN PHARM INDS INC	5MG	A077499	001	Dec 27, 2007	Jul CAHN
--------------------	-----	---------	-----	--------------	----------

	10MG	A077499	002	Dec 27, 2007	Jul CAHN
--	------	---------	-----	--------------	----------

CETIRIZINE HYDROCHLORIDE HIVES

IPCA LABS LTD	5MG	A202277	001	Mar 11, 2014	Feb NEWA
---------------	-----	---------	-----	--------------	----------

	10MG	A202277	003	Mar 11, 2014	Feb NEWA
--	------	---------	-----	--------------	----------

SUN PHARM INDS INC	5MG	A077499	003	Dec 27, 2007	Jul CAHN
--------------------	-----	---------	-----	--------------	----------

	10MG	A077499	004	Dec 27, 2007	Jul CAHN
--	------	---------	-----	--------------	----------

TABLET, CHEWABLE;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

@ CARACO	5MG	A077631	004	Jan 11, 2008	Feb DISC
----------	-----	---------	-----	--------------	----------

@	10MG	A077631	003	Jan 11, 2008	Feb DISC
---	------	---------	-----	--------------	----------

@ SUN PHARM INDS INC	5MG	A077631	004	Jan 11, 2008	Jul CAHN
----------------------	-----	---------	-----	--------------	----------

@	10MG	A077631	003	Jan 11, 2008	Jul CAHN
---	------	---------	-----	--------------	----------

CETIRIZINE HYDROCHLORIDE HIVES RELIEF

@ CARACO	5MG	A077631	001	Jan 11, 2008	Feb DISC
----------	-----	---------	-----	--------------	----------

@	10MG	A077631	002	Jan 11, 2008	Feb DISC
---	------	---------	-----	--------------	----------

@ SUN PHARM INDS INC	5MG	A077631	001	Jan 11, 2008	Jul CAHN
----------------------	-----	---------	-----	--------------	----------

@	10MG	A077631	002	Jan 11, 2008	Jul CAHN
---	------	---------	-----	--------------	----------

CIMETIDINE

TABLET;ORAL

CIMETIDINE

@ WATSON LABS	200MG	A075425	001	Jul 29, 1999	May DISC
---------------	-------	---------	-----	--------------	----------

DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL

DEXBROMPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE SULFATE

+ AVANTHI INC	6MG;120MG	A078648	001	Feb 27, 2013	Jan CRLD
---------------	-----------	---------	-----	--------------	----------

DISOPHROL

@ SCHERING PLOUGH	6MG;120MG	N013483	004	Sep 13, 1982	Jan DISC
-------------------	-----------	---------	-----	--------------	----------

DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN

CAPSULE;ORAL

IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE

>D>	STRIDES ARCOLAB LTD	25MG;EQ 200MG FREE ACID AND	A200888	001	Mar 05, 2012	Aug CAHN
-----	---------------------	-----------------------------	---------	-----	--------------	----------

		POTASSIUM SALT				
--	--	----------------	--	--	--	--

>A>	STRIDES PHARMA	25MG;EQ 200MG FREE ACID AND	A200888	001	Mar 05, 2012	Aug CAHN
-----	----------------	-----------------------------	---------	-----	--------------	----------

		POTASSIUM SALT				
--	--	----------------	--	--	--	--

DIPHENHYDRAMINE HYDROCHLORIDE; NAPROXEN SODIUM

TABLET;ORAL

ALEVE PM

+ BAYER HLTHCARE	25MG;220MG	N205352	001	Jan 17, 2014	Jan NEWA
------------------	------------	---------	-----	--------------	----------

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED RELEASE;ORAL

NEXIUM

ASTRAZENECA LP	EQ 20MG BASE	N204655	001	Mar 28, 2014	Apr CMS2
----------------	--------------	---------	-----	--------------	----------

NEXIUM 24HR					
-------------	--	--	--	--	--

+ ASTRAZENECA LP	EQ 20MG BASE	N204655	001	Mar 28, 2014	Apr CTNA
------------------	--------------	---------	-----	--------------	----------

FAMOTIDINE

TABLET;ORAL

FAMOTIDINE

@ WATSON LABS	10MG	A075404	001	Nov 28, 2001	May DISC
---------------	------	---------	-----	--------------	----------

FLUTICASONE PROPIONATE

SPRAY, METERED;NASAL
FLONASE ALLERGY RELIEF

+ GLAXOSMITHKLINE CONS 0.05MG/SPRAY

N205434 001 Jul 23, 2014 Jul NEWA

IBUPROFEN

SUSPENSION;ORAL
CHILDREN'S ELIXSURE

MOBERG PHARMA NORTH 100MG/5ML

N021604 001 Jan 07, 2004 May CAHN

TABLET;ORAL

IBUPROFEN

AMNEAL PHARMS 200MG

A079233 001 Mar 18, 2014 Mar NEWA

@ WATSON LABS 200MG

A070435 001 Mar 05, 1986 May DISC

IBUPROFEN; PHENYLEPHRINE HYDROCHLORIDE

TABLET;ORAL

IBUPROFEN AND PHENYLEPHRINE HYDROCHLORIDE

PERRIGO R AND D 200MG;10MG

A203200 001 Jul 03, 2014 Jun NEWA

LEVONORGESTREL

TABLET;ORAL

FALLBACK SOLO

LUPIN LTD 1.5MG

A201446 001 Jun 19, 2014 Jun NEWA

LEVONORGESTREL

>A> PERRIGO R AND D 1.5MG

A202334 001 Aug 20, 2014 Aug NEWA

MINOXIDIL

AEROSOL, FOAM;TOPICAL
WOMEN'S ROGAINE

+ JOHNSON AND JOHNSON 5%

N021812 002 Feb 28, 2014 Feb NEWA

NONOXYNOL-9

SPONGE;VAGINAL
TODAY

>D> + AZTIQ PHARMA 1GM

N018683 001 Apr 01, 1983 Aug CAHN

>A> + MAYER LABS INC 1GM

N018683 001 Apr 01, 1983 Aug CAHN

TRIAMCINOLONE ACETONIDE

SPRAY, METERED;NASAL
NASACORT ALLERGY 24 HOUR

+ SANOFI AVENTIS US 0.055MG/SPRAY

N020468 002 Oct 11, 2013 Jul CRLD

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 8 AUGUST 2014

NO AUGUST 2014 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of List of Orphan Designations and Approvals is available at:

<http://www.fda.gov/orphan/designat/list.htm>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO AUGUST 2014 ADDITIONS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE - TRIUMEQ</u>						
N 205551	001				>A> NCE	Aug 12, 2018
<u>ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE - XARTEMIS XR</u>						
N 204031	001	6488962	Jun 20, 2020	DP	NP	Mar 11, 2017
		7976870	Jun 01, 2027	U-1498		
		8372432	Mar 11, 2029	DP U-1499		
		8377453	Nov 19, 2029	DP U-1499		
		8394408	Mar 11, 2029	DP		
		8597681	Dec 21, 2030	DP		
		8658631	May 16, 2032	DP		
		8668929	Mar 11, 2029	U-1499		
		8741885	May 16, 2032	DP U-1499		
<u>ACETYLCYSTEINE - ACETADOTE</u>						
N 021539	001	8653061	Aug 24, 2025	U-1373		
		8722738	Apr 06, 2032	U-1373		
<u>ACYCLOVIR - SITAVIG</u>						
N 203791	001	>A> 8592434	Jun 16, 2030	DP U-1460		
		8747896	Jun 03, 2027	DP U-1460		
		>A> 8791127	Mar 23, 2027	DP U-1460		
<u>ACYCLOVIR; HYDROCORTISONE - XERESE</u>						
N 022436	001	6514980	Jan 24, 2019	DP U-1006	NPP	Jan 22, 2017
		6514980	Jan 24, 2019	DP U-1484		
		7223387	May 13, 2023	DP U-1006		
		7223387	May 13, 2023	DP U-1484		
		RE39264	Aug 02, 2016	DP U-1006		
		RE39264	Aug 02, 2016	DP U-1484		
<u>ADAPALENE - ADAPALENE</u>						
A 200298	001				PC	Oct 25, 2014
<u>ADAPALENE - DIFFERIN</u>						
N 021753	001	8703820	Mar 12, 2023	U-1078		
<u>ADAPALENE - DIFFERIN</u>						
N 022502	001	8709392	Sep 15, 2026	DP U-1078		
<u>ADENOSINE - ADENOSINE</u>						
A 077425	001				PC	Mar 22, 2014
<u>ALBUTEROL SULFATE - VENTOLIN HFA</u>						
N 020983	001	7500444	Feb 26, 2026	DP		
		7500444*PED	Aug 26, 2026			
<u>ALCAFTADINE - LASTACFT</u>						
N 022134	001	8664215	Oct 05, 2029	U-1493		
<u>ALISKIREN HEMIFUMARATE - TEKTRUNA</u>						
N 021985	001	8617595	Feb 19, 2026	DP		
<u>ALISKIREN HEMIFUMARATE - TEKTRUNA</u>						
N 021985	002	8617595	Feb 19, 2026	DP		
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u>						
N 022545	001	8613949	Dec 21, 2029	DP		
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u>						
N 022545	002	8613949	Dec 21, 2029	DP		
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u>						
N 022545	003	8613949	Dec 21, 2029	DP		
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u>						
N 022545	004	8613949	Dec 21, 2029	DP		
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N 200045	001	8618174	Nov 15, 2021	DP		
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N 200045	002	8618174	Nov 15, 2021	DP		
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N 200045	003	8618174	Nov 15, 2021	DP		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N 200045 004	8618174	Nov 15, 2021	DP			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N 200045 005	8618174	Nov 15, 2021	DP			
<u>ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTRUNA HCT</u>						
N 022107 001	8618172	Jul 13, 2028	DP			
<u>ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTRUNA HCT</u>						
N 022107 002	8618172	Jul 13, 2028	DP			
<u>ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTRUNA HCT</u>						
N 022107 003	8618172	Jul 13, 2028	DP			
<u>ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTRUNA HCT</u>						
N 022107 004	8618172	Jul 13, 2028	DP			
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 001	8697125	Jan 22, 2029	DP			
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 002	8697125	Jan 22, 2029	DP			
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 003	8697125	Jan 22, 2029	DP			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 001	8637079	Jan 23, 2029	DP			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 002	8637079	Jan 23, 2029	DP			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 003	8637079	Jan 23, 2029	DP			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 004	8637079	Jan 23, 2029	DP			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 005	8637079	Jan 23, 2029	DP			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 006	8637079	Jan 23, 2029	DP			
<u>ALVIMOPAN - ENTEREG</u>						
N 021775 001 >A>	8112290	Jul 31, 2030	U-1443			
	8645160	Jun 18, 2029	U-1485			
<u>AMINOLEVULINIC ACID HYDROCHLORIDE - LEVULAN</u>						
N 020965 001 >A>	8758418	May 01, 2018	U-289			
<u>APIXABAN - ELIQUIS</u>						
N 202155 001	6413980	Dec 22, 2019	DS DP U-1200		>A> I-661	Aug 21, 2017
	6413980	Dec 22, 2019	DS DP U-1501		I-681	Mar 03, 2017
	6967208	Feb 03, 2023	DS DP U-1167		>A> I-690	Aug 21, 2017
	6967208	Feb 03, 2023	DS DP U-1200		>A> I-691	Aug 21, 2017
	6967208	Feb 03, 2023	DS DP U-1323			
	6967208	Feb 03, 2023	DS DP U-1501			
	6967208	Feb 03, 2023	DS DP U-1502			
<u>APIXABAN - ELIQUIS</u>						
N 202155 002					>A> I-661	Aug 21, 2017
					>A> I-690	Aug 21, 2017
					>A> I-691	Aug 21, 2017
<u>APREMILAST - OTEZLA</u>						
N 205437 001	6020358	Oct 30, 2018	DS DP U-1504		NCE	Mar 21, 2019
	6962940	Mar 19, 2023	U-1504			
	7208516	Mar 19, 2023	U-1505			
	7427638	Nov 17, 2024	DS DP			
	7659302	Mar 19, 2023	U-1505			
	7893101	Dec 09, 2023	DS DP			
	8455536	Mar 19, 2023	U-1505			
>A>	8802717	Mar 19, 2023	U-1561			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>APREMILAST - OTEZLA</u>						
N 205437 002	6020358	Oct 30, 2018	DS DP U-1504		NCE	Mar 21, 2019
	6962940	Mar 19, 2023	U-1504			
	7208516	Mar 19, 2023	U-1505			
	7427638	Nov 17, 2024	DS DP			
	7659302	Mar 19, 2023	U-1505			
	7893101	Dec 09, 2023	DS DP			
	8455536	Mar 19, 2023	U-1505			
	>A> 8802717	Mar 19, 2023	U-1561			
<u>APREMILAST - OTEZLA</u>						
N 205437 003	6020358	Oct 30, 2018	DS DP U-1504		NCE	Mar 21, 2019
	6962940	Mar 19, 2023	U-1504			
	7208516	Mar 19, 2023	U-1505			
	7427638	Nov 17, 2024	DS DP			
	7659302	Mar 19, 2023	U-1505			
	7893101	Dec 09, 2023	DS DP			
	8455536	Mar 19, 2023	U-1505			
	>A> 8802717	Mar 19, 2023	U-1561			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 001	8642600	Jan 28, 2022	U-1492		M-137	Jun 09, 2017
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	8759350	Mar 02, 2027	U-1529			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 002	8642600	Jan 28, 2022	U-1492		M-137	Jun 09, 2017
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	8759350	Mar 02, 2027	U-1529			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 003	8642600	Jan 28, 2022	U-1492		M-137	Jun 09, 2017
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	8759350	Mar 02, 2027	U-1529			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 004	8642600	Jan 28, 2022	U-1492		M-137	Jun 09, 2017
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	8759350	Mar 02, 2027	U-1529			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 005	8642600	Jan 28, 2022	U-1492		M-137	Jun 09, 2017
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	8759350	Mar 02, 2027	U-1529			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 006	8642600	Jan 28, 2022	U-1492		M-137	Jun 09, 2017
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	8759350	Mar 02, 2027	U-1529			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021713 001	8642600	Jan 28, 2022	U-1492		M-137	Jun 09, 2017
	8642600*PED	Jul 28, 2022				
	8759350	Mar 02, 2027	U-1529			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021729 002	8642600	Jan 28, 2022	U-1492		M-137	Jun 09, 2017
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	8759350	Mar 02, 2027	U-1529			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021729 003	8642600	Jan 28, 2022	U-1492		M-137	Jun 09, 2017
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	8759350	Mar 02, 2027	U-1529			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021729 004	8642600	Jan 28, 2022	U-1492		M-137	Jun 09, 2017
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021729 005	8642600	Jan 28, 2022	U-1492		M-137	Jun 09, 2017
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021866 001					M-137	Jun 09, 2017
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 001	8722679	Oct 19, 2024	DP			
	8759351	Aug 06, 2023	DP U-1530			
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 002	8722679	Oct 19, 2024	DP			
	8759351	Aug 06, 2023	DP U-1530			
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117 001	8022228	Apr 06, 2026	DS DP			
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117 002	8022228	Apr 06, 2026	DS DP			
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N 206352 001	5849911	Jun 20, 2017	DS DP U-167		NP	Jun 02, 2017
	6087383	Dec 21, 2018	DS DP			
<u>ATORVASTATIN CALCIUM; EZETIMIBE - LIPTRUZET</u>						
N 200153 001	5686104	Nov 11, 2014	DP U-1400			
	5686104*PED	May 11, 2015				
	5969156	Jul 08, 2016	DS			
	5969156*PED	Jan 08, 2017				
<u>ATORVASTATIN CALCIUM; EZETIMIBE - LIPTRUZET</u>						
N 200153 002	5686104	Nov 11, 2014	DP U-1400			
	5686104*PED	May 11, 2015				
	5969156	Jul 08, 2016	DS			
	5969156*PED	Jan 08, 2017				
<u>ATORVASTATIN CALCIUM; EZETIMIBE - LIPTRUZET</u>						
N 200153 003	5686104	Nov 11, 2014	DP U-1400			
	5686104*PED	May 11, 2015				
	5969156	Jul 08, 2016	DS			
	5969156*PED	Jan 08, 2017				
<u>ATORVASTATIN CALCIUM; EZETIMIBE - LIPTRUZET</u>						
N 200153 004	5686104	Nov 11, 2014	DP U-1400			
	5686104*PED	May 11, 2015				
	5969156	Jul 08, 2016	DS			
	5969156*PED	Jan 08, 2017				
<u>AXITINIB - INLYTA</u>						
N 202324 001 >A>	8791140	Aug 05, 2030	DS			
<u>AXITINIB - INLYTA</u>						
N 202324 002 >A>	8791140	Aug 05, 2030	DS			
<u>BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED - DUAVEE</u>						
N 022247 001					NP	Oct 03, 2016
<u>BECLOMETHASONE DIPROPIONATE - QVAR 80</u>						
N 020911 001	5683677	Nov 04, 2014	DP			
	5776432	Jul 07, 2015	DP U-645			
	6446627	Dec 18, 2017	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BECLOMETHASONE DIPROPIONATE - OVAR 40</u>						
N 020911 002	5683677	Nov 04, 2014	DP			
	5776432	Jul 07, 2015	DP U-645			
	6446627	Dec 18, 2017	DP			
<u>BEDAQUILINE FUMARATE - SIRTURO</u>						
N 204384 001	8546428	Mar 19, 2029	DS DP U-1321			
<u>BELINOSTAT - BELEODAO</u>						
N 206256 001	6888027	Sep 27, 2021	DS DP U-1544		NCE ODE	Jul 03, 2019 Jul 03, 2021
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249 001	8791270	Jan 12, 2026	DP U-1542			
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249 002	8791270	Jan 12, 2026	DP U-1542			
<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ACANYA</u>						
N 050819 001	8663699	Jun 03, 2029	U-124			
<u>BEPOTASTINE BESILATE - BEPREVE</u>						
N 022288 001	8784789	Sep 05, 2024	DP			
<u>BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE HYDRATE - CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE</u>						
A 201615 001					PC	Sep 27, 2014
<u>BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE HYDRATE - TACLONEX</u>						
N 022185 001					>A> NPP	Aug 29, 2017
<u>BIMATOPROST - LUMIGAN</u>						
N 022184 001	8772338	Mar 16, 2025	DP U-1528			
<u>BIMATOPROST - LATISSE</u>						
N 022369 001	8263054	Jan 15, 2023	U-1277			
	8632760	Jan 15, 2023	U-1487			
	8758733	Jan 15, 2023	U-1487			
<u>BORTEZOMIB - VELCADE</u>						
N 021602 001					>A> M-139 ODE	Aug 08, 2017 Jun 20, 2015
<u>BRIMONIDINE TARTRATE; TIMOLOL MALEATE - COMBIGAN</u>						
N 021398 001	8748425	Apr 19, 2022	DP U-1524			
<u>BROMFENAC SODIUM - PROLENSA</u>						
N 203168 001	8669290	Jan 16, 2024	DP			
	8754131	Jan 16, 2024	DP			
<u>BROMOCRIPTINE MESYLATE - CYCLOSET</u>						
N 020866 001	8613947	Apr 30, 2032	DP U-976			
<u>BUDESONIDE - UCERIS</u>						
N 203634 001	8784888	Jun 09, 2020	DP			
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N 021929 001	8616196	Apr 07, 2029	DP			
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N 021929 002	8616196	Apr 07, 2029	DP			
<u>BUPRENORPHINE - BUTRANS</u>						
N 021306 001	>A> 6344211	Dec 18, 2015	U-1072			
	>A> 6344211	Dec 18, 2015	U-1556			
	>A> RE41408	Sep 29, 2017	U-1072			
	>A> RE41408	Sep 29, 2017	U-1556			
	>A> RE41489	Sep 29, 2017	U-1072			
	>A> RE41489	Sep 29, 2017	U-1556			
	>A> RE41571	Sep 29, 2017	U-1072			
	>A> RE41571	Sep 29, 2017	U-1556			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BUPRENORPHINE - BUTRANS</u>						
N 021306 002	>A> 6344211	Dec 18, 2015	U-1072			
	>A> 6344211	Dec 18, 2015	U-1556			
	>A> RE41408	Sep 29, 2017	U-1072			
	>A> RE41408	Sep 29, 2017	U-1556			
	>A> RE41489	Sep 29, 2017	U-1072			
	>A> RE41489	Sep 29, 2017	U-1556			
	>A> RE41571	Sep 29, 2017	U-1072			
	>A> RE41571	Sep 29, 2017	U-1556			
<u>BUPRENORPHINE - BUTRANS</u>						
N 021306 003	>A> 6344211	Dec 18, 2015	U-1072			
	>A> 6344211	Dec 18, 2015	U-1556			
	>A> RE41408	Sep 29, 2017	U-1072			
	>A> RE41408	Sep 29, 2017	U-1556			
	>A> RE41489	Sep 29, 2017	U-1072			
	>A> RE41489	Sep 29, 2017	U-1556			
	>A> RE41571	Sep 29, 2017	U-1072			
	>A> RE41571	Sep 29, 2017	U-1556			
<u>BUPRENORPHINE - BUTRANS</u>						
N 021306 004	>A> 6344211	Dec 18, 2015	U-1072			
	>A> 6344211	Dec 18, 2015	U-1556			
	>A> RE41408	Sep 29, 2017	U-1072			
	>A> RE41408	Sep 29, 2017	U-1556			
	>A> RE41489	Sep 29, 2017	U-1072			
	>A> RE41489	Sep 29, 2017	U-1556			
	>A> RE41571	Sep 29, 2017	U-1072			
	>A> RE41571	Sep 29, 2017	U-1556			
<u>BUPRENORPHINE - BUTRANS</u>						
N 021306 005	6264980	Dec 18, 2015	DP			
	>A> 6344211	Dec 18, 2015	U-1072			
	>A> 6344211	Dec 18, 2015	U-1556			
	>A> RE41408	Sep 29, 2017	U-1072			
	>A> RE41408	Sep 29, 2017	U-1556			
	>A> RE41489	Sep 29, 2017	U-1072			
	>A> RE41489	Sep 29, 2017	U-1556			
	>A> RE41571	Sep 29, 2017	U-1072			
	>A> RE41571	Sep 29, 2017	U-1556			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 001	8658198	Dec 03, 2027	DP U-1494			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 002	8658198	Dec 03, 2027	DP U-1494			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - BUNAVAIL</u>						
N 205637 001	6159498	Oct 18, 2016	DP		NP	Jun 06, 2017
	7579019	Jan 22, 2020	U-1521			
	8147866	Jul 23, 2027	DP U-1521			
	8703177	Aug 20, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - BUNAVAIL</u>						
N 205637 002	6159498	Oct 18, 2016	DP		NP	Jun 06, 2017
	7579019	Jan 22, 2020	U-1521			
	8147866	Jul 23, 2027	DP U-1521			
	8703177	Aug 20, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - BUNAVAIL</u>						
N 205637 003	6159498	Oct 18, 2016	DP		NP	Jun 06, 2017
	7579019	Jan 22, 2020	U-1521			
	8147866	Jul 23, 2027	DP U-1521			
	8703177	Aug 20, 2032	DP			
<u>CABAZITAXEL - JEVTANA KIT</u>						
N 201023 001	5847170	Mar 26, 2021	DS DP			
<u>CALCIPOTRIENE - SORILUX</u>						
N 022563 001	8263580	Sep 27, 2028	DP U-1280			
	8269128	May 26, 2026	DP U-1280			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 001	>A> 7943582	Feb 26, 2029	DS DP U-493		>A> NC	Aug 08, 2017
	>A> 7943788	Jul 14, 2027	DS DP		>A> NCE	Mar 29, 2018
	>A> 8222219	Jul 30, 2024	U-493			
	>A> 8513202	Dec 03, 2027	DS DP U-493			
	>A> 8785403	Jul 30, 2024	DP			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 002	>A> 7943582	Feb 26, 2029	DS DP U-493		>A> NC	Aug 08, 2017
	>A> 7943788	Jul 14, 2027	DS DP		>A> NCE	Mar 29, 2018
	>A> 8222219	Jul 30, 2024	U-493			
	>A> 8513202	Dec 03, 2027	DS DP U-493			
	>A> 8785403	Jul 30, 2024	DP			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 003	>A> 7943582	Feb 26, 2029	DS DP U-493		>A> NC	Aug 08, 2017
	>A> 7943788	Jul 14, 2027	DS DP		>A> NCE	Mar 29, 2018
	>A> 8222219	Jul 30, 2024	U-493			
	>A> 8513202	Dec 03, 2027	DS DP U-493			
	>A> 8785403	Jul 30, 2024	DP			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 004	>A> 7943582	Feb 26, 2029	DS DP U-493		>A> NC	Aug 08, 2017
	>A> 7943788	Jul 14, 2027	DS DP		>A> NCE	Mar 29, 2018
	>A> 8222219	Jul 30, 2024	U-493			
	>A> 8513202	Dec 03, 2027	DS DP U-493			
	>A> 8785403	Jul 30, 2024	DP			
<u>CERITINIB - ZYKADIA</u>						
N 205755 001	7153964	Feb 26, 2021	DS DP		NCE	Apr 29, 2019
	7893074	Apr 25, 2026	DS DP		ODE	Apr 29, 2021
	7964592	Jan 13, 2027	DS DP			
	8039474	Jun 29, 2030	DS DP			
	8039479	Jun 29, 2030	DS DP			
	8377921	Nov 20, 2027	U-1179			
	8703787	Feb 02, 2032	U-1179			
<u>CLEVIDIPINE - CLEVIPREX</u>						
N 022156 001	8658676	Oct 10, 2031	DP			
<u>CLEVIDIPINE - CLEVIPREX</u>						
N 022156 002	8658676	Oct 10, 2031	DP			
<u>CLEVIDIPINE - CLEVIPREX</u>						
N 022156 003	5739152	Apr 14, 2015	DP U-893			
	5856346	Jan 05, 2021	DS DP U-893			
	8658676	Oct 10, 2031	DP			
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - STRIBILD</u>						
N 203100 001	8633219	Oct 11, 2031	DP U-257		NP	Aug 27, 2015
	8716264	Jan 13, 2024	DP U-257			
<u>CRIZOTINIB - XALKORI</u>						
N 202570 001	8785632	Mar 01, 2025	DS			
<u>CRIZOTINIB - XALKORI</u>						
N 202570 002	8785632	Mar 01, 2025	DS			
<u>CYANOCOBALAMIN - NASCOBAL</u>						
N 021642 001	8003353	Jun 11, 2024	U-817			
<u>CYCLOSPORINE - RESTASIS</u>						
N 050790 001	8633162	Aug 27, 2024	U-1479			
	8642556	Aug 27, 2024	DP			
	8648048	Aug 27, 2024	U-1483			
	8685930	Aug 27, 2024	DP			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 001					ODE	Apr 30, 2020
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 002					ODE	Apr 30, 2020
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 022512 001					I-682	Apr 04, 2017
					I-683	Apr 04, 2017

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 022512	002				I-682 I-683	Apr 04, 2017 Apr 04, 2017
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806	001				I-678 ODE	Jan 08, 2017 Jan 09, 2021
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806	002				I-678 ODE	Jan 08, 2017 Jan 09, 2021
<u>DALBAVANCIN HYDROCHLORIDE - DALVANCE</u>						
N 021883	001	6900175	Dec 25, 2023	U-1517	NCE	May 23, 2019
		7115564	Nov 14, 2023	DP	GAIN	May 23, 2024
		7119061	Nov 14, 2023	DP		
		8143212	Nov 14, 2023	U-1517		
<u>DALFAMPRIDINE - AMPYRA</u>						
N 022250	001	8663685	Jan 18, 2025	U-1030		
<u>DANTROLENE SODIUM - RYANODEX</u>						
N 205579	001	7758890	Jul 01, 2025	DP		
		8110225	Dec 24, 2022	DP		
		8604072	Dec 24, 2022	DP		
		8685460	Feb 15, 2023	U-1546		
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293	001	6414126	Oct 04, 2020	DS DP U-493	NCE	Jan 08, 2019
		6515117	Oct 04, 2020	DS DP U-493		
		6936590	Oct 04, 2020	U-493		
		7851502	Aug 19, 2028	DP		
		7919598	Dec 16, 2029	DS		
		8221786	Mar 21, 2028	DP		
		8361972	Mar 21, 2028	U-493		
		8501698	Jun 20, 2027	DP U-493		
		8685934	May 26, 2030	U-1522		
		8716251	Mar 21, 2028	DP		
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293	002	6414126	Oct 04, 2020	DS DP U-493	NCE	Jan 08, 2019
		6515117	Oct 04, 2020	DS DP U-493		
		6936590	Oct 04, 2020	U-493		
		7851502	Aug 19, 2028	DP		
		7919598	Dec 16, 2029	DS		
		8221786	Mar 21, 2028	DP		
		8361972	Mar 21, 2028	U-493		
		8501698	Jun 20, 2027	DP U-493		
		8685934	May 26, 2030	U-1522		
		8716251	Mar 21, 2028	DP		
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976	001	8597876	Jun 23, 2019	U-1305		
		8597876*PED	Dec 23, 2019			
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976	002	8597876	Jun 23, 2019	U-1305		
		8597876*PED	Dec 23, 2019			
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976	003	8597876	Jun 23, 2019	U-1305		
		8597876*PED	Dec 23, 2019			
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976	004	8597876	Jun 23, 2019	U-1305		
		8597876*PED	Dec 23, 2019			
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976	005	8597876	Jun 23, 2019	U-1305		
		8597876*PED	Dec 23, 2019			
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976	006	8597876	Jun 23, 2019	U-1305		
		8597876*PED	Dec 23, 2019			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DASATINIB - SPRYCEL</u>						
N 021986 001	8680103	Feb 04, 2025	DP			
<u>DASATINIB - SPRYCEL</u>						
N 021986 002	8680103	Feb 04, 2025	DP			
<u>DASATINIB - SPRYCEL</u>						
N 021986 003	8680103	Feb 04, 2025	DP			
<u>DASATINIB - SPRYCEL</u>						
N 021986 004	8680103	Feb 04, 2025	DP			
<u>DASATINIB - SPRYCEL</u>						
N 021986 005	8680103	Feb 04, 2025	DP			
<u>DASATINIB - SPRYCEL</u>						
N 021986 006	8680103	Feb 04, 2025	DP			
<u>DESOXIMETASONE - TOPICORT</u>						
N 204141 001	8277780	Sep 01, 2028	DP U-1408			
	8715624	May 26, 2026	DP U-1408			
<u>DESVENLAFAXINE SUCCINATE - PRISTIO</u>						
N 021992 001	6673838	Mar 01, 2022	DS U-860			
	6673838	Mar 01, 2022	DS U-1364			
<u>DESVENLAFAXINE SUCCINATE - PRISTIO</u>						
N 021992 002	6673838	Mar 01, 2022	DS U-860			
	6673838	Mar 01, 2022	DS U-1364			
<u>DEXAMETHASONE - OZURDEX</u>						
N 022315 001					I-686	Jun 29, 2017
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N 022287 001	6664276	Jan 30, 2023	DS DP U-949			
	6664276	Jan 30, 2023	DS DP U-950			
	6664276	Jan 30, 2023	DS DP U-951			
	6664276	Jan 30, 2023	DS DP U-1507			
	6664276*PED	Jul 30, 2023				
	8722084	Oct 15, 2023	DP			
>A>	8784885	Oct 15, 2023	DP U-1552			
>A>	8784885	Oct 15, 2023	DP U-1553			
>A>	8784885	Oct 15, 2023	DP U-1554			
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N 022287 002	6664276	Jan 30, 2023	DS DP U-949			
	6664276	Jan 30, 2023	DS DP U-950			
	6664276	Jan 30, 2023	DS DP U-951			
	6664276	Jan 30, 2023	DS DP U-1507			
	6664276*PED	Jul 30, 2023				
	8722084	Oct 15, 2023	DP			
	8722084*PED	Apr 15, 2024				
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 001					M-61 PED	Jun 17, 2016 Dec 17, 2016
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 002	8648106	Jan 04, 2032	DP		M-61 PED	Jun 17, 2016 Dec 17, 2016
	8648106*PED	Jul 04, 2032				
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 003	8648106	Jan 04, 2032	DP		M-61 PED	Jun 17, 2016 Dec 17, 2016
	8648106*PED	Jul 04, 2032				
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - DEXMETHYLPHENIDATE HYDROCHLORIDE</u>						
A 078992 003					PC	May 18, 2014
<u>DEXTROMETHORPHAN HYDROBROMIDE; QUINIDINE SULFATE - NUEDEXTA</u>						
N 021879 001	RE38115	Jan 26, 2016	DP	Y		
<u>DICLOFENAC - ZORVOLEX</u>						
N 204592 001	8679544	Apr 23, 2030	DP		>A> I-692	Aug 22, 2017
<u>DICLOFENAC - ZORVOLEX</u>						
N 204592 002	8679544	Apr 23, 2030	DP		>A> I-692	Aug 22, 2017
<u>DICLOFENAC EPOLAMINE - FLECTOR</u>						
N 021234 001	5607690	Apr 13, 2019	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DICLOFENAC POTASSIUM - ZIPSOR</u>						
N 022202 001	6287594	Jan 15, 2019	DP			
	8623920	Feb 24, 2029	U-1482			
<u>DICLOFENAC SODIUM - DICLOFENAC SODIUM</u>						
A 202027 001					PC	Nov 23, 2014
<u>DICLOFENAC SODIUM - PENNSAID</u>						
N 020947 001	8741956	Jul 10, 2029	U-1435			
<u>DICLOFENAC SODIUM - PENNSAID</u>						
N 204623 001	8217078	Jul 10, 2029	U-1477		NP	Jan 16, 2017
	8252838	Apr 21, 2028	DP U-1489			
	8546450	Aug 09, 2030	U-1435			
	8546450	Aug 09, 2030	U-1436			
	8563613	Oct 17, 2027	DP U-1488			
	8618164	Jul 10, 2029	U-1477			
	8741956	Jul 10, 2029	U-1435			
<u>DIMETHYL FUMARATE - TECFIDERA</u>						
N 204063 001	8759393	Oct 29, 2019	DP			
<u>DIMETHYL FUMARATE - TECFIDERA</u>						
N 204063 002	8759393	Oct 29, 2019	DP			
<u>DIPHENHYDRAMINE HYDROCHLORIDE; NAPROXEN SODIUM - ALEVE PM</u>						
N 205352 001					NC	Jan 17, 2017
<u>DOXYCYCLINE - ORACEA</u>						
N 050805 001	8709478	Apr 07, 2024	U-1063			
<u>DOXYCYCLINE HYCLATE - DORYX</u>						
N 050795 001	8715724	Feb 03, 2028	DP			
<u>DOXYCYCLINE HYCLATE - DORYX</u>						
N 050795 002	8715724	Feb 03, 2028	DP			
<u>DOXYCYCLINE HYCLATE - DORYX</u>						
N 050795 003	8715724	Feb 03, 2028	DP			
<u>DOXYCYCLINE HYCLATE - DORYX</u>						
N 050795 004	8715724	Feb 03, 2028	DP			
<u>DOXYCYCLINE HYCLATE - DORYX</u>						
N 050795 005	8715724	Feb 03, 2028	DP			
<u>DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM - BEYAZ</u>						
N 022532 001	8617597	Feb 08, 2030	DP			
<u>DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM - SAFYRAL</u>						
N 022574 001	8617597	Feb 08, 2030	DP			
<u>DROXIDOPA - NORTHERA</u>						
N 203202 001					NCE	Feb 18, 2019
					ODE	Feb 18, 2021
<u>DROXIDOPA - NORTHERA</u>						
N 203202 002					NCE	Feb 18, 2019
					ODE	Feb 18, 2021
<u>DROXIDOPA - NORTHERA</u>						
N 203202 003					NCE	Feb 18, 2019
					ODE	Feb 18, 2021
<u>DULOXETINE HYDROCHLORIDE - DULOXETINE HYDROCHLORIDE</u>						
A 090745 001					PC	Jun 09, 2014
<u>DULOXETINE HYDROCHLORIDE - DULOXETINE HYDROCHLORIDE</u>						
A 090745 002					PC	Jun 09, 2014
<u>DULOXETINE HYDROCHLORIDE - DULOXETINE HYDROCHLORIDE</u>						
A 090745 003					PC	Jun 09, 2014
<u>DULOXETINE HYDROCHLORIDE - DULOXETINE HYDROCHLORIDE</u>						
A 090774 001					PC	Jun 09, 2014
<u>DULOXETINE HYDROCHLORIDE - DULOXETINE HYDROCHLORIDE</u>						
A 090774 002					PC	Jun 09, 2014
<u>DULOXETINE HYDROCHLORIDE - DULOXETINE HYDROCHLORIDE</u>						
A 090774 003					PC	Jun 09, 2014

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DULOXETINE HYDROCHLORIDE - DULOXETINE HYDROCHLORIDE</u>						
A 090778 001					PC	Jun 09, 2014
<u>DULOXETINE HYDROCHLORIDE - DULOXETINE HYDROCHLORIDE</u>						
A 090778 002					PC	Jun 09, 2014
<u>DULOXETINE HYDROCHLORIDE - DULOXETINE HYDROCHLORIDE</u>						
A 090778 003					PC	Jun 09, 2014
<u>EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - ATRIPLA</u>						
N 021937 001	8716264	Jan 13, 2024	DP U-257			
<u>EFINACONAZOLE - JUBLIA</u>						
N 203567 001	7214506	Oct 05, 2021	U-281		NCE	Jun 06, 2019
	8039494	Jul 08, 2030	U-281			
	8486978	Oct 24, 2030	DP			
<u>ELIGLUSTAT TARTRATE - CERDELGA</u>						
N 205494 001					>A> NCE	Aug 19, 2019
					>A> ODE	Aug 19, 2021
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 001					>A> ODE	Aug 26, 2021
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 002					>A> ODE	Aug 26, 2021
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 003					>A> ODE	Aug 26, 2021
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 004					>A> ODE	Aug 26, 2021
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 005					>A> ODE	Aug 26, 2021
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 001	>A> 7579449	Nov 05, 2025	DS		>A> NCE	Aug 01, 2019
	>A> 7713938	Apr 15, 2027	DS DP			
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 002	>A> 7579449	Nov 05, 2025	DS		>A> NCE	Aug 01, 2019
	>A> 7713938	Apr 15, 2027	DS DP			
<u>EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE - COMPLERA</u>						
N 202123 001	8716264	Jan 13, 2024	DP U-257			
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 001	8716264	Jan 13, 2024	DP U-257			
<u>ENALAPRIL MALEATE - EPANED KIT</u>						
N 204308 001	>A> 8778366	Nov 06, 2032	U-3			
	>A> 8778366	Nov 06, 2032	U-185			
<u>ENTECAVIR - BARACLUDE</u>						
N 021797 001					NPP	Mar 20, 2017
					PED	Sep 20, 2017
<u>ENTECAVIR - BARACLUDE</u>						
N 021797 002					NPP	Mar 20, 2017
					PED	Sep 20, 2017
<u>ENTECAVIR - BARACLUDE</u>						
N 021798 001					NPP	Mar 20, 2017
					PED	Sep 20, 2017
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM 24HR</u>						
N 204655 001	5690960	Nov 25, 2014	DP U-1509		RTO	Mar 28, 2017
	5714504	Feb 03, 2015	DP U-1509			
	5877192	May 27, 2014	U-1509			
	5900424	May 04, 2016	DS U-1509			
	6369085	May 25, 2018	DS DP U-1509			
	6428810	Nov 03, 2019	DP U-1509			
	6875872	May 27, 2014	DS			
	7411070	May 25, 2018	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ESOMEPRAZOLE SODIUM - NEXIUM IV</u>						
N 021689 001	5877192	May 27, 2014	U-643		D-138	Mar 04, 2017
	5877192	May 27, 2014	U-1495		I-679	Mar 04, 2017
	5877192*PED	Nov 27, 2014				
	6143771	May 27, 2015	DP U-643			
	6143771	May 27, 2015	DP U-1495			
<u>ESOMEPRAZOLE SODIUM - NEXIUM IV</u>						
N 021689 002	5877192	May 27, 2014	U-643		D-138	Mar 04, 2017
	5877192	May 27, 2014	U-1495		I-679	Mar 04, 2017
	5877192*PED	Nov 27, 2014				
	6143771	May 27, 2015	DP U-643			
	6143771	May 27, 2015	DP U-1495			
<u>ESTRADIOL - EVAMIST</u>						
N 022014 001	6978945	Jul 31, 2022	DP			
<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - MINASTRIN 24 FE</u>						
N 203667 001	6667050	Apr 06, 2019	DP U-1			
<u>ETHIODIZED OIL - LIPIODOL</u>						
N 009190 001					ODE	Apr 04, 2021
<u>ETONOGESTREL - NEXPLANON</u>						
N 021529 002	8722037	Sep 28, 2027	DP			
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 001	8778962	Feb 18, 2022	U-1541			
	8778962*PED	Aug 18, 2022				
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 002	8778962	Feb 18, 2022	U-1541			
	8778962*PED	Aug 18, 2022				
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 003	8778962	Feb 18, 2022	U-1541			
	8778962*PED	Aug 18, 2022				
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 004	8778962	Feb 18, 2022	U-1541			
	8778962*PED	Aug 18, 2022				
<u>EVEROLIMUS - AFINITOR DISPERZ</u>						
N 203985 001	8617598	Sep 27, 2022	DP			
	8617598*PED	Mar 27, 2023				
	8778962	Feb 18, 2022	U-1541			
	8778962*PED	Aug 18, 2022				
<u>EVEROLIMUS - AFINITOR DISPERZ</u>						
N 203985 002	8617598	Sep 27, 2022	DP			
	8617598*PED	Mar 27, 2023				
	8778962	Feb 18, 2022	U-1541			
	8778962*PED	Aug 18, 2022				
<u>EVEROLIMUS - AFINITOR DISPERZ</u>						
N 203985 003	8617598	Sep 27, 2022	DP			
	8617598*PED	Mar 27, 2023				
	8778962	Feb 18, 2022	U-1541			
	8778962*PED	Aug 18, 2022				
<u>EXENATIDE SYNTHETIC - BYDUREON</u>						
N 022200 001	8216180	Jan 12, 2028	DP			
	8439864	Mar 25, 2028	DP			
<u>EZETIMIBE - ZETIA</u>						
N 021445 001	7612058	Oct 30, 2025	U-1027			
	7612058	Oct 30, 2025	U-1173			
	7612058*PED	Apr 30, 2026				
<u>FENTANYL - SUBSYS</u>						
N 202788 001	8486972	Apr 27, 2030	DP			
	8486973	Apr 27, 2030	U-55			
<u>FENTANYL - SUBSYS</u>						
N 202788 002	8486972	Apr 27, 2030	DP			
	8486973	Apr 27, 2030	U-55			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FENTANYL - SUBSYS</u>						
N 202788 003	8486972	Apr 27, 2030	DP			
	8486973	Apr 27, 2030	U-55			
<u>FENTANYL - SUBSYS</u>						
N 202788 004	8486972	Apr 27, 2030	DP			
	8486973	Apr 27, 2030	U-55			
<u>FENTANYL - SUBSYS</u>						
N 202788 005	8486972	Apr 27, 2030	DP			
	8486973	Apr 27, 2030	U-55			
<u>FENTANYL - SUBSYS</u>						
N 202788 006	8486972	Apr 27, 2030	DP			
	8486973	Apr 27, 2030	U-55			
<u>FENTANYL - SUBSYS</u>						
N 202788 007	8486972	Apr 27, 2030	DP			
	8486973	Apr 27, 2030	U-55			
<u>FENTANYL CITRATE - FENTORA</u>						
N 021947 001	8728441	Mar 26, 2019	U-1514			
	8753611	Mar 26, 2019	U-1514			
	8765100	Mar 26, 2019	DP			
<u>FENTANYL CITRATE - FENTORA</u>						
N 021947 002	8728441	Mar 26, 2019	U-1514			
	8753611	Mar 26, 2019	U-1514			
	8765100	Mar 26, 2019	DP			
<u>FENTANYL CITRATE - FENTORA</u>						
N 021947 003	8728441	Mar 26, 2019	U-1514			
	8753611	Mar 26, 2019	U-1514			
	8765100	Mar 26, 2019	DP			
<u>FENTANYL CITRATE - FENTORA</u>						
N 021947 004	8728441	Mar 26, 2019	U-1514			
	8753611	Mar 26, 2019	U-1514			
	8765100	Mar 26, 2019	DP			
<u>FENTANYL CITRATE - FENTORA</u>						
N 021947 005	8728441	Mar 26, 2019	U-1514			
	8753611	Mar 26, 2019	U-1514			
	8765100	Mar 26, 2019	DP			
<u>FERUMOXYTOL - FERAHEME</u>						
N 022180 001	6599498	Jun 30, 2023	DS DP			
<u>FLORBETABEN F-18 - NEURACEQ</u>						
N 204677 001	7907135	Mar 18, 2029	DS DP	U-1497	NCE	Mar 21, 2019
<u>FLUOCINOLONE ACETONIDE; HYDROQUINONE; TRETINOIN - TRI-LUMA</u>						
N 021112 001	8653053	Oct 25, 2022	DP			
<u>FLUOCINONIDE - FLUOCINONIDE</u>						
A 090256 001					PC	Jul 13, 2014
<u>FLUTEMETAMOL F-18 - VIZAMYL</u>						
N 203137 001	7270800	Jan 24, 2023	DS DP	U-336	NCE	Oct 25, 2018
	7351401	Jan 24, 2023	DS DP	U-336		
	8691185	Jan 24, 2023		U-336		
<u>FLUTEMETAMOL F-18 - VIZAMYL</u>						
N 203137 002	7270800	Jan 24, 2023	DS DP	U-336	NCE	Oct 25, 2018
	7351401	Jan 24, 2023	DS DP	U-336		
	8691185	Jan 24, 2023		U-336		
<u>FLUTICASONE FUROATE - VERAMYST</u>						
N 022051 001	8147461	Oct 15, 2028	DP			
	8347879	Jul 15, 2028	DP			
	8752543	Apr 05, 2026	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE FUROATE - ARNUITY ELLIPTA</u>						
N 205625 001	>A> 5873360	Feb 23, 2016	DP		>A> NP	Aug 20, 2017
	>A> 7101866	Aug 03, 2021	DS DP U-1559			
	>A> 7629335	Aug 03, 2021	DP			
	>A> 8113199	Oct 23, 2027	DP			
	>A> 8161968	Feb 05, 2028	DP			
	>A> 8201556	Feb 05, 2029	DP			
	>A> 8534281	Aug 10, 2029	DP			
	>A> 8746242	Oct 11, 2030	DP			
<u>FLUTICASONE FUROATE - ARNUITY ELLIPTA</u>						
N 205625 002	>A> 5873360	Feb 23, 2016	DP		>A> NP	Aug 20, 2017
	>A> 7101866	Aug 03, 2021	DS DP U-1559			
	>A> 7629335	Aug 03, 2021	DP			
	>A> 8113199	Oct 23, 2027	DP			
	>A> 8161968	Feb 05, 2028	DP			
	>A> 8201556	Feb 05, 2029	DP			
	>A> 8534281	Aug 10, 2029	DP			
	>A> 8746242	Oct 11, 2030	DP			
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 001	8746242	Oct 10, 2030	DP		NP	May 10, 2016
	>A> RE44874	Mar 23, 2023	DS DP U-1548			
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N 021433 001	7500444	Feb 26, 2026	DP			
	7500444*PED	Aug 26, 2026				
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N 021433 002	7500444	Feb 26, 2026	DP			
	7500444*PED	Aug 26, 2026				
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N 021433 003	7500444	Feb 26, 2026	DP			
	7500444*PED	Aug 26, 2026				
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA</u>						
N 021254 001	>A> 7500444	Feb 26, 2026	DP			
	>A> 7500444*PED	Aug 26, 2026				
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA</u>						
N 021254 002	>A> 7500444	Feb 26, 2026	DP			
	>A> 7500444*PED	Aug 26, 2026				
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA</u>						
N 021254 003	>A> 7500444	Feb 26, 2026	DP			
	>A> 7500444*PED	Aug 26, 2026				
<u>FORMOTEROL FUMARATE - PERFOROMIST</u>						
N 022007 001	8623922	Jun 22, 2021	DP			
<u>GABAPENTIN ENACARBIL - HORIZANT</u>						
N 022399 001	8686034	Jan 24, 2025	U-1231		ODE	Jun 06, 2019
	8686034	Jan 24, 2025	U-1247			
	>A> 8795725	Jun 10, 2029	DP U-1231			
	>A> 8795725	Jun 10, 2029	DP U-1247			
<u>GABAPENTIN ENACARBIL - HORIZANT</u>						
N 022399 002	8686034	Jan 24, 2025	U-1231		ODE	Jun 06, 2019
	8686034	Jan 24, 2025	U-1247			
	>A> 8795725	Jun 10, 2029	DP U-1231			
	>A> 8795725	Jun 10, 2029	DP U-1247			
<u>GADOBUTROL - GADAVIST</u>						
N 201277 001					I-688	Jun 11, 2017
<u>GADOBUTROL - GADAVIST</u>						
N 201277 002					I-688	Jun 11, 2017
<u>GADOBUTROL - GADAVIST</u>						
N 201277 003					I-688	Jun 11, 2017
<u>GADOBUTROL - GADAVIST</u>						
N 201277 004					I-688	Jun 11, 2017
<u>GADOBUTROL - GADAVIST</u>						
N 201277 005					I-688	Jun 11, 2017

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>GADOBUTROL - GADAVIST</u>						
N 201277	006				I-688 NCE	Jun 11, 2017 Mar 14, 2016
<u>GLATIRAMER ACETATE - COPAXONE</u>						
N 020622	003	6054430	May 24, 2014	DS		
		6342476	May 24, 2014	U-441	NP	Jan 28, 2017
		6362161	May 24, 2014	DS		
		7199098	May 24, 2014	DS		
		8232250	Aug 19, 2030	U-441		
		8367605	May 24, 2014	DS		
		8399413	Sep 06, 2030	U-441		
<u>GLYCEROL PHENYLBUTYRATE - RAVICTI</u>						
N 203284	001	8642012	Sep 22, 2030	U-1383		
<u>HEXAMINOLEVULINATE HYDROCHLORIDE - CYSVIEW KIT</u>						
N 022555	001	7348361	Nov 06, 2020	DP U-1087		
<u>HYDROCODONE BITARTRATE - ZOXYDRO ER</u>						
N 202880	001	6228398	Nov 01, 2019	DP		
<u>HYDROCODONE BITARTRATE - ZOXYDRO ER</u>						
N 202880	002	6228398	Nov 01, 2019	DP		
<u>HYDROCODONE BITARTRATE - ZOXYDRO ER</u>						
N 202880	003	6228398	Nov 01, 2019	DP		
<u>HYDROCODONE BITARTRATE - ZOXYDRO ER</u>						
N 202880	004	6228398	Nov 01, 2019	DP		
<u>HYDROCODONE BITARTRATE - ZOXYDRO ER</u>						
N 202880	005	6228398	Nov 01, 2019	DP		
<u>HYDROCODONE BITARTRATE - ZOXYDRO ER</u>						
N 202880	006	6228398	Nov 01, 2019	DP		
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552	001	8476284	Dec 28, 2026	U-1456	I-680	Feb 12, 2017
		8476284	Dec 28, 2026	U-1491	I-689	Jul 28, 2017
		8497277	Dec 28, 2026	U-1456	ODE	Feb 12, 2021
		8497277	Dec 28, 2026	U-1491	>A> ODE	Jul 28, 2021
		8697711	Dec 28, 2026	DS DP		
		8703780	Dec 28, 2026	U-1491		
		8735403	Dec 28, 2026	DS DP		
		8754090	Jun 03, 2031	U-1456		
		8754091	Dec 28, 2026	DP		
<u>IBUPROFEN - CALDOLOR</u>						
N 022348	002	8735452	Sep 30, 2029	U-981		
<u>ICATIBANT ACETATE - FIRAZYR</u>						
N 022150	001	5648333	Jul 15, 2015	DS DP U-1187		
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057	001				NP	Jul 26, 2015
<u>IDELALISIB - ZYDELIG</u>						
N 205858	001	>A> 6800620	Apr 24, 2021	DS U-1560	NCE	Jul 23, 2019
		>A> 6949535	Apr 24, 2021	DS U-1560		
		>A> 8138195	Apr 24, 2021	DS DP		
		>A> 8492389	Apr 24, 2021	DS DP		
		>A> 8637533	Apr 24, 2021	DS DP		
		>A> RE44599	Jul 21, 2025	U-1558		
		>A> RE44638	Aug 05, 2025	DS DP		
<u>IDELALISIB - ZYDELIG</u>						
N 205858	002	>A> 6800620	Apr 24, 2021	DS U-1560	NCE	Jul 23, 2019
		>A> 6949535	Apr 24, 2021	DS U-1560		
		>A> 8138195	Apr 24, 2021	DS DP		
		>A> 8492389	Apr 24, 2021	DS DP		
		>A> 8637533	Apr 24, 2021	DS DP		
		>A> RE44599	Jul 21, 2025	U-1558		
		>A> RE44638	Aug 05, 2025	DS DP		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021335 001	RE43932	Jan 16, 2019	DS DP			
	RE43932*PED	Jul 16, 2019				
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021335 002	RE43932	Jan 16, 2019	DS DP			
	RE43932*PED	Jul 16, 2019				
<u>INDOMETHACIN - TIVORBEX</u>						
N 204768 001	8734847	Apr 23, 2030	DP		NP	Feb 24, 2017
<u>INDOMETHACIN - TIVORBEX</u>						
N 204768 002	8734847	Apr 23, 2030	DP		NP	Feb 24, 2017
<u>INGENOL MEBUTATE - PICATO</u>						
N 202833 001	8716271	Dec 18, 2026	U-1440			
	8735375	Dec 18, 2026	U-1440			
<u>INGENOL MEBUTATE - PICATO</u>						
N 202833 002	8716271	Dec 18, 2026	U-1440			
	8735375	Dec 18, 2026	U-1440			
<u>INSULIN ASPART RECOMBINANT - NOVOLOG FLEXTOUCH</u>						
N 020986 005	>A> 5618913	Jun 07, 2014	DS DP			
	>A> 5618913*PED	Dec 07, 2014				
	>A> 5866538	Jun 20, 2017	DP			
	>A> 5866538*PED	Dec 20, 2017				
	6899699	Jan 02, 2022	DP			
	7686786	Aug 03, 2026	DP			
	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR FLEXTOUCH</u>						
N 021536 005	>A> 5750497	Jun 16, 2019	DS DP U-668			
	>A> 5866538	Jun 20, 2017	DP			
	6899699	Jan 02, 2022	DP			
	7686786	Aug 03, 2026	DP			
	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
<u>INSULIN GLARGINE RECOMBINANT - LANTUS SOLOSTAR</u>						
N 021081 002	8679069	Apr 12, 2025	DP			
<u>INSULIN GLULISINE RECOMBINANT - APIDRA SOLOSTAR</u>						
N 021629 003	8679069	Apr 12, 2025	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 001	6071497	May 15, 2015	DP U-1533		NP	Jun 27, 2017
	6428771	May 15, 2015	DP U-1533			
	6444226	Jun 29, 2020	DP U-1534			
	6652885	Jun 29, 2020	U-1535			
	6663898	Sep 30, 2014	DP			
	6906030	Sep 30, 2014	DP			
	7276534	Sep 30, 2014	DP U-1536			
	7305986	Jan 16, 2023	DP			
	7464706	Mar 02, 2023	DP			
	7648960	Jun 29, 2020	U-1535			
	7943178	Jun 29, 2020	DP U-1535			
	7943572	Aug 10, 2026	U-1539			
	8119593	Aug 11, 2029	U-1537			
	8133514	Sep 30, 2014	DP			
	8146588	Apr 24, 2023	DP			
	8156936	Jan 16, 2023	DP			
	8215300	Nov 24, 2022	DP			
	8227409	Mar 08, 2031	DP U-1538			
	8258095	Aug 11, 2029	U-1537			
	8389470	Jun 29, 2020	DP			
	8394414	May 15, 2015	DP U-1533			
	8424518	Oct 17, 2031	DP			
	8485180	Mar 25, 2030	DP			
	8499757	Feb 19, 2032	DP			
	8551528	Jun 11, 2030	DP			
	8623817	Sep 18, 2029	U-1537			
	8636001	Jul 12, 2032	DP			
	8729019	Jun 06, 2028	DP			
	8734845	Jun 11, 2030	DP			
	8778403	Jun 11, 2030	DP U-1538			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 002	6071497	May 15, 2015	DP U-1533		NP	Jun 27, 2017
	6428771	May 15, 2015	DP U-1533			
	6444226	Jun 29, 2020	DP U-1534			
	6652885	Jun 29, 2020	U-1535			
	6663898	Sep 30, 2014	DP			
	6906030	Sep 30, 2014	DP			
	7276534	Sep 30, 2014	DP U-1536			
	7305986	Jan 16, 2023	DP			
	7464706	Mar 02, 2023	DP			
	7648960	Jun 29, 2020	U-1535			
	7943178	Jun 29, 2020	DP U-1535			
	8119593	Aug 11, 2029	U-1537			
	8133514	Sep 30, 2014	DP			
	8146588	Apr 24, 2023	DP			
	8156936	Jan 16, 2023	DP			
	8215300	Nov 24, 2022	DP			
	8227409	Mar 08, 2031	DP U-1538			
	8258095	Aug 11, 2029	U-1537			
	8389470	Jun 29, 2020	DP			
	8394414	May 15, 2015	DP U-1533			
	8485180	Mar 25, 2030	DP			
	8499757	Feb 19, 2032	DP			
	8551528	Jun 11, 2030	DP			
	8636001	Jul 12, 2032	DP			
	8729019	Jun 06, 2028	DP			
	8734845	Jun 11, 2030	DP			
	8778403	Jun 11, 2030	DP U-1538			
<u>IOFLUPANE I-123 - DATSCAN</u>						
N 022454 001	5310912	Feb 25, 2015	DS			
<u>IVACAFTOR - KALYDECO</u>						
N 203188 001	8754224	Dec 28, 2026	DS DP			
<u>IVERMECTIN - SKLICE</u>						
N 202736 001 >A>	8791153	Oct 12, 2027	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>KETOCONAZOLE - XOLEGEL</u>						
N 021946 001	8735393	Dec 04, 2018	DP			
<u>KETOROLAC TROMETHAMINE - ACULAR LS</u>						
N 021528 001	8648107	May 28, 2024	DP			
<u>KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE - Omidria</u>						
N 205388 001	8173707	Jul 30, 2023	U-1518		NP	May 30, 2017
	8586633	Jul 30, 2023	DP			
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115 001	8637512	Jun 14, 2028	DP			
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115 002	8637512	Jun 14, 2028	DP			
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115 003	8637512	Jun 14, 2028	DP			
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115 004	8637512	Jun 14, 2028	DP			
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115 005	8637512	Jun 14, 2028	DP			
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115 006	8637512	Jun 14, 2028	DP			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 001	8626531	Oct 23, 2020	U-1210			
	8648095	May 15, 2023	U-1216			
	8741929	Mar 08, 2028	U-1414			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 002	8626531	Oct 23, 2020	U-1210			
	8648095	May 15, 2023	U-1216			
	8741929	Mar 08, 2028	U-1414			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 003	8626531	Oct 23, 2020	U-1210			
	8648095	May 15, 2023	U-1216			
	8741929	Mar 08, 2028	U-1414			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 004	8626531	Oct 23, 2020	U-1210			
	8648095	May 15, 2023	U-1216			
	8741929	Mar 08, 2028	U-1414			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 005	8626531	Oct 23, 2020	U-1210			
	8648095	May 15, 2023	U-1216			
	8741929	Mar 08, 2028	U-1414			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 006	8626531	Oct 23, 2020	U-1210			
	8648095	May 15, 2023	U-1216			
	8741929	Mar 08, 2028	U-1414			
<u>LEVALBUTEROL TARTRATE - XOPENEX HFA</u>						
N 021730 001 >A>	8765153	Dec 08, 2023	DP			
<u>LIDOCAINE HYDROCHLORIDE - AKTEN</u>						
N 022221 001	8759401	Jul 24, 2026	DP U-1523			
<u>LINACLOTIDE - LINZESS</u>						
N 202811 001	8748573	Jun 20, 2031	U-1515			
	8748573	Jun 20, 2031	U-1516			
	>A> 8802628	Jul 24, 2031	DP			
<u>LINACLOTIDE - LINZESS</u>						
N 202811 002	8748573	Jun 20, 2031	U-1515			
	8748573	Jun 20, 2031	U-1516			
	>A> 8802628	Jul 24, 2031	DP			
<u>LINAGLIPTIN - TRADJENTA</u>						
N 201280 001	8673927	Aug 23, 2027	U-1503			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 001	8673927	Aug 23, 2027	U-1503			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 002	8673927	Aug 23, 2027	U-1503			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 003	8673927	Aug 23, 2027	U-1503			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 001	8618135	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 002	8618135	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 003	8618135	Mar 07, 2025	U-1316			
<u>LOPINAVIR; RITONAVIR - KALETRA</u>						
N 021906 001	8691878 8691878*PED	Aug 25, 2024 Feb 25, 2025	U-1513			
<u>LOPINAVIR; RITONAVIR - KALETRA</u>						
N 021906 002	8691878 8691878*PED	Aug 25, 2024 Feb 25, 2025	U-1513			
<u>LORCASERIN HYDROCHLORIDE - BELVIO</u>						
N 022529 001	8697686	Dec 20, 2025	DS DP			
<u>LOXAPINE - ADASUVE</u>						
N 022549 001	7052679 7537009 8074644	Oct 26, 2021 Oct 28, 2024 Jul 25, 2022	DP DP DP			
<u>LUBIPROSTONE - AMITIZA</u>						
N 021908 001	8748481 8779187	Sep 01, 2025 Jul 23, 2027	U-1520 DP			
<u>LUBIPROSTONE - AMITIZA</u>						
N 021908 002	8748481 8779187	Sep 01, 2025 Jan 23, 2027	U-1519 DP			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 001	8729085	May 26, 2026	DP			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 002	8729085	May 26, 2026	DP			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 003	8729085	May 26, 2026	DP			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 004	8729085	May 26, 2026	DP			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 005	5532372 8729085	Jul 02, 2018 May 26, 2026	DS DP			
<u>MEMANTINE HYDROCHLORIDE - NAMENDA</u>						
N 021487 001	5061703 5061703*PED	Apr 11, 2015 Oct 11, 2015	U-539			
<u>MEMANTINE HYDROCHLORIDE - NAMENDA</u>						
N 021487 002	5061703 5061703*PED	Apr 11, 2015 Oct 11, 2015	U-539			
<u>MEMANTINE HYDROCHLORIDE - NAMENDA</u>						
N 021627 001	5061703 5061703*PED	Apr 11, 2015 Oct 11, 2015	U-539			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MEMANTINE HYDROCHLORIDE - NAMENDA XR</u>						
N 022525 001	5061703	Apr 11, 2015	U-539		M-138	Jul 03, 2017
	5061703*PED	Oct 11, 2015			PED	Jan 03, 2018
	8039009	Mar 24, 2029	U-539			
	8039009*PED	Sep 24, 2029				
	8168209	Nov 22, 2025	DP			
	8168209*PED	May 22, 2026				
	8173708	Nov 22, 2025	U-539			
	8173708*PED	May 22, 2026				
	8283379	Nov 22, 2025	U-539			
	8283379*PED	May 22, 2026				
	8329752	Nov 22, 2025	DP			
	8329752*PED	May 22, 2026				
	8362085	Nov 22, 2025	U-539			
	8362085*PED	May 22, 2026				
<u>MEMANTINE HYDROCHLORIDE - NAMENDA XR</u>						
N 022525 002	5061703	Apr 11, 2015	U-539		M-138	Jul 03, 2017
	5061703*PED	Oct 11, 2015			PED	Jan 03, 2018
	8039009	Mar 24, 2029	U-539			
	8039009*PED	Sep 24, 2029				
	8168209	Nov 22, 2025	DP			
	8168209*PED	May 22, 2026				
	8173708	Nov 22, 2025	U-539			
	8173708*PED	May 22, 2026				
	8283379	Nov 22, 2025	U-539			
	8283379*PED	May 22, 2026				
	8329752	Nov 22, 2025	DP			
	8329752*PED	May 22, 2026				
	8362085	Nov 22, 2025	U-539			
	8362085*PED	May 22, 2026				
<u>MEMANTINE HYDROCHLORIDE - NAMENDA XR</u>						
N 022525 003	5061703	Apr 11, 2015	U-539		M-138	Jul 03, 2017
	5061703*PED	Oct 11, 2015			PED	Jan 03, 2018
	8039009	Mar 24, 2029	U-539			
	8039009*PED	Sep 24, 2029				
	8168209	Nov 22, 2025	DP			
	8168209*PED	May 22, 2026				
	8173708	Nov 22, 2025	U-539			
	8173708*PED	May 22, 2026				
	8283379	Nov 22, 2025	U-539			
	8283379*PED	May 22, 2026				
	8329752	Nov 22, 2025	DP			
	8329752*PED	May 22, 2026				
	8362085	Nov 22, 2025	U-539			
	8362085*PED	May 22, 2026				
<u>MEMANTINE HYDROCHLORIDE - NAMENDA XR</u>						
N 022525 004	5061703	Apr 11, 2015	U-539		M-138	Jul 03, 2017
	5061703*PED	Oct 11, 2015			PED	Jan 03, 2018
	8039009	Mar 24, 2029	U-539			
	8039009*PED	Sep 24, 2029				
	8168209	Nov 22, 2025	DP			
	8168209*PED	May 22, 2026				
	8173708	Nov 22, 2025	U-539			
	8173708*PED	May 22, 2026				
	8283379	Nov 22, 2025	U-539			
	8283379*PED	May 22, 2026				
	8329752	Nov 22, 2025	DP			
	8329752*PED	May 22, 2026				
	8362085	Nov 22, 2025	U-539			
	8362085*PED	May 22, 2026				
<u>MEMANTINE HYDROCHLORIDE - NAMENDA XR</u>						
N 022525 004	5061703	Apr 11, 2015	U-539		M-138	Jul 03, 2017
	5061703*PED	Oct 11, 2015			PED	Jan 03, 2018
	8039009	Mar 24, 2029	U-539			
	8039009*PED	Sep 24, 2029				
	8168209	Nov 22, 2025	DP			
	8168209*PED	May 22, 2026				
	8173708	Nov 22, 2025	U-539			
	8173708*PED	May 22, 2026				
	8283379	Nov 22, 2025	U-539			
	8283379*PED	May 22, 2026				
	8329752	Nov 22, 2025	DP			
	8329752*PED	May 22, 2026				
	8362085	Nov 22, 2025	U-539			
	8362085*PED	May 22, 2026				
<u>MENOTROPINS (FSH; LH) - MENOPUR</u>						
N 021663 001					D-139	Feb 19, 2017

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MENTHOL; METHYL SALICYLATE - SALONPAS</u>						
N 022029 001	>A> 8809615	Jan 03, 2030	DP			
<u>MENTHOL; METHYL SALICYLATE - SALONPAS</u>						
N 022029 002	>A> 8809615	Jan 03, 2030	DP			
<u>MERCAPTOPYRINE - PURIXAN</u>						
N 205919 001					ODE	Apr 28, 2021
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR</u>						
N 022024 001	8668931	Sep 19, 2023	DP			
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR</u>						
N 022024 002	8668931	Sep 19, 2023	DP			
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 001	8628799	Jul 13, 2025	DP		M-134	May 24, 2016
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 002					M-134	May 24, 2016
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 003					M-134	May 24, 2016
<u>METHOTREXATE - OTREXUP</u>						
N 204824 001	RE44846	Aug 10, 2019	DP			
	RE44847	Aug 10, 2019	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 002	RE44846	Aug 10, 2019	DP			
	RE44847	Aug 10, 2019	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 003	RE44846	Aug 10, 2019	DP			
	RE44847	Aug 10, 2019	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 004	RE44846	Aug 10, 2019	DP			
	RE44847	Aug 10, 2019	DP U-1442			
<u>METHOTREXATE - RASUVO</u>						
N 205776 001	8664231	Jun 01, 2029	U-1442			
<u>METHOTREXATE - RASUVO</u>						
N 205776 002	8664231	Jun 01, 2029	U-1442			
<u>METHOTREXATE - RASUVO</u>						
N 205776 003	8664231	Jun 01, 2029	U-1442			
<u>METHOTREXATE - RASUVO</u>						
N 205776 004	8664231	Jun 01, 2029	U-1442			
<u>METHOTREXATE - RASUVO</u>						
N 205776 005	8664231	Jun 01, 2029	U-1442			
<u>METHOTREXATE - RASUVO</u>						
N 205776 006	8664231	Jun 01, 2029	U-1442			
<u>METHOTREXATE - RASUVO</u>						
N 205776 007	8664231	Jun 01, 2029	U-1442			
<u>METHOTREXATE - RASUVO</u>						
N 205776 008	8664231	Jun 01, 2029	U-1442			
<u>METHOTREXATE - RASUVO</u>						
N 205776 009	8664231	Jun 01, 2029	U-1442			
<u>METHOTREXATE - RASUVO</u>						
N 205776 010	8664231	Jun 01, 2029	U-1442			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 001	8632802	Oct 07, 2025	DP			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 002	8632802	Oct 07, 2025	DP			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 003	8632802	Oct 07, 2025	DP			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 004	8632802	Oct 07, 2025	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N 021121 001	8629179	Jul 31, 2017	DP			
	8629179*PED	Jan 31, 2018				
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N 021121 002	8629179	Jul 31, 2017	DP			
	8629179*PED	Jan 31, 2018				
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N 021121 003	8629179	Jul 31, 2017	DP			
	8629179*PED	Jan 31, 2018				
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N 021121 004	8629179	Jul 31, 2017	DP			
	8629179*PED	Jan 31, 2018				
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLIVANT XR</u>						
N 202100 001	8778390	Feb 15, 2031	DP U-1543			
<u>METRONIDAZOLE - METRONIDAZOLE</u>						
N 205223 001					NP	Mar 24, 2017
<u>MILTEFOSINE - IMPAVIDO</u>						
N 204684 001					NCE ODE	Mar 19, 2019 Mar 19, 2021
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N 050808 006	8722650	Jun 24, 2025	U-1078			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N 050808 007	8722650	Jun 24, 2025	U-1078			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N 050808 008	8722650	Jun 24, 2025	U-1078			
<u>MINOXIDIL - WOMEN'S ROGAINE</u>						
N 021812 002					NP	Feb 28, 2017
<u>MIRABEGRON - MYRBETRIO</u>						
N 202611 001	RE44872	Dec 18, 2023	U-1527			
<u>MIRABEGRON - MYRBETRIO</u>						
N 202611 002	RE44872	Dec 18, 2023	U-1527			
<u>MOMETASONE FUROATE - ASMANEX HFA</u>						
N 205641 001	5889015	Jan 27, 2014	U-645			
	5889015*PED	Jul 27, 2014				
	6057307	Jan 27, 2014	DP U-645			
	6057307*PED	Jul 27, 2014				
	6068832	Aug 27, 2017	DP U-645			
	6365581	Jan 27, 2014	U-645			
	6365581*PED	Jul 27, 2014				
<u>MOMETASONE FUROATE - ASMANEX HFA</u>						
N 205641 002	5889015	Jan 27, 2014	U-645			
	5889015*PED	Jul 27, 2014				
	6057307	Jan 27, 2014	DP U-645			
	6057307*PED	Jul 27, 2014				
	6068832	Aug 27, 2017	DP U-645			
	6365581	Jan 27, 2014	U-645			
	6365581*PED	Jul 27, 2014				
<u>MORPHINE SULFATE - AVINZA</u>						
N 021260 001	6066339	Nov 25, 2017	DP			
<u>MORPHINE SULFATE - AVINZA</u>						
N 021260 002	6066339	Nov 25, 2017	DP			
<u>MORPHINE SULFATE - AVINZA</u>						
N 021260 003	6066339	Nov 25, 2017	DP			
<u>MORPHINE SULFATE - AVINZA</u>						
N 021260 004	6066339	Nov 25, 2017	DP			
<u>MORPHINE SULFATE - AVINZA</u>						
N 021260 005	6066339	Nov 25, 2017	DP			
<u>MORPHINE SULFATE - AVINZA</u>						
N 021260 006	6066339	Nov 25, 2017	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 001	7682633	Jun 19, 2027	U-1510			
	8158156	Jun 19, 2027	U-1510			
	8685443	Jul 03, 2025	U-1508			
	8685444	Jul 03, 2025	DP			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 002	7682633	Jun 19, 2027	U-1510			
	8158156	Jun 19, 2027	U-1510			
	8685443	Jul 03, 2025	U-1508			
	8685444	Jul 03, 2025	DP			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 003	7682633	Jun 19, 2027	U-1510			
	8158156	Jun 19, 2027	U-1510			
	8685443	Jul 03, 2025	U-1508			
	8685444	Jul 03, 2025	DP			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 004	7682633	Jun 19, 2027	U-1510			
	8158156	Jun 19, 2027	U-1510			
	8685443	Jul 03, 2025	U-1508			
	8685444	Jul 03, 2025	DP			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 005	7682633	Jun 19, 2027	U-1510			
	8158156	Jun 19, 2027	U-1510			
	8685443	Jul 03, 2025	U-1508			
	8685444	Jul 03, 2025	DP			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 006	7682633	Jun 19, 2027	U-1510			
	8158156	Jun 19, 2027	U-1510			
	8685443	Jul 03, 2025	U-1508			
	8685444	Jul 03, 2025	DP			
<u>MYCOPHENOLIC ACID - MYCOPHENOLIC ACID</u>						
A 091248 001					PC	Jul 07, 2014
<u>NAFTIFINE HYDROCHLORIDE - NAFTIN</u>						
N 204286 001	8778365	Jan 31, 2033	DP			
<u>NALOXONE HYDROCHLORIDE - EVZIO</u>						
N 205787 001	7731686	Jun 10, 2026	DP			
	7731690	Jan 15, 2025	DP			
	7749194	Oct 30, 2028	DP			
	7918823	Nov 23, 2024	DP			
	7947017	Mar 12, 2028	DP			
	8016788	Mar 21, 2025	DP			
	8021344	Nov 02, 2029	DP			
	8206360	Feb 27, 2027	DP			
	8223610	Apr 10, 2029	DP			
	8231573	Nov 25, 2028	DP			
	8313466	Nov 23, 2024	DP			
	8361029	Nov 23, 2024	DP			
	8425462	Nov 23, 2024	DP			
	8608698	Nov 23, 2024	DP			
	8627816	Feb 04, 2032	DP			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777 001	6277384	Dec 22, 2018	DP			
	6696066	Dec 22, 2018	DP			
	7674799	Mar 30, 2025	DP			
	7674800	Mar 30, 2025	DS			
	7683072	Mar 30, 2025	DS			
	8673355	Dec 22, 2018	DP			
>A>	8822487	Dec 22, 2018	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777 002	6277384	Dec 22, 2018	DP			
	6696066	Dec 22, 2018	DP			
	7674799	Mar 30, 2025	DP			
	7674800	Mar 30, 2025	DS			
	7683072	Mar 30, 2025	DS			
	8673355	Dec 22, 2018	DP			
>A>	8822487	Dec 22, 2018	DP			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777 003	6277384	Dec 22, 2018	DP			
	6696066	Dec 22, 2018	DP			
	7674799	Mar 30, 2025	DP			
	7674800	Mar 30, 2025	DS			
	7683072	Mar 30, 2025	DS			
	8673355	Dec 22, 2018	DP			
>A>	8822487	Dec 22, 2018	DP			
<u>NEVIRAPINE - NEVIRAPINE</u>						
A 203411 001					PC	Oct 12, 2014
<u>NEVIRAPINE - NEVIRAPINE</u>						
A 205258 001					PC	Oct 12, 2014
<u>NIACIN - NIACIN</u>						
A 076250 001					PC	Mar 19, 2014
<u>NIACIN - NIACIN</u>						
A 076378 001					PC	Mar 19, 2014
<u>NIACIN - NIACIN</u>						
A 076378 002					PC	Mar 19, 2014
<u>NICOTINE - NICODERM CO</u>						
N 020165 004	8663680	Feb 13, 2020	DP			
<u>NICOTINE - NICODERM CO</u>						
N 020165 005	8663680	Feb 13, 2020	DP			
<u>NICOTINE - NICODERM CO</u>						
N 020165 006	8663680	Feb 13, 2020	DP			
<u>NITRIC OXIDE - INOMAX</u>						
N 020845 002	>A> 8776794	Jan 06, 2031	DP U-1226		M-132	Dec 21, 2013
	>A> 8776794*PED	Jul 06, 2031			PED	Jun 21, 2014
	>A> 8776795	Jan 06, 2031	DP U-1226			
	>A> 8776795*PED	Jul 06, 2031				
	>A> 8795741	Jun 30, 2029	U-1286			
	>A> 8795741*PED	Dec 30, 2029				
<u>NITRIC OXIDE - INOMAX</u>						
N 020845 003	>A> 8776794	Jan 06, 2031	DP U-1226		M-132	Dec 21, 2013
	>A> 8776794*PED	Jul 06, 2031			PED	Jun 21, 2014
	>A> 8776795	Jan 06, 2031	DP U-1226			
	>A> 8776795*PED	Jul 06, 2031				
	>A> 8795741	Jun 30, 2029	U-1286			
	>A> 8795741*PED	Dec 30, 2029				
<u>OLIVE OIL; SOYBEAN OIL - CLINOLIPID 20%</u>						
N 204508 001	5840757	Nov 24, 2015	DP		NP	Oct 03, 2016

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OLODATEROL HYDROCHLORIDE - STRIVERDI RESPIMAT</u>						
N 203108 001	>A> 5964416	Oct 04, 2016	DP		NCE	Jul 31, 2019
	>A> 6149054	Dec 19, 2016	DP			
	>A> 6176442	Oct 04, 2016	DP			
	>A> 6453795	Dec 05, 2016	DP			
	>A> 6726124	Oct 04, 2016	DP			
	>A> 6846413	Aug 28, 2018	DP			
	>A> 6977042	Aug 28, 2018	DP			
	>A> 6988496	Feb 23, 2020	DP U-1547			
	>A> 7056916	Dec 07, 2023	DS DP			
	>A> 7104470	Oct 04, 2016	DP			
	>A> 7220742	May 12, 2025	DS DP U-1547			
	>A> 7246615	May 31, 2016	DP			
	>A> 7284474	Aug 26, 2024	DP			
	>A> 7396341	Oct 10, 2026	DP U-1547			
	>A> 7491719	Nov 10, 2023	DS DP			
	>A> 7727984	Nov 10, 2023	DS			
	>A> 7786111	Nov 10, 2023	DP			
	>A> 7802568	Feb 26, 2019	DP			
	>A> 7837235	Mar 13, 2028	DP			
	>A> 7896264	May 26, 2025	DP			
	>A> 7988001	Aug 04, 2021	DP			
	>A> 8034809	May 12, 2025	U-1547			
	>A> 8044046	Nov 10, 2023	U-1547			
<u>OLOPATADINE HYDROCHLORIDE - PATADAY</u>						
N 021545 001	5641805	Jun 06, 2015	U-765	Y		
	5641805*PED	Dec 06, 2015				
<u>OMEGA-3-CARBOXYLIC ACIDS - EPANOVA</u>						
N 205060 001	5792795	May 13, 2016	DP			
	5948818	May 13, 2016	DP			
	7960370	Feb 07, 2025	DP			
	8383678	Feb 07, 2025	DP U-1511			
<u>ORITAVANCIN DIPHOSPHATE - ORBACTIV</u>						
N 206334 001					>A> NCE	Aug 06, 2019
					>A> GAIN	Aug 06, 2024
<u>OSPENIFENE - OSPHENA</u>						
N 203505 001	8642079	Mar 01, 2028	DP			
	8772353	Feb 13, 2024	U-1369			
	8772353	Feb 13, 2024	U-1370			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 001	>A> 8821930	Apr 13, 2027	DP			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 002	>A> 8821930	Apr 13, 2027	DP			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 003	>A> 8821930	Apr 13, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 001	>A> 8309060	Nov 20, 2023	DP U-1556			
	>A> 8808741	Aug 24, 2027	U-1556			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 002	>A> 8309060	Nov 20, 2023	DP U-1556			
	>A> 8808741	Aug 24, 2027	U-1556			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 003	>A> 8309060	Nov 20, 2023	DP U-1556			
	>A> 8808741	Aug 24, 2027	U-1556			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 004	>A> 8309060	Nov 20, 2023	DP U-1556			
	>A> 8808741	Aug 24, 2027	U-1556			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 005	>A> 8309060	Nov 20, 2023	DP U-1556			
	>A> 8808741	Aug 24, 2027	U-1556			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 006	>A> 8309060	Nov 20, 2023	DP U-1556			
	>A> 8808741	Aug 24, 2027	U-1556			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 007	>A> 8309060	Nov 20, 2023	DP U-1556			
	>A> 8808741	Aug 24, 2027	U-1556			
<u>OXYCODONE HYDROCHLORIDE - OXECTA</u>						
N 202080 001	8637540	Nov 26, 2023	DP			
<u>OXYCODONE HYDROCHLORIDE - OXECTA</u>						
N 202080 002	8637540	Nov 26, 2023	DP			
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N 021372 001	5202333	Apr 13, 2015	DS DP U-528		I-684	May 27, 2017
	5202333*PED	Oct 13, 2015			M-136	May 27, 2017
	7947724	Jan 30, 2024	DP		PED	Nov 27, 2017
	7947724*PED	Jul 30, 2024			PED	Nov 27, 2017
	7947725	Jan 30, 2024	DP			
	7947725*PED	Jul 30, 2024				
	7960424	Jan 30, 2024	DP			
	7960424*PED	Jul 30, 2024				
	8518981	Jan 30, 2024	DP			
	8518981*PED	Jul 30, 2024				
	8598218	Jan 30, 2024	DP			
	8598218*PED	Jul 30, 2024				
	8598219	Jan 30, 2024	DP			
	8598219*PED	Jul 30, 2024				
	8729094	Jan 30, 2024	DP U-528			
	8729094*PED	Jul 30, 2024				
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N 021372 002	5202333	Apr 13, 2015	DS DP U-901		I-684	May 27, 2017
	5202333*PED	Oct 13, 2015			M-136	May 27, 2017
	7947724	Jan 30, 2024	DP		PED	Nov 27, 2017
	7947724*PED	Jul 30, 2024			PED	Nov 27, 2017
	7947725	Jan 30, 2024	DP			
	7947725*PED	Jul 30, 2024				
	7960424	Jan 30, 2024	DP			
	7960424*PED	Jul 30, 2024				
	8518981	Jan 30, 2024	DP			
	8518981*PED	Jul 30, 2024				
	8598218	Jan 30, 2024	DP			
	8598218*PED	Jul 30, 2024				
	8598219	Jan 30, 2024	DP			
	8598219*PED	Jul 30, 2024				
<u>PANTOPRAZOLE SODIUM - PROTONIX IV</u>						
N 020988 001	8754108	Nov 17, 2021	DP			
	8754108*PED	May 17, 2022				
<u>PAROXETINE MESYLATE - BRISDELLE</u>						
N 204516 001	8658663	Apr 06, 2029	DS DP U-904			
<u>PEGVISOMANT - SOMAVERT</u>						
N 021106 004	>A> 5849535	Mar 25, 2017	DS			
	>A> 6057292	Sep 21, 2015	U-507			
<u>PEGVISOMANT - SOMAVERT</u>						
N 021106 005	>A> 5849535	Mar 25, 2017	DS			
	>A> 6057292	Sep 21, 2015	U-507			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 001	8772497	May 16, 2026	DS			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 002	8772497	May 16, 2026	DS			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 003	8772497	May 16, 2026	DS			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 004	8772497	May 16, 2026	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 005	8772497	May 16, 2026	DS			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 006	8772497	May 16, 2026	DS			
<u>PERFLUTREN - DEFINITY</u>						
N 021064 001	8658205	Apr 20, 2019	DP			
	8685441	Jan 13, 2019	U-665			
<u>POLIDOCANOL - VARITHENA</u>						
N 205098 001	8734833	May 26, 2020	DS DP			
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 001	8626531	Oct 23, 2020	U-1361			
	8673939	May 15, 2023	U-1360			
	8735428	May 15, 2023	U-1360			
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 002	8626531	Oct 23, 2020	U-1361			
	8673939	May 15, 2023	U-1360			
	8735428	May 15, 2023	U-1360			
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 003	8626531	Oct 23, 2020	U-1361			
	8673939	May 15, 2023	U-1360			
	8735428	May 15, 2023	U-1360			
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 004	8626531	Oct 23, 2020	U-1361			
	8673939	May 15, 2023	U-1360			
	8735428	May 15, 2023	U-1360			
<u>POSACONAZOLE - NOXAFIL</u>						
N 205596 001	5661151	Jul 19, 2019	DS DP U-1454			
	5703079	Aug 26, 2014	DS DP U-1454			
	8410077	Mar 13, 2029	DP			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421 001	8679533	Sep 08, 2029	DP U-219			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421 002	8679533	Sep 08, 2029	DP U-219			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421 003	8679533	Sep 08, 2029	DP U-219			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421 004	8679533	Sep 08, 2029	DP U-219			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421 005	8679533	Sep 08, 2029	DP U-219			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421 006	8679533	Sep 08, 2029	DP U-219			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421 007	8679533	Sep 08, 2029	DP U-219			
<u>PROPRANOLOL HYDROCHLORIDE - HEMANGEOL</u>						
N 205410 001	8338489	Oct 16, 2028	U-1496		NP ODE	Mar 14, 2017 Mar 14, 2021
<u>RALOXIFENE HYDROCHLORIDE - RALOXIFENE HYDROCHLORIDE</u>						
A 078193 001					PC	Sep 24, 2014
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N 205786 001	7169780	Oct 03, 2023	DS DP			
	7217713	Oct 21, 2022	U-257			
	7435734	Oct 21, 2022	U-257			
	7754731	Mar 11, 2029	DS DP U-257			
<u>RASAGILINE MESYLATE - AZILECT</u>						
N 021641 001					I-685	May 29, 2017
<u>RASAGILINE MESYLATE - AZILECT</u>						
N 021641 002					I-685	May 29, 2017

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>REGORAFENIB - STIVARGA</u>						
N 203085 001	8637553	Jul 08, 2029	DS DP			
	8680124	Jul 20, 2028	U-1506			
<u>RIFAXIMIN - XIFAXAN</u>						
N 021361 001	8518949	Feb 27, 2026	DP			
	8741904	Feb 27, 2026	DS U-1526			
<u>RIFAXIMIN - XIFAXAN</u>						
N 022554 001	8642573	Oct 02, 2029	U-1481			
	8741904	Feb 27, 2026	DS U-1526			
<u>RITONAVIR - NORVIR</u>						
N 022417 001	8691878	Aug 25, 2024	U-688			
	8691878*PED	Feb 25, 2025				
<u>ROFLUMILAST - DALIRESP</u>						
N 022522 001	8618142	Mar 08, 2024	DP			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 001	8722693	Jun 12, 2028	DS DP			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 002	8722693	Jun 12, 2028	DS DP			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 003	8722693	Jun 12, 2028	DS DP			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 004	8722693	Jun 12, 2028	DS DP			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 005	8722693	Jun 12, 2028	DS DP			
<u>SAPROPTERIN DIHYDROCHLORIDE - KUVAN</u>						
N 022181 001	7566462	Nov 16, 2025	DP		NPP	Apr 23, 2017
	7566462*PED	May 16, 2026			ODE	Dec 13, 2014
	7566714	Nov 17, 2024	U-989		PED	Jun 13, 2015
	7566714*PED	May 17, 2025			PED	Oct 23, 2017
	7612073	Nov 17, 2024	U-1010			
	7612073*PED	May 17, 2025				
	7727987	Nov 17, 2024	DP			
	7727987*PED	May 17, 2025				
	7947681	Nov 17, 2024	U-1156			
	7947681*PED	May 17, 2025				
	8003126	Nov 16, 2025				
	8003126*PED	May 17, 2015				
	8067416	Nov 17, 2024	U-989			
	8067416*PED	May 17, 2025				
	8318745	Nov 17, 2024	DP			
	8318745*PED	May 17, 2025				
	RE43797	Nov 17, 2024	U-1156			
	RE43797*PED	May 17, 2025				
<u>SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA</u>						
N 022350 001					M-134	May 24, 2016
<u>SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA</u>						
N 022350 002					M-134	May 24, 2016
<u>SILDENAFIL CITRATE - REVATIO</u>						
N 021845 001					D-137	Jan 31, 2017
					M-133	Jan 31, 2017
<u>SILDENAFIL CITRATE - REVATIO</u>						
N 022473 001					D-137	Jan 31, 2017
					M-133	Jan 31, 2017
<u>SILDENAFIL CITRATE - REVATIO</u>						
N 203109 001					D-137	Jan 31, 2017
					M-133	Jan 31, 2017
<u>SIMEPREVIR SODIUM - OLYSIO</u>						
N 205123 001	8741926	Jul 28, 2026	DS U-1467			
	8754106	Jul 28, 2026	DS U-1467			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SIROLIMUS - SIROLIMUS</u>						
A 201676 003					PC	Jul 15, 2014
<u>SODIUM OXYBATE - XYREM</u>						
N 021196 001	8731963	Dec 17, 2022	U-1110			
	8772306	Mar 15, 2033	U-1532			
<u>SOFOSBUVIR - SOVALDI</u>						
N 204671 001	8618076	Dec 11, 2030	DS DP U-1470			
	8633309	Mar 26, 2029	DS DP U-1470			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 008	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 009	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 010	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
<u>SORAFENIB TOSYLATE - NEXAVAR</u>						
N 021923 001	8618141	Feb 11, 2023	U-1480			
<u>SUMATRIPTAN SUCCINATE - SUMAVEL DOSEPRO</u>						
N 022239 001	6174304	Dec 13, 2015	DP			
	6251091	Dec 09, 2016	DP			
	6280410	Mar 27, 2017	DP			
	6681810	Dec 13, 2015	DP			
	8241243	Aug 10, 2023	DP			
	8491524	Nov 21, 2022	DP			
<u>SUVOREXANT - BELSOMRA</u>						
N 204569 001					>A> NCE	Aug 13, 2019
<u>SUVOREXANT - BELSOMRA</u>						
N 204569 002					>A> NCE	Aug 13, 2019
<u>SUVOREXANT - BELSOMRA</u>						
N 204569 003					>A> NCE	Aug 13, 2019
<u>SUVOREXANT - BELSOMRA</u>						
N 204569 004					>A> NCE	Aug 13, 2019
<u>TALIGLUCERASE ALFA - ELELYSO</u>						
N 022458 001	8741620	Feb 24, 2024	DS DP		>A> NPP	Aug 27, 2017
<u>TASIMELTEON - HETLIOZ</u>						
N 205677 001	5856529	Dec 09, 2017	DS DP U-1486		NCE	Jan 31, 2019
	8785492	Jan 25, 2033	U-1486		ODE	Jan 31, 2021
<u>TAVABOROLE - KERYDIN</u>						
N 204427 001	7582621	May 26, 2027	U-718		NCE	Jul 07, 2019
	7767657	May 22, 2027	DP			
<u>TAZAROTENE - FABIOR</u>						
N 202428 001	>A> 8808716	Feb 24, 2030	DP			
<u>TECHNETIUM TC-99M TILMANOCEPT - LYMPHOSEEK KIT</u>						
N 202207 001					I-687	Jun 13, 2017
<u>TEDIZOLID PHOSPHATE - SIVEXTRO</u>						
N 205435 001	7816379	Feb 23, 2028	DS DP U-282		NCE	Jun 20, 2019
	8420676	Feb 23, 2028	DS DP U-282		GAIN	Jun 20, 2024
	8426389	Dec 31, 2030	DS DP U-282			
<u>TEDIZOLID PHOSPHATE - SIVEXTRO</u>						
N 205436 001	7816379	Feb 23, 2028	DS DP U-282		NCE	Jun 20, 2019
	8420676	Feb 23, 2028	DS DP U-282		GAIN	Jun 20, 2024
	8426389	Dec 31, 2030	DS DP U-282			
<u>TELMISARTAN - TELMISARTAN</u>						
A 078710 001					PC	Jul 07, 2014
<u>TELMISARTAN - TELMISARTAN</u>						
A 078710 002					PC	Jul 07, 2014

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TELMISARTAN - TELMISARTAN</u>						
A 078710 003					PC	Jul 07, 2014
<u>TEMOZOLOMIDE - TEMODAR</u>						
N 022277 001	8623868	Feb 21, 2023	DP			
<u>TEMSIROLIMUS - TORISEL</u>						
N 022088 001	5362718	Feb 15, 2019	DS DP	Y		
	5362718*PED	Aug 15, 2019				
	8722700	Jul 25, 2023	DP			
	8722700*PED	Jan 25, 2024				
>A>	8791097	May 10, 2032	U-1550			
>A>	8791097	May 10, 2032	U-1551			
	RE44768	Feb 15, 2019	DS DP			
	RE44768*PED	Aug 15, 2019				
<u>TESAMORELIN ACETATE - EGRIFTA</u>						
N 022505 001	5861379	May 26, 2020	DS DP U-1100			
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 001	8729057	Oct 12, 2026	DP			
	8741881	Oct 12, 2026	U-1103			
	8754070	Oct 12, 2026	DP			
	8759329	Oct 12, 2026	DP			
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 002 >A>	6503894	Aug 30, 2020	U-1103			
	8729057	Oct 12, 2026	DP			
	8741881	Oct 12, 2026	U-1103			
	8754070	Oct 12, 2026	DP			
	8759329	Oct 12, 2026	DP			
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 003 >A>	6503894	Aug 30, 2020	U-1103			
	8729057	Oct 12, 2026	DP			
	8741881	Oct 12, 2026	U-1103			
	8754070	Oct 12, 2026	DP			
	8759329	Oct 12, 2026	DP			
<u>TESTOSTERONE - AXIRON</u>						
N 022504 001	8784878	Jul 13, 2023	DP U-1545			
<u>TESTOSTERONE - VOGELIXO</u>						
N 204399 002	8785426	Feb 11, 2034	DP U-1531		NP	Jun 04, 2017
<u>TESTOSTERONE - VOGELIXO</u>						
N 204399 003	8785426	Feb 11, 2034	DP U-1531		NP	Jun 04, 2017
<u>TESTOSTERONE - NATESTO</u>						
N 205488 001	8574622	Feb 04, 2024	DP		NP	May 28, 2017
>A>	8784869	Feb 04, 2024	DP			
>A>	8784882	Feb 04, 2024	DP U-1557			
<u>TESTOSTERONE UNDECANOATE - AVEED</u>						
N 022219 001	7718640	Mar 14, 2027	DP		NP	Mar 05, 2017
	8338395	Feb 27, 2026	U-1500			
<u>THALIDOMIDE - THALOMID</u>						
N 020785 001	8626531	Oct 23, 2020	U-1465			
<u>THALIDOMIDE - THALOMID</u>						
N 020785 002	8626531	Oct 23, 2020	U-1465			
<u>THALIDOMIDE - THALOMID</u>						
N 020785 003	8626531	Oct 23, 2020	U-1465			
<u>THALIDOMIDE - THALOMID</u>						
N 020785 004	8626531	Oct 23, 2020	U-1465			
<u>TIMOLOL MALEATE - ISTALOL</u>						
N 021516 001	6645963	Nov 16, 2018	DP			
<u>TOFACITINIB CITRATE - XELJANZ</u>						
N 203214 001					M-135	Feb 21, 2017
<u>TOLVAPTAN - SAMSCA</u>						
N 022275 001	5753677	May 19, 2020	U-978			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TOLVAPTAN - SAMSCA</u>						
N 022275 002	5753677	May 19, 2020	U-978			
<u>TOLVAPTAN - SAMSCA</u>						
N 022275 003	5753677	May 19, 2020	U-978			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 001	8663683	Nov 16, 2027	DP U-106			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 002	8663683	Nov 16, 2027	DP U-106			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 003	8663683	Nov 16, 2027	DP U-106			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 004	8663683	Nov 16, 2027	DP U-106			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 001	8652527	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 002	8652527	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 003	8652527	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 004	8652527	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 005	8652527	Mar 19, 2033	DP			
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 001					I-678 ODE	Jan 08, 2017 Jan 08, 2021
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 002					I-678 ODE	Jan 08, 2017 Jan 08, 2021
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 003					I-678 ODE	Jan 08, 2017 Jan 08, 2021
<u>TRANEXAMIC ACID - LYSTEDA</u>						
N 022430 001 >A>	8791160	Mar 04, 2025	DP U-1182			
<u>TRAVOPROST - IZBA</u>						
N 204822 001	8722735	Oct 10, 2029	DP		NP	May 15, 2017
	8754123	May 19, 2029	DP			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 001	8653137	Sep 05, 2028	U-1437			
	8658694	Sep 05, 2028	U-1437			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 002	8653137	Sep 05, 2028	U-1437			
	8658694	Sep 05, 2028	U-1437			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 003	8653137	Sep 05, 2028	U-1437			
	8658694	Sep 05, 2028	U-1437			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 004	8653137	Sep 05, 2028	U-1437			
	8658694	Sep 05, 2028	U-1437			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 001	8747897	Oct 08, 2029	DP			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 002	8747897	Oct 08, 2029	DP			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 003	8747897	Oct 08, 2029	DP			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 004	8747897	Oct 08, 2029	DP			
<u>ULIPRISTAL ACETATE - ELLA</u>						
N 022474 001	8735380	Feb 20, 2029	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>UMECLIDINIUM BROMIDE - INCRUSE ELLIPTA</u>						
N 205382 001	5873360	Feb 23, 2016	DP			
	7488827	Apr 27, 2025	DS DP			
	7498440	Apr 27, 2025	DS DP			
	8113199	Oct 23, 2027	DP			
	8161968	Feb 05, 2028	DP			
	8183257	Jul 27, 2025	U-1476			
	8201556	Feb 05, 2029	DP			
	8309572	Apr 27, 2025	U-1476			
	8534281	Aug 10, 2029	DP			
	8746242	Oct 11, 2030	DP			
<u>UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - ANORO ELLIPTA</u>						
N 203975 001	8746242	Oct 11, 2030	DP		NP	Dec 18, 2016
	RE44874	Mar 23, 2023	DS DP U-1476			
<u>UROFOLLITROPIN - BRAVELLE</u>						
N 021289 001					D-139	Feb 19, 2017
<u>VALSARTAN - VALSARTAN</u>						
A 077492 001					PC	Jan 03, 2015
<u>VALSARTAN - VALSARTAN</u>						
A 077492 002					PC	Jan 03, 2015
<u>VALSARTAN - VALSARTAN</u>						
A 077492 003					PC	Jan 03, 2015
<u>VALSARTAN - VALSARTAN</u>						
A 077492 004					PC	Jan 03, 2015
<u>VANDETANIB - CAPRELSA</u>						
N 022405 001	8642608	Feb 06, 2022	U-1490			
<u>VANDETANIB - CAPRELSA</u>						
N 022405 002	8642608	Feb 06, 2022	U-1490			
<u>VARDENAFIL HYDROCHLORIDE - STAXYN</u>						
N 200179 001	8613950	Dec 23, 2028	DP			
<u>VEMURAFENIB - ZELBORAF</u>						
N 202429 001 >A>	8741920	Jul 27, 2030	DS DP			
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N 022567 001	8673921	Jun 05, 2022	DS DP			
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N 022567 002	8673921	Jun 05, 2022	DS DP			
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N 022567 003	8673921	Jun 05, 2022	DS DP			
<u>VORAPAXAR SULFATE - ZONTIVITY</u>						
N 204886 001	7235567	Jun 13, 2021	DS DP		NCE	May 08, 2019
	7304078	Apr 06, 2024	DS DP U-1512			
<u>VORINOSTAT - ZOLINZA</u>						
N 021991 001	8450372	Mar 18, 2028	U-892			
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 204447 001	8722684	Nov 11, 2030	DS DP			
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 204447 002	8722684	Nov 11, 2030	DS DP			
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 204447 003	8722684	Nov 11, 2030	DS DP			
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 204447 004	8722684	Nov 11, 2030	DS DP			
<u>ZICONOTIDE ACETATE - PRIALT</u>						
N 021060 001	8653033	Oct 01, 2024	U-48			
	8653033	Oct 01, 2024	U-55			
	8765680	Oct 01, 2024	U-48			
	8765680	Oct 01, 2024	U-55			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ZICONOTIDE ACETATE - PRIALT</u>						
N 021060 002	8653033	Oct 01, 2024	U-48			
	8653033	Oct 01, 2024	U-55			
	8765680	Oct 01, 2024	U-48			
	8765680	Oct 01, 2024	U-55			
<u>ZICONOTIDE ACETATE - PRIALT</u>						
N 021060 003	8653033	Oct 01, 2024	U-48			
	8653033	Oct 01, 2024	U-55			
	8765680	Oct 01, 2024	U-48			
	8765680	Oct 01, 2024	U-55			
<u>ZICONOTIDE ACETATE - PRIALT</u>						
N 021060 004	8653033	Oct 01, 2024	U-48			
	8653033	Oct 01, 2024	U-55			
	8765680	Oct 01, 2024	U-48			
	8765680	Oct 01, 2024	U-55			
<u>ZOLMITRIPTAN - ZOMIG</u>						
N 021450 003	6750237	Nov 28, 2020	DP			
	6750237*PED	May 28, 2021				
	7220767	Nov 28, 2020	DP			
	7220767*PED	May 28, 2021				

Footnote:

1. Patents are published upon receipt by the Orange book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).

2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 34th Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at
<http://www.accessdata.fda.gov/scripts/cder/ob/docs/pattermsall.cfm>

The current complete list of exclusivity terms is available at
<http://www.accessdata.fda.gov/scripts/cder/ob/docs/excltermsall.cfm>